<html lang="en"><head><!-- Shady DOM styles for custom-style --><!-- Shady DOM styles for dom-template --><!-- Shady DOM styles for dom-repeat --><!-- Shady DOM styles for array-selector --><!-- Shady DOM styles for dom-if --><!-- Shady DOM styles for state-modifier --><style scope="state-modifier">a[inherit].state-modifier {
  color: inherit;
}</style><!-- Shady DOM styles for browser-ui --><!-- Shady DOM styles for outlined-text-field --><style scope="outlined-text-field">outlined-text-field {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: column;
}

outlined-text-field span.outlined-text-field {
  display: flex;
  flex-direction: row;
  align-items: center;
}

outlined-text-field input.outlined-text-field {
  height: 40px;
  padding: 0 33px 0 16px;
  
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  flex-grow: 1;
}

outlined-text-field[orig] input.outlined-text-field {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-text-field[dense] input.outlined-text-field {
  height: 32px;
}

outlined-text-field[uppercase] input.outlined-text-field {
  text-transform: uppercase;
}

outlined-text-field:not([wizard-focused]):hover input.outlined-text-field {
  border-color: #737375;
  color: #414447;
}

outlined-text-field:not([wizard-focused]):focus-within input.outlined-text-field,outlined-text-field[wizard-focused] input.outlined-text-field {
  border-color: #3574e0;
  caret-color: #80a5f1;
}

outlined-text-field[wizard-focused] input.outlined-text-field {
  border-width: 2px;
}

outlined-text-field input.outlined-text-field::placeholder {
  color: #65686c;
}

outlined-text-field[uppercase] input.outlined-text-field::placeholder {
  text-transform: none;
}</style><!-- Shady DOM styles for mat-keyword-editor --><!-- Shady DOM styles for mat-chips-input --><!-- Shady DOM styles for mat-input-chip --><!-- Shady DOM styles for pat-dialog --><style scope="pat-dialog">pat-dialog {
  background: white;
  position: absolute;
  border-radius: 8px;
  
  box-shadow: 0 24px 38px 3px rgb(0 0 0 / 14%),
              0 9px 46px 8px rgb(0 0 0 / 12%),
              0 11px 15px -7px rgb(0 0 0 / 20%);
  z-index: 1;
  display: flex;
  flex-direction: column;
}

pat-dialog:not([open]) {
  display: none;
}</style><!-- Shady DOM styles for mat-tabs --><!-- Shady DOM styles for filter-chip --><style scope="filter-chip">filter-chip {
  align-items: center;
  background-color: #fff;
  border-color: #dadce0;
  border-radius: 8px;
  border-style: solid;
  border-width: 1px;
  color: #606368;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 32px;
  letter-spacing: 0.2px;
  padding: 0 16px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

filter-chip[disabled] {
  background-color: #e8e8e8;
  border-color: #e8e8e8;
  color: #a9abad;
  cursor: auto;
}

filter-chip svg.filter-chip {
  visibility: collapse;
  font-size: 18px;
  width: 0;
  height: 18px;
}

filter-chip[selected] svg.filter-chip {
  visibility: visible;
  margin: 0 8px;
  width: 18px;
}

filter-chip[selected] svg.filter-chip path.filter-chip {
  fill: #4577d1;
}

filter-chip:not([disabled]):hover {
  background-color: #f7f8f8;
  border-color: #d7d9dc;
  color: #454649;
}

filter-chip:not([disabled]):hover:active {
  background-color: #eff0f0;
  border-color: #d2d5d8;
  color: #222326;
}

filter-chip:not([disabled]):focus {
  background-color: #e7e8e8;
  border-color: #232528;
  color: #202124;
}

filter-chip:not([disabled])[selected] {
  background-color: #e9f0fd;
  border-color: #e9f0fd;
  color: #4577d1;
  padding-left: 0;
}

filter-chip:not([disabled]):focus[selected] {
  background-color: #d5e1fb;
  border-color: #d5e1fb;
  color: #2550a0;
}

filter-chip:not([disabled]):hover[selected] {
  box-shadow: rgba(0, 0, 0, 0.2) 0px 3px 1px -2px,
    rgba(0, 0, 0, 0.14) 0px 2px 2px 0px, rgba(0, 0, 0, 0.12) 0px 1px 5px 0px;
}

filter-chip:not([disabled]):hover:active[selected] {
  background-color: #abc8f2;
  border-color: #abc8f2;
  color: #2a54a3;
}</style><!-- Shady DOM styles for figure-callout --><!-- Shady DOM styles for mat-button --><style scope="mat-button-0">.mat-button-0 {
  ;
  align-items: center;
  border-radius: 4px;
  color: hsl(217 4% 39%); 
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: 0.2px;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
}

.mat-button-0[filled] {
  background-color: hsl(217 73% 54%); 
  color: white;
}

.mat-button-0[filled]:hover {
  background-color: hsl(217 60% 47%);
}

.mat-button-0[filled]:focus {
  background-color: hsl(217 59% 44%);
}

.mat-button-0[filled]:active {
  background-color: hsl(217 59% 45%);
}

.mat-button-0[filled][disabled] {
  background-color: hsl(217 2% 90%); 
  color: hsl(217 1% 65%);
}</style><!-- Shady DOM styles for search-term-wizard --><style scope="search-term-wizard">search-term-wizard:not([open]) {
  display: none;
}

search-term-wizard .header.search-term-wizard {
  border-bottom: 1px solid #e5e5e5;
  padding: 24px;
  padding-bottom: 0;
}

search-term-wizard .title.search-term-wizard {
  color: #3c4043;
  font-family: Google Sans,Roboto,Arial,sans-serif;
  font-size: 22px;
  user-select: none;
  margin: 0 48px;
}

search-term-wizard #panels.search-term-wizard > *.search-term-wizard:not([selected]) {
  display: none;
}</style><!-- Shady DOM styles for outlined-textarea --><style scope="outlined-textarea">outlined-textarea {
  display: flex;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  flex-direction: row;
  
  position: relative;
}

outlined-textarea span.outlined-textarea {
  display: flex;
  flex-direction: column;
  flex-grow: 1;
  justify-content: center;
}

outlined-textarea span.right-button-container.outlined-textarea {
  position: absolute;
  right: 0;
  height: 100%;
}

outlined-textarea textarea.outlined-textarea {
  padding: 16px 16px 0 16px;
  border-color: #b0b3b6;
  border-width: 1px;
  border-style: solid;
  border-radius: 8px;
  caret-color: #3c78e0;
  color: #6a6c71;
  font-size: 14px;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
  resize: none;
}

outlined-textarea[dense] textarea.outlined-textarea {
  padding: 8px;
}

outlined-textarea[has-icon] textarea.outlined-textarea {
  padding-right: 38px;
}

outlined-textarea[orig] textarea.outlined-textarea {
  border-color: #e5e5e5;
  
  border-radius: 0;
}

outlined-textarea:not([rows]) textarea.outlined-textarea {
  height: 40px;
}

outlined-textarea textarea.resizable.outlined-textarea {
  resize: vertical;
}

outlined-textarea textarea.outlined-textarea:focus,outlined-textarea[wizard-focused] textarea.outlined-textarea,outlined-textarea textarea.outlined-textarea:focus:hover {
  border-color: #3574e0 !important;
  
  outline: none !important;
}

outlined-textarea textarea.outlined-textarea:hover {
  border-color: #202124;
  color: #414447;
}

outlined-textarea.hasValue textarea.outlined-textarea {
  border-color: #888d91;
  color: #45474a;
}

outlined-textarea #helperText.outlined-textarea {
  color: #6a6c71;
  font-size: 12px;
  letter-spacing: 0.3px;
  margin-left: 17px;
  margin-top: 6px;
  user-select: none;
}

outlined-textarea:not([helper-text]) #helperText.outlined-textarea {
  display: none;
}

outlined-textarea[error] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
  color: #3d4043;
}

outlined-textarea textarea.outlined-textarea::placeholder {
  font-size: 14px;
  font-weight: 400;
}

outlined-textarea:not([error]):not([disabled]) textarea.outlined-textarea::placeholder {
  color: #6a6c71;
}

outlined-textarea[error] textarea.outlined-textarea::placeholder {
  color: #c84132;
}

outlined-textarea[error] #helperText.outlined-textarea {
  color: #cd5648;
}

outlined-textarea[error] textarea.outlined-textarea:focus {
  border-color: #c84031;
  border-width: 2px;
  outline: none !important;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover {
  border-color: #97231b;
}

outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover::placeholder,outlined-textarea[error]:not([disabled]) textarea.outlined-textarea:hover + #helperText.outlined-textarea {
  color: #a94945;
}

outlined-textarea[disabled] textarea.outlined-textarea {
  border-color: #e9e9e9;
  color: #b5b6b8;
}

outlined-textarea[disabled] #helperText.outlined-textarea {
  color: #c4c6c7;
}

outlined-textarea[error][disabled] {
  opacity: 50%;
}

outlined-textarea[error][disabled] textarea.outlined-textarea {
  border-color: #cb4b3d;
  caret-color: #ca493a;
}

outlined-textarea[error][disabled] #helperText.outlined-textarea,outlined-textarea[error][disabled] textarea.outlined-textarea {
  color: #a94945;
}

outlined-textarea[error][disabled] textarea.outlined-textarea::placeholder {
  color: #c84132;
}</style><!-- Shady DOM styles for chemistry-search-term-wizard --><style scope="chemistry-search-term-wizard">chemistry-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

chemistry-search-term-wizard .suggestions.chemistry-search-term-wizard {
  margin-top: 4px;
}

chemistry-search-term-wizard > span.chemistry-search-term-wizard svg.chemistry-search-term-wizard {
  margin-right: 24px;
}

chemistry-search-term-wizard path.chemistry-search-term-wizard {
  fill: #5f6368;
}

chemistry-search-term-wizard .help.chemistry-search-term-wizard {
  margin-left: 12px;
  margin-right: 0;
  cursor: pointer;
}

chemistry-search-term-wizard outlined-text-field.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard mat-button.chemistry-search-term-wizard {
  margin-left: 48px;
}

chemistry-search-term-wizard filter-chip.chemistry-search-term-wizard {
  margin-right: 4px;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard {
  flex-grow: 1;
}

chemistry-search-term-wizard outlined-text-field[batchMode].chemistry-search-term-wizard {
  display: none;
}

chemistry-search-term-wizard outlined-textarea.chemistry-search-term-wizard:not([batchMode]) {
  display: none;
}</style><!-- Shady DOM styles for text-search-term-wizard --><style scope="text-search-term-wizard">text-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
}

text-search-term-wizard > span.text-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

text-search-term-wizard > span.text-search-term-wizard svg.text-search-term-wizard {
  margin-right: 24px;
}

text-search-term-wizard path.text-search-term-wizard {
  fill: #5f6368;
}

text-search-term-wizard outlined-text-field.text-search-term-wizard {
  flex-grow: 1;
}

text-search-term-wizard mat-button.text-search-term-wizard {
  margin-left: 48px;
}

text-search-term-wizard filter-chip.text-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for classification-wizard --><style scope="classification-wizard">classification-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

classification-wizard > span.classification-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

classification-wizard .suggestions.classification-wizard {
  margin-top: 4px;
}

classification-wizard > span.classification-wizard svg.classification-wizard {
  margin-right: 24px;
}

classification-wizard path.classification-wizard {
  fill: #5f6368;
}

classification-wizard outlined-text-field.classification-wizard {
  flex-grow: 1;
}

classification-wizard mat-button.classification-wizard {
  margin-left: 48px;
}

classification-wizard filter-chip.classification-wizard {
  margin-right: 4px;
}

classification-wizard .no-matches.classification-wizard {
  margin-left: 64px;
}

classification-wizard .table-container.classification-wizard {
  max-height: 300px;
  overflow: scroll;
  margin-top: 8px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar {
  -webkit-appearance: none;
  width: 10px;
}

classification-wizard .table-container.classification-wizard::-webkit-scrollbar-thumb {
  border-radius: 5px;
  background-color: #5f636880;
  -webkit-box-shadow: 0 0 1px rgba(255,255,255,.5);
}

classification-wizard table.classification-wizard {
  margin-left: 51px;
  max-width: 575px;
}

classification-wizard tr.classification-wizard {
  margin-top: 4px;
}

classification-wizard tr.classification-wizard suggestive-chip.classification-wizard {
  margin-right: 8px;
}

classification-wizard #spinner.classification-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}</style><!-- Shady DOM styles for suggestive-chip --><!-- Shady DOM styles for mat-checkbox --><!-- Shady DOM styles for measure-search-term-wizard --><style scope="measure-search-term-wizard">measure-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

measure-search-term-wizard > span.measure-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

measure-search-term-wizard .suggestions.measure-search-term-wizard {
  margin-top: 4px;
}

measure-search-term-wizard > span.measure-search-term-wizard svg.measure-search-term-wizard {
  margin-right: 24px;
}

measure-search-term-wizard path.measure-search-term-wizard {
  fill: #5f6368;
}

measure-search-term-wizard outlined-text-field.measure-search-term-wizard {
  flex-grow: 1;
}

measure-search-term-wizard mat-button.measure-search-term-wizard {
  margin-left: 48px;
}

measure-search-term-wizard filter-chip.measure-search-term-wizard {
  margin-right: 4px;
}</style><!-- Shady DOM styles for numerical-search-term-wizard --><style scope="numerical-search-term-wizard">numerical-search-term-wizard {
  display: flex;
  flex-direction: column;
  padding: 24px;
  padding-top: 0;
  max-width: 674px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
  flex-wrap: wrap;
  margin-top: 16px;
}

numerical-search-term-wizard .suggestions.numerical-search-term-wizard {
  margin-top: 4px;
}

numerical-search-term-wizard > span.numerical-search-term-wizard svg.numerical-search-term-wizard {
  margin-right: 24px;
}

numerical-search-term-wizard path.numerical-search-term-wizard {
  fill: #5f6368;
}

numerical-search-term-wizard outlined-text-field.numerical-search-term-wizard,numerical-search-term-wizard outlined-textarea.numerical-search-term-wizard {
  flex-grow: 1;
}

numerical-search-term-wizard mat-button.numerical-search-term-wizard {
  margin-left: 48px;
}

numerical-search-term-wizard filter-chip.numerical-search-term-wizard {
  margin-right: 4px;
}

numerical-search-term-wizard #spinner.numerical-search-term-wizard {
  justify-content: space-around;
  margin-left: 48px;
  transform: scale(0.5);
}

numerical-search-term-wizard #suggestions.numerical-search-term-wizard {
  margin-left: 58px;
  display: flex;
  flex-direction: column;
  align-items: flex-start;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard {
  display: flex;
  flex-direction: row;
  align-items: center;
}

numerical-search-term-wizard .suggestion.numerical-search-term-wizard mat-checkbox.numerical-search-term-wizard {
  margin-right: 8px;
}</style><!-- Shady DOM styles for text-button --><style scope="text-button">text-button {
  align-items: center;
  border-radius: 4px;
  cursor: pointer;
  font-family: "Google Sans", Roboto, Arial, sans-serif;
  font-size: 14px;
  font-weight: 500;
  height: 36px;
  letter-spacing: .25px;
  margin: 6px 0;
  padding: 0 8px;
  user-select: none;
  display: inline-flex;
  white-space: nowrap;
  line-height: 36px;
  text-decoration: none;
  text-transform: none;
  color: #5f6368;
}

text-button:hover {
  background-color: #f8f9fa;
}

text-button:active {
  background-color: #d5e2fa;
}

text-button[selected] {
  background-color: #e8f0fe;
  color: #1967d2;
}

text-button[selected]:active {
  background-color: #d2e3fc;
}</style><!-- Shady DOM styles for mat-spinner --><!-- Shady DOM styles for requery-tile --><style scope="requery-tile">requery-tile {
  display: flex;
  justify-content: space-between;
  align-items: center;
  box-sizing: border-box;
  min-height: 40px;
  padding: 8px 12px 8px 8px;
  gap: 8px;

  border-radius: 16px;
  background: #f7f8f9;
  color: #1f1f1f;
}

requery-tile:hover {
  background: #d7d8d9;
}

requery-tile > [slot="image"] {
  flex-shrink: 0;

  border-radius: 8px;

  background: #fff;
}

.label.requery-tile {
  flex-grow: 999;

  font: 16px/20px "Google Sans", Roboto, Arial, sans-serif;
  font-weight: 500;
}

.search-icon.requery-tile {
  flex-shrink: 0;

  width: 24px;
  height: 24px;
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/search/default/24px.svg');
}</style><!-- Shady DOM styles for s-more-inline --><style scope="s-more-inline">s-more-inline {
  display: block;
  margin-top: 24px;
  padding: 16px;
  padding-top: 0;
  position: relative;

  line-height: 18px;
  text-overflow: ellipsis;
  white-space: nowrap;
  cursor: pointer;
}

hr.s-more-inline {
  background-color: #dadce0;
  margin-top: 18px;
  position: absolute;
  border: 0;
  height: 1px;
  left: 0;
  width: 100%;
}

.button.s-more-inline {
  display: flex;
  align-items: center;
  justify-content: center;

  position: relative; 
  margin: 0 auto;

  font: 400 14px Roboto, arial, sans-serif;
  height: 36px;
  width: 300px;
  border-radius: 18px;
  background-color: #f1f3f4;
}

.button.s-more-inline:hover {
  background-color: #d8d7dc;
}

.button.s-more-inline > [slot] {
  padding-right: 8px;
}

.expand.s-more-inline {
  display: inline-block;
  width: 20px;
  height: 20px;
}

.expand.less.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_less/default/20px.svg');
}

.expand.more.s-more-inline {
  background-image: url('https://fonts.gstatic.com/s/i/short-term/release/googlesymbols/expand_more/default/20px.svg');
}</style><!-- Shady DOM styles for workspace-ui-search --><!-- Shady DOM styles for keyword-wizard --><style scope="keyword-wizard">keyword-wizard {
  display: inline-block;
}

iron-icon.keyword-wizard {
  height: 20px;
    width: 20px;
    color: #999;
    cursor: pointer;
}

iron-icon[active].keyword-wizard {
  color: #4285f4 !important;
}

iron-icon.keyword-wizard:hover {
  color: #ccc;
}

#wizardIcon.keyword-wizard {
  padding-left: 1px;
    height: 16px;
    width: 16px;
    margin: 4px 1px 1px 1px;
}

#wizard.keyword-wizard {
  padding: 0;
    left: 0;
    top: 37px;
    position: absolute;
    background-color: white;
    z-index: 2;
    overflow: hidden;
}

.wizard-header.keyword-wizard {
  display: block;
    width: 100%;
    color: #737373;
    text-transform: uppercase;
    font-size: 13px;
    margin: 16px 0 6px 12px;
}

.filter-chips.keyword-wizard {
  margin-left: 20px;
}

.chip.keyword-wizard {
  background-color: #ebebeb;
    color: #6a6a6a;
    display: inline-block;
    font-size: 13px;
    font-family: inherit;
    border-radius: 12px;
    padding: 6px 12px;
}

.chip.keyword-wizard:hover {
  cursor: pointer;
}

.chip[selected].keyword-wizard {
  background-color: #4285f4;
    color: white;
}

.input-label.keyword-wizard {
  display: inline-block;
    font-size: 13px;
    font-family: inherit;
}

.keyword-input.keyword-wizard {
  display: inline-block;
    border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    padding: 3px;
}

.keyword-input.keyword-wizard::placeholder {
  font-style: italic;
}

.keyword-input.keyword-wizard:hover,.keyword-input.keyword-wizard:focus {
  border-color: #4284f4;
    border-width: 1px;
    outline: none;
}

.cpc-field.keyword-wizard {
  display: inline-block;
    margin: 6px 0 0 24px;
}

#checkboxCPC.keyword-wizard:hover {
  cursor: pointer;
}

.checkbox-label.keyword-wizard {
  font-size: 13px;
    font-style: italic;
    color: #737373;
}

.chemistry-field.keyword-wizard {
  display: block;
}

#inputChem.input-batch.keyword-wizard {
  height: 150px;
    border: 1px solid #dfe1e5;
    padding: 6px;
}

#inputChem.keyword-wizard {
  resize: none;
    height: 15px;
    vertical-align: text-top;
    font-size: 13px;
    font-family: inherit;
    padding: 2px;
}

.chem-type-label.keyword-wizard {
  display: inline;
    font-size: 13px;
    margin-left: 12px;
    margin-right: 4px;
}

#chemType.keyword-wizard {
  border-top: 0;
    border-left: 0;
    border-right: 0;
    border-bottom: 1px solid #dfe1e5;
    margin: 6px;
    padding: 2px;
    outline: none;
    font-family: inherit;
    font-size: 13px;
}

.import.keyword-wizard {
  font-size: 13px;
    font-family: inherit;
}

.import-text.keyword-wizard {
  vertical-align: middle;
    display: inline-block;
}

.import-button.keyword-wizard {
  margin: 6px 0 0 24px;
}

.import-button.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.import-button.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard {
  float: right;
    padding: 12px;
}

.wizard-buttons.keyword-wizard button.keyword-wizard {
  border: 0;
    border-radius: 4px;
    padding: 6px 12px;
    margin: 2px;
    font-family: inherit;
    background-color: #4284f4;
    color: white;
}

.wizard-buttons.keyword-wizard button.keyword-wizard:hover {
  cursor: pointer;
}

@media screen and (max-width: 700px) {
#wizard.keyword-wizard {
  width: 275px;
}

.chip.keyword-wizard {
  margin: 4px 2px;
}

.keyword-input.keyword-wizard {
  width: 82%;
      margin: 4px 12px 12px 24px;
}

.search-within.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 225px;
      margin: 12px 0 6px 0;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  display: none;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  margin-top: 6px;
}

#inputChem.keyword-wizard {
  width: 82%;
      padding: 2px;
      margin: 8px 12px 12px 24px;
}

#inputChem.input-batch.keyword-wizard {
  width: 220px;
      padding: 4px;
}

#chemType.keyword-wizard {
  width: 150px;
}

.import-text.keyword-wizard {
  margin: 6px 12px 6px 24px;
      width: 220px;
}

iron-icon.help-header.keyword-wizard {
  display: none;
}

}

@media screen and (min-width: 700px) {
#wizard.keyword-wizard {
  width: 540px;
}

.chip.keyword-wizard {
  margin: 0 2px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard {
  width: 240px;
      margin: 12px 16px 6px 6px;
}

.cpc-inputs.keyword-wizard {
  display: inline;
}

.find-patents.keyword-wizard .keyword-input.keyword-wizard {
  width: 53%;
      margin: 4px 10px;
}

.cpc-field.keyword-wizard .keyword-input.keyword-wizard::placeholder,#inputAnd.keyword-wizard::placeholder,#inputExact.keyword-wizard::placeholder,#inputOr.keyword-wizard::placeholder,#inputMinus.keyword-wizard::placeholder {
  color: white;
}

.find-patents.keyword-wizard .input-label.keyword-wizard {
  width: 35%;
      margin-left: 24px;
}

.search-by.keyword-wizard .keyword-input.keyword-wizard {
  width: 42%;
      margin: 6px 4px;
}

.search-by.keyword-wizard .input-label.keyword-wizard {
  width: 55px;
      margin-left: 24px;
}

#inputChem.keyword-wizard {
  width: 290px;
      margin: 2px 12px 2px 6px;
}

#inputChem.input-batch.keyword-wizard {
  width: 280px;
      padding: 6px;
}

.import-text.keyword-wizard {
  margin: 6px 12px;
      width: 415px;
}

#chemType.keyword-wizard {
  width: 105px;
}

iron-icon.keyword-wizard:hover.help-header {
  cursor: default;
}

iron-icon.help-header.keyword-wizard {
  height: 16px;
      padding: 0 2px 2px 2px;
      color: #a3a3a3;
}

.help.keyword-wizard p.keyword-wizard {
  margin: 0 0 8px 0
}

.help.keyword-wizard .q.keyword-wizard {
  font-family: monospace;
      color: #0b8043;
      white-space: nowrap;
}

.help.keyword-wizard {
  z-index: 4;
      position: absolute;
      right: 10px;
      padding: 12px;
      border-radius: 2px;
      border: 1px solid #e0e0e0;
      box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.2), 0 6px 10px 0 rgba(0, 0, 0, 0.3);
      background: white;
      font-size: 13px;
      line-height: 20px;
      width: 450px;
      max-height: 400px;
      overflow: auto;
}

#withinHelp.keyword-wizard {
  top: 75px;
}

#chemHelp.keyword-wizard {
  top: 0;
}

#searchBooleanHelp.keyword-wizard {
  top: 140px;
}

}</style><!-- Shady DOM styles for bottom-bar --><style scope="bottom-bar">.fixed.bottom-bar {
  display: block;
  position: fixed;
  height: 46px;
  bottom: 0;
}

.fixed[medium].bottom-bar {
  height: 280px;
}

.fixed[large].bottom-bar {
  height: 480px;
}

.shadow.bottom-bar {
  background: white;
  padding: 16px;
  border-radius: 8px 8px 0px 0px;
  box-shadow: 0px 8px 10px 1px rgba(0,0,0,.14), 0px 3px 14px 2px rgba(0,0,0,.12), 0px 5px 5px -3px rgba(0,0,0,.2);
}

.oneline.bottom-bar {
  white-space: nowrap;
  overflow: hidden;
  text-overflow: ellipsis;
  cursor: pointer;
}

.button.bottom-bar {
  cursor: pointer;
}

.buttonAlign.bottom-bar {
  margin-top: -4px;
}

.header.bottom-bar {
  height: 30px;
  font-family: 'Google Sans';
  font-size: 18px;
  padding-bottom: 8px;
}

.list.bottom-bar {
  overflow-y: auto;
  line-height: 20px;
}

.definition.bottom-bar {
  padding: 0px 0px 4px 0px;
  cursor: pointer;
}

[medium].bottom-bar .content.bottom-bar {
  height: 230px;
}

[large].bottom-bar .content.bottom-bar {
  height: 430px;
}

[medium].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 200px;
}

[large].bottom-bar .content.bottom-bar .list.bottom-bar {
  height: 400px;
}

[hidden].bottom-bar {
  display: none;
}

.label.bottom-bar {
  font-family: 'Google Sans';
  font-size: 12px;
  line-height: 16px;
  font-weight: 400;
  padding: 6px 0px 4px 0px;
  color: #1f1f1f;
}

[pad].bottom-bar {
  margin-left: 16px;
}

.layout.vertical.bottom-bar {
  display: flex;
  flex-direction: column;
}

.layout.horizontal.bottom-bar {
  display: flex;
  flex-direction: row;
}

.flex.bottom-bar {
  flex: 1;
  flex-basis: 0.000000001px;
}

.layout.start.bottom-bar {
  align-items: flex-start;
}

.layout.center.bottom-bar {
  align-items: center;
}

.layout.end.bottom-bar {
  align-items: flex-end;
}

.flex-2.bottom-bar {
  flex: 2;
}

.flex-3.bottom-bar {
  flex: 3;
}

.flex-4.bottom-bar {
  flex: 4;
}

.flex-5.bottom-bar {
  flex: 5;
}

.flex-6.bottom-bar {
  flex: 6;
}

.flex-7.bottom-bar {
  flex: 7;
}

.flex-8.bottom-bar {
  flex: 8;
}

.flex-9.bottom-bar {
  flex: 9;
}

.flex-10.bottom-bar {
  flex: 10;
}

.flex-11.bottom-bar {
  flex: 11;
}

.flex-12.bottom-bar {
  flex: 12;
}</style><!-- Shady DOM styles for landscape-link --><!-- Shady DOM styles for landscape-summary-box --><!-- Shady DOM styles for search-state --><!-- Shady DOM styles for iron-overlay-backdrop --><!-- Shady DOM styles for opaque-animation --><!-- Shady DOM styles for iron-dropdown --><style scope="iron-dropdown">iron-dropdown {
  position: fixed;
}

#contentWrapper.iron-dropdown  > * {
  overflow: auto;
}

#contentWrapper.animating.iron-dropdown  > * {
  overflow: hidden;
}</style><!-- Shady DOM styles for iron-meta --><!-- Shady DOM styles for iron-icon --><style scope="iron-icon-0">.iron-icon-0 {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;-ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;-ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
        position: relative;

        vertical-align: middle;

        fill: currentcolor;
        stroke: none;

        width: 24px;
        height: 24px;;
}

.iron-icon-0[hidden] {
  display: none;
}</style><!-- Shady DOM styles for iron-iconset-svg --><!-- Shady DOM styles for iron-list --><!-- Shady DOM styles for paper-icon-item --><!-- Shady DOM styles for paper-item-body --><!-- Shady DOM styles for paper-item --><!-- Shady DOM styles for dropdown-menu --><style scope="dropdown-menu">dropdown-menu {
  display: inline-block;
        line-height: 24px;
}

.label.dropdown-menu {
  cursor: pointer;
        color: #666;
        align-items: center;
        margin-right: 8px;
        display: inline-block;
        padding: 2px 0;
}

#selected.dropdown-menu {
  color: #212121;
}

.label[open].dropdown-menu {
  border-color: #e0e0e0;
}

iron-dropdown.dropdown-menu {
  margin-top: 26px;
}

iron-icon.dropdown-menu {
  height: 15px;
        width: 15px;
}

#menu.dropdown-menu {
  max-height: 300px;
        padding: 8px 0;
        background: white;
        display: block;
        border-radius: 2px;
        box-shadow: 0 0 2px rgba(0,0,0,0.12), 0 2px 2px rgba(0,0,0,0.24);
}

.item.dropdown-menu {
  cursor: pointer;
        color: rgba(0,0,0,.87);
        font-size: 13px;
        line-height: 18px;
        padding: 6px 18px;
}

.item.dropdown-menu:hover {
  background-color: #e0e0e0;
}

.item[selected].dropdown-menu {
  background-color: #e0e0e0;
}

[multi].dropdown-menu .item.dropdown-menu {
  padding: 6px 18px 6px 34px;
}

[multi].dropdown-menu .item[selected].dropdown-menu {
  background-image: url('https://www.gstatic.com/images/icons/material/system/2x/done_grey600_24dp.png');
        background-position: 8px center;
        background-size: 16px;
        background-repeat: no-repeat;
}</style><!-- Shady DOM styles for chips-input --><!-- Shady DOM styles for input-chip --><!-- Shady DOM styles for keyword-editor --><!-- Shady DOM styles for paper-ripple --><!-- Shady DOM styles for paper-button --><!-- Shady DOM styles for date-editor --><!-- Shady DOM styles for metadata-editor --><!-- Shady DOM styles for restrict-editor --><!-- Shady DOM styles for overlay-tooltip --><style scope="overlay-tooltip">overlay-tooltip {
  display: none;
        color: #fff;
        background-color: #000;
        padding: 10px 12px;
        border-radius: 3px;
        font-size: 13px;
        font-weight: normal;
        line-height: normal;
        position: fixed;
        z-index: 100;
}

#arrow.overlay-tooltip {
  width: 0;
        height: 0;
        border-style: solid;
        border-width: 0 6px 8px 6px;
        border-color: transparent transparent #000 transparent;
        position: absolute;
        top: -8px;
        left: calc(50% - 6px);
}</style><!-- Shady DOM styles for query-renderer --><!-- Shady DOM styles for result-nav --><style scope="result-nav">result-nav {
  display: block;
        white-space: nowrap;
        padding: 0 30px;
        line-height: 30px;
        height: 30px;
        margin-top: 17px;
        font-weight: 500;
        font-size: 15px;
}

state-modifier.result-nav {
  color: #333;
}

state-modifier[disabled].result-nav {
  pointer-events: none;
        color: #ccc;
}</style><!-- Shady DOM styles for raw-html --><!-- Shady DOM styles for paper-material --><style scope="paper-material-0">.paper-material-0 {
  display: block;
        position: relative;
}

.paper-material-0[elevation="1"] {
  box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14),
                    0 1px 5px 0 rgba(0, 0, 0, 0.12),
                    0 3px 1px -2px rgba(0, 0, 0, 0.2);
}

.paper-material-0[elevation="2"] {
  box-shadow: 0 4px 5px 0 rgba(0, 0, 0, 0.14),
                    0 1px 10px 0 rgba(0, 0, 0, 0.12),
                    0 2px 4px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="3"] {
  box-shadow: 0 6px 10px 0 rgba(0, 0, 0, 0.14),
                    0 1px 18px 0 rgba(0, 0, 0, 0.12),
                    0 3px 5px -1px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="4"] {
  box-shadow: 0 8px 10px 1px rgba(0, 0, 0, 0.14),
                    0 3px 14px 2px rgba(0, 0, 0, 0.12),
                    0 5px 5px -3px rgba(0, 0, 0, 0.4);
}

.paper-material-0[elevation="5"] {
  box-shadow: 0 16px 24px 2px rgba(0, 0, 0, 0.14),
                    0  6px 30px 5px rgba(0, 0, 0, 0.12),
                    0  8px 10px -5px rgba(0, 0, 0, 0.4);
}

.paper-material-0[animated] {
  transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
}

.paper-material-0 {
  ;
}</style><!-- Shady DOM styles for search-box --><style scope="search-box">.layout.horizontal.search-box,.layout.vertical.search-box {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-box {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-box {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-box {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-box {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-box {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-box,.layout.center-center.search-box {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-box,.layout.center-center.search-box {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-box {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-box {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-box {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.inputbox.search-box {
  border: 1px solid #ccc;
        padding: 0 12px;
        background: white;
}

.inputbox[focused].search-box {
  border: 1px solid #4285f4 !important;
}

.inputbox.search-box:hover {
  border: 1px solid #999;
}

#searchInput.search-box {
  font-family: inherit;
        font-size: 16px;
        padding: 8px 0;
        outline: none;
        border-right: none;
        width: 100%;
        margin-right: 0;
        border: 0;
}

#searchButton.search-box {
  cursor: pointer;
        background-color: #4285f4;
        border: none;
        color: #fff;
        vertical-align: top;
        width: 70px;
        height: 37px;
        outline: none;
}

.suggest-bg.search-box {
  display: inline-block;
        min-width: 0;
        white-space: nowrap;
}

#suggestMenu.search-box {
  position: absolute;
        margin-top: 38px;
        width: 100%;
        background: white;
        z-index: 1;
}

#suggestMenu.search-box .row.search-box {
  font-size: 13px;
        line-height: 28px;
        white-space: nowrap;
        overflow: hidden;
        text-overflow: ellipsis;
        padding: 4px 2px;
        cursor: pointer;
}

.row[selected].search-box {
  background: rgba(0, 0, 0, 0.05);
}

.suggest-icon.search-box {
  height: 20px;
        width: 20px;
        padding: 0 12px 0 6px;
        transition: transform .15s linear;
        transform: scale(1);
}

.suggest-icon[hide].search-box {
  transform: scale(0);
}

#corpora.search-box {
  padding: 6px 0;
        user-select: none;
}

#corpora.search-box iron-icon.search-box {
  height: 20px;
        width: 20px;
        color: #ccc;
        cursor: pointer;
}

#corpora.search-box iron-icon[active].search-box {
  color: #4285f4 !important;
}

#corpora.search-box iron-icon.search-box:hover {
  color: #999;
}</style><!-- Shady DOM styles for iron-media-query --><!-- Shady DOM styles for paper-header-panel --><!-- Shady DOM styles for iron-a11y-announcer --><style scope="iron-a11y-announcer">iron-a11y-announcer {
  display: inline-block;
        position: fixed;
        clip: rect(0px,0px,0px,0px);
}</style><!-- Shady DOM styles for iron-autogrow-textarea --><!-- Shady DOM styles for iron-input --><!-- Shady DOM styles for paper-input-char-counter --><!-- Shady DOM styles for paper-input-container --><!-- Shady DOM styles for paper-input-error --><!-- Shady DOM styles for paper-input --><!-- Shady DOM styles for paper-textarea --><!-- Shady DOM styles for paper-toast --><style scope="paper-toast-0">.paper-toast-0 {
  display: block;
        position: fixed;
        background-color: #323232;
        color: #f1f1f1;
        min-height: 48px;
        min-width: 288px;
        padding: 16px 24px;
        box-sizing: border-box;
        box-shadow: 0 2px 5px 0 rgba(0, 0, 0, 0.26);
        border-radius: 2px;
        margin: 12px;
        font-size: 14px;
        cursor: default;
        -webkit-transition: -webkit-transform 0.3s, opacity 0.3s;
        transition: transform 0.3s, opacity 0.3s;
        opacity: 0;
        -webkit-transform: translateY(100px);
        transform: translateY(100px);font-family: 'Roboto', 'Noto', sans-serif;
        -webkit-font-smoothing: antialiased;
}

.paper-toast-0.capsule {
  border-radius: 24px;
}

.paper-toast-0.fit-bottom {
  width: 100%;
        min-width: 0;
        border-radius: 0;
        margin: 0;
}

.paper-toast-0.paper-toast-open {
  opacity: 1;
        -webkit-transform: translateY(0px);
        transform: translateY(0px);
}</style><!-- Shady DOM styles for paper-toolbar --><!-- Shady DOM styles for search-footer --><style scope="search-footer">#footer.search-footer {
  font-size: 13px;
        margin-top: 10px;
        background: #fafafa;
        padding: 20px 10px;
        align-items: center;
        border-top: 1px solid #ebebeb;
}

#footer.search-footer .links.search-footer > *.search-footer {
  display: inline-block;
        margin: 0 12px;
}

.layout.horizontal.search-footer,.layout.vertical.search-footer {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-footer {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-footer {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-footer {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-footer {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-footer {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-footer {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-footer {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-footer {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-footer {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-footer,.layout.center-center.search-footer {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-footer {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-footer {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-footer {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-footer,.layout.center-center.search-footer {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-footer {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-footer {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-footer {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-footer {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-footer {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-footer {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-footer {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-footer {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-footer {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-footer {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-footer {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-footer {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-footer {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-header --><style scope="search-header">search-header {
  display: block;
}

.lockup-logo.search-header,.lockup-text.search-header {
  display: inline-block;
}

.lockup-logo.search-header {
  width: 74px;
        height: 24px;
        background-image: url('https://www.gstatic.com/images/branding/googlelogo/1x/googlelogo_color_74x24dp.png');
        background-size: 74px 24px;
}

.lockup-text.search-header {
  font-family: "Product Sans", Arial, Helvetica, sans-serif;

        
        font-size: 22.1px;

        
        text-rendering: optimizeLegibility;

        
        position: relative;
        top: -6px;
        left: -5px;

        
        -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
}

.lockup-brand.search-header {
  opacity: 0.54;
}

@media (-webkit-min-device-pixel-ratio: 1.5), (min-resolution: 144dpi) {
.lockup-logo.search-header {
  background-image: url('https://www.gstatic.com/images/branding/googlelogo/2x/googlelogo_color_74x24dp.png');
}

.lockup-text.search-header {
  font-size: 21.3px;
          left: -7px;
}

}

header.search-header {
  background-color: #fafafa;
        border-bottom: 1px solid #ebebeb;
        color: #333;
        height: 60px;
        width: 100%;
        z-index: 1;
        display: block;
}

[latestStyle].search-header header.search-header {
  background-color: transparent;
}

.headerpad.search-header {
  margin-left: 16px;
}

[wide].search-header .headerpad.search-header {
  margin-left: 32px;
}

.leftheader.search-header {
  width: 322px;
}

header.search-header h1.search-header {
  display: none;
}

header.search-header h1.search-header state-modifier.search-header {
  color: #777;
        text-decoration: none;
        display: inline-block;
}

[wide].search-header header.search-header h1.search-header {
  box-sizing: border-box;
        margin: 0;
        padding: 20px 0 10px;
        font-size: 20px;
        font-weight: 400;
        white-space: nowrap;
        display: block;
}

search-box.search-header {
  height: 37px;
        padding: 0 16px;
        width: 900px;
        align-self: center;
}

.layout.horizontal.search-header,.layout.vertical.search-header {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-header {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-header {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-header {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-header {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-header {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-header {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-header {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-header {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-header {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-header,.layout.center-center.search-header {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-header {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-header {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-header {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-header,.layout.center-center.search-header {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-header {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-header {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-header {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-header {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-header {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-header {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-header {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-header {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-header {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-header {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-header {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-header {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-header {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}</style><!-- Shady DOM styles for search-ui --><style scope="search-ui-0">.search-ui-0 paper-button.search-ui {
  display: inline-block;
        text-align: center;
        font-family: inherit;
}

.search-ui-0 .layout.horizontal.search-ui,.search-ui-0 .layout.vertical.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.search-ui-0 .layout.inline.search-ui {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.search-ui-0 .layout.horizontal.search-ui {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.search-ui-0 .layout.vertical.search-ui {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.search-ui-0 .layout.wrap.search-ui {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.search-ui-0 .layout.no-wrap.search-ui {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .flex.search-ui {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.search-ui-0 .flex-auto.search-ui {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.search-ui-0 .flex-none.search-ui {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.search-ui-0 .layout.start.search-ui {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.search-ui-0 .layout.center.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.search-ui-0 .layout.end.search-ui {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.search-ui-0 .layout.baseline.search-ui {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.search-ui-0 .layout.start-justified.search-ui {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.search-ui-0 .layout.center-justified.search-ui,.search-ui-0 .layout.center-center.search-ui {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.search-ui-0 .layout.end-justified.search-ui {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.search-ui-0 .layout.around-justified.search-ui {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.search-ui-0 .layout.justified.search-ui {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.search-ui-0 .self-start.search-ui {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.search-ui-0 .self-center.search-ui {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.search-ui-0 .self-end.search-ui {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.search-ui-0 .self-stretch.search-ui {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.search-ui-0 .self-baseline.search-ui {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.search-ui-0 .layout.start-aligned.search-ui {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.search-ui-0 .layout.end-aligned.search-ui {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.search-ui-0 .layout.center-aligned.search-ui {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.search-ui-0 .layout.between-aligned.search-ui {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.search-ui-0 .layout.around-aligned.search-ui {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.search-ui-0 {
  display: block;
        min-width: 350px;
        height: 100%;
}

.search-ui-0 #content.search-ui {
  height: 100%;
}

.search-ui-0 #leftBarOverflow.search-ui {
  padding-right: 16px;
}

.search-ui-0 [wide].search-ui #leftBarOverflow.search-ui {
  overflow: auto;
}

.search-ui-0 #leftBar.search-ui {
  box-sizing: border-box;
        color: #666;
        font-size: 13px;
        padding: 16px 0 16px 16px;
        border-bottom: 1px solid #e5e5e5;
}

.search-ui-0 [wide].search-ui #leftBar.search-ui {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;

        -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
        position: relative;
        width: 350px;
        margin-bottom: 0;
        padding-bottom: 0;
        border-bottom: none;
}

@media print {
.search-ui-0 #leftBar.search-ui {
  display: none !important;
}

}

.search-ui-0 #leftBar.search-ui h3.search-ui {
  text-transform: uppercase;
        font-size: 13px;
        font-weight: normal;
        margin-top: 6px;
        margin-bottom: 6px;
        cursor: default;
        display: inline-block;
        color: #a3a3a3;
}

.search-ui-0 #closeButton.search-ui {
  position: absolute;
        right: 0;
}

.search-ui-0 #searchTermsHeader.search-ui {
  position: relative;
}

.search-ui-0 #searchTermsQ.search-ui iron-icon.search-ui {
  height: 16px;
        padding: 0 2px 2px 2px;
        color: #a3a3a3;
}

.search-ui-0 #searchTermsHeader.search-ui:hover iron-icon.search-ui {
  color: #4285f4;
}

.search-ui-0 #closeLeftBar.search-ui {
  height: 16px;
        width: 16px;
        padding: 0 0 8px 0;
        cursor: pointer;
}

.search-ui-0 #compactQuery.search-ui iron-icon.search-ui {
  height: 20px;
}

.search-ui-0 #backToResultsButton.search-ui {
  color: #fff;
        background: #4285f4;
        margin-top: 20px;
        text-align: center;
}

.search-ui-0 #main.search-ui {
  display: block;
        min-height: calc(100vh - 127px);
}

@media print {
.search-ui-0 [wide].search-ui main.search-ui {
  margin-left: 0;
}

}</style><!-- Shady DOM styles for import-list --><!-- Shady DOM styles for iron-request --><!-- Shady DOM styles for iron-ajax --><!-- Shady DOM styles for paper-dialog --><!-- Shady DOM styles for coverage-stats --><!-- Shady DOM styles for iron-image --><!-- Shady DOM styles for iron-selector --><!-- Shady DOM styles for paper-card --><!-- Shady DOM styles for paper-checkbox --><!-- Shady DOM styles for landing-page --><!-- Shady DOM styles for remote-fetch --><!-- Shady DOM styles for paper-spinner --><style scope="paper-spinner-0">.paper-spinner-0 {
  display: inline-block;
        position: relative;
        width: 28px;
        height: 28px;
}

.paper-spinner-0 #spinnerContainer.paper-spinner {
  width: 100%;
        height: 100%;

        
        direction: ltr;
}

.paper-spinner-0 #spinnerContainer.active.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite;
        animation: container-rotate-paper-spinner-0 1568ms linear infinite;
}

@-webkit-keyframes container-rotate-paper-spinner-0 {
to {
  -webkit-transform: rotate(360deg)
}

}

@keyframes container-rotate-paper-spinner-0 {
to {
  transform: rotate(360deg)
}

}

.paper-spinner-0 .spinner-layer.paper-spinner {
  position: absolute;
        width: 100%;
        height: 100%;
        opacity: 0;
        white-space: nowrap;
        color: #4285f4;
}

.paper-spinner-0 .layer-1.paper-spinner {
  color: #4285f4;
}

.paper-spinner-0 .layer-2.paper-spinner {
  color: #db4437;
}

.paper-spinner-0 .layer-3.paper-spinner {
  color: #f4b400;
}

.paper-spinner-0 .layer-4.paper-spinner {
  color: #0f9d58;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0;
        -webkit-animation-duration: 5332ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-name: fill-unfill-rotate-paper-spinner-0;
        animation-duration: 5332ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
        opacity: 1;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-1.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-1-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-2.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-2-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-3.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-3-fade-in-out-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .spinner-layer.layer-4.paper-spinner {
  -webkit-animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
        animation-name: fill-unfill-rotate-paper-spinner-0, layer-4-fade-in-out-paper-spinner-0;
}

@-webkit-keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  -webkit-transform: rotate(135deg)
}

25% {
  -webkit-transform: rotate(270deg)
}

37.5% {
  -webkit-transform: rotate(405deg)
}

50% {
  -webkit-transform: rotate(540deg)
}

62.5% {
  -webkit-transform: rotate(675deg)
}

75% {
  -webkit-transform: rotate(810deg)
}

87.5% {
  -webkit-transform: rotate(945deg)
}

to {
  -webkit-transform: rotate(1080deg)
}

}

@keyframes fill-unfill-rotate-paper-spinner-0 {
12.5% {
  transform: rotate(135deg)
}

25% {
  transform: rotate(270deg)
}

37.5% {
  transform: rotate(405deg)
}

50% {
  transform: rotate(540deg)
}

62.5% {
  transform: rotate(675deg)
}

75% {
  transform: rotate(810deg)
}

87.5% {
  transform: rotate(945deg)
}

to {
  transform: rotate(1080deg)
}

}

@-webkit-keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@keyframes layer-1-fade-in-out-paper-spinner-0 {
0% {
  opacity: 1
}

25% {
  opacity: 1
}

26% {
  opacity: 0
}

89% {
  opacity: 0
}

90% {
  opacity: 1
}

to {
  opacity: 1
}

}

@-webkit-keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-2-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

15% {
  opacity: 0
}

25% {
  opacity: 1
}

50% {
  opacity: 1
}

51% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@keyframes layer-3-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

40% {
  opacity: 0
}

50% {
  opacity: 1
}

75% {
  opacity: 1
}

76% {
  opacity: 0
}

to {
  opacity: 0
}

}

@-webkit-keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes layer-4-fade-in-out-paper-spinner-0 {
0% {
  opacity: 0
}

65% {
  opacity: 0
}

75% {
  opacity: 1
}

90% {
  opacity: 1
}

to {
  opacity: 0
}

}

.paper-spinner-0 .circle-clipper.paper-spinner {
  display: inline-block;
        position: relative;
        width: 50%;
        height: 100%;
        overflow: hidden;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after {
  left: 45%;
        width: 10%;
        border-top-style: solid;
}

.paper-spinner-0 .spinner-layer.paper-spinner::after,.paper-spinner-0 .circle-clipper.paper-spinner::after {
  content: '';
        box-sizing: border-box;
        position: absolute;
        top: 0;
        border-width: 3px;
        border-radius: 50%;
}

.paper-spinner-0 .circle-clipper.paper-spinner::after {
  bottom: 0;
        width: 200%;
        border-style: solid;
        border-bottom-color: transparent !important;
}

.paper-spinner-0 .circle-clipper.left.paper-spinner::after {
  left: 0;
        border-right-color: transparent !important;
        -webkit-transform: rotate(129deg);
        transform: rotate(129deg);
}

.paper-spinner-0 .circle-clipper.right.paper-spinner::after {
  left: -100%;
        border-left-color: transparent !important;
        -webkit-transform: rotate(-129deg);
        transform: rotate(-129deg);
}

.paper-spinner-0 .active.paper-spinner .gap-patch.paper-spinner::after,.paper-spinner-0 .active.paper-spinner .circle-clipper.paper-spinner::after {
  -webkit-animation-duration: 1333ms;
        -webkit-animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        -webkit-animation-iteration-count: infinite;
        animation-duration: 1333ms;
        animation-timing-function: cubic-bezier(0.4, 0.0, 0.2, 1);
        animation-iteration-count: infinite;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.left.paper-spinner::after {
  -webkit-animation-name: left-spin-paper-spinner-0;
        animation-name: left-spin-paper-spinner-0;
}

.paper-spinner-0 .active.paper-spinner .circle-clipper.right.paper-spinner::after {
  -webkit-animation-name: right-spin-paper-spinner-0;
        animation-name: right-spin-paper-spinner-0;
}

@-webkit-keyframes left-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(130deg)
}

50% {
  -webkit-transform: rotate(-5deg)
}

to {
  -webkit-transform: rotate(130deg)
}

}

@keyframes left-spin-paper-spinner-0 {
0% {
  transform: rotate(130deg)
}

50% {
  transform: rotate(-5deg)
}

to {
  transform: rotate(130deg)
}

}

@-webkit-keyframes right-spin-paper-spinner-0 {
0% {
  -webkit-transform: rotate(-130deg)
}

50% {
  -webkit-transform: rotate(5deg)
}

to {
  -webkit-transform: rotate(-130deg)
}

}

@keyframes right-spin-paper-spinner-0 {
0% {
  transform: rotate(-130deg)
}

50% {
  transform: rotate(5deg)
}

to {
  transform: rotate(-130deg)
}

}

.paper-spinner-0 #spinnerContainer.cooldown.paper-spinner {
  -webkit-animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
        animation: container-rotate-paper-spinner-0 1568ms linear infinite, fade-out-paper-spinner-0 400ms cubic-bezier(0.4, 0.0, 0.2, 1);
}

@-webkit-keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}

@keyframes fade-out-paper-spinner-0 {
0% {
  opacity: 1
}

to {
  opacity: 0
}

}</style><!-- Shady DOM styles for paper-spinner-lite --><!-- Shady DOM styles for concept-card --><!-- Shady DOM styles for concept-mention --><style scope="concept-mention">.block.concept-mention {
  display: block;
}

[hidden].concept-mention {
  display: none !important;
}

.invisible.concept-mention {
  visibility: hidden !important;
}

.relative.concept-mention {
  position: relative;
}

.fit.concept-mention {
  position: absolute;
        top: 0;
        right: 0;
        bottom: 0;
        left: 0;
}

body.fullbleed.concept-mention {
  margin: 0;
        height: 100vh;
}

.scroll.concept-mention {
  -webkit-overflow-scrolling: touch;
        overflow: auto;
}

.fixed-bottom.concept-mention,.fixed-left.concept-mention,.fixed-right.concept-mention,.fixed-top.concept-mention {
  position: fixed;
}

.fixed-top.concept-mention {
  top: 0;
        left: 0;
        right: 0;
}

.fixed-right.concept-mention {
  top: 0;
        right: 0;
        bottom: 0;
}

.fixed-bottom.concept-mention {
  right: 0;
        bottom: 0;
        left: 0;
}

.fixed-left.concept-mention {
  top: 0;
        bottom: 0;
        left: 0;
}

#target.concept-mention:hover {
  background-color: #e8f0fe;
}

#target[noicon].concept-mention {
  padding: 1px;
}

#target.concept-mention:hover[noicon] {
  border: 1px solid #e8f0fe;
        padding: 0;
}

#target.concept-mention {
  display: inline-block;
}

.inline-icon.concept-mention {
  cursor: pointer;
        height: 12px;
        width: 12px;
        padding-left: 4px;
        color: #5e6368;
}

concept-card.concept-mention {
  z-index: 1;
        position: absolute;
}</style><!-- Shady DOM styles for fterm-concept-card --><!-- Shady DOM styles for fterm-concept-mention --><!-- Shady DOM styles for paper-fab --><!-- Shady DOM styles for paper-icon-button --><!-- Shady DOM styles for paper-icon-button-light --><!-- Shady DOM styles for classification-tree --><style scope="classification-tree">.layout.horizontal.classification-tree,.layout.vertical.classification-tree {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.classification-tree {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.classification-tree {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.classification-tree {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.classification-tree {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.classification-tree {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.classification-tree,.layout.center-center.classification-tree {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.classification-tree {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.classification-tree {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.classification-tree {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

classification-tree {
  display: block;
        line-height: 20px;
}

.wrap.classification-tree {
  padding: 6px 12px;
}

.wrap.classification-tree:hover {
  background: #fafafa;
}

.description.classification-tree {
  padding-left: 4px;
}

iron-icon.classification-tree {
  color: #eaeaea;
}

.code[first].classification-tree {
  font-weight: 500;
}

.code[additional].classification-tree {
  font-style: italic;
}</style><!-- Shady DOM styles for classification-viewer --><style scope="classification-viewer">.table.classification-viewer {
  border: 1px solid #eaeaea;
        display: block;
}

.more.classification-viewer {
  padding: 6px 12px;
        cursor: pointer;
        font-style: italic;
        color: #aaa;
}

.more.classification-viewer:hover {
  background: #fafafa;
}

.chip.classification-viewer {
  display: inline-block;
        padding: 4px 6px;
        border-radius: 2px;
}

.chip[additional].classification-viewer {
  font-style: italic;
}</style><!-- Shady DOM styles for image-carousel --><!-- Shady DOM styles for image-viewer --><!-- Shady DOM styles for patent-result --><style scope="patent-result">#wrapper.patent-result {
  padding: 20px;
        max-width: 1050px;
        outline: 0;
}

.scroll-target.patent-result:before {
  display: block;
        content: '';
        visibility: hidden;
}

h1.patent-result {
  font-weight: 500;
        font-size: 20px;
        margin: 0 0 20px 0;
}

h3.patent-result {
  font-size: 15px;
        font-weight: 500;
        margin: 28px 0 18px 0;
}

dl.patent-result {
  line-height: 1.5;
        font-size: 0;
}

dt.patent-result,dd.patent-result {
  display: inline;
        font-size: 13px;
        margin: 0;
}

dt.patent-result {
  font-weight: 500;
        color: #000;
}

dt.patent-result::after {
  content: ': ';
}

dd.patent-result {
  color: #aaa;
}

dd.patent-result ~ dd.patent-result::before {
  content: ', ';
}

dt.patent-result + dd.patent-result::before {
  content: '';
}

dd.patent-result ~ dt.patent-result::before {
  display: block;
        content: '';
        margin-top: 8px;
}

dd.patent-result core-icon.patent-result {
  width: 14px;
        height: 14px;
        vertical-align: top;
        color: inherit;
}

.table.patent-result {
  display: table;
        border-collapse: collapse;
        border-spacing: 0;
        border: 1px solid #eaeaea;
        width: 100%;
        box-sizing: border-box;
}

.tr.patent-result {
  display: table-row;
        border-bottom: 1px solid #eaeaea;
}

.th.patent-result,.td.patent-result {
  display: table-cell;
        padding: 10px 12px;
}

.thead.patent-result {
  display: table-header-group;
}

.tbody.patent-result {
  display: table-row-group;
}

.th.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.td.patent-result {
  vertical-align: top;
}

.td.patent-result > p.patent-result {
  margin-top: 0;
}

.nowrap.patent-result {
  white-space: nowrap;
}

.knowledge-card.patent-result {
  border: 1px solid #e5e5e5;
        border-radius: 2px;
}

.knowledge-card.patent-result > header.patent-result {
  -webkit-font-smoothing: antialiased;
        -moz-osx-font-smoothing: grayscale;
        background: #4285f4;
        color: #fff;
        padding: 20px 12px;
}

.knowledge-card.patent-result > header.patent-result state-modifier.patent-result,.knowledge-card.patent-result > header.patent-result a.patent-result {
  color: inherit;
        margin: 0 12px 0 0;
        display: inline-block;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result,.knowledge-card.patent-result > header.patent-result .tagline.patent-result {
  margin: 0;
        font-weight: normal;
        padding-top: 4px;
}

.knowledge-card.patent-result > header.patent-result h2.patent-result {
  font-size: 20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result {
  background: #3367d6;
        padding: 10px 12px;
        margin: 20px -12px -20px;
}

.knowledge-card.patent-result .knowledge-card-action-bar.patent-result core-icon.patent-result {
  margin-right: 12px;
        width: 24px;
        height: 24px;
}

.knowledge-card.patent-result dl.patent-result {
  padding: 16px 12px;
}

.knowledge-card.patent-result hr.patent-result {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 0;
}

.main-link.patent-result {
  margin: 14px;
        font-weight: 500;
}

.footer.patent-result h3.patent-result state-modifier.patent-result,.footer.patent-result h3.patent-result a.patent-result {
  float: right;
        font-weight: 400;
        font-size: 13px;
        line-height: 24px;
}

.footer.patent-result dl.patent-result {
  margin-left: 30px;
}

.footer.patent-result > ul.patent-result > li.patent-result {
  margin-bottom: 8px;
}

h3.patent-result .righthead.patent-result {
  color: #aaa;
        font-weight: 400;
        font-size: 13px;
        cursor: help;
}

.tooltip-hint.patent-result {
  border-bottom: 1px dotted #ccc;
}

[marginRight].patent-result {
  margin-right: 60px;
}

.flex-width.patent-result {
  min-width: 0;
        word-break: break-word;
}

.responsive-table.patent-result {
  width: 100%;
        overflow-x: auto;
        overflow-y: hidden;
}

.layout.horizontal.patent-result,.layout.vertical.patent-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-result,.layout.center-center.patent-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-result,.layout.center-center.patent-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

.flex.patent-result,.flex-1.patent-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-2.patent-result {
  -ms-flex: 2;
        -webkit-flex: 2;
        flex: 2;
}

.flex-3.patent-result {
  -ms-flex: 3;
        -webkit-flex: 3;
        flex: 3;
}

.flex-4.patent-result {
  -ms-flex: 4;
        -webkit-flex: 4;
        flex: 4;
}

.flex-5.patent-result {
  -ms-flex: 5;
        -webkit-flex: 5;
        flex: 5;
}

.flex-6.patent-result {
  -ms-flex: 6;
        -webkit-flex: 6;
        flex: 6;
}

.flex-7.patent-result {
  -ms-flex: 7;
        -webkit-flex: 7;
        flex: 7;
}

.flex-8.patent-result {
  -ms-flex: 8;
        -webkit-flex: 8;
        flex: 8;
}

.flex-9.patent-result {
  -ms-flex: 9;
        -webkit-flex: 9;
        flex: 9;
}

.flex-10.patent-result {
  -ms-flex: 10;
        -webkit-flex: 10;
        flex: 10;
}

.flex-11.patent-result {
  -ms-flex: 11;
        -webkit-flex: 11;
        flex: 11;
}

.flex-12.patent-result {
  -ms-flex: 12;
        -webkit-flex: 12;
        flex: 12;
}

@media print {
#text.patent-result {
  flex-direction: column-reverse !important;
}

}

patent-result-ref-list.patent-result {
  width: 100%;
}

patent-result-ref-list.patent-result + patent-result-ref-list.patent-result {
  margin-left: 10px;
}

[narrow].patent-result {
  flex-direction: column-reverse !important;
}

.famheader.patent-result {
  text-align: left;
        white-space: nowrap;
        background-color: #fafafa;
        color: #757575;
}

.collapse.patent-result {
  color: #616161;
        font-size: 13px;
        cursor: pointer;
}

#imageDrag.patent-result {
  position: fixed;
        cursor: col-resize;
}

#imageDrag.patent-result div.patent-result {
  width: 4px;
        height: 100%;
        margin: 0 4px;
        background: #eee;
}

#imageDrag.patent-result:hover {
  background: #eee;
}

#imageDrag.patent-result:hover div.patent-result {
  background: #ccc;
}

.imageWrapper.patent-result {
  position: fixed;
        top: 60px;
        background: white;
        margin-left: 12px;
}

#notices.patent-result {
  padding: 20px;
}

#figures.patent-result {
  background: #efefef;
}

.headerButton.patent-result {
  color: #3c80f6;
        cursor: pointer;
        display: inline-block;
        padding: 0 14px;
        line-height: 27px;
}

.headerButton.patent-result iron-icon.patent-result {
  width: 16px;
        height: 16px;
}

.tr.conceptDomain.patent-result {
  display: table-row;
}

.responsive-grid.patent-result {
  display: grid;
        gap: 8px;
        grid-template-columns: none;
}</style><!-- Shady DOM styles for family-viewer --><!-- Shady DOM styles for app-row --><!-- Shady DOM styles for application-timeline --><style scope="application-timeline">.layout.horizontal.application-timeline,.layout.vertical.application-timeline {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.application-timeline {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.application-timeline {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.application-timeline {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.application-timeline {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.application-timeline {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.application-timeline,.layout.center-center.application-timeline {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.application-timeline {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.application-timeline {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.application-timeline {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.wrap.application-timeline {
  padding: 16px 12px;
}

.event.application-timeline {
  padding: 3px 0;
}

[date].application-timeline {
  color: #5f6368;
        font-size: 13px;
        padding: 3px 0;
        width: 70px;
        line-height: 16px;
}

[critical].application-timeline [date].application-timeline {
  color: #202124;
        font-weight: 500;
        line-height: 18px;
}

.line.application-timeline {
  margin: 9px 6px;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
}

.dot.application-timeline {
  margin: 3px 0;
        border-radius: 4px;
        background: #dadce0;
        width: 4px;
        height: 4px;
        display: inline-block;
}

[critical].application-timeline .line.application-timeline {
  background: #4285f4;
}

[current].application-timeline .line.application-timeline {
  background: #81c995;
}

[current][critical].application-timeline .line.application-timeline {
  background: #81c995;
}

.title.application-timeline {
  font-size: 13px;
        padding: 3px 0;
        line-height: 16px;
}

.title-text.application-timeline {
  color: #5f6368;
}

.description-item.application-timeline {
  font-size: 12px;
        padding: 6px 0;
        max-width: 300px;
}

#legal.application-timeline {
  height: 14px;
        width: 14px;
        padding: 0 3px 1px 3px;
        vertical-align: text-bottom;
}

#icon.application-timeline {
  height: 12px;
        width: 12px;
        padding: 0 3px 3px 3px;
        vertical-align: text-bottom;
}

.unknown.application-timeline {
  font-style: italic;
}

.not_active.application-timeline {
  text-decoration: line-through;
}

.active.application-timeline {
  font-weight: 500;
}

#cc[this].application-timeline {
  color: #202124 !important;
        text-decoration: underline;
}

#cc[this].not_active.application-timeline {
  text-decoration: line-through underline;
}

hr.application-timeline {
  border: none;
        height: 1px;
        background: #e5e5e5;
        margin: 10px 0 16px 0;
}

.header.application-timeline {
  font-size: 13px;
        line-height: 20px;
        font-weight: 500;
        color: #202124;
        padding-bottom: 8px;
}

.block.application-timeline {
  padding: 0 6px 0 0;
}

.year.application-timeline {
  color: #5f6368;
        font-size: 13px;
        font-weight: 500;
        padding: 3px 1px;
        width: 70px;
}

.expand.application-timeline {
  cursor: pointer;
        padding: 6px 0 3px 0;
}</style><!-- Shady DOM styles for patent-text --><style scope="patent-text">.layout.horizontal.patent-text,.layout.vertical.patent-text {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.patent-text {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.patent-text {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.patent-text {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.patent-text {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.patent-text {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.patent-text {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.patent-text {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.patent-text {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.patent-text {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.patent-text,.layout.center-center.patent-text {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.patent-text {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.patent-text {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.patent-text {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.patent-text,.layout.center-center.patent-text {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.patent-text {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.patent-text {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.patent-text {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.patent-text {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.patent-text {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.patent-text {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.patent-text {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.patent-text {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.patent-text {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.patent-text {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.patent-text {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.patent-text {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.patent-text {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

patent-text {
  display: block;
}

#text.patent-text {
  line-height: 20px;
        min-width: 0;
}

#margin.patent-text {
  width: 16px;
}

#createHighlight.patent-text {
  position: relative;
        width: 16px;
        height: 16px;
        cursor: pointer;
}

.notranslate.patent-text > .google-src-text.patent-text {
  display: none;
}

.notranslate.patent-text:hover,mark.patent-text {
  background-color: #fbfcae;
}

.description-paragraph.patent-text {
  margin-block-start: 1em;
        margin-block-end: 1em;
}

.claim-text.patent-text {
  margin: 14px 0 0 20px;
}

.claim-dependent.patent-text {
  margin-left: 40px;
        color: #888;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim-text.patent-text {
  height: 0;
        width: 0;
        visibility: hidden;
}

[hide-claims].patent-text .claim-dependent.patent-text .claim.patent-text:after {
  content: "…"
}

.patent-full-image.patent-text {
  max-width: 100%;
        height: auto;
}

.small-patent-image.patent-text {
  display: inline;
}

ul.patent-text {
  padding: 0 0 0 50px;
}

li.patent-text {
  list-style-type: none;
        position: relative;
}

ol.claims.patent-text li.patent-text {
  list-style-type: decimal;
        font-weight: bold;
}

ol.claims.patent-text li.patent-text > *.patent-text {
  font-weight: normal;
}

li.patent-text > para-num.patent-text {
  position: absolute;
        left: -45px;
        color: #888;
}

mark.patent-text {
  background: #fff59d;
}

mark.searchText.patent-text {
  background: #80deea;
}

.searchTextHeader.patent-text {
  font-weight: 500;
}

pre.patent-text {
  white-space: pre-wrap;
}

heading.patent-text {
  display: block;
        font-weight: 500;
        font-size: 13px;
}

#comment.patent-text {
  width: 16px;
        height: 16px;
}

[has-search][no-results].patent-text {
  display: none;
}

.highlight.patent-text {
  background-color: #fef7e0;
}</style><!-- Shady DOM styles for para-num --><!-- Shady DOM styles for result-container --><style scope="result-container">paper-spinner.result-container {
  position: absolute;
        
        top: calc(50%  + 56px - 16px);
        left: calc(50% + 175px - 16px);
}</style><!-- Shady DOM styles for scholar-result --><!-- Shady DOM styles for search-result --><style scope="search-result">.layout.horizontal.search-result,.layout.vertical.search-result {
  display: -ms-flexbox;
        display: -webkit-flex;
        display: flex;
}

.layout.inline.search-result {
  display: -ms-inline-flexbox;
        display: -webkit-inline-flex;
        display: inline-flex;
}

.layout.horizontal.search-result {
  -ms-flex-direction: row;
        -webkit-flex-direction: row;
        flex-direction: row;
}

.layout.vertical.search-result {
  -ms-flex-direction: column;
        -webkit-flex-direction: column;
        flex-direction: column;
}

.layout.wrap.search-result {
  -ms-flex-wrap: wrap;
        -webkit-flex-wrap: wrap;
        flex-wrap: wrap;
}

.layout.no-wrap.search-result {
  -ms-flex-wrap: nowrap;
        -webkit-flex-wrap: nowrap;
        flex-wrap: nowrap;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.flex.search-result {
  -ms-flex: 1 1 0.000000001px;
        -webkit-flex: 1;
        flex: 1;
        -webkit-flex-basis: 0.000000001px;
        flex-basis: 0.000000001px;
}

.flex-auto.search-result {
  -ms-flex: 1 1 auto;
        -webkit-flex: 1 1 auto;
        flex: 1 1 auto;
}

.flex-none.search-result {
  -ms-flex: none;
        -webkit-flex: none;
        flex: none;
}

.layout.start.search-result {
  -ms-flex-align: start;
        -webkit-align-items: flex-start;
        align-items: flex-start;
}

.layout.center.search-result,.layout.center-center.search-result {
  -ms-flex-align: center;
        -webkit-align-items: center;
        align-items: center;
}

.layout.end.search-result {
  -ms-flex-align: end;
        -webkit-align-items: flex-end;
        align-items: flex-end;
}

.layout.baseline.search-result {
  -ms-flex-align: baseline;
        -webkit-align-items: baseline;
        align-items: baseline;
}

.layout.start-justified.search-result {
  -ms-flex-pack: start;
        -webkit-justify-content: flex-start;
        justify-content: flex-start;
}

.layout.center-justified.search-result,.layout.center-center.search-result {
  -ms-flex-pack: center;
        -webkit-justify-content: center;
        justify-content: center;
}

.layout.end-justified.search-result {
  -ms-flex-pack: end;
        -webkit-justify-content: flex-end;
        justify-content: flex-end;
}

.layout.around-justified.search-result {
  -ms-flex-pack: distribute;
        -webkit-justify-content: space-around;
        justify-content: space-around;
}

.layout.justified.search-result {
  -ms-flex-pack: justify;
        -webkit-justify-content: space-between;
        justify-content: space-between;
}

.self-start.search-result {
  -ms-align-self: flex-start;
        -webkit-align-self: flex-start;
        align-self: flex-start;
}

.self-center.search-result {
  -ms-align-self: center;
        -webkit-align-self: center;
        align-self: center;
}

.self-end.search-result {
  -ms-align-self: flex-end;
        -webkit-align-self: flex-end;
        align-self: flex-end;
}

.self-stretch.search-result {
  -ms-align-self: stretch;
        -webkit-align-self: stretch;
        align-self: stretch;
}

.self-baseline.search-result {
  -ms-align-self: baseline;
        -webkit-align-self: baseline;
        align-self: baseline;
}

.layout.start-aligned.search-result {
  -ms-flex-line-pack: start;  
        -ms-align-content: flex-start;
        -webkit-align-content: flex-start;
        align-content: flex-start;
}

.layout.end-aligned.search-result {
  -ms-flex-line-pack: end;  
        -ms-align-content: flex-end;
        -webkit-align-content: flex-end;
        align-content: flex-end;
}

.layout.center-aligned.search-result {
  -ms-flex-line-pack: center;  
        -ms-align-content: center;
        -webkit-align-content: center;
        align-content: center;
}

.layout.between-aligned.search-result {
  -ms-flex-line-pack: justify;  
        -ms-align-content: space-between;
        -webkit-align-content: space-between;
        align-content: space-between;
}

.layout.around-aligned.search-result {
  -ms-flex-line-pack: distribute;  
        -ms-align-content: space-around;
        -webkit-align-content: space-around;
        align-content: space-around;
}

search-result {
  display: block;
        font-size: 13px;
}

#mainContainer.search-result {
  min-height: calc(100vh - 127px);
        color: #333;
}

#compactQuery.search-result {
  padding: 18px 20px 10px 20px;
        cursor: pointer;
}

#compactQuery.search-result > span.search-result {
  padding: 0 14px 0 0;
}

#compactQuery.search-result iron-icon.search-result {
  padding-right: 6px;
        height: 16px;
        width: 16px;
}</style><!-- Shady DOM styles for webdoc-result --><!-- Shady DOM styles for iron-pages --><!-- Shady DOM styles for paper-tab --><!-- Shady DOM styles for paper-tabs --><!-- Shady DOM styles for debug-info --><!-- Shady DOM styles for search-paging --><!-- Shady DOM styles for search-result-item --><!-- Shady DOM styles for search-result-image --><!-- Shady DOM styles for search-result-entities --><!-- Shady DOM styles for search-result-measures --><!-- Shady DOM styles for search-results --><!-- Shady DOM styles for summary-box --><!-- Shady DOM styles for timeline-page --><!-- Shady DOM styles for iron-localstorage --><!-- Shady DOM styles for search-app --><style scope="search-app">search-app {
  display: block;
        height: 100%;
}

#toast.search-app {
  min-height: 64px;
        min-width: 742px;
}</style><style>body {transition: opacity ease-in 0.2s; } 
body[unresolved] {opacity: 0; display: block; overflow: hidden; position: relative; } 
</style>
    <title>ES2916601T3 - 
  Compositions comprising bacterial strains
 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/ES2916601T3/en">
    <meta name="description" content="
   
    A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.
   
 
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="
  Compositions comprising bacterial strains
 
     ">
    <meta name="DC.date" content="2019-05-13" scheme="dateSubmitted">
    <meta name="DC.description" content="
   
    A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.
   
 
   ">
    <meta name="citation_patent_application_number" content="ES:19725068T">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/88/f4/67/3cf6561673245d/ES2916601T3.pdf">
    <meta name="citation_patent_number" content="ES:2916601:T3">
    <meta name="DC.date" content="2022-07-04" scheme="issue">
    <meta name="DC.contributor" content="Imke Elisabeth MULDER" scheme="inventor">
    <meta name="DC.contributor" content="Parthena Fotiadou" scheme="inventor">
    <meta name="DC.contributor" content="Amy Beth HOLT" scheme="inventor">
    <meta name="DC.contributor" content="Suaad Ahmed" scheme="inventor">
    <meta name="DC.contributor" content="Anna Ettorre" scheme="inventor">
    <meta name="DC.contributor" content="Samantha Yuille" scheme="inventor">
    <meta name="DC.contributor" content="Ted Dinan" scheme="inventor">
    <meta name="DC.contributor" content="John Cryan" scheme="inventor">
    <meta name="DC.contributor" content="4D Pharma Research Ltd" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      body { transition: none; }
    </style>

    <script src="https://apis.google.com/_/scs/abc-static/_/js/k=gapi.lb.en.IKZeRvoAYNY.O/m=client/rt=j/sv=1/d=1/ed=1/am=AAAQ/rs=AHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw/cb=gapi.loaded_0?le=scs" async=""></script><script>
      window.version = 'patent-search.search_20240531_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <style>[hidden]:not([style-scope]):not(.style-scope) {
  display: none !important;
}

</style><style></style><style></style><style></style><style></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,300,300italic,400italic,500,500italic,700,700italic"><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Mono:400,700"><style></style><style></style><style>
  html, body {
    min-width: 100%;
    width: 100%;
    min-height: 100%;
    height: 100%;
  }

  body {
    background-color: #fff;
    font-family: 'Roboto', sans-serif;
    color: #333;
    margin: 0;
    padding: 0;
    /*
     * Turn off https://github.com/WICG/ScrollAnchoring/blob/master/explainer.md
     * https://memegen.googleplex.com/5230756293246976
     */
    overflow-anchor: none;
  }

  body h1, body h2, body h3 {
    -webkit-font-smoothing: antialiased;
    -moz-osx-font-smoothing: grayscale;
  }

  body a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  body a:visited {
    color: #3c80f6;
  }

  body a[open-result]:visited {
    color: #7e57c2;
  }

  /* For Firefox */
  a:link {
    color: #3c80f6;
    text-decoration: none;
  }

  a:visited {
    color: #3c80f6;
  }

  a[open-result]:visited {
    color: #7e57c2;
  }

  ::selection , body ::selection {
    background-color: #c6dafc;
    color: #333;
  }
</style><link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.html">
  <style>[hidden] { display: none !important; }</style><script type="text/javascript" charset="UTF-8" src="https://apis.google.com/js/client.js" gapi_processed="true"></script></head>
  <body>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20240531_RC00/scs/compiled_dir/search-app-vulcanized.js"></script><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span><span style="font-size: 13px; white-space: pre-wrap; display: inline-block; position: absolute; left: -99999px; top: -99999px; max-width: 217px;"></span>
    <search-app>
    
    <remote-fetch class="style-scope search-app"></remote-fetch>
    <search-state class="style-scope search-app"></search-state>
    <browser-ui class="style-scope search-app"></browser-ui>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    
      <search-result id="result" class="style-scope search-app">
    
    
    <search-ui mode="result" class="style-scope search-result x-scope search-ui-0">
    
    
    
    <div id="content" class="style-scope search-ui" wide="">
      <search-header show-search="" class="style-scope search-ui">
    
    
    <div class="style-scope search-header" wide="">
      <header class="style-scope search-header">
        <div class="layout horizontal headerpad style-scope search-header">
          <div class="layout horizontal leftheader style-scope search-header">
            <h1 class="style-scope search-header">
              <state-modifier inherit="" act="{&quot;type&quot;: &quot;HOME&quot;}" class="style-scope search-header"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                <div class="lockup style-scope search-header">
                  <span class="lockup-logo style-scope search-header"></span>
                  <span class="lockup-text style-scope search-header">
                    <span class="lockup-brand style-scope search-header">&nbsp;Patents</span>
                  </span>
                </div>
              </a></state-modifier>
            </h1>
          </div>
          
            <search-box class="style-scope search-header">
    
    <div class="layout horizontal style-scope search-box" style="position: relative;">
      <div class="inputbox flex layout horizontal style-scope search-box">
        <div class="suggest-bg flex style-scope search-box">
          <input name="q" id="searchInput" data-proto="SEARCH_INPUT" autocomplete="off" class="style-scope search-box">
        </div>
        <div id="corpora" class="style-scope search-box">
          <iron-icon icon="icons:lightbulb-outline" id="patentIcon" class="style-scope search-box x-scope iron-icon-0" active=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M9 21c0 .55.45 1 1 1h4c.55 0 1-.45 1-1v-1H9v1zm3-19C8.14 2 5 5.14 5 9c0 2.38 1.19 4.47 3 5.74V17c0 .55.45 1 1 1h6c.55 0 1-.45 1-1v-2.26c1.81-1.27 3-3.36 3-5.74 0-3.86-3.14-7-7-7zm2.85 11.1l-.85.6V16h-4v-2.3l-.85-.6C7.8 12.16 7 10.63 7 9c0-2.76 2.24-5 5-5s5 2.24 5 5c0 1.63-.8 3.16-2.15 4.1z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#patentIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include patents
    </div>
  </overlay-tooltip>
          <iron-icon icon="social:school" id="nplIcon" class="style-scope search-box x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M5 13.18v4L12 21l7-3.82v-4L12 17l-7-3.82zM12 3L1 9l11 6 9-4.91V17h2V9L12 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
          <overlay-tooltip positioning-target="#nplIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Include non-patent literature
    </div>
  </overlay-tooltip>
          <keyword-wizard id="wizardIcon" class="style-scope search-box">


<div id="wizardContainer" class="style-scope keyword-wizard">
  <iron-icon icon="image:tune" id="wizardIcon" class="style-scope keyword-wizard x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M3 17v2h6v-2H3zM3 5v2h10V5H3zm10 16v-2h8v-2h-8v-2h-2v6h2zM7 9v2H3v2h4v2h2V9H7zm14 4v-2H11v2h10zm-6-4h2V7h4V5h-4V3h-2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
  <paper-material elevation="2" id="wizard" class="style-scope keyword-wizard x-scope paper-material-0" hidden="">
    
    

    
    
    <div class="search-within style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Search within
        <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="within"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="withinHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search within the title, abstract, claims, or full patent document</b>: You can
          restrict your search to a specific field using field names.</p>
        <p class="style-scope keyword-wizard">Use <span class="q style-scope keyword-wizard">TI=</span> to search in the title, <span class="q style-scope keyword-wizard">AB=</span> for the
          abstract, <span class="q style-scope keyword-wizard">CL=</span> for the claims, or <span class="q style-scope keyword-wizard">TAC=</span> for
          all three. For example, <span class="q style-scope keyword-wizard">TI=(safety belt)</span>.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Search by Cooperative Patent Classifications (CPCs)</b>: These are commonly used to
          represent ideas in place of keywords, and can also be entered in a search term box. If
          you're searching for<span class="q style-scope keyword-wizard">seat belts</span>, you could also search for
          <span class="q style-scope keyword-wizard">B60R22/00</span> to retrieve documents that mention safety belts or body
          harnesses. <span class="q style-scope keyword-wizard">CPC=B60R22</span> will match documents with exactly this CPC,
          <span class="q style-scope keyword-wizard">CPC=B60R22/low</span> matches documents with this CPC or a child
          classification of this CPC.
        </p>
          <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="filter-chips style-scope keyword-wizard">
        <span class="chip style-scope keyword-wizard" id="title" selected="">Title</span>
        <span class="chip style-scope keyword-wizard" id="abstract" selected="">Abstract</span>
        <span class="chip style-scope keyword-wizard" id="claims" selected="">Claims</span>
        <span class="chip style-scope keyword-wizard" id="fullDoc" selected="">Full Document</span>
      </div>
      
      <div class="cpc-field style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputCPC" class="style-scope keyword-wizard">or CPC</label></span>
        <div class="cpc-inputs style-scope keyword-wizard">
          <input class="keyword-input style-scope keyword-wizard" id="inputCPC" placeholder="Or search with CPC">
          <input type="checkbox" id="childCPC" checked="" class="style-scope keyword-wizard">
          <label class="checkbox-label style-scope keyword-wizard" for="childCPC">
            Include child classifications
          </label>
        </div>
      </div>
    </div>
    
    <div class="find-patents style-scope keyword-wizard">
      <span class="wizard-header style-scope keyword-wizard">
        Find patents
        <iron-icon class="help-header style-scope keyword-wizard x-scope iron-icon-0" icon="icons:help-outline" id="searchBoolean"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </span>
      
      <div class="help style-scope keyword-wizard" id="searchBooleanHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Keywords and boolean syntax (USPTO or EPO format)</b>:
          <span class="q style-scope keyword-wizard">seat belt</span> searches these two words, or their plurals and close
          synonyms. <span class="q style-scope keyword-wizard">"seat belt"</span> searches this exact phrase, in order.
          <span class="q style-scope keyword-wizard">-seat -belt</span> searches for documents not containing either word.
        </p>
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">For searches using boolean logic</b>, the default operator is
          <span class="q style-scope keyword-wizard">AND</span> with left associativity. <i class="style-scope keyword-wizard">Note:</i> this means
          <span class="q style-scope keyword-wizard">safety OR seat belt</span> is searched as <span class="q style-scope keyword-wizard">(safety OR seat)
          AND belt</span>. Each word automatically includes plurals and close synonyms. Adjacent
          words that are implicitly ANDed together, such as <span class="q style-scope keyword-wizard">(safety belt)</span>,
          are treated as a phrase when generating synonyms.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputAnd" class="style-scope keyword-wizard">with ALL of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputAnd" placeholder="with ALL of the words">
      </div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputExact" class="style-scope keyword-wizard">with the EXACT PHRASE</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputExact" placeholder="with the EXACT PHRASE"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputOr" class="style-scope keyword-wizard">with AT LEAST ONE of the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputOr" placeholder="with AT LEAST ONE of the words"></div>
      <div class="style-scope keyword-wizard">
        <span class="input-label style-scope keyword-wizard"><label for="inputMinus" class="style-scope keyword-wizard">WITHOUT the words</label></span>
        <input class="keyword-input style-scope keyword-wizard" id="inputMinus" placeholder="WITHOUT the words"></div>
    </div>
    <div class="search-by style-scope keyword-wizard">
      <div class="wizard-header style-scope keyword-wizard">
          Search by
          <iron-icon icon="icons:help-outline" class="help-header style-scope keyword-wizard x-scope iron-icon-0" id="chem"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </div>
      
      <div class="help style-scope keyword-wizard" id="chemHelp" hidden="">
        <p class="style-scope keyword-wizard"><b class="style-scope keyword-wizard">Chemistry searches</b> match terms (trade names, IUPAC names, etc.
          extracted from the entire document, and processed from .MOL files.)
        </p>
        <p class="style-scope keyword-wizard">Substructure (use <span class="q style-scope keyword-wizard">SSS=</span>) and similarity (use
          <span class="q style-scope keyword-wizard">~</span>) searches are limited to one per search at the top-level
          <span class="q style-scope keyword-wizard">AND</span> condition. Exact searches can be used multiple times throughout
          the search query.
        </p>
        <p class="style-scope keyword-wizard">Searching by SMILES or InChi key requires no special syntax. To search by SMARTS, use
          <span class="q style-scope keyword-wizard">SMARTS=</span>.
        </p>
        <p class="style-scope keyword-wizard">To search for multiple molecules, select "Batch" in the "Type" menu. Enter multiple
          molecules separated by whitespace or by comma.
        </p>
        <a href="https://support.google.com/faqs/answer/7049475" target="_blank" class="style-scope keyword-wizard">Learn More</a>
      </div>
      
      <div class="chemistry-field style-scope keyword-wizard">
          <span class="input-label style-scope keyword-wizard"><label for="inputChem" class="style-scope keyword-wizard">Chemistry</label></span>
          <span class="chem-type-label style-scope keyword-wizard"><label for="chemType" hidden="" class="style-scope keyword-wizard">Type</label></span>
          <select id="chemType" class="style-scope keyword-wizard">
            <option value="identical" class="style-scope keyword-wizard">Identical</option>
            <option value="substructure" class="style-scope keyword-wizard">Substructure</option>
            <option value="smarts" class="style-scope keyword-wizard">SMARTS</option>
            <option value="similarity" class="style-scope keyword-wizard">Similarity</option>
            <option value="batch" class="style-scope keyword-wizard">Batch</option>
          </select>
          <textarea class="keyword-input style-scope keyword-wizard" id="inputChem" placeholder="Trade name, SMILES, InChiKey"></textarea>
      </div>
      <div class="import style-scope keyword-wizard">
        <div class="wizard-header style-scope keyword-wizard">
          Patent numbers
        </div>
        <span class="import-button style-scope keyword-wizard">
          <a href="https://patents.google.com/import" class="style-scope keyword-wizard"><button class="style-scope keyword-wizard">Import</button></a>
        </span>
        <p class="import-text style-scope keyword-wizard">
          Search specific patents by importing a CSV or list of patent publication or application numbers.
        </p>
      </div>
    </div>
    
    <div class="wizard-buttons style-scope keyword-wizard">
      <button type="reset" class="style-scope keyword-wizard">Close</button>
      <button type="button" autofocus="" class="style-scope keyword-wizard">Add</button>
    </div>
  
  </paper-material>
</div>
</keyword-wizard>
          <overlay-tooltip positioning-target="#wizardIcon" direction="bottom" class="style-scope search-box" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Display advanced search options
    </div>
  </overlay-tooltip>
        </div>
      </div>
      <paper-material id="suggestMenu" class="style-scope search-box x-scope paper-material-0" elevation="1" hidden="">
    
    

    
        <template is="dom-repeat" class="style-scope search-box"></template>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Sorry, we couldn't find this patent number.
        </div>
        <div class="row style-scope search-box" hidden="">
          <iron-icon class="suggest-icon style-scope search-box x-scope iron-icon-0" icon="error"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm1 15h-2v-2h2v2zm0-4h-2V7h2v6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> 
        </div>
      
  </paper-material>
      <button id="searchButton" class="style-scope search-box"><iron-icon class="style-scope search-box x-scope iron-icon-0" icon="search"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></button>
    </div>
  </search-box>
          <template is="dom-if" class="style-scope search-header"></template>
          <div class="flex style-scope search-header"></div>
          
            <div id="header-container" class="style-scope search-header">
              <result-nav class="style-scope search-header">
    
    <div class="style-scope result-nav" hidden="">
      <state-modifier id="current" act="{&quot;type&quot;: &quot;BACK_TO_RESULTS&quot;}" inherit="" class="style-scope result-nav"><a id="link" href="#" class="style-scope state-modifier" inherit=""><span class="style-scope result-nav"></span> of
      <template is="dom-if" class="style-scope result-nav"></template>
      0<template is="dom-if" class="style-scope result-nav"></template></a></state-modifier>
      <state-modifier id="prevResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-left" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M15.41 7.41L14 6l-6 6 6 6 1.41-1.41L10.83 12z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier><state-modifier id="nextResult" inherit="" act="{&quot;type&quot;: &quot;NAV_RESULT&quot;, &quot;result&quot;: &quot;$id&quot;, &quot;page&quot;: $page}" class="style-scope result-nav" disabled=""><a id="link" href="#" class="style-scope state-modifier" inherit="">
        <iron-icon icon="chevron-right" class="style-scope result-nav x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M10 6L8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      </a></state-modifier>
      <overlay-tooltip positioning-target="#prevResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Previous result
    </div>
  </overlay-tooltip>
      <overlay-tooltip positioning-target="#nextResult" direction="bottom" arrow="" class="style-scope result-nav" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip"></div>
    <div class="style-scope overlay-tooltip">
      Next result
    </div>
  </overlay-tooltip>
    </div>
  </result-nav>
            </div>
          <template is="dom-if" class="style-scope search-header"></template>
        </div>
      </header>
    </div>
  </search-header>

      <div class="layout horizontal style-scope search-ui">
        <template is="dom-if" class="style-scope search-ui"></template>

        <div id="main" class="style-scope search-ui">
          <search-term-wizard class="style-scope search-ui"><pat-dialog open="" class="style-scope search-term-wizard">
  <span class="header style-scope search-term-wizard">
    <span class="title style-scope search-term-wizard">Search tools</span>
    <span id="language" class="style-scope search-term-wizard">
      <text-button id="textButton" selected="" class="style-scope search-term-wizard">Text
</text-button>
      <text-button id="classificationButton" class="style-scope search-term-wizard">Classification
</text-button>
      <text-button id="chemistryButton" class="style-scope search-term-wizard">Chemistry
</text-button>
      <text-button id="measureButton" class="style-scope search-term-wizard">Measure
</text-button>
      <text-button id="numbersButton" class="style-scope search-term-wizard">Numbers
</text-button>
    </span>
  </span>
  <span id="panels" class="style-scope search-term-wizard">
    <text-search-term-wizard id="textPanel" class="style-scope search-term-wizard" selected=""><span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Type a concept you want to search for here" class="style-scope text-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Type a concept you want to search for here">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="title" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Title</filter-chip>
  <filter-chip id="abstract" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Abstract</filter-chip>
  <filter-chip id="claims" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope text-search-term-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope text-search-term-wizard"></path>
  </svg>
  <filter-chip id="all" selected="" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
All</filter-chip>
  <filter-chip id="any" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Any</filter-chip>
  <filter-chip id="exact" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="not" class="style-scope text-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Not</filter-chip>
</span>
<span class="style-scope text-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope text-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope text-search-term-wizard">Add AND condition</span></mat-button></span></text-search-term-wizard>
    <classification-wizard id="classificationPanel" class="style-scope search-term-wizard"><span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope classification-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Enter a CPC here" uppercase="" class="style-scope classification-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Enter a CPC here">
  
</span>
</outlined-text-field>
</span>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<template is="dom-if" class="style-scope classification-wizard"></template>
<span class="style-scope classification-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope classification-wizard">
    <path d="M16 16.925q2.05 0 3.488-1.437Q20.925 14.05 20.925 12t-1.437-3.488Q18.05 7.075 16 7.075q-.625 0-1.2.15t-1.075.425q.7.925 1.087 2.025.388 1.1.388 2.325t-.388 2.325q-.387 1.1-1.087 2.025.5.275 1.075.425.575.15 1.2.15Zm-4-2.075q.45-.575.688-1.313.237-.737.237-1.537 0-.8-.237-1.538Q12.45 9.725 12 9.15q-.45.575-.688 1.312-.237.738-.237 1.538t.237 1.537q.238.738.688 1.313Zm-4 2.075q.625 0 1.2-.15t1.075-.425q-.7-.925-1.087-2.025Q8.8 13.225 8.8 12t.388-2.325q.387-1.1 1.087-2.025-.5-.275-1.075-.425-.575-.15-1.2-.15-2.05 0-3.487 1.437Q3.075 9.95 3.075 12t1.438 3.488Q5.95 16.925 8 16.925ZM8 19.2q-3 0-5.1-2.1Q.8 15 .8 12q0-3 2.1-5.1Q5 4.8 8 4.8q1.125 0 2.137.312 1.013.313 1.863.913.85-.6 1.863-.913Q14.875 4.8 16 4.8q3 0 5.1 2.1Q23.2 9 23.2 12q0 3-2.1 5.1-2.1 2.1-5.1 2.1-1.125 0-2.137-.313-1.013-.312-1.863-.912-.85.6-1.863.912Q9.125 19.2 8 19.2Z" class="style-scope classification-wizard"></path>
  </svg>
  <filter-chip id="notExact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These CPCs and their children
  </filter-chip>
  <filter-chip selected="" id="exact" class="style-scope classification-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>

    These exact CPCs
  </filter-chip>
</span>
<span class="style-scope classification-wizard">
  <mat-button id="button" filled="" class="style-scope classification-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope classification-wizard">Add AND condition</span></mat-button>
</span></classification-wizard>
    <chemistry-search-term-wizard id="chemistryPanel" class="style-scope search-term-wizard"><span class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="textField" placeholder="Trade name, SMILES, InChI Key" class="style-scope chemistry-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Trade name, SMILES, InChI Key">
  
</span>
</outlined-text-field>
  <outlined-textarea id="textArea" placeholder="Enter multiple SMILES or InChI Keys, one per line" rows="4" class="style-scope chemistry-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple SMILES or InChI Keys, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
  <a href="https://support.google.com/faqs/answer/7049475#zippy=%2Csearching-by-chemistry" target="_blank" class="style-scope chemistry-search-term-wizard">
    <svg class="help style-scope chemistry-search-term-wizard" xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49">
      <path d="M11.95 18q.525 0 .888-.363.362-.362.362-.887t-.362-.887q-.363-.363-.888-.363t-.888.363q-.362.362-.362.887t.362.887q.363.363.888.363Zm-.9-3.85h1.85q0-.825.188-1.3.187-.475 1.062-1.3.65-.65 1.025-1.238.375-.587.375-1.412 0-1.4-1.025-2.15T12.1 6q-1.425 0-2.312.75-.888.75-1.238 1.8l1.65.65q.125-.45.563-.975Q11.2 7.7 12.1 7.7q.8 0 1.2.437.4.438.4.963 0 .5-.3.937-.3.438-.75.813-1.1.975-1.35 1.475-.25.5-.25 1.825ZM12 22q-2.075 0-3.9-.788-1.825-.787-3.175-2.137-1.35-1.35-2.137-3.175Q2 14.075 2 12t.788-3.9q.787-1.825 2.137-3.175 1.35-1.35 3.175-2.138Q9.925 2 12 2t3.9.787q1.825.788 3.175 2.138 1.35 1.35 2.137 3.175Q22 9.925 22 12t-.788 3.9q-.787 1.825-2.137 3.175-1.35 1.35-3.175 2.137Q14.075 22 12 22Zm0-2q3.35 0 5.675-2.325Q20 15.35 20 12q0-3.35-2.325-5.675Q15.35 4 12 4 8.65 4 6.325 6.325 4 8.65 4 12q0 3.35 2.325 5.675Q8.65 20 12 20Zm0-8Z" class="style-scope chemistry-search-term-wizard"></path>
    </svg>
  </a>
</span>
<span id="chemQuantifiers" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M5 21.2q-1.4 0-2-1.25-.6-1.25.3-2.325l5.5-6.7V5.15h-.825q-.475 0-.8-.338Q6.85 4.475 6.85 4q0-.475.325-.813.325-.337.8-.337h8.05q.475 0 .8.337.325.338.325.813 0 .475-.325.812-.325.338-.8.338H15.2v5.775l5.5 6.7q.9 1.075.3 2.325-.6 1.25-2 1.25Zm2.15-3.275h9.7l-3.275-3.85h-3.15Zm-2 1h13.7l-5.925-7.2V5.15h-1.85v6.575Zm6.85-6.9Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="exact" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact</filter-chip>
  <filter-chip id="exactBatch" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Exact Batch</filter-chip>
  <filter-chip id="similar" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Similar</filter-chip>
  <filter-chip id="substructure" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure</filter-chip>
  <filter-chip id="smarts" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Substructure (SMARTS)</filter-chip>
</span>
<span id="location" class="style-scope chemistry-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope chemistry-search-term-wizard">
    <path d="M8 18.025h8v-2.1H8Zm0-4h8v-2.1H8ZM6.075 22.2q-.95 0-1.612-.662-.663-.663-.663-1.613V4.075q0-.95.663-1.613.662-.662 1.612-.662h8L20.2 7.925v12q0 .95-.662 1.613-.663.662-1.613.662Zm6.85-13.125v-5h-6.85v15.85h11.85V9.075Zm-6.85-5v5-5 15.85-15.85Z" class="style-scope chemistry-search-term-wizard"></path>
  </svg>
  <filter-chip id="fullDocuments" selected="" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Full documents</filter-chip>
  <filter-chip id="claims" class="style-scope chemistry-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Claims only</filter-chip>
</span>
<span class="style-scope chemistry-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope chemistry-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope chemistry-search-term-wizard">Add AND condition</span></mat-button>
</span>
</chemistry-search-term-wizard>
    <measure-search-term-wizard id="measurePanel" class="style-scope search-term-wizard"><span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M4.1 18.15q-.95 0-1.612-.663-.663-.662-.663-1.612v-7.75q0-.95.663-1.613Q3.15 5.85 4.1 5.85h15.8q.95 0 1.613.662.662.663.662 1.613v7.75q0 .95-.662 1.612-.663.663-1.613.663Zm0-2.275h15.8v-7.75H17V12h-2V8.125h-2V12h-2V8.125H9V12H7V8.125H4.1v7.75ZM7 12h2Zm4 0h2Zm4 0h2Zm-3 0Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="measureExpression" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="1.5 mm, 20 ft, 400-500 fahrenheit, 800 MHz, 0.01-100 mol">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope measure-search-term-wizard">
    <path d="M3.875 20.15V8.85h4.25v11.3Zm6 0V3.85h4.25v16.3Zm6 0v-7.3h4.25v7.3Z" class="style-scope measure-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="context" placeholder="activity, wavelength, embossing depth, absorption" class="style-scope measure-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="activity, wavelength, embossing depth, absorption">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope measure-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope measure-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope measure-search-term-wizard">Add AND condition</span></mat-button>
</span>
</measure-search-term-wizard>
    <numerical-search-term-wizard id="numericalPanel" class="style-scope search-term-wizard"><span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M3.85 15.275V13h10.3v2.275Zm0-4.275V8.725h16.3V11Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-textarea id="batch" placeholder="Enter multiple Patent Application and Publication Numbers, one per line" rows="4" class="style-scope numerical-search-term-wizard"><span class="style-scope outlined-textarea">
  <textarea id="textarea" autocomplete="off" autocorrect="off" spellcheck="false" tabindex="0" aria-disabled="false" wrap="soft" class="style-scope outlined-textarea" rows="4" placeholder="Enter multiple Patent Application and Publication Numbers, one per line">  </textarea>
  <div id="helperText" class="style-scope outlined-textarea"> </div>
</span>
<span class="right-button-container style-scope outlined-textarea">
  
</span>
</outlined-textarea>
</span>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<template is="dom-if" class="style-scope numerical-search-term-wizard"></template>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="m10.825 23.45-1.6-1.625L10.9 20.15H8q-.35.9-1.162 1.488-.813.587-1.838.587-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.025.588-1.837Q2.95 16.35 3.85 16V8q-.9-.35-1.487-1.163Q1.775 6.025 1.775 5q0-1.35.938-2.288Q3.65 1.775 5 1.775q1.025 0 1.838.587Q7.65 2.95 8 3.85h2.9L9.225 2.175l1.6-1.625L15.275 5l-4.45 4.45-1.6-1.625L10.9 6.15H8q-.25.65-.725 1.125T6.15 8v8q.65.25 1.125.725T8 17.85h2.9l-1.675-1.675 1.6-1.625 4.45 4.45ZM19 22.225q-1.35 0-2.287-.937-.938-.938-.938-2.288 0-1.05.588-1.863.587-.812 1.487-1.137V8q-.9-.325-1.487-1.137-.588-.813-.588-1.863 0-1.35.938-2.288.937-.937 2.287-.937 1.35 0 2.288.937.937.938.937 2.288 0 1.05-.587 1.863Q21.05 7.675 20.15 8v8q.9.35 1.488 1.163.587.812.587 1.837 0 1.35-.937 2.288-.938.937-2.288.937ZM5 19.95q.4 0 .675-.275T5.95 19q0-.4-.275-.675T5 18.05q-.4 0-.675.275T4.05 19q0 .4.275.675T5 19.95Zm14 0q.4 0 .675-.275T19.95 19q0-.4-.275-.675T19 18.05q-.4 0-.675.275T18.05 19q0 .4.275.675t.675.275Zm-14-14q.4 0 .675-.275T5.95 5q0-.4-.275-.675T5 4.05q-.4 0-.675.275T4.05 5q0 .4.275.675T5 5.95Zm14 0q.4 0 .675-.275T19.95 5q0-.4-.275-.675T19 4.05q-.4 0-.675.275T18.05 5q0 .4.275.675T19 5.95ZM5 19Zm14 0ZM5 5Zm14 0Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <filter-chip id="applicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Application Numbers</filter-chip>
  <filter-chip id="publicationNumbers" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Publication Numbers</filter-chip>
  <filter-chip id="either" selected="" class="style-scope numerical-search-term-wizard"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" preserveAspectRatio="none" class="style-scope filter-chip">
  <path d="M18.9 35.7 7.7 24.5 9.85 22.35 18.9 31.4 38.1 12.2 40.25 14.35Z" class="style-scope filter-chip"></path>
</svg>
Either</filter-chip>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M12 22.2q-2.1 0-3.962-.8-1.863-.8-3.25-2.175Q3.4 17.85 2.6 15.988 1.8 14.125 1.8 12t.8-3.988q.8-1.862 2.188-3.237Q6.175 3.4 8.038 2.6 9.9 1.8 12 1.8q2.125 0 3.988.8 1.862.8 3.237 2.175Q20.6 6.15 21.4 8.012q.8 1.863.8 3.988t-.8 3.988q-.8 1.862-2.175 3.237Q17.85 20.6 15.988 21.4q-1.863.8-3.988.8Zm-1-2.325v-1.95q-.8 0-1.387-.575-.588-.575-.588-1.4v-.975L4.275 10.2q-.075.45-.137.9-.063.45-.063.9 0 3 1.975 5.25T11 19.875Zm6.85-2.525q.5-.55.888-1.175.387-.625.65-1.313.262-.687.4-1.412.137-.725.137-1.45 0-2.425-1.338-4.438-1.337-2.012-3.612-2.887v.375q0 .825-.587 1.4-.588.575-1.388.575h-2v2q0 .4-.287.687-.288.288-.688.288h-2v2h5.95q.425 0 .713.287.287.288.287.688v2.975h1q.65 0 1.163.387.512.388.712 1.013Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryFilter" placeholder="Restrict search to these countries" class="style-scope numerical-search-term-wizard" value=""><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Restrict search to these countries">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <svg xmlns="http://www.w3.org/2000/svg" height="24" width="24" fill="#041E49" class="style-scope numerical-search-term-wizard">
    <path d="M2.85 18.225V15.95h6.3v2.275Zm0-5.075v-2.3h12.3v2.3Zm0-5.1V5.775h18.3V8.05Z" class="style-scope numerical-search-term-wizard"></path>
  </svg>
  <outlined-text-field id="countryOrder" placeholder="Prefer results from these countries in this order" class="style-scope numerical-search-term-wizard" value="US, EP, WO, JP, CN"><span class="style-scope outlined-text-field">
  <input id="input" spellcheck="false" autocomplete="off" class="style-scope outlined-text-field" aria-disabled="false" placeholder="Prefer results from these countries in this order">
  
</span>
</outlined-text-field>
</span>
<span class="style-scope numerical-search-term-wizard">
  <mat-button id="button" filled="" class="style-scope numerical-search-term-wizard x-scope mat-button-0" disabled=""><span slot="label" class="style-scope numerical-search-term-wizard">Add AND condition</span></mat-button>
</span>
</numerical-search-term-wizard>
  </span>

</pat-dialog>
</search-term-wizard>
          
      <div content="" class="style-scope search-result">
        <div id="mainContainer" class="vertical layout style-scope search-result">
          <template is="dom-if" class="style-scope search-result"></template>
          <result-container class="style-scope search-result">
    

    <paper-spinner class="style-scope result-container x-scope paper-spinner-0" aria-hidden="true" hidden=""><div id="spinnerContainer" class="  style-scope paper-spinner"><div class="spinner-layer layer-1 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-2 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-3 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div><div class="spinner-layer layer-4 style-scope paper-spinner"><div class="circle-clipper left style-scope paper-spinner"></div><div class="circle-clipper right style-scope paper-spinner"></div></div></div></paper-spinner>
    
      <patent-result class="style-scope result-container">
    
    
    <div class="layout horizontal style-scope patent-result">
      <div style="width: 1200px; height: auto; overflow: auto;" class="style-scope patent-result">
        <div id="wrapper" tabindex="0" class="style-scope patent-result">
          <result-tags class="style-scope patent-result"></result-tags>
          <h1 id="title" class="scroll-target style-scope patent-result">
            
  Compositions comprising bacterial strains
 
     </h1>
          <div class="horizontal layout style-scope patent-result">
            
            <div class="flex-3 style-scope patent-result" style="margin-top:-20px;overflow:hidden;" marginright="">
              <section id="abstract" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Abstract</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="abstract" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><abstract mxw-id="PA514275047" lang="EN" source="national office" load-source="google" class="style-scope patent-text">
  <p class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición que comprende una cepa bacteriana del género Megasphaera, para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16S que es por lo menos un 97% idéntica a la SEQ ID NO: 1.</span>A composition comprising a bacterial strain of the genus Megasphaera, for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO : 1.</span>
  </p>
</abstract>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <section id="classifications" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Classifications</div>
                  <div id="machineClassifiedWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">machine-classified</div>
                  <div id="machineClassifiedCPCWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">cpc-machine-classified</div>
                  <div id="machineClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-machine-classified</div>
                  <div class="style-scope patent-result" hidden="">&nbsp;</div>
                  <div id="familyClassifiedFtermWarning" class="righthead tooltip-hint style-scope patent-result" hidden="">fterm-family-classified</div>
                </h3>
                <overlay-tooltip positioning-target="#machineClassifiedWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedCPCWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The CPC classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#familyClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned based on a patent family member containing these classification codes.
    </div>
  </overlay-tooltip>
                <overlay-tooltip positioning-target="#machineClassifiedFtermWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The F-term classifications are assigned by a computer and are not a legal conclusion. <br class="style-scope patent-result"> Google has not performed a legal analysis and makes no representation as to the accuracy of the classifications listed.
    </div>
  </overlay-tooltip>
                <classification-viewer class="style-scope patent-result">
    
    <div class="table style-scope classification-viewer">
      
        <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" first="true" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
      <template is="dom-repeat" class="style-scope classification-viewer"></template>
      
      <div class="style-scope classification-viewer">
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L"><a id="link" href="#" class="style-scope state-modifier">A23L</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/00"><a id="link" href="#" class="style-scope state-modifier">A23L33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/10"><a id="link" href="#" class="style-scope state-modifier">A23L33/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/135"><a id="link" href="#" class="style-scope state-modifier">A23L33/135</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or derivatives thereof, e.g. probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L"><a id="link" href="#" class="style-scope state-modifier">A23L</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/00"><a id="link" href="#" class="style-scope state-modifier">A23L33/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23L33/40"><a id="link" href="#" class="style-scope state-modifier">A23L33/40</a></state-modifier>
                  <span class="description style-scope classification-tree">Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/12"><a id="link" href="#" class="style-scope state-modifier">A61K35/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/14"><a id="link" href="#" class="style-scope state-modifier">A61K35/14</a></state-modifier>
                  <span class="description style-scope classification-tree">Blood; Artificial blood</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/17"><a id="link" href="#" class="style-scope state-modifier">A61K35/17</a></state-modifier>
                  <span class="description style-scope classification-tree">Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/12"><a id="link" href="#" class="style-scope state-modifier">A61K35/12</a></state-modifier>
                  <span class="description style-scope classification-tree">Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/28"><a id="link" href="#" class="style-scope state-modifier">A61K35/28</a></state-modifier>
                  <span class="description style-scope classification-tree">Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/00"><a id="link" href="#" class="style-scope state-modifier">A61K35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing materials or reaction products thereof with undetermined constitution</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/66"><a id="link" href="#" class="style-scope state-modifier">A61K35/66</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms or materials therefrom</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/74"><a id="link" href="#" class="style-scope state-modifier">A61K35/74</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K35/741"><a id="link" href="#" class="style-scope state-modifier">A61K35/741</a></state-modifier>
                  <span class="description style-scope classification-tree">Probiotics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0012"><a id="link" href="#" class="style-scope state-modifier">A61K9/0012</a></state-modifier>
                  <span class="description style-scope classification-tree">Galenical forms characterised by the site of application</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/0053"><a id="link" href="#" class="style-scope state-modifier">A61K9/0053</a></state-modifier>
                  <span class="description style-scope classification-tree">Mouth and digestive tract, i.e. intraoral and peroral administration</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/00"><a id="link" href="#" class="style-scope state-modifier">A61K9/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations characterised by special physical form</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/14"><a id="link" href="#" class="style-scope state-modifier">A61K9/14</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K9/19"><a id="link" href="#" class="style-scope state-modifier">A61K9/19</a></state-modifier>
                  <span class="description style-scope classification-tree">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P1/00"><a id="link" href="#" class="style-scope state-modifier">A61P1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the alimentary tract or the digestive system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/00"><a id="link" href="#" class="style-scope state-modifier">A61P11/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the respiratory system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P11/06"><a id="link" href="#" class="style-scope state-modifier">A61P11/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antiasthmatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/00"><a id="link" href="#" class="style-scope state-modifier">A61P17/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for dermatological disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P17/06"><a id="link" href="#" class="style-scope state-modifier">A61P17/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Antipsoriatics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/00"><a id="link" href="#" class="style-scope state-modifier">A61P19/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P19/02"><a id="link" href="#" class="style-scope state-modifier">A61P19/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P29/00"><a id="link" href="#" class="style-scope state-modifier">A61P29/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/00"><a id="link" href="#" class="style-scope state-modifier">A61P3/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/08"><a id="link" href="#" class="style-scope state-modifier">A61P3/08</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P3/10"><a id="link" href="#" class="style-scope state-modifier">A61P3/10</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P35/00"><a id="link" href="#" class="style-scope state-modifier">A61P35/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Antineoplastic agents</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/00"><a id="link" href="#" class="style-scope state-modifier">A61P37/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for immunological or allergic disorders</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/02"><a id="link" href="#" class="style-scope state-modifier">A61P37/02</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunomodulators</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P37/06"><a id="link" href="#" class="style-scope state-modifier">A61P37/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Immunosuppressants, e.g. drugs for graft rejection</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P"><a id="link" href="#" class="style-scope state-modifier">A61P</a></state-modifier>
                  <span class="description style-scope classification-tree">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61P43/00"><a id="link" href="#" class="style-scope state-modifier">A61P43/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N"><a id="link" href="#" class="style-scope state-modifier">C12N</a></state-modifier>
                  <span class="description style-scope classification-tree">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/00"><a id="link" href="#" class="style-scope state-modifier">C12N1/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12N1/20"><a id="link" href="#" class="style-scope state-modifier">C12N1/20</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria; Culture media therefor</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2002/00"><a id="link" href="#" class="style-scope state-modifier">A23V2002/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Food compositions, function of food ingredients or processes for food or foodstuffs</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/00"><a id="link" href="#" class="style-scope state-modifier">A23V2200/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Function of food ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/30"><a id="link" href="#" class="style-scope state-modifier">A23V2200/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2200/308"><a id="link" href="#" class="style-scope state-modifier">A23V2200/308</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23"><a id="link" href="#" class="style-scope state-modifier">A23</a></state-modifier>
                  <span class="description style-scope classification-tree">FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V"><a id="link" href="#" class="style-scope state-modifier">A23V</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/00"><a id="link" href="#" class="style-scope state-modifier">A23V2200/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Function of food ingredients</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A23V2200/30"><a id="link" href="#" class="style-scope state-modifier">A23V2200/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A23V2200/324"><a id="link" href="#" class="style-scope state-modifier">A23V2200/324</a></state-modifier>
                  <span class="description style-scope classification-tree">Foods, ingredients or supplements having a functional effect on health having an effect on the immune system</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A"><a id="link" href="#" class="style-scope state-modifier">A</a></state-modifier>
                  <span class="description style-scope classification-tree">HUMAN NECESSITIES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61"><a id="link" href="#" class="style-scope state-modifier">A61</a></state-modifier>
                  <span class="description style-scope classification-tree">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K"><a id="link" href="#" class="style-scope state-modifier">A61K</a></state-modifier>
                  <span class="description style-scope classification-tree">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="A61K45/00"><a id="link" href="#" class="style-scope state-modifier">A61K45/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Medicinal preparations containing active ingredients not provided for in groups A61K31/00&nbsp;-&nbsp;A61K41/00</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="A61K45/06"><a id="link" href="#" class="style-scope state-modifier">A61K45/06</a></state-modifier>
                  <span class="description style-scope classification-tree">Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C"><a id="link" href="#" class="style-scope state-modifier">C</a></state-modifier>
                  <span class="description style-scope classification-tree">CHEMISTRY; METALLURGY</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12"><a id="link" href="#" class="style-scope state-modifier">C12</a></state-modifier>
                  <span class="description style-scope classification-tree">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R"><a id="link" href="#" class="style-scope state-modifier">C12R</a></state-modifier>
                  <span class="description style-scope classification-tree">INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="C12R2001/00"><a id="link" href="#" class="style-scope state-modifier">C12R2001/00</a></state-modifier>
                  <span class="description style-scope classification-tree">Microorganisms ; Processes using microorganisms</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="C12R2001/01"><a id="link" href="#" class="style-scope state-modifier">C12R2001/01</a></state-modifier>
                  <span class="description style-scope classification-tree">Bacteria or Actinomycetales ; using bacteria or Actinomycetales</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        
          <classification-tree class="style-scope classification-viewer">
    
    <div class="style-scope classification-tree">
      <div class="layout horizontal wrap style-scope classification-tree">
        <div class="flex style-scope classification-tree">
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y"><a id="link" href="#" class="style-scope state-modifier">Y</a></state-modifier>
                  <span class="description style-scope classification-tree">GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02"><a id="link" href="#" class="style-scope state-modifier">Y02</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A"><a id="link" href="#" class="style-scope state-modifier">Y02A</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree" hidden="">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" data-cpc="Y02A50/00"><a id="link" href="#" class="style-scope state-modifier">Y02A50/00</a></state-modifier>
                  <span class="description style-scope classification-tree">TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          
            
              <div class="style-scope classification-tree">
                <concept-mention class="style-scope classification-tree">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                  <state-modifier class="code style-scope classification-tree" act="{&quot;type&quot;: &quot;QUERY_ADD_CPC&quot;, &quot;cpc&quot;: &quot;$cpc&quot;}" additional="true" data-cpc="Y02A50/30"><a id="link" href="#" class="style-scope state-modifier">Y02A50/30</a></state-modifier>
                  <span class="description style-scope classification-tree">Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change</span>
                
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
              </div>
            <template is="dom-if" class="style-scope classification-tree"></template>
            <template is="dom-if" class="style-scope classification-tree"></template>
          <template is="dom-repeat" class="style-scope classification-tree"></template>
        </div>
      </div>
    </div>
  </classification-tree>
        <template is="dom-repeat" class="style-scope classification-viewer"></template>
        <div class="more style-scope classification-viewer" style="" hidden="">View 24 more classifications</div>
        <div class="more style-scope classification-viewer">Hide more classifications</div>
      </div>
      <template is="dom-if" class="style-scope classification-viewer"></template>
    </div>
  </classification-viewer>
              </section>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              <template is="dom-if" class="style-scope patent-result"></template>
              
              
                <section class="style-scope patent-result">
                  <h3 class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Landscapes</div>
                  </h3>
                  <div class="responsive-grid style-scope patent-result">
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Health &amp; Medical Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Health &amp; Medical Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    
                      <landscape-link class="style-scope patent-result"><state-modifier act="{&quot;type&quot;:&quot;QUERY_SET_TERM&quot;,&quot;term&quot;:&quot;$term&quot;,&quot;origin&quot;:&quot;LANDSCAPE_LINK&quot;}" class="style-scope landscape-link" data-term="Life Sciences &amp; Earth Sciences"><a id="link" href="#" class="style-scope state-modifier">
  <requery-tile class="area style-scope landscape-link">
<span class="label style-scope requery-tile">
    Life Sciences &amp; Earth Sciences
  </span>
<span class="search-icon style-scope requery-tile"></span>
</requery-tile>
</a></state-modifier>
</landscape-link>
                    <template is="dom-repeat" class="style-scope patent-result"></template>
                  </div>
                  <s-more-inline class="style-scope patent-result"><hr aria-hidden="true" class="style-scope s-more-inline">

<div class="button style-scope s-more-inline">
  <span slot="expand_text" class="style-scope patent-result">Show more</span>
  <span class="expand more style-scope s-more-inline"></span>
</div>
<div class="button style-scope s-more-inline" hidden="">
  <span slot="collapse_text" class="style-scope patent-result">Show less</span>
  <span class="expand less style-scope s-more-inline"></span>
</div>
</s-more-inline>
                </section>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
            <div class="flex-2 style-scope patent-result">
              <section class="knowledge-card style-scope patent-result">
                <header class="style-scope patent-result">
                  <h2 id="pubnum" class="style-scope patent-result">ES2916601T3</h2>
                  <p class="tagline style-scope patent-result">Spain</p>
                  <overlay-tooltip positioning-target="#pubnum" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                    <div style="max-width: 300px;" class="style-scope patent-result">Translation of granted European patent ( former B3)</div>
                  
    </div>
  </overlay-tooltip>

                  <div class="knowledge-card-action-bar style-scope patent-result">
                    <a target="_blank" class="style-scope patent-result" href="https://patentimages.storage.googleapis.com/88/f4/67/3cf6561673245d/ES2916601T3.pdf"><iron-icon icon="description" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download PDF</a>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_FIND_PRIOR_ART&quot;, &quot;keywords&quot;: $keywords, &quot;before&quot;: &quot;$before&quot;}" class="style-scope patent-result" data-keywords="[&quot;cancer&quot;,&quot;compositions&quot;,&quot;bacterial strain&quot;,&quot;treatment&quot;,&quot;composition&quot;]" data-before="20180511"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="find-in-page" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 19.59V8l-6-6H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c.45 0 .85-.15 1.19-.4l-4.43-4.43c-.8.52-1.74.83-2.76.83-2.76 0-5-2.24-5-5s2.24-5 5-5 5 2.24 5 5c0 1.02-.31 1.96-.83 2.75L20 19.59zM9 13c0 1.66 1.34 3 3 3s3-1.34 3-3-1.34-3-3-3-3 1.34-3 3z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Find Prior Art
                    </a></state-modifier>
                    <state-modifier inherit="" act="{&quot;type&quot;: &quot;QUERY_SIMILAR_DOCUMENTS&quot;, &quot;id&quot;: &quot;$id&quot;}" class="style-scope patent-result" data-id="patent/ES2916601T3"><a id="link" href="#" class="style-scope state-modifier" inherit="">
                      <iron-icon icon="editor:functions" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M18 4H6v2l6.5 6L6 18v2h12v-3h-7l5-5-5-5h7z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Similar
                    </a></state-modifier>
                  </div>
                </header>

                <dl class="important-people style-scope patent-result">
                  
                    <dt class="style-scope patent-result">Other languages</dt>
                    <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2916601T3/es"><a id="link" href="#" class="style-scope state-modifier">Spanish</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                  
                  <dt class="style-scope patent-result">Inventor</dt>
                  <dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Imke Elisabeth MULDER"><a id="link" href="#" class="style-scope state-modifier">Imke Elisabeth MULDER</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Parthena Fotiadou"><a id="link" href="#" class="style-scope state-modifier">Parthena Fotiadou</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Amy Beth HOLT"><a id="link" href="#" class="style-scope state-modifier">Amy Beth HOLT</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Suaad Ahmed"><a id="link" href="#" class="style-scope state-modifier">Suaad Ahmed</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Anna Ettorre"><a id="link" href="#" class="style-scope state-modifier">Anna Ettorre</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Samantha Yuille"><a id="link" href="#" class="style-scope state-modifier">Samantha Yuille</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="Ted Dinan"><a id="link" href="#" class="style-scope state-modifier">Ted Dinan</a></state-modifier></dd><dd class="style-scope patent-result"><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_INVENTOR&quot;, &quot;inventor&quot;: &quot;$inventor&quot;}" class="style-scope patent-result" data-inventor="John Cryan"><a id="link" href="#" class="style-scope state-modifier">John Cryan</a></state-modifier></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>

                  
                  <dt class="style-scope patent-result">
                    <span class="tooltip-hint style-scope patent-result" id="assigneeWarning">Current Assignee</span>
                    <overlay-tooltip positioning-target="#assigneeWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                      The listed assignees may be inaccurate.<br class="style-scope patent-result">
                      Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.
                    
    </div>
  </overlay-tooltip>
                  </dt>
                  <dd class="style-scope patent-result">
                    
    4D Pharma Research Ltd
  
                  </dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                  <template is="dom-if" class="style-scope patent-result"></template>
                </dl>

                <hr class="style-scope patent-result">

                <application-timeline class="style-scope patent-result">
    
    
    <div class="wrap style-scope application-timeline">
      <div class="header style-scope application-timeline">Worldwide applications</div>
      <div class="event style-scope application-timeline">
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2019</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW108116449A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2019267170A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2019267170A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4056192A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP22162255.8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SI3743086T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SI</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SI201930216T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/RS63273B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">RS</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: RS20220465A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2019215346A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2019/062238</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3099209A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3099209A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20210008393A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020207035244A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/BR112020022833A2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">BR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: BR112020022833-8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/LT3743086T/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">LT</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: LTEPPCT/EP2019/062238T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/HRP20220578T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">HR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: HRP20220578TT</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2019267171A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2019267171A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MD3743086T2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MD</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MDE20201221T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP7058449B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2020545563A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2021523895A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2020562128A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/PL3743086T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">PL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PL19725068T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3790564A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP19725067.3A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Withdrawn</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG11202011031UA/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG11202011031UA</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP4066845A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP22162425.7A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/WO2019215345A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">WO</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: PCT/EP2019/062236</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Search and Examination</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/DK3743086T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">DK</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: DK19725068.1T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/TW202011975A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">TW</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: TW108116469A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/KR20210008391A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">KR</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: KR1020207035242A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Application Discontinuation</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN112512539A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201980031512.5A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/MX2020012061A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">MX</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: MX2020012061A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/EP3743086B1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">EP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: EP19725068.1A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/SG11202011028SA/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">SG</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: SG11202011028SA</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline" this="">ES</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: ES19725068T</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CN112601534A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CN</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CN201980031147.8A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CA3098971A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">CA</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CA3098971A</div>
                <div class="style-scope application-timeline">Filing date: 2019-05-13</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2020</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US11419902B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/013,026</div>
                <div class="style-scope application-timeline">Filing date: 2020-09-04</div>
                <div class="style-scope application-timeline">Legal status: Active</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/IL278471B2/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">IL</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: IL278471A</div>
                <div class="style-scope application-timeline">Filing date: 2020-11-03</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20210275605A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/095,427</div>
                <div class="style-scope application-timeline">Filing date: 2020-11-11</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2022</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/JP2022088631A/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="active style-scope application-timeline">JP</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: JP2022062741A</div>
                <div class="style-scope application-timeline">Filing date: 2022-04-05</div>
                <div class="style-scope application-timeline">Legal status: Pending</div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/CY1125211T1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="unknown style-scope application-timeline">CY</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: CY20221100367T</div>
                <div class="style-scope application-timeline">Filing date: 2022-05-27</div>
                <div class="style-scope application-timeline">Legal status: </div>
              
    </div>
  </overlay-tooltip>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/US20230158083A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">US</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: US17/847,336</div>
                <div class="style-scope application-timeline">Filing date: 2022-06-23</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        
          <span class="block style-scope application-timeline">
            <span class="year style-scope application-timeline">2023</span>
            <span class="dot style-scope application-timeline"></span>
            
              <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/AU2023200562A1/en"><a id="link" href="#" class="style-scope state-modifier">
                <span id="cc" class="not_active style-scope application-timeline">AU</span>
              </a></state-modifier>
              <overlay-tooltip positioning-target="#cc" direction="bottom" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
                <div class="style-scope application-timeline">Application number: AU2023200562A</div>
                <div class="style-scope application-timeline">Filing date: 2023-02-03</div>
                <div class="style-scope application-timeline">Legal status: Abandoned</div>
              
    </div>
  </overlay-tooltip>
            <template is="dom-repeat" class="style-scope application-timeline"></template>
          </span>
        <template is="dom-repeat" class="style-scope application-timeline"></template>
      </div>
      <hr class="style-scope application-timeline">
      <div class="header style-scope application-timeline">Application ES19725068T events <iron-icon id="legal" icon="icons:help-outline" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M11 18h2v-2h-2v2zm1-16C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8zm0-14c-2.21 0-4 1.79-4 4h2c0-1.1.9-2 2-2s2 .9 2 2c0 2-3 1.75-3 5h2c0-2.25 3-2.5 3-5 0-2.21-1.79-4-4-4z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        <overlay-tooltip positioning-target="#legal" direction="right" class="style-scope application-timeline" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
          <div style="max-width: 300px;" class="style-scope application-timeline">
            A timeline of key events for this patent application, including priority claims, publications, legal status, reassignments, and litigation.<br class="style-scope application-timeline"><br class="style-scope application-timeline">
            Google has not performed a legal analysis and makes no representation as to the accuracy or completeness of the events listed.
          </div>
        
    </div>
  </overlay-tooltip>
      </div>
      <div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="filed style-scope application-timeline">2019-05-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;QUERY_SEARCH_ASSIGNEE&quot;, &quot;assignee&quot;: &quot;$assignee&quot;}" class="style-scope application-timeline" data-assignee="4D Pharma Research Ltd"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Application filed by 4D Pharma Research Ltd</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="granted style-scope application-timeline">2022-07-04</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Application granted</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="publication style-scope application-timeline">2022-07-04</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope application-timeline" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier"><span class="title-text style-scope application-timeline">Publication of ES2916601T3</span></a></state-modifier><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" current="" critical=""><div date="" class="legal-status style-scope application-timeline">Status</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Active</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><div class="event layout horizontal style-scope application-timeline" critical=""><div date="" class="legal-status style-scope application-timeline">2039-05-13</div><div class="line style-scope application-timeline"></div><div class="flex title style-scope application-timeline"><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template><span class="title-text style-scope application-timeline">Anticipated expiration</span><template is="dom-if" class="style-scope application-timeline"></template><template is="dom-if" class="style-scope application-timeline"></template></div></div><template is="dom-repeat" strip-whitespace="" class="style-scope application-timeline"></template>
      
        <div class="event layout horizontal expand style-scope application-timeline">
          Show all events <iron-icon style="height: 15px; width: 15px;" icon="expand-more" class="style-scope application-timeline x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M16.59 8.59L12 13.17 7.41 8.59 6 10l6 6 6-6z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope application-timeline"></template>
          <template is="dom-if" class="style-scope application-timeline"></template>
        </div>
      <template is="dom-if" class="style-scope application-timeline"></template>
    </div>
  </application-timeline>
                <hr class="style-scope patent-result">

                <dl class="links style-scope patent-result">
                  <dt class="style-scope patent-result">Info</dt>

                  
                  <dd class="style-scope patent-result"><a href="#patentCitations" class="style-scope patent-result">Patent citations (36)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#citedBy" class="style-scope patent-result">Cited by (10)</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#similarDocuments" class="style-scope patent-result">Similar documents</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  
                  <dd class="style-scope patent-result"><a href="#relatedApplications" class="style-scope patent-result">Priority and Related Applications</a></dd>
                  <template is="dom-if" restamp="" class="style-scope patent-result"></template>

                  <dt class="style-scope patent-result">External links</dt>

                  <dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=ES&amp;NR=2916601T3&amp;KC=T3&amp;FT=D">Espacenet</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://globaldossier.uspto.gov/#/result/publication/ES/2916601/1">Global Dossier</a></dd><dd class="style-scope patent-result"><a target="_blank" class="style-scope patent-result" href="https://patents.stackexchange.com/questions/tagged/ES2916601T3">Discuss</a></dd><template is="dom-repeat" strip-whitespace="" class="style-scope patent-result"></template>
                </dl>
              </section>
            </div>
          </div>

          <div id="text" class="horizontal layout style-scope patent-result">
            <div class="flex flex-width style-scope patent-result" marginright="">
              <section id="description" class="style-scope patent-result">
                <h3 class="layout horizontal style-scope patent-result">
                  <div class="flex style-scope patent-result">Description</div>
                  <div class="righthead style-scope patent-result">translated from Spanish</div>
                </h3>
                <patent-text name="description" id="descriptionText" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><description mxw-id="PDES335314204" lang="EN" load-source="google" class="style-scope patent-text">
  
  <p class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DESCRIPCIÓN</span>DESCRIPTION</span>
    </b>
  </p>
  <p id="p0001" num="0001" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones que comprenden cepas bacterianas</span>Compositions comprising bacterial strains</span>
  </p>
  <p id="p0002" num="0002" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CAMPO TÉCNICO</span>TECHNICAL FIELD</span>
    </b>
  </p>
  <p id="p0003" num="0003" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esta invención pertenece al campo de las composiciones que comprenden cepas bacterianas aisladas del tracto digestivo de mamíferos y el uso de tales composiciones en el tratamiento de enfermedades, en particular cáncer, y en particular para estimular el sistema inmunitario en el tratamiento de enfermedades, como se define en las reivindicaciones.</span>This invention belongs to the field of compositions comprising bacterial strains isolated from the digestive tract of mammals and the use of such compositions in the treatment of diseases, in particular cancer, and in particular to stimulate the immune system in the treatment of diseases, such as defined in the claims.</span>
  </p>
  <p id="p0004" num="0004" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">ANTECEDENTES DE LA INVENCIÓN</span>BACKGROUND OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0005" num="0005" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cree que el intestino humano es estéril <i class="style-scope patent-text">in utero</i>, pero está expuesto a una gran variedad de microbios maternos y ambientales inmediatamente después del nacimiento. A partir de entonces, se produce un período dinámico de colonización y sucesión microbiana, que está influenciado por factores como el modo de administración, el medio ambiente, la dieta y el genotipo del huésped, todos los cuales impactan en la composición del microbiota intestinal, particularmente durante los primeros años de vida. Posteriormente, el microbiota se estabiliza y se vuelve similar a la adulta [1] El microbiota intestinal humana contiene más de 500-1000 filotipos diferentes que pertenecen esencialmente a dos divisiones bacterianas principales, Bacteroidetes y Firmicutes [2] Las relaciones simbióticas con éxito que surgen de la colonización bacteriana del intestino humano han proporcionado una amplia variedad de funciones metabólicas, estructurales, protectoras y otras funciones beneficiosas. Las actividades metabólicas mejoradas del intestino colonizado aseguran que los componentes dietéticos que de otro modo no serían digeribles se degraden con la liberación de subproductos que proporcionan una importante fuente de nutrientes para el huésped. De manera similar, la importancia inmunológica del microbiota intestinal está bien reconocida y se ejemplifica en animales libres de gérmenes que tienen un sistema inmunitario deteriorado que se reconstituye funcionalmente después de la introducción de bacterias comensales [3-5].</span>The human intestine is believed to be sterile <i class="style-scope patent-text">in utero</i> , but is exposed to a wide variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession ensues, which is influenced by factors such as mode of administration, environment, diet, and host genotype, all of which impact the composition of the gut microbiota. particularly during the first years of life. Subsequently, the microbiota stabilizes and becomes adult-like [1] The human gut microbiota contains more than 500-1000 different phylotypes essentially belonging to two main bacterial divisions, Bacteroidetes and Firmicutes [2] Successful symbiotic relationships that arise from bacterial colonization of the human intestine have provided a wide variety of metabolic, structural, protective, and other beneficial functions. The enhanced metabolic activities of the colonized intestine ensure that otherwise indigestible dietary components are degraded with the release of by-products that provide an important source of nutrients for the host. Similarly, the immunological importance of the gut microbiota is well recognized and is exemplified in germ-free animals that have an impaired immune system that is functionally reconstituted after the introduction of commensal bacteria [3-5].</span>
  </p>
  <p id="p0006" num="0006" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se han documentado cambios drásticos en la composición del microbiota en trastornos gastrointestinales como la enfermedad inflamatoria intestinal (IBD). Por ejemplo, los niveles de bacterias <i class="style-scope patent-text">Clostridium </i>clúster XlVa se reducen en pacientes con IBD, mientras que el número de <i class="style-scope patent-text">E. coli </i>aumenta, lo que sugiere un cambio en el equilibrio de simbiontes y patobiontes dentro del intestino [6-9]. Curiosamente, esta disbiosis microbiana también se asocia con desequilibrios en las poblaciones de células T efectoras.</span>Drastic changes in the composition of the microbiota have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of <i class="style-scope patent-text">Clostridium</i> cluster XlVa bacteria are reduced in IBD patients, while the number of <i class="style-scope patent-text">E. coli</i> is increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9]. Interestingly, this microbial dysbiosis is also associated with imbalances in effector T cell populations.</span>
  </p>
  <p id="p0007" num="0007" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En reconocimiento del efecto positivo potencial que ciertas cepas bacterianas pueden tener en el intestino animal, se han propuesto varias cepas para su uso en el tratamiento de varias enfermedades (ver, por ejemplo, [10­ 13]). Además, ciertas cepas, incluyendo principalmente las cepas de <i class="style-scope patent-text">Lactobacillus </i>y <i class="style-scope patent-text">Bifidobacterium, </i>se han propuesto para su uso en el tratamiento de varias enfermedades inflamatorias y autoinmunes que no están directamente relacionadas con los intestinos (ver [14] y [15] para revisiones). Sin embargo, la relación entre diferentes enfermedades y diferentes cepas bacterianas, y los efectos precisos de cepas bacterianas particulares en el intestino y a nivel sistémico y en cualquier tipo particular de enfermedad, están pobremente caracterizados.</span>In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, several strains have been proposed for use in the treatment of various diseases (see, eg, [10-13]). In addition, certain strains, including primarily <i class="style-scope patent-text">Lactobacillus</i> and <i class="style-scope patent-text">Bifidobacterium strains,</i> have been proposed for use in the treatment of various inflammatory and autoimmune diseases that are not directly related to the intestines (see [14] and [15] for reviews). However, the relationship between different diseases and different bacterial strains, and the precise effects of particular bacterial strains at the gut and systemic level and on any particular type of disease, are poorly characterized.</span>
  </p>
  <p id="p0008" num="0008" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La WO2015038731 analiza un método para tratar el cáncer de colon mediante la alteración de una biopelícula colónica mediante la administración de un agente antimicrobiano o un agente probiótico. La solicitud enumera una gran cantidad de bacterias que pueden usarse en un probiótico, pero no proporciona ninguna demostración de la eficacia de ninguna de las bacterias en el tratamiento del cáncer de colon. En cambio, esta solicitud se centra en el potencial diagnóstico de las biopelículas en el cáncer colorrectal.</span>WO2015038731 discusses a method for treating colon cancer by altering a colonic biofilm by administering an antimicrobial agent or a probiotic agent. The application lists a large number of bacteria that can be used in a probiotic, but provides no demonstration of the efficacy of any of the bacteria in treating colon cancer. Instead, this application focuses on the diagnostic potential of biofilms in colorectal cancer.</span>
  </p>
  <p id="p0009" num="0009" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El número de registro de la base de datos EMBL XP002787383 proporciona una secuencia génica de ARNr 16S de una <i class="style-scope patent-text">Megasphaera sp </i>propuesta, mientras que el número de registro de la base de datos EMBL XP002787384 proporciona un gen ARNr 16S de una cepa de <i class="style-scope patent-text">Megasphaera massiliensis. </i>Estos documentos detallan el análisis genómico de cepas aisladas y no proporcionan orientación sobre el beneficio terapéutico de <i class="style-scope patent-text">Megasphaera</i>.</span>EMBL database accession number XP002787383 provides a 16S rRNA gene sequence from a proposed <i class="style-scope patent-text">Megasphaera sp</i> , while EMBL database accession number XP002787384 provides a 16S rRNA gene from a <i class="style-scope patent-text">Megasphaera massiliensis strain.</i> These documents detail the genomic analysis of isolates and do not provide guidance on the therapeutic benefit of <i class="style-scope patent-text">Megasphaera</i> .</span>
  </p>
  <p id="p0010" num="0010" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ahmed et al (presentado en Frontiers Cellular Neuroscience) considera la caracterización <i class="style-scope patent-text">in vitro </i>de cepas bacterianas derivadas del microbiota intestinal. La US2004/120963 describe composiciones que contienen bacterias capaces de convertir el ácido láctico en ácido butírico y un método para prevenir/tratar la acidemia hiperláctica en el tracto digestivo y el cáncer de colon usando las mismas. La CN104415060A describe una composición comestible que comprende inulina y ácido butírico que produce bacterias. La JPS5557520 describe la preparación de una sustancia carcinostática tratando las paredes celulares de bacterias que pertenecen al género <i class="style-scope patent-text">Bacteroides, </i>etc. con una enzima y dializando con agua. La US2017/354697 describe el tratamiento de infección por <i class="style-scope patent-text">Clostridium difficile. </i>La US2016/223553 describe la formación de biopelículas para definir el riesgo de cáncer de colon. La WO2017122197A1 describe bacterias que utilizan ácido láctico modificadas genéticamente para secretas enzimas degradadoras de polisacáridos. La US2016199424A1 describe composiciones probióticas y prebióticas y métodos de uso de las mismas para la modulación del microbioma. La WO2004085628 describe bacterias que utilizan ácido 
láctico y su uso terapéutico. Nallabelli et al. (Scientific Reports, 6(1), 2016) describe análisis de secuencias de genoma y bioquímicos de la cepa de <i class="style-scope patent-text">Megasphaera </i>sp. DISK18 de la placa dental de un individuo sano. Padmanabhan et al. (Standards in Genomic Sciences, 8(3), 2013) divulga una secuencia de genoma finalizada no contigua y la descripción de <i class="style-scope patent-text">Megasphaera massiliensis </i>sp. nov.</span>Ahmed et al (featured in Frontiers Cellular Neuroscience) consider the <i class="style-scope patent-text">in vitro</i> characterization of bacterial strains derived from the gut microbiota. US2004/120963 describes compositions containing bacteria capable of converting lactic acid to butyric acid and a method for preventing/treating hyperlactic acidemia in the digestive tract and colon cancer using the same. CN104415060A describes an edible composition comprising inulin and butyric acid producing bacteria. JPS5557520 describes the preparation of a carcinostatic substance by treating cell walls of bacteria belonging to the genus <i class="style-scope patent-text">Bacteroides,</i> etc. with an enzyme and dialyzing with water. US2017/354697 describes the treatment of <i class="style-scope patent-text">Clostridium difficile infection.</i> US2016/223553 describes the formation of biofilms to define the risk of colon cancer. WO2017122197A1 describes genetically modified lactic acid-using bacteria to secrete polysaccharide-degrading enzymes. US2016199424A1 describes probiotic and prebiotic compositions and methods of using them for the modulation of the microbiome. WO2004085628 describes bacteria that use acid  lactic acid and its therapeutic use. Nallabelli et al. (Scientific Reports, 6(1), 2016) describes biochemical and genome sequence analyzes of the <i class="style-scope patent-text">Megasphaera</i> sp. DISK18 from dental plaque of a healthy individual. Padmanabhan et al. (Standards in Genomic Sciences, 8(3), 2013) discloses a non-contiguous finalized genome sequence and description of <i class="style-scope patent-text">Megasphaera massiliensis</i> sp. nov.</span>
  </p>
  <p id="p0011" num="0011" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Hay un requisito en la técnica para nuevos métodos de tratamiento de enfermedades. También hay un requisito para caracterizar los efectos potenciales de las bacterias intestinales para que puedan desarrollarse nuevas terapias que usen bacterias intestinales.</span>There is a requirement in the art for new methods of treating diseases. There is also a requirement to characterize the potential effects of gut bacteria so that new therapies using gut bacteria can be developed.</span>
  </p>
  <p id="p0012" num="0012" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SUMARIO DE LA INVENCIÓN</span>SUMMARY OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0013" num="0013" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16S que es por lo menos un 97% idéntica a la SEQ ID NO: 1. La invención proporciona además una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1; (a) para su uso en el tratamiento o prevención del cáncer, (b) para su uso en el tratamiento, prevención o retraso de la inmunosenescencia, (c) para su uso como adyuvante de vacunas, o (d) para su uso en terapia con células T con receptores de antígenos quiméricos (CAR-T), terapia de células madre mesenquimales (MSC), o terapia de trasplante de células madre; en un sujeto humano.</span>The invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in the treatment of diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to the SEQ ID NO: 1. The invention further provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; (a) for use in the treatment or prevention of cancer, (b) for use in the treatment, prevention, or delay of immunosenescence, (c) for use as an adjuvant to vaccines, or (d) for use in chimeric antigen receptor T cell (CAR-T) therapy, mesenchymal stem cell (MSC) therapy, or stem cell transplant therapy; in a human subject.</span>
  </p>
  <p id="p0014" num="0014" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención también proporciona una composición que comprende una célula de la cepa bacteriana como se define en las reivindicaciones, en donde la célula expresa uno o más antígenos heterólogos; para su uso como una vacuna; opcionalmente en donde la célula presenta el uno o más antígenos heterólogos. La invención también proporciona una célula de la cepa bacteriana como se define en las reivindicaciones, en donde la célula expresa uno o más antígenos heterólogos; para su uso como una vacuna; opcionalmente en donde la célula presenta el uno o más antígenos heterólogos.</span>The invention also provides a composition comprising a cell of the bacterial strain as defined in the claims, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens. The invention also provides a cell of the bacterial strain as defined in the claims, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
  </p>
  <p id="p0015" num="0015" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención proporciona además una cepa bacteriana para su uso en terapia, en donde la cepa bacteriana tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o un 99,9% idéntica a cualquiera de las SEQ ID NO: 8, 11 o 12. La invención también proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por cualquiera de las SEQ ID NO: 8, 10, 11 o 12 para su uso en terapia.</span>The invention further provides a bacterial strain for use in therapy, wherein the bacterial strain has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to any one of SEQ ID NO: 8 , 11 or 12. The invention also provides a bacterial strain having the 16S rRNA sequence represented by any of SEQ ID NO: 8, 10, 11 or 12 for use in therapy.</span>
  </p>
  <p id="p0016" num="0016" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han desarrollado nuevas composiciones que comprenden una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>que puede usarse para estimular el sistema inmunitario y tratar y prevenir enfermedades, en particular cáncer.</span>The inventors have developed new compositions comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that can be used to stimulate the immune system and treat and prevent diseases, in particular cancer.</span>
  </p>
  <p id="p0017" num="0017" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 97% idéntica a la SEQ ID NO: 1. Preferiblemente, la cepa bacteriana es de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>Therefore, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 97 % identical to SEQ ID NO: 1. Preferably, the bacterial strain is of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0018" num="0018" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1; para su uso en el tratamiento o la prevención del cáncer, como el melanoma metastásico, el cáncer de mama, el cáncer de ovario, el cáncer de cuello uterino, el neuroblastoma, el glioblastoma, el carcinoma, el cáncer de pulmón, la leucemia linfocítica crónica, cáncer de próstata, linfoma y/o cáncer gástrico. En aspectos adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1, para su uso en el tratamiento o la prevención del cáncer, como el cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In further aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; for use in the treatment or prevention of cancer, such as metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, lymphocytic leukemia chronic, prostate cancer, lymphoma and/or gastric cancer. In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in the treatment or prevention of cancer, such as colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0019" num="0019" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1, para su uso en el tratamiento, prevención o retraso de la inmunosenescencia.</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in the treatment, prevention or delay of immunosenescence.</span>
  </p>
  <p id="p0020" num="0020" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1, para su uso como adyuvante de vacunas.</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use as a vaccine adjuvant.</span>
  </p>
  <p id="p0021" num="0021" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En aspectos adicionales, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1, para su uso en la potenciación de una terapia celular, tal como CAR-T. 
</span>In additional aspects, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1, for use in enhancing a cell therapy, such as CAR-T. </span>
  </p>
  <p id="p0022" num="0022" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, la bacteria usada en la invención es la cepa depositada con el número de registro 42787 en NCIMB.</span>Preferably, the bacterium used in the invention is the strain deposited under accession number 42787 at NCIMB.</span>
  </p>
  <p id="p0023" num="0023" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">BREVE DESCRIPCIÓN DE LOS DIBUJOS</span>BRIEF DESCRIPTION OF THE DRAWINGS</span>
    </b>
  </p>
  <p id="p0024" num="0024" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 1</b>: Niveles de expresión de tubulina p3: inmunotinción e imagenología celular (Figura 1A); inmunotransferencia (Figura 1B)</span> <b class="style-scope patent-text">Figure 1</b> : p3 tubulin expression levels: immunostaining and cell imaging (Figure 1A); Western blot (Figure 1B)</span>
  </p>
  <p id="p0025" num="0025" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 2 </b>: Niveles de expresión de MAP2: inmunotinción e imagenología celular (Figura 2A); inmunotransferencia (Figura 2B); veces el cambio en la expresión (Figura 2C)</span> <b class="style-scope patent-text">Figure 2</b> : MAP2 expression levels: immunostaining and cell imaging (Figure 2A); immunoblot (Figure 2B); fold change in expression (Figure 2C)</span>
  </p>
  <p id="p0026" num="0026" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 3 </b>: Cambio en la expresión de DRD2</span> <b class="style-scope patent-text">Figure 3</b> : Change in DRD2 expression</span>
  </p>
  <p id="p0027" num="0027" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 4 </b>: Cambio en la expresión de Casp3</span> <b class="style-scope patent-text">Figure 4</b> : Change in Casp3 expression</span>
  </p>
  <p id="p0028" num="0028" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 5 </b>: Cambio en la viabilidad celular</span> <b class="style-scope patent-text">Figure 5</b> : Change in cell viability</span>
  </p>
  <p id="p0029" num="0029" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 6 </b>: fenotipado celular de células auxiliares T CD4 (Figura 6A); células CD4+ activadas (Figura 6B); células Tregs (Figura 6C); células T citotóxicas CD8 (Figura 6D); células activadas CD8+ (Figura 6E); células B (Figura 6F); Proporción CD8/Tregs (Figura 6G); Proporción CD8 activadas/Tregs (Figura 6H).</span> <b class="style-scope patent-text">Figure 6</b> : Cellular phenotyping of CD4 T helper cells (Figure 6A); activated CD4+ cells (FIG. 6B); Treg cells (FIG. 6C); CD8 cytotoxic T cells (FIG. 6D); activated CD8+ cells (FIG. 6E); B cells (FIG. 6F); CD8/Tregs ratio (FIG. 6G); Activated CD8/Tregs ratio (Figure 6H).</span>
  </p>
  <p id="p0030" num="0030" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 7 </b>: Análisis de citoquinas de IL-1 p (Figura 7A); TNF-a (Figura 7B); IL-23 (Figura 7C); IL-6 (Figura 7D); MIP-3a (Figura 7E); CXCL9 (Figura 7F); M<sup class="style-scope patent-text">c </sup>P-1 (Figura 7G); IL-10 (Figura 7H); GM-CSF (Figura 7I).</span> <b class="style-scope patent-text">Figure 7</b> : Cytokine analysis of IL-1p (Figure 7A); TNF-a (FIG. 7B); IL-23 (FIG. 7C); IL-6 (FIG. 7D); MIP-3a (FIG. 7E); CXCL9 (FIG. 7F); M <sup class="style-scope patent-text">c</sup> P-1 (FIG. 7G); IL-10 (FIG. 7H); GM-CSF (FIG. 7I).</span>
  </p>
  <p id="p0031" num="0031" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 8 </b>: Estrategia de regulación usada para analizar las diferentes poblaciones de células inmunitarias (células CD4, CD8 y CD 19+) mediante citometría de flujo para los datos presentados en la Figura 6.</span> <b class="style-scope patent-text">Figure 8</b> : Regulation strategy used to analyze the different populations of immune cells (CD4, CD8, and CD 19+ cells) using flow cytometry for the data presented in Figure 6.</span>
  </p>
  <p id="p0032" num="0032" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 9 </b>: Secreción de Interleucina-8 (IL-8)).</span> <b class="style-scope patent-text">Figure 9</b> : Secretion of Interleukin-8 (IL-8)).</span>
  </p>
  <p id="p0033" num="0033" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 10</b>: Cambio en la actividad de la histona deacetilasa (HDAC)</span> <b class="style-scope patent-text">Figure 10</b> : Change in histone deacetylase (HDAC) activity</span>
  </p>
  <p id="p0034" num="0034" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 11A</b>: Cambios inducidos por cepas en la actividad de histona deacetilasa de células completas y lisado celular; <b class="style-scope patent-text">Figura 11B</b>: producción de metabolitos por cepas; <b class="style-scope patent-text">Figura 11C</b>: cambios inducidos por ácido en la actividad de histona deacetilasa.</span> <b class="style-scope patent-text">Figure 11A</b> : Strain-induced changes in histone deacetylase activity of whole cells and cell lysate; <b class="style-scope patent-text">Figure 11B</b> : Metabolite production by strains; <b class="style-scope patent-text">Figure 11C</b> : Acid-induced changes in histone deacetylase activity.</span>
  </p>
  <p id="p0035" num="0035" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 12A</b>: inhibición de HDAC1; <b class="style-scope patent-text">Figura 12B</b>: inhibición de HDAC2; <b class="style-scope patent-text">Figura 12C</b>: Inhibición de HDAC3.</span> <b class="style-scope patent-text">Figure 12A</b> : HDAC1 inhibition; <b class="style-scope patent-text">Figure 12B</b> : HDAC2 inhibition; <b class="style-scope patent-text">Figure 12C</b> : HDAC3 inhibition.</span>
  </p>
  <p id="p0036" num="0036" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 13A</b>: Inhibición de HDAC de Clase I; <b class="style-scope patent-text">Figura 13B</b>: inhibición de HDAC1; <b class="style-scope patent-text">Figura 13C</b>: inhibición de HDAC2; <b class="style-scope patent-text">Figura 13D</b>: inhibición de HDAC3.</span> <b class="style-scope patent-text">Figure 13A</b> : Class I HDAC inhibition; <b class="style-scope patent-text">Figure 13B</b> : HDAC1 inhibition; <b class="style-scope patent-text">Figure 13C</b> : HDAC2 inhibition; <b class="style-scope patent-text">Figure 13D</b> : HDAC3 inhibition.</span>
  </p>
  <p id="p0037" num="0037" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 14</b>: Efectos sobre la función de barrera intestinal.</span> <b class="style-scope patent-text">Figure 14</b> : Effects on intestinal barrier function.</span>
  </p>
  <p id="p0038" num="0038" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 15</b>: Cambios en la expresión hipocampal del Receptor 4 tipo Toll (TLR-4).</span> <b class="style-scope patent-text">Figure 15</b> : Changes in hippocampal expression of Toll-like Receptor 4 (TLR-4).</span>
  </p>
  <p id="p0039" num="0039" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 16</b>: Cambios en la expresión hipocampal de TNF-a.</span> <b class="style-scope patent-text">Figure 16</b> : Changes in hippocampal expression of TNF-α.</span>
  </p>
  <p id="p0040" num="0040" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 17</b>: Cambios en la expresión hipocampal de interleucina-1 p (IL-1 p).</span> <b class="style-scope patent-text">Figure 17</b> : Changes in hippocampal expression of interleukin-1p (IL-1p).</span>
  </p>
  <p id="p0041" num="0041" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 18</b>: Cambios en la expresión hipocampal de interleucina-6 (IL-6).</span> <b class="style-scope patent-text">Figure 18</b> : Changes in hippocampal expression of interleukin-6 (IL-6).</span>
  </p>
  <p id="p0042" num="0042" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 19</b>: Cambios en la expresión hipocampal de CD11b.</span> <b class="style-scope patent-text">Figure 19</b> : Changes in hippocampal expression of CD11b.</span>
  </p>
  <p id="p0043" num="0043" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 20</b>: Cambios en la expresión de la amígdala de TLR-4.</span> <b class="style-scope patent-text">Figure 20</b> : Changes in amygdala expression of TLR-4.</span>
  </p>
  <p id="p0044" num="0044" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 21</b>: Cambios en la expresión de la amígdala de CD11b.</span> <b class="style-scope patent-text">Figure 21</b> : Changes in CD11b amygdalin expression.</span>
  </p>
  <p id="p0045" num="0045" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 22</b>: Cambios en la expresión de la amígdala de IL-6.</span> <b class="style-scope patent-text">Figure 22</b> : Changes in amygdalin expression of IL-6.</span>
  </p>
  <p id="p0046" num="0046" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 23</b>: Cambios en la expresión de la corteza prefrontal de TLR-4.</span> <b class="style-scope patent-text">Figure 23</b> : Changes in prefrontal cortex expression of TLR-4.</span>
  </p>
  <p id="p0047" num="0047" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 24</b>: Cambios en la expresión de la corteza prefrontal de CD11b.</span> <b class="style-scope patent-text">Figure 24</b> : Changes in prefrontal cortex expression of CD11b.</span>
  </p>
  <p id="p0048" num="0048" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 25</b>: Cambios en la expresión de la corteza prefrontal de IL-6.</span> <b class="style-scope patent-text">Figure 25</b> : Changes in prefrontal cortex expression of IL-6.</span>
  </p>
  <p id="p0049" num="0049" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 26</b>: Efecto sobre la producción de interferón-Y a partir de esplenocitos de ratón de ratones a los que se les 
administró MRx0029.</span> <b class="style-scope patent-text">Figure 26</b> : Effect on interferon-Y production from mouse splenocytes from mice given  administered MRx0029.</span>
  </p>
  <p id="p0050" num="0050" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 27</b>: Efecto sobre la producción de IL-1 p a partir de esplenocitos de ratón de ratones a los que se les administró MRx0029.</span> <b class="style-scope patent-text">Figure 27</b> : Effect on IL-1p production from mouse splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0051" num="0051" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 28</b>: Efecto sobre la producción de IL-6 a partir de esplenocitos de ratón de ratones a los que se les administró MRx0029.</span> <b class="style-scope patent-text">Figure 28</b> : Effect on IL-6 production from mouse splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0052" num="0052" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 29</b>: Efecto sobre la producción de TNF-a a partir de esplenocitos de ratones a los que se les administró MRx0029.</span> <b class="style-scope patent-text">Figure 29</b> : Effect on TNF-α production from splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0053" num="0053" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 30</b>: Efecto sobre la producción de CXCL1 a partir de esplenocitos de ratones a los que se les administró MRx0029.</span> <b class="style-scope patent-text">Figure 30</b> : Effect on CXCL1 production from splenocytes of mice administered MRx0029.</span>
  </p>
  <p id="p0054" num="0054" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 31</b>: Expresión génica de MAP2 en la línea celular SKMEL2 después de varios tratamientos, con respecto a GAPDH. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 31</b> : MAP2 gene expression in the SKMEL2 cell line after various treatments, with respect to GAPDH. “YCFA” = YCFA+</span>
  </p>
  <p id="p0055" num="0055" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 32</b>: Supervivencia clonogénica de la línea celular SKMEL2 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 32</b> : Clonogenic survival of the SKMEL2 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0056" num="0056" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 33</b>: Crecimiento en agar blando de la línea celular SKMEL2 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 33</b> : Growth in soft agar of the SKMEL2 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0057" num="0057" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 34</b>: Señalización de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la línea celular SKMEL2 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 34</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL2 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0058" num="0058" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 35</b>: Expresión génica de MAP2 en la línea celular SKMEL28 después de varios tratamientos, con respecto a GAPDH. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 35</b> : MAP2 gene expression in the SKMEL28 cell line after various treatments, with respect to GAPDH. “YCFA” = YCFA+</span>
  </p>
  <p id="p0059" num="0059" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 36</b>: Supervivencia clonogénica de la línea celular SKMEL28 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 36</b> : Clonogenic survival of the SKMEL28 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0060" num="0060" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 37</b>: Crecimiento en agar blando de la línea celular SKMEL28 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 37</b> : Growth in soft agar of the SKMEL28 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0061" num="0061" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 38</b>: Señalización de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la línea celular SKMEL28 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 38</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL28 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0062" num="0062" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 39</b>: Expresión génica de MAP2 en la línea celular SKMEL31 después de varios tratamientos, con respecto a GAPDH. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 39</b> : MAP2 gene expression in the SKMEL31 cell line after various treatments, with respect to GAPDH. “YCFA” = YCFA+</span>
  </p>
  <p id="p0063" num="0063" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 40</b>: Supervivencia clonogénica de la línea celular SKMEL31 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 40</b> : Clonogenic survival of the SKMEL31 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0064" num="0064" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 41</b>: Crecimiento en agar blando de la línea celular SKMEL31 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 41</b> : Growth in soft agar of the SKMEL31 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0065" num="0065" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 42</b>: Señalización de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la línea celular SKMEL31 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 42</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the SKMEL31 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0066" num="0066" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 43</b>: Expresión génica de MAP2 en la línea celular 451Lu después de varios tratamientos, con respecto a GAPDH. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 43</b> : MAP2 gene expression in the 451Lu cell line after various treatments, with respect to GAPDH. “YCFA” = YCFA+</span>
  </p>
  <p id="p0067" num="0067" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 44</b>: Supervivencia clonogénica de la línea celular 451Lu después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 44</b> : Clonogenic survival of the 451Lu cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0068" num="0068" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 45</b>: Crecimiento en agar blando de la línea celular 451Lu después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 45</b> : Growth in soft agar of the 451Lu cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0069" num="0069" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 46</b>: Señalización de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la línea celular 451 Lu después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 46</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the 451 Lu cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0070" num="0070" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 47</b>: Expresión génica de MAP2 en la línea celular F1T-29 después de varios tratamientos, con respecto a GAPDH. “YCFA” = YCFA+ 
</span> <b class="style-scope patent-text">Figure 47</b> : MAP2 gene expression in the F1T-29 cell line after various treatments, with respect to GAPDH. “YCFA” = YCFA+ </span>
  </p>
  <p id="p0071" num="0071" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 48</b>: Supervivencia clonogénica de la línea celular HT-29 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 48</b> : Clonogenic survival of the HT-29 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0072" num="0072" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 49A</b>: Crecimiento en agar blando de la línea celular HT-29 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 49A</b> : Growth in soft agar of the HT-29 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0073" num="0073" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 49B</b>: Crecimiento en agar blando de la línea celular HT-29 después de varios tratamientos (fotografía de placas de agar). “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 49B</b> : Growth in soft agar of the HT-29 cell line after various treatments (photograph of agar plates). “YCFA” = YCFA+</span>
  </p>
  <p id="p0074" num="0074" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 50</b>: Señalización de ERK (ERK1 y 2 fosforilados (p44 y p42)/ERK total) en la línea celular HT29 después de varios tratamientos. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 50</b> : ERK signaling (phosphorylated ERK1 and 2 (p44 and p42)/total ERK) in the HT29 cell line after various treatments. “YCFA” = YCFA+</span>
  </p>
  <p id="p0075" num="0075" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 51</b>: Descripción general de la vía MAP-quinasa (de [72]).</span> <b class="style-scope patent-text">Figure 51</b> : Overview of the MAP-kinase pathway (from [72]).</span>
  </p>
  <p id="p0076" num="0076" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 52</b>: Expresión de ARN de GPR109a en células Caco-2 diferenciadas (A) sin y (B) con tratamiento con miristato de forbol además de MRx0029. “YCFA” = YCFA+</span> <b class="style-scope patent-text">Figure 52</b> : GPR109a RNA expression in differentiated Caco-2 cells (A) without and (B) with phorbol myristate treatment in addition to MRx0029. “YCFA” = YCFA+</span>
  </p>
  <p id="p0077" num="0077" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 53</b>: Inducción de la secreción de IL-8 a partir de células HT29 por (A) MRx0029 con medio acondicionado y (B) MRx0029 solo.</span> <b class="style-scope patent-text">Figure 53</b> : Induction of IL-8 secretion from HT29 cells by (A) MRx0029 with conditioned medium and (B) MRx0029 alone.</span>
  </p>
  <p id="p0078" num="0078" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 54</b>: Análisis de metabolitos para la cepa NCIMB 42787 de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span> <b class="style-scope patent-text">Figure 54</b> : Metabolite analysis for <i class="style-scope patent-text">Megasphaera massiliensis strain NCIMB 42787.</i> </span>
  </p>
  <p id="p0079" num="0079" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 55</b>: Producción de ácido valérico en el sobrenadante de las cepas MRx0029 y <i class="style-scope patent-text">Megasphaera massiliensis </i>de referencia.</span> <b class="style-scope patent-text">Figure 55</b> : Production of valeric acid in the supernatant of the reference strains MRx0029 and <i class="style-scope patent-text">Megasphaera massiliensis</i> .</span>
  </p>
  <p id="p0080" num="0080" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 56</b>: Producción y consumo de ácidos orgánicos por las cepas MRx0029 y <i class="style-scope patent-text">Megasphaera massiliensis </i>de referencia.</span> <b class="style-scope patent-text">Figure 56</b> : Production and consumption of organic acids by the MRx0029 and <i class="style-scope patent-text">Megasphaera massiliensis</i> reference strains.</span>
  </p>
  <p id="p0081" num="0081" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 57</b>: Supresión de NSE/Enolasa 2 por MRX029. “YCFA” = YCFA+.</span> <b class="style-scope patent-text">Figure 57</b> : Suppression of NSE/Enolase 2 by MRX029. "YCFA" = YCFA+.</span>
  </p>
  <p id="p0082" num="0082" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 58</b>: Producción y consumo de ácidos orgánicos por NCIMB 42787, NCIMB 43385, NCIMB 43388 y NCIMB 43389.</span> <b class="style-scope patent-text">Figure 58</b> : Production and consumption of organic acids by NCIMB 42787, NCIMB 43385, NCIMB 43388, and NCIMB 43389.</span>
  </p>
  <p id="p0083" num="0083" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 59</b>: Regulación por incremento de la secreción de IL-6 en células U373 por NCIMB 42787 y otras cepas depositadas (n=3).</span> <b class="style-scope patent-text">Figure 59</b> : Upregulation of IL-6 secretion in U373 cells by NCIMB 42787 and other deposited strains (n=3).</span>
  </p>
  <p id="p0084" num="0084" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 60</b>: Supresión de enolasa 2 por NCIMB 42787, NCIMB 43385, NCIMB 43388, NCIMB 43389, NCIMB 43386 y NCIMB 43387.</span> <b class="style-scope patent-text">Figure 60</b> : Suppression of enolase 2 by NCIMB 42787, NCIMB 43385, NCIMB 43388, NCIMB 43389, NCIMB 43386, and NCIMB 43387.</span>
  </p>
  <p id="p0085" num="0085" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 61A</b>: NCIMB 42787 y otras depositadas aumentan la expresión de MAP2; <b class="style-scope patent-text">Figura 61B y C</b>: Modulación de los niveles de citoquinas y promotor de NP<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B-AP1 por NCIMB 42787.</span> <b class="style-scope patent-text">Figure 61A</b> : NCIMB 42787 and others deposited increase MAP2 expression; <b class="style-scope patent-text">Figure 61B and C</b> : Modulation of NP <b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b> B-AP1 promoter and cytokine levels by NCIMB 42787.</span>
  </p>
  <p id="p0086" num="0086" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 62</b>: NCIMB 42787 produce ácido butírico, valérico y hexanoico</span> <b class="style-scope patent-text">Figure 62</b> : NCIMB 42787 produces butyric, valeric and hexanoic acid</span>
  </p>
  <p id="p0087" num="0087" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 63</b>: Actividad inmunoestimuladora de metabolitos producidos por NCIMB 42787.</span> <b class="style-scope patent-text">Figure 63</b> : Immunostimulatory activity of metabolites produced by NCIMB 42787.</span>
  </p>
  <p id="p0088" num="0088" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 64</b>: Análisis del papel de los metabolitos en la actividad inmunoestimuladora de NCIMB 42787.</span> <b class="style-scope patent-text">Figure 64</b> : Analysis of the role of metabolites in the immunostimulatory activity of NCIMB 42787.</span>
  </p>
  <p id="p0089" num="0089" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 65</b>: La cepa NCIMB 43387 de <i class="style-scope patent-text">Megasphaera </i>afecta a la expresión del ARNm de IDO-1 del colon en ratones BALB/c.</span> <b class="style-scope patent-text">Figure 65</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43387</i> affects colonic IDO-1 mRNA expression in BALB/c mice.</span>
  </p>
  <p id="p0090" num="0090" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 66</b>: Las cepas NCIMB 43385 y NCIMB 43387 de <i class="style-scope patent-text">Megasphaera </i>afectan a la expresión del ARNm de Tph1 del colon en ratones BALB/c.</span> <b class="style-scope patent-text">Figure 66</b> : Megasphaera strains NCIMB 43385 and NCIMB <i class="style-scope patent-text">43387</i> affect colonic Tph1 mRNA expression in BALB/c mice.</span>
  </p>
  <p id="p0091" num="0091" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 67</b>: la cepa NCIMB 43385 de <i class="style-scope patent-text">Megasphaera </i>modula la producción de IPNy e IL-6 tras la estimulación con ConA de esplenocitos de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 67</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43385</i> modulates IPNy and IL-6 production after ConA stimulation of splenocytes from BALB/c mice.</span>
  </p>
  <p id="p0092" num="0092" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 68</b>: La cepa NCIMB 43385 de <i class="style-scope patent-text">Megasphaera </i>modula la expresión de IL-6 y CD11b en el cerebro de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 68</b> : Megasphaera strain NCIMB <i class="style-scope patent-text">43385</i> modulates the expression of IL-6 and CD11b in the brain of BALB/c mice.</span>
  </p>
  <p id="p0093" num="0093" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <b class="style-scope patent-text">Figura 69</b>: NCIMB 42787 modula la expresión de TLR4 en la amígdala de ratones BALB/c.</span> <b class="style-scope patent-text">Figure 69</b> : NCIMB 42787 modulates TLR4 expression in the amygdala of BALB/c mice.</span>
  </p>
  <p id="p0094" num="0094" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">DIVULGACIÓN DE LA INVENCIÓN</span>DISCLOSURE OF THE INVENTION</span>
    </b>
  </p>
  <p id="p0095" num="0095" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas </span>bacterial strains</span>
      </i>
    </b>
    
  </p>
  <p id="p0096" num="0096" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención, como se define en las reivindicaciones, comprenden una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera. </i>Los Ejemplos demuestran que las bacterias de este género son útiles para estimular el sistema inmunitario y para tratar enfermedades, en particular cáncer. Las cepas bacterianas preferidas son las de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>The compositions of the invention, as defined in the claims, comprise a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> The Examples demonstrate that bacteria of this genus are useful for stimulating the immune system and for treating diseases, in particular cancer. Preferred bacterial strains are those of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0097" num="0097" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos de especies de <i class="style-scope patent-text">Megasphaera </i>para su uso en la invención incluyen <i class="style-scope patent-text">Megasphaera elsdenii, Megasphaera cerevisiae, Megasphaera massiliensis, Megasphaera indica, Megasphaera paucivorans, Megasphaera sueciensis </i>y <i class="style-scope patent-text">Megasphaera micronuciformis. </i>Un ejemplo adicional de una especie de <i class="style-scope patent-text">Megasphaera </i>para su uso en la invención es <i class="style-scope patent-text">Megasphaera hexanoica. </i>Los <i class="style-scope patent-text">Megasphaera </i>son microbios gastrointestinales obligadamente anaeróbicos, fermentadores de lactato, de mamíferos rumiantes y no rumiantes, incluyendo los humanos.</span>Examples of <i class="style-scope patent-text">Megasphaera</i> species for use in the invention include <i class="style-scope patent-text">Megasphaera elsdenii, Megasphaera cerevisiae, Megasphaera massiliensis, Megasphaera indica, Megasphaera paucivorans, Megasphaera sueciensis,</i> and <i class="style-scope patent-text">Megasphaera micronuciformis.</i> A further example of a <i class="style-scope patent-text">Megasphaera</i> species for use in the invention is <i class="style-scope patent-text">Megasphaera hexanoica.</i> <i class="style-scope patent-text">Megasphaera</i> are obligately anaerobic, lactate-fermenting gastrointestinal microbes of ruminant and non-ruminant mammals, including humans.</span>
  </p>
  <p id="p0098" num="0098" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa tipo de <i class="style-scope patent-text">M massiliensis </i>es NP3 (=CSUR P245=DSM 26228) [16]. El número de registro del GenBank para las secuencias del gen ARNr 16S de la cepa NP3 de <i class="style-scope patent-text">M massiliensis </i>es JX424772.1.</span>The type strain of <i class="style-scope patent-text">M massiliensis</i> is NP3 (=CSUR P245=DSM 26228) [16]. The GenBank accession number for the 16S rRNA gene sequences of the <i class="style-scope patent-text">M massiliensis</i> strain NP3 is JX424772.1.</span>
  </p>
  <p id="p0099" num="0099" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A la bacteria <i class="style-scope patent-text">Megasphaera massiliensis </i>probada en los Ejemplos se hace referencia en la presente como cepa MRx0029. En la SEQ ID NO: 1 se proporciona una secuencia de ARNr 16S para la cepa MRx0029 que se probó.</span>The <i class="style-scope patent-text">Megasphaera massiliensis</i> bacterium tested in the Examples is referred to herein as strain MRx0029. A 16S rRNA sequence for strain MRx0029 that was tested is given in SEQ ID NO: 1.</span>
  </p>
  <p id="p0100" num="0100" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa MRx0029 fue depositada en la autoridad de depósito internacional NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Escocia) por 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB252ZS, Escocia) el 13 de julio de 2017 como <i class="style-scope patent-text">“Megasphaera massiliensis </i>MRx0029” y se le asignó el número de registro nCiMB 42787.</span>Strain MRx0029 was deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB252ZS, Scotland) on 13 July 2017 as <i class="style-scope patent-text">“Megasphaera massiliensis</i> MRx0029” and assigned nCiMB registration number 42787.</span>
  </p>
  <p id="p0101" num="0101" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se espera que las cepas bacterianas estrechamente relacionadas con la cepa probada en los Ejemplos sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 97%, 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO: 1. Preferiblemente, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 1.</span>Bacterial strains closely related to the strain tested in the Examples are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 97%, 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO: 1. Preferably, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 1.</span>
  </p>
  <p id="p0102" num="0102" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se espera que las cepas bacterianas que son biotipos de las cepas MRx0029 sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer. Un biotipo es una cepa estrechamente relacionada que tiene características fisiológicas y bioquímicas iguales o muy similares.</span>Bacterial strains that are biotypes of the MRx0029 strains are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.</span>
  </p>
  <p id="p0103" num="0103" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invención pueden identificarse secuenciando otras secuencias de nucleótidos para las cepas MRx0029. Por ejemplo, puede secuenciarse sustancialmente el genoma completo y una cepa de biotipo para su uso en la invención puede tener por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia en por lo menos un 80% de su genoma completo (por ejemplo, en por lo menos el 85%, 90%, 95% o 99%, o en su genoma completo). Otras secuencias adecuadas para su uso en la identificación de cepas de biotipo pueden incluir hsp60 o secuencias repetitivas como BOX, ERIC, (GTG)5o REP o [17]. Las cepas de biotipo pueden tener secuencias con por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia con la secuencia correspondiente de las cepas MRx0029.</span>Strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention can be identified by sequencing other nucleotide sequences for the MRx0029 strains. For example, substantially the entire genome can be sequenced, and a biotype strain for use in the invention can be at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% of sequence identity to at least 80% of its entire genome (for example, to at least 85%, 90%, 95%, or 99%, or to its entire genome). Other sequences suitable for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)5 or REP or [17]. Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to the corresponding sequence of MRx0029 strains.</span>
  </p>
  <p id="p0104" num="0104" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invención pueden identificarse usando cepas MRx0029 y análisis de fragmentos de restricción y/o análisis por PCR, por ejemplo usando polimorfismo de longitud de fragmento amplificado fluorescente (FAFLP) e identificación de elemento de ADN repetitivo (rep)-PCR, o realización de perfiles de proteínas, o secuenciación parcial de ADNr 16S o 23S. En realizaciones preferidas, tales técnicas pueden usarse para identificar otras cepas de <i class="style-scope patent-text">Megasphaera massiliensis</i>.</span>Alternatively, strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention can be identified using MRx0029 strains and restriction fragment analysis and/or PCR analysis, for example using fluorescent amplified fragment length polymorphism ( FAFLP) and repetitive DNA element identification (rep)-PCR, or protein profiling, or partial 16S or 23S rDNA sequencing. In preferred embodiments, such techniques can be used to identify other <i class="style-scope patent-text">Megasphaera massiliensis</i> strains.</span>
  </p>
  <p id="p0105" num="0105" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas que son biotipos de las cepas MRx0029 y que son adecuadas para su uso en la invención son cepas que proporcionan el mismo patrón que la cepa MRx0029 cuando se analizan mediante análisis de restricción de ADN ribosómico amplificado (ARDRA), por ejemplo, cuando se usa la enzima de restricción Sau3AI (para métodos ejemplares y orientación, consultar, por ejemplo, [18]). Alternativamente, las cepas de biotipo se identifican como cepas que tienen los mismos patrones de fermentación de carbohidratos que las cepas MRx0029.</span>In certain embodiments, the strains that are biotypes of the MRx0029 strains and that are suitable for use in the invention are strains that provide the same pattern as the MRx0029 strain when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), e.g. example, when using the restriction enzyme Sau3AI (for exemplary methods and guidance, see, eg, [18]). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as the MRx0029 strains.</span>
  </p>
  <p id="p0106" num="0106" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras cepas de <i class="style-scope patent-text">Megasphaera </i>que son útiles en las composiciones y métodos de la invención, como los biotipos de la cepa MRx0029, pueden identificarse usando cualquier método o estrategia apropiados, incluyendo los ensayos descritos en los Ejemplos. Por ejemplo, las cepas para su uso en la invención pueden identificarse añadiéndolas al lisado celular o a células completas y analizando la expresión de MAP2, la expresión de DRD2, los niveles de citoquinas o la supervivencia celular. En particular, las cepas bacterianas que tienen patrones de crecimiento, tipo metabólico y/o antígenos de superficie similares a las cepas MRx0029 pueden ser útiles en la invención. Una cepa útil tendrá una actividad inmunomoduladora comparable a las cepas MRx0029. En particular, una cepa de biotipo provocará efectos comparables sobre la expresión de MAP2, la expresión de DRD2, los niveles 
de citoquinas o la supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Una cepa de biotipo puede provocar efectos comparables sobre la actividad inhibidora de histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos.</span>Other <i class="style-scope patent-text">Megasphaera</i> strains that are useful in the compositions and methods of the invention, such as biotypes of strain MRx0029, can be identified using any appropriate method or strategy, including the assays described in the Examples. For example, strains for use in the invention can be identified by adding them to cell lysate or whole cells and analyzing for MAP2 expression, DRD2 expression, cytokine levels, or cell survival. In particular, bacterial strains that have similar growth patterns, metabolic type, and/or surface antigens to the MRx0029 strains may be useful in the invention. A useful strain will have immunomodulatory activity comparable to the MRx0029 strains. In particular, a biotype strain will elicit comparable effects on MAP2 expression, DRD2 expression, levels  of cytokines or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A biotype strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples.</span>
  </p>
  <p id="p0107" num="0107" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las cepas bacterianas útiles en la invención pueden identificarse realizando perfiles rutinariamente de la producción y el consumo de metabolitos por una cepa bacteriana. Los inventores han descubierto que la cepa bacteriana usada en los Ejemplos produce butirato, ácido valérico y ácido hexanoico y consume acetato y propionato (ver las Figuras 54-56). También se descubrió que las cepas Ref 1, Ref 2 y Ref 3 de <i class="style-scope patent-text">Megasphaera massiliensis </i>consumen y producen estos metabolitos (ver las Figuras 54-56). Por lo tanto, en algunas realizaciones, la cepa bacteriana de la invención produce uno o más de los metabolitos butirato, ácido valérico y ácido hexanoico. En algunas realizaciones, la cepa bacteriana de la invención consume uno o ambos de acetato y propionato. En realizaciones preferidas, la cepa bacteriana de la invención produce butirato, ácido valérico y ácido hexanoico y consume acetato y propionato.</span>In some embodiments, bacterial strains useful in the invention can be identified by routinely profiling the production and consumption of metabolites by a bacterial strain. The inventors have found that the bacterial strain used in the Examples produces butyrate, valeric acid and hexanoic acid and consumes acetate and propionate (see Figures 54-56). <i class="style-scope patent-text">Megasphaera massiliensis</i> strains Ref 1, Ref 2 and Ref 3 were also found to consume and produce these metabolites (see Figures 54-56). Therefore, in some embodiments, the bacterial strain of the invention produces one or more of the metabolites butyrate, valeric acid, and hexanoic acid. In some embodiments, the bacterial strain of the invention consumes one or both of acetate and propionate. In preferred embodiments, the bacterial strain of the invention produces butyrate, valeric acid, and hexanoic acid and consumes acetate and propionate.</span>
  </p>
  <p id="p0108" num="0108" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una cepa particularmente preferida de la invención es la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis. </i>Esta es la cepa ejemplar probada en los Ejemplos y que ha demostrado ser eficaz para tratar enfermedades. Por lo tanto, la invención proporciona una célula, como una célula aislada, de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis</i>, o un derivado de la misma. La invención también proporciona una composición que comprende una célula de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis, </i>o un derivado de la misma. La invención también proporciona un cultivo biológicamente puro de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis. </i>La invención también proporciona una célula de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis, </i>o un derivado de la misma, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>A particularly preferred strain of the invention is <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029.</i> This is the exemplary strain tested in the Examples and has been shown to be effective in treating disease. Thus, the invention provides a cell, as an isolated cell, of <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029, or a derivative thereof. The invention also provides a composition comprising a cell of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029,</i> or a derivative thereof. The invention also provides a biologically pure culture of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029.</i> The invention also provides a cell of <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029,</i> or a derivative thereof, for use in therapy, in particular for the diseases described herein.</span>
  </p>
  <p id="p0109" num="0109" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una cepa particularmente preferida de la invención es la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42787. Esta es la cepa MRx0029 ejemplar probada en los Ejemplos y que ha demostrado ser eficaz para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer. Por lo tanto, la invención proporciona una célula, tal como una célula aislada, de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42787, o un derivado de la misma. La invención también proporciona una composición que comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42787, o un derivado de la misma. La invención también proporciona un cultivo biológicamente puro de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42787. La invención también proporciona una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42787, o un derivado de la misma, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>A particularly preferred strain of the invention is the <i class="style-scope patent-text">Megasphaera massiliensis</i> strain deposited under accession number NCIMB 42787. This is the exemplary MRx0029 strain tested in the Examples and has been shown to be effective in stimulating the immune system and in treating and preventing disease, in particularly cancer. Therefore, the invention provides a cell, such as an isolated cell, of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 42787, or a derivative thereof. The invention also provides a composition comprising a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 42787, or a derivative thereof. The invention also provides a biologically pure culture of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 42787. The invention also provides a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 42787, or a derivative thereof, for their use in therapy, in particular for the diseases described herein.</span>
  </p>
  <p id="p0111" num="0111" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un derivado de la cepa de la invención puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) a partir de la original. Un derivado de una cepa de la invención puede modificarse, por ejemplo a nivel genético, sin extirpar la actividad biológica. En particular, una cepa derivada de la invención es terapéuticamente activa. Una cepa derivada tendrá una actividad terapéutica comparable a la cepa MRx0029. En particular, una cepa derivada provocará efectos comparables sobre la expresión de MAP2, la expresión de DRD2, los niveles de citoquinas o la supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Una cepa derivada puede provocar efectos comparables sobre la actividad inhibidora de la histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Un derivado de la cepa MRx0029 será generalmente un biotipo de la cepa MRx0029.</span>A derivative of the strain of the invention may be a daughter strain (progeny) or a cultivated strain (subcloned) from the original. A derivative of a strain of the invention can be modified, for example at the genetic level, without removing biological activity. In particular, a strain derived from the invention is therapeutically active. A derived strain will have comparable therapeutic activity to the MRx0029 strain. In particular, a derived strain will elicit comparable effects on MAP2 expression, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative of strain MRx0029 will generally be a biotype of strain MRx0029.</span>
  </p>
  <p id="p0112" num="0112" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las referencias a células de la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis </i>abarcan cualquier célula que tenga las mismas características de seguridad y eficacia terapéutica que la cepa MRx0029, y tales células están abarcadas por la invención.</span>References to <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029 cells encompass any cell that has the same safety and therapeutic efficacy characteristics as strain MRx0029, and such cells are encompassed by the invention.</span>
  </p>
  <p id="p0113" num="0113" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las cepas bacterianas en las composiciones de la invención son viables y capaces de colonizar parcial o totalmente el intestino.</span>In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonizing the intestine.</span>
  </p>
  <p id="p0114" num="0114" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>aumentan la activación de citoquinas inflamatorias como IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 y/o <sup class="style-scope patent-text">i</sup>L-6.</span>The inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains increase the activation of inflammatory cytokines such as IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 and/or <sup class="style-scope patent-text">i</sup> L-6.</span>
  </p>
  <p id="p0115" num="0115" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>aumentan la activación de las células inmunitarias y mejoran la secreción de citoquinas como IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 y/o IL-6.</span>The inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains increase the activation of immune cells and enhance the secretion of cytokines such as IL-1 p, TNF-a, MIP-3a, IL-23, IL-8 and/or IL-6 .</span>
  </p>
  <p id="p0116" num="0116" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 42787, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como el neuroblastoma. En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 42787, o un 
derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 42787, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited with the NCIMB under accession number NCIMB 42787, or a  derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma , gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0117" num="0117" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las cepas bacterianas en las composiciones de la invención son viables y capaces de colonizar parcial o totalmente el intestino.</span>In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonizing the intestine.</span>
  </p>
  <p id="p0118" num="0118" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención no comprende una célula de la cepa 42787 de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>In certain embodiments, the composition of the invention does not comprise a <i class="style-scope patent-text">Megasphaera massiliensis strain 42787 cell.</i> </span>
  </p>
  <p id="p0119" num="0119" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 42787.</span>In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under NCIMB accession number 42787.</span>
  </p>
  <p id="p0120" num="0120" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 42787.</span>In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the bacterial strain is not the strain deposited under NCIMB accession number 42787.</span>
  </p>
  <p id="p0121" num="0121" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estas cepas bacterianas fueron depositadas ante la autoridad de depósito internacional NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Escocia) por 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Escocia) el 6 de mayo de 2019 como <i class="style-scope patent-text">Megasphaera massiliensis </i>(con los números de registro NCIMB 43388 y NCIMB 43389) y <i class="style-scope patent-text">Megasphaera spp. </i>(números de registro NCIMB 43385, NCIMB 43386 y NCIMB 43387). Por consiguiente, en una realización alternativa, las composiciones de la invención comprenden una o más de estas cepas bacterianas, o biotipos o derivados de las mismas. Para evitar dudas, la Ref 1 mencionada anteriormente es la cepa depositada con el número de registro NCIMB 43385, la Ref 2 mencionada anteriormente es la cepa depositada con el número de registro NCIMB 43388, y la Ref 3 mencionada anteriormente es la cepa depositada con el número de registro NCIMB 43389.</span>These bacterial strains were deposited with the International Depository Authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Cornhill Road, Aberdeen, AB25 2ZS, Scotland) on 6 May 2019 as <i class="style-scope patent-text">Megasphaera massiliensis</i> (with accession numbers NCIMB 43388 and NCIMB 43389) and <i class="style-scope patent-text">Megasphaera spp.</i> (NCIMB registry numbers 43385, NCIMB 43386, and NCIMB 43387). Therefore, in an alternative embodiment, the compositions of the invention comprise one or more of these bacterial strains, or biotypes or derivatives thereof. For the avoidance of doubt, the above-mentioned Ref 1 is the strain deposited under registration number NCIMB 43385, the above-mentioned Ref 2 is the strain deposited under registration number NCIMB 43388, and the above-mentioned Ref 3 is the strain deposited under registration number NCIMB 43388. NCIMB registration number 43389.</span>
  </p>
  <p id="p0122" num="0122" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se espera que las cepas bacterianas estrechamente relacionadas con las cepas probadas en los Ejemplos sean eficaces para estimular el sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer.</span>Bacterial strains closely related to the strains tested in the Examples are also expected to be effective in stimulating the immune system and in treating and preventing disease, particularly cancer.</span>
  </p>
  <p id="p0123" num="0123" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención es la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43388. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43388, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43388, o un derivado de la misma, para su uso en la estimulación del sistema inmunitario y para el tratamiento y la prevención de enfermedades, en particular cáncer. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43388, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43388. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43388, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0124" num="0124" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona el uso de una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43388, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invención proporciona el uso de una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43388, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides the use of a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43388, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and preventing diseases, in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides the use of a composition comprising the strain deposited in the NCIMB under registration number NCIMB 43388, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0125" num="0125" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición para el uso de acuerdo con la invención no comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43388. En algunas realizaciones, la cepa bacteriana en las composiciones para el uso de acuerdo con la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43388. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43388.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43388. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain is not the strain deposited under NCIMB Accession Number 43388. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> where the bacterial strain is not the strain deposited under the registration number NCIMB 43388.</span>
  </p>
  <p id="p0126" num="0126" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, en ciertas realizaciones, la cepa bacteriana para su uso en la invención es la <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43389. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43389, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43389, o un derivado de la misma, para su uso en la estimulación del sistema 
inmunitario y para tratar y prevenir enfermedades, en particular cáncer. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43389, para su uso en cualquiera de las enfermedades descritas en la presente.</span>Accordingly, in certain embodiments, the bacterial strain for use in the invention is <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under NCIMB Accession Number 43389. In certain embodiments, the invention provides a cell of the strain deposited under NCIMB Accession Number 43389, or a derivative thereof, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43389, or a derivative thereof, for use in stimulating the immune system.  immune system and to treat and prevent disease, particularly cancer. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43389, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0127" num="0127" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43389, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43389, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43389, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at NCIMB under registration number NCIMB 43389, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0128" num="0128" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición para su uso de acuerdo con la invención no comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43389. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43389. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43389.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43389. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43389. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> where the bacterial strain is not the strain deposited under the registration number NCIMB 43389.</span>
  </p>
  <p id="p0129" num="0129" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO:9. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO:9. En ciertas realizaciones, la invención proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO:9 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:9. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO:9. In certain embodiments, the invention provides a bacterial strain having a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:9 for use in therapy.</span>
  </p>
  <p id="p0130" num="0130" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO:10. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 10. En ciertas realizaciones, la invención proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO: 10 para su uso en terapia. En ciertas realizaciones, la invención proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 10 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 98%, 99%, 99.5%, or 99.9% identical to SEQ ID NO:10. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 10. In certain embodiments, the invention provides a bacterial strain that has a 16S rRNA sequence that is at least 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 10 for use in therapy. In certain embodiments, the invention provides a bacterial strain having the 16S rRNA sequence represented by SEQ ID NO: 10 for use in therapy.</span>
  </p>
  <p id="p0131" num="0131" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% idéntica a la secuencia de ARNr 16S de una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>. La cepa bacteriana para su uso en la invención es del género <i class="style-scope patent-text">Megasphaera</i>.</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical. to the 16S rRNA sequence of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> . The bacterial strain for use in the invention is of the genus <i class="style-scope patent-text">Megasphaera</i> .</span>
  </p>
  <p id="p0132" num="0132" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB 43385. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43385, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43385, o un derivado de la misma, para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43385, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43385. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, or a derivative thereof, for use in stimulating the immune system and treating and preventing disease, in particular cancer. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43385, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0133" num="0133" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43385, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43385, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43385, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at the NCIMB under registration number NCIMB 43385, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0134" num="0134" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención no comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43385. En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43385. En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa 
bacteriana no es la cepa depositada con el número de registro NCIMB 43385.</span>In certain embodiments, the composition of the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 43385. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under accession number NCIMB 43385. In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the strain  bacterial is not the strain deposited under accession number NCIMB 43385.</span>
  </p>
  <p id="p0136" num="0136" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB 43386. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43386, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43386, o un derivado de la misma, para su uso en la estimulación del sistema inmunitario y para el tratamiento y la prevención de enfermedades, en particular cáncer. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43386, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43386. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43386, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0138" num="0138" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43386, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para tratar y prevenir enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43386, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with the registration number NCIMB 43386, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and to treat and prevent diseases. , in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at the NCIMB under registration number NCIMB 43386, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer , ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0140" num="0140" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición para su uso de acuerdo con la invención no comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43386. En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43386. En algunas realizaciones, la cepa bacteriana en las composiciones para su uso de acuerdo con la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43386.</span>In certain embodiments, the composition for use according to the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under accession number NCIMB 43386. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43386. In some embodiments, the bacterial strain in compositions for use according to the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> in where the bacterial strain is not the strain deposited under NCIMB accession number 43386.</span>
  </p>
  <p id="p0142" num="0142" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención es la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB 43387. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43387, o un derivado de la misma, para su uso en terapia. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43387, o un derivado de la misma, para su uso en la estimulación del sistema inmunitario y para el tratamiento y la prevención de enfermedades, en particular cáncer. En ciertas realizaciones, la invención proporciona una célula de la cepa depositada con el número de registro NCIMB 43387, para su uso en cualquiera de las enfermedades descritas en la presente.</span>In certain embodiments, the bacterial strain for use in the invention is the <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB 43387. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, or a derived from it, for use in therapy. In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, or a derivative thereof, for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer. . In certain embodiments, the invention provides a cell of the strain deposited under accession number NCIMB 43387, for use in any of the diseases described herein.</span>
  </p>
  <p id="p0144" num="0144" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en el NCIMB con el número de registro NCIMB 43387, o un derivado o biotipo de la misma, preferiblemente para su uso en la estimulación del sistema inmunitario y para el tratamiento y prevención de enfermedades, en particular cáncer, más preferiblemente cáncer de cerebro, como neuroblastoma. En realizaciones preferidas, la invención proporciona una composición que comprende la cepa depositada en NCIMB con el número de registro NCIMB 43387, o un derivado o biotipo de la misma, preferiblemente para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>In preferred embodiments, the invention provides a composition comprising the strain deposited in the NCIMB with registration number NCIMB 43387, or a derivative or biotype thereof, preferably for use in the stimulation of the immune system and for the treatment and prevention of diseases, in particular cancer, more preferably brain cancer, such as neuroblastoma. In preferred embodiments, the invention provides a composition comprising the strain deposited at NCIMB under accession number NCIMB 43387, or a derivative or biotype thereof, preferably for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
  </p>
  <p id="p0146" num="0146" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención no comprende una célula de la cepa <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 43387. En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43387. En algunas realizaciones, la cepa bacteriana en las composiciones de la invención es una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en donde la cepa bacteriana no es la cepa depositada con el número de registro NCIMB 43387.</span>In certain embodiments, the composition of the invention does not comprise a cell of the strain <i class="style-scope patent-text">Megasphaera massiliensis</i> deposited under registry number NCIMB 43387. In some embodiments, the bacterial strain in the compositions of the invention is a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the bacterial strain is not the strain deposited under registry number NCIMB 43387. In some embodiments, the bacterial strain in compositions of the invention is a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> wherein the bacterial strain is not the strain deposited under NCIMB registration number 43387.</span>
  </p>
  <p id="p0148" num="0148" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a la SEQ ID NO:8. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a la SEQ ID NO: 11. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a la SEQ ID NO: 12. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a las SEQ ID NO: 8, 11 o 12. En ciertas realizaciones, la invención proporciona una cepa bacteriana que tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a las SEQ ID NO: 8, 11 o 12 para su uso en terapia. 
</span>In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO:8. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 11. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 12. In certain embodiments, the bacterial strain for use in the invention has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to SEQ ID NO: 8, 11 or 12. In certain embodiments, the invention provides a bacterial strain having a 16S rRNA sequence which is at least 99.5% or 99.9% identical to SEQ ID NO: 8, 11 or 12 for use in therapy. </span>
  </p>
  <p id="p0149" num="0149" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 8. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO: 11. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por la SEQ ID NO:12. En ciertas realizaciones, la cepa bacteriana para su uso en la invención tiene la secuencia de ARNr 16S representada por las SEQ ID NO: 8, 11 o 12. En ciertas realizaciones, la invención proporciona una cepa bacteriana que tiene la secuencia de ARNr 16S representada por las SEQ ID NO: 8, 11 o 12 para su uso en terapia.</span>In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 8. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 11. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO:12. In certain embodiments, the bacterial strain for use in the invention has the 16S rRNA sequence represented by SEQ ID NO: 8, 11 or 12. In certain embodiments, the invention provides a bacterial strain having the 16S rRNA sequence represented by SEQ ID NO: 8, 11 or 12 for use in therapy.</span>
  </p>
  <p id="p0151" num="0151" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">También se espera que las cepas bacterianas que son biotipos de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 sean eficaces para estimular el sistema inmunitario y tratar y prevenir enfermedades. en particular cáncer. Un biotipo es una cepa estrechamente relacionada que tiene características fisiológicas y bioquímicas iguales o muy similares.</span>Bacterial strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 are also expected to be effective in stimulating the immune system and treating and preventing diseases. particularly cancer. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.</span>
  </p>
  <p id="p0153" num="0153" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona las cepas bacterianas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o biotipos de las mismas, para su uso en terapia.</span>In certain embodiments, the invention provides bacterial strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, or biotypes thereof, for use in therapy.</span>
  </p>
  <p id="p0155" num="0155" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas que son biotipos de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invención pueden identificarse secuenciando otras secuencias de nucleótidos para una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. Por ejemplo, puede secuenciarse sustancialmente el genoma completo y una cepa de biotipo para su uso en la invención puede tener por lo menos un 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia en por lo menos el 80% de su genoma completo (por ejemplo, en por lo menos el 85%, 90%, 95% o 99%, o en su genoma completo). Otras secuencias adecuadas para su uso en la identificación de cepas de biotipo pueden incluir hsp60 o secuencias repetitivas como BOX, ERIC, (GTG)5 o REP. Las cepas de biotipo pueden tener secuencias con por lo menos un 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% o 99,9% de identidad de secuencia con la secuencia correspondiente de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389.</span>Strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention may be identified by sequencing other sequences of nucleotides for one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389. For example, substantially the entire genome and a biotype strain can be sequenced for use in invention may have at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity in at least 80% of its genome-wide (eg, at least 85%, 90%, 95%, or 99%, or genome-wide). Other sequences suitable for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)5 or REP. Biotype strains may have sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity with the corresponding sequence from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389.</span>
  </p>
  <p id="p0157" num="0157" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, las cepas que son biotipos de una o más de las cepas depositadas con los números de registro NCIMB 43385, <sup class="style-scope patent-text">n</sup>C<sup class="style-scope patent-text">i</sup>MB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invención pueden identificarse usando uno o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y análisis de fragmentos de restricción y/o análisis de PCR, por ejemplo usando polimorfismo de longitud de fragmento amplificado fluorescente (FAFLP) e identificación de elemento de ADN repetitivo (rep)-PCR, o realización de perfiles de proteínas o secuenciación parcial de ADNr 16S o 23S. En realizaciones preferidas, tales técnicas pueden usarse para identificar otras cepas de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>Alternatively, strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, <sup class="style-scope patent-text">n</sup> C <sup class="style-scope patent-text">i</sup> MB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention may identified using one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389 and restriction fragment analysis and/or PCR analysis, for example using length polymorphism Fluorescent Amplified Fragment (FAFLP) and repetitive DNA element identification (rep)-PCR, or protein profiling or partial 16S or 23S rDNA sequencing. In preferred embodiments, such techniques can be used to identify other strains of <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0159" num="0159" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas que son biotipos de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 y que son adecuadas para su uso en la invención son cepas que proporcionan el misma patrón que una o más de las cepas depositadas con los números de registro NCiMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 cuando se analiza mediante análisis de restricción de ADN ribosómico amplificado (ARDRA), por ejemplo, cuando se usa la enzima de restricción Sau3AI. Alternativamente, las cepas de biotipo se identifican como cepas que tienen los mismos patrones de fermentación de carbohidratos que una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389.</span>In certain embodiments, strains that are biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 and that are suitable for use in the invention are strains that give the same pattern as one or more of the strains deposited under accession numbers NCiMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389 when analyzed by amplified ribosomal DNA restriction analysis (ARDRA), e.g. example, when the restriction enzyme Sau3AI is used. Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389.</span>
  </p>
  <p id="p0161" num="0161" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Otras cepas que son útiles en las composiciones y métodos de la invención, como los biotipos de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, pueden identificarse usando cualquier método o estrategia apropiados, incluyendo los ensayos descritos en los Ejemplos. Por ejemplo, las cepas para su uso en la invención pueden identificarse añadiéndolas al lisado celular o a células completas y analizando la expresión de MAP2, la expresión de DRD2, los niveles de citoquinas o la supervivencia celular. En particular, las cepas bacterianas que tienen patrones de crecimiento, tipo metabólico y/o antígenos de superficie similares a una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCiMB 43389 pueden ser útiles en la invención. Una cepa útil tendrá una actividad inmunomoduladora comparable a una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. En particular, una cepa de biotipo provocará efectos comparables sobre la expresión de MAP2, expresión de DRD2, niveles de citoquinas o supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Una cepa de biotipo puede provocar efectos comparables sobre la actividad inhibidora de histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos.</span>Other strains that are useful in the compositions and methods of the invention, such as biotypes of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, can be identified using any appropriate method or strategy, including the assays described in the Examples. For example, strains for use in the invention can be identified by adding them to cell lysate or whole cells and analyzing for MAP2 expression, DRD2 expression, cytokine levels, or cell survival. In particular, bacterial strains that have growth patterns, metabolic type, and/or surface antigens similar to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCiMB 43389 may be useful in the invention. A useful strain will have comparable immunomodulatory activity to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389. In particular, a biotype strain will elicit comparable effects on the MAP2 expression, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A biotype strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples.</span>
  </p>
  <p id="p0163" num="0163" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las cepas preferidas de la invención son cepas depositadas con los números de 
registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. Estas son cepas ejemplares analizadas en los Ejemplos y que han demostrado ser eficaces para tratar enfermedades. Por tanto, la invención proporciona una célula, como una célula aislada, de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas. La invención también proporciona una composición que comprende una célula de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas. La invención también proporciona un cultivo biológicamente puro de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, o un derivado de las mismas, para su uso en terapia, en particular para las enfermedades descritas en la presente.</span>In certain embodiments, preferred strains of the invention are strains deposited under accession numbers  registration NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389. These are exemplary strains discussed in the Examples and have been shown to be effective in treating disease. Thus, the invention provides a cell, such as an isolated cell, from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof. . The invention also provides a composition comprising a cell from one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof. The invention also provides a biologically pure culture of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389, or a derivative thereof, for use in therapy. , in particular for the diseases described herein.</span>
  </p>
  <p id="p0165" num="0165" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Un derivado de la cepa de la invención puede ser una cepa hija (progenie) o una cepa cultivada (subclonada) a partir de la original. Un derivado de una cepa de la invención puede modificarse, por ejemplo a nivel genético, sin eliminar la actividad biológica. En particular, una cepa derivada de la invención es terapéuticamente activa. Una cepa derivada tendrá una actividad terapéutica comparable a una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389. En particular, una cepa derivada provocará efectos comparables sobre la expresión de MAP2, expresión de DRD2, niveles de citoquinas o supervivencia celular como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Una cepa derivada puede provocar efectos comparables sobre la actividad inhibidora de la histona deacetilasa como se muestra en los Ejemplos, que pueden identificarse usando los protocolos de cultivo y administración descritos en los Ejemplos. Un derivado de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389 será generalmente un biotipo de una o más de las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 y/o NCIMB 43389, respectivamente.</span>A derivative of the strain of the invention may be a daughter strain (progeny) or a cultivated strain (subcloned) from the original. A derivative of a strain of the invention can be modified, for example at the genetic level, without eliminating biological activity. In particular, a strain derived from the invention is therapeutically active. A derivative strain will have therapeutic activity comparable to one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389. In particular, a derivative strain will elicit comparable effects on expression of MAP2, DRD2 expression, cytokine levels, or cell survival as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative strain can elicit comparable effects on histone deacetylase inhibitory activity as shown in the Examples, which can be identified using the culture and administration protocols described in the Examples. A derivative of one or more of the strains deposited under accession numbers NCIMB 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388 and/or NCIMB 43389 will generally be a biotype of one or more of the strains deposited under accession numbers NCIMB 43385. , NCIMB 43386, NCIMB 43387, NCIMB 43388, and/or NCIMB 43389, respectively.</span>
  </p>
  <p id="p0167" num="0167" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han descubierto que la cepa bacteriana usada en los Ejemplos produce ácido 2-metilpropanoico y ácido 3-metil-butanoico y consume ácido fórmico (ver Figura 58). También se descubrió que las cepas depositadas con los números de registro NCIMB 43385, NC<sup class="style-scope patent-text">i</sup>M<sup class="style-scope patent-text">b </sup>43388 y NCIMB 43389 producían ácido 2-metilpropanoico y ácido 3-metil-butanoico. Además, también se descubrió que las cepas depositadas con los números de registro NCIMB 43385 y NCIMB 43388 consumían ácido fórmico.</span>The inventors have found that the bacterial strain used in the Examples produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid (see Figure 58). Strains deposited under accession numbers NCIMB 43385, NC <sup class="style-scope patent-text">i</sup> M <sup class="style-scope patent-text">b</sup> 43388 and NCIMB 43389 were also found to produce 2-methyl-propanoic acid and 3-methyl-butanoic acid. In addition, strains deposited under accession numbers NCIMB 43385 and NCIMB 43388 were also found to consume formic acid.</span>
  </p>
  <p id="p0169" num="0169" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, en algunas realizaciones, la cepa bacteriana de la invención produce uno o más de los metabolitos ácido 2-metil-propanoico y ácido 3-metil-butanoico. En algunas realizaciones, la cepa bacteriana de la invención consume ácido fórmico. En algunas realizaciones, la cepa bacteriana de la invención produce ácido 2-metil-propanoico y ácido 3-metil-butanoico y consume ácido fórmico. En realizaciones preferidas, la cepa bacteriana de la invención produce butirato, ácido valérico, ácido hexanoico, ácido 2-metil-propanoico y ácido 3-metil-butanoico, y consume acetato, propionato y ácido fórmico.</span>Therefore, in some embodiments, the bacterial strain of the invention produces one or more of the metabolites 2-methyl-propanoic acid and 3-methyl-butanoic acid. In some embodiments, the bacterial strain of the invention consumes formic acid. In some embodiments, the bacterial strain of the invention produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid. In preferred embodiments, the bacterial strain of the invention produces butyrate, valeric acid, hexanoic acid, 2-methyl-propanoic acid, and 3-methyl-butanoic acid, and consumes acetate, propionate, and formic acid.</span>
  </p>
  <p id="p0171" num="0171" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la producción de butirato y/o ácido valérico genera secreción de IL-8. Por consiguiente, en ciertas realizaciones, las composiciones de la invención pueden estimular el sistema inmunitario a través de la producción de butirato y/o ácido valérico.</span>In certain embodiments, the production of butyrate and/or valeric acid generates secretion of IL-8. Accordingly, in certain embodiments, the compositions of the invention can stimulate the immune system through the production of butyrate and/or valeric acid.</span>
  </p>
  <p id="p0173" num="0173" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención no comprenden <i class="style-scope patent-text">Megasphaera elsdenii. </i>En ciertas realizaciones, la cepa bacteriana útil en las composiciones y métodos de la invención no es <i class="style-scope patent-text">Megasphaera elsdenii.</i> </span>In certain embodiments, the compositions of the invention do not comprise <i class="style-scope patent-text">Megasphaera elsdenii.</i> In certain embodiments, the bacterial strain useful in the compositions and methods of the invention is not <i class="style-scope patent-text">Megasphaera elsdenii.</i> </span>
  </p>
  <p id="p0175" num="0175" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Usos terapéuticos</span>therapeutic uses</span>
    </i>
  </p>
  <p id="p0177" num="0177" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estimulación del sistema inmunitario</span>Stimulation of the immune system</span>
    </i>
  </p>
  <p id="p0179" num="0179" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos muestran que la administración de las composiciones para su uso de acuerdo con la invención puede llevar a una estimulación inmunitaria en células mononucleares de sangre periférica humanas (PBMC). Como se ha demostrado que la administración de las composiciones de la invención tiene un efecto inmunoestimulador sobre las PBMC, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por activación inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de enfermedades mediante la estimulación del sistema inmunitario. En ciertas realizaciones, las composiciones de la invención son para su uso en la promoción de promover una respuesta inmunitaria.</span>The examples show that administration of the compositions for use according to the invention can lead to immune stimulation in human peripheral blood mononuclear cells (PBMC). As administration of the compositions of the invention has been shown to have an immunostimulatory effect on PBMCs, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by increased immune response. In certain embodiments, the compositions of the invention are for use in treating disease by stimulating the immune system. In certain embodiments, the compositions of the invention are for use in promoting an immune response.</span>
  </p>
  <p id="p0181" num="0181" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones para su uso de acuerdo con la invención puede llevar a una disminución del porcentaje de Tregs en las PBMC (Figura 6C). Las Tregs, también conocidas como células T supresoras, son una población de células T que funcionan para suprimir la respuesta inmunitaria. Las Tregs se caracterizan por la alta expresión del marcador de superficie celular CD25 y la baja expresión de CD127 [19]. Como se ha demostrado que la administración de las composiciones de la invención 
reduce selectivamente la población de Tregs (Figura 6C), las composiciones para su uso de acuerdo con la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por un aumento en el porcentaje de Tregs en una población celular. En una realización, las composiciones para su uso de acuerdo con la invención pueden ser útiles para tratar o prevenir enfermedades caracterizadas por un aumento en el porcentaje de Tregs en una población celular. En una realización, las composiciones de la invención pueden ser útiles para el tratamiento o prevención de enfermedades caracterizadas por un aumento en el porcentaje de células CD4+CD25+CD127- en una población celular. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades disminuyendo el porcentaje de Tregs en las poblaciones celulares. En una realización, las composiciones de la invención son para su uso en la reducción de la supresión de la respuesta inmunitaria por Tregs. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria mediante la reducción selectiva de Tregs. En una realización, las composiciones de la invención son para su uso en la inmunoestimulación, en donde las composiciones de la invención reducen el número o porcentaje de Tregs.</span>The Examples show that the administration of the compositions for use according to the invention can lead to a decrease in the percentage of Tregs in PBMC (Figure 6C). Tregs, also known as suppressor T cells, are a population of T cells that function to suppress the immune response. Tregs are characterized by high expression of the cell surface marker CD25 and low expression of CD127 [19]. As it has been shown that the administration of the compositions of the invention  selectively reduces the population of Tregs (Figure 6C), the compositions for use according to the invention may be useful in the treatment of diseases characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, compositions for use according to the invention may be useful for treating or preventing diseases characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, the compositions of the invention may be useful for the treatment or prevention of diseases characterized by an increase in the percentage of CD4+CD25+CD127- cells in a cell population. In one embodiment, the compositions of the invention are for use in treating or preventing disease by lowering the percentage of Tregs in cell populations. In one embodiment, the compositions of the invention are for use in reducing suppression of the immune response by Tregs. In one embodiment, the compositions of the invention are for use in stimulating the immune response through the selective reduction of Tregs. In one embodiment, the compositions of the invention are for use in immunostimulation, wherein the compositions of the invention reduce the number or percentage of Tregs.</span>
  </p>
  <p id="p0183" num="0183" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los ejemplos demuestran que las composiciones de la invención pueden ser capaces de dirigirse selectivamente a las Tregs, sin afectar significativamente a células como células B, células T CD4 o células T CD8. Por lo tanto, las composiciones de la invención pueden reducir selectivamente las Tregs en las PBMC, sin afectar significativamente al porcentaje de los otros tipos de células analizadas. En una realización, las composiciones de la invención son para su uso en la reducción selectiva del número o porcentaje de Tregs, en donde el número o porcentaje de células T CD4 no cambia significativamente. En una realización, las composiciones de la invención son para su uso en la reducción selectiva del número o porcentaje de Tregs, en donde el número o porcentaje de células T CD8 no cambia significativamente. En una realización, las composiciones de la invención son para su uso en la reducción selectiva del número o porcentaje de Tregs, en donde el número o porcentaje de células B no cambia significativamente. En una realización adicional, las composiciones de la invención son para su uso en la reducción selectiva del número o porcentaje de Tregs, en donde el número o porcentaje de células B, células T CD4 y/o células T CD8 no cambia significativamente.</span>The examples demonstrate that the compositions of the invention may be able to selectively target Tregs, without significantly affecting cells such as B cells, CD4 T cells or CD8 T cells. Therefore, the compositions of the invention can selectively reduce Tregs in PBMC, without significantly affecting the percentage of the other cell types tested. In one embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of CD4 T cells does not change significantly. In one embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of CD8 T cells does not change significantly. In one embodiment, the compositions of the invention are for use in the selective reduction of the number or percentage of Tregs, wherein the number or percentage of B cells does not change significantly. In a further embodiment, the compositions of the invention are for use in selectively reducing the number or percentage of Tregs, wherein the number or percentage of B cells, CD4 T cells, and/or CD8 T cells does not change significantly.</span>
  </p>
  <p id="p0185" num="0185" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La disminución en el porcentaje de Tregs fue particularmente sorprendente porque la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis </i>produce butirato, y el butirato se ha asociado con niveles de células Tregs aumentados en sangre y una actividad de Tregs aumentada [20]. Por lo tanto, era inesperado que las composiciones de la invención llevaran a una disminución en el porcentaje de Tregs en las PBMC.</span>The decrease in the percentage of Tregs was particularly surprising because the <i class="style-scope patent-text">Megasphaera massiliensis</i> strain MRx0029 produces butyrate, and butyrate has been associated with increased blood Treg cell levels and increased Treg activity [20]. Therefore, it was unexpected that the compositions of the invention lead to a decrease in the percentage of Tregs in PBMC.</span>
  </p>
  <p id="p0187" num="0187" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la proporción de células CD8 a células Tregs. Las células T CD8+ (células CD8) son células T citotóxicas y desempeñan un papel clave en la defensa inmunitaria contra los patógenos intracelulares. Como se ha demostrado que la administración de las composiciones de la invención aumenta la proporción tanto de las células CD8/Tregs como de las células CD8/Tregs activadas (Figura 6G y Figura 6H), las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en la proporción de células CD8/Tregs y/o CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por la disminución de la proporción de células CD8/Tregs. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por la disminución de la proporción de células CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o la prevención de enfermedades disminuyendo el porcentaje de células Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs. En una realización, las composiciones de la invención son para su uso en el tratamiento o la prevención de enfermedades disminuyendo el porcentaje de células Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs, en donde el aumento en la proporción de células CD8/Tregs da como resultado la inmunoestimulación. En otra realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o la prevención de enfermedades disminuyendo el porcentaje de células Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs, en donde el aumento en la proporción de células CD8/Tregs activadas da como resultado la estimulación inmunitaria. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria aumentando la proporción de células CD8/Tregs. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria aumentando la proporción de células CD8/Tregs activadas.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the ratio of CD8 cells to Treg cells. CD8+ T cells (CD8 cells) are cytotoxic T cells and play a key role in immune defense against intracellular pathogens. As administration of the compositions of the invention has been shown to increase the proportion of both CD8/Tregs cells and activated CD8/Tregs cells (Figure 6G and Figure 6H), the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the proportion of activated CD8/Tregs and/or CD8/Tregs cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by decreased CD8/Treg cell ratios. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decreased ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio, wherein the increase in CD8/Treg cell ratio results in immunostimulation. In another embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by decreasing the percentage of Treg cells in cell populations, thereby increasing the CD8/Treg cell ratio, wherein the increase in ratio of activated CD8/Treg cells results in immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the ratio of CD8/Treg cells. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the ratio of activated CD8/Treg cells.</span>
  </p>
  <p id="p0189" num="0189" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en el porcentaje de células CD19+CD3- en las PBMC (Figura 6F). Por lo tanto, la administración de las composiciones de la invención puede llevar a un aumento del porcentaje de células B en una población celular. Como se ha demostrado que la administración de las composiciones de la invención aumenta el porcentaje de células B, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en el número o porcentaje de células B. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en el número o porcentaje de células B. En una realización, las composiciones de la invención son para su uso en el tratamiento o 
prevención de enfermedades caracterizadas por una disminución del número o porcentaje de células CD19+CD3-. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando el número o porcentaje de células B en poblaciones celulares, en donde el aumento en el número o porcentaje de células B da como resultado una estimulación inmunitaria. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria aumentando el número o porcentaje de células B.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the percentage of CD19+CD3- cells in PBMC (Figure 6F). Therefore, administration of the compositions of the invention can lead to an increase in the percentage of B cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of B cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of B cells. In one embodiment, The compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of B cells. In one embodiment, the compositions of the invention are for use in the treatment or  prevention of diseases characterized by a decrease in the number or percentage of CD19+CD3- cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of B cells in cell populations, wherein the increase in the number or percentage of B cells results in immune stimulation. . In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of B cells.</span>
  </p>
  <p id="p0191" num="0191" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en el porcentaje de células T-citotóxicas CD8 (Figura 6D) en las PBMC. Por lo tanto, la administración de las composiciones de la invención puede llevar a un aumento del porcentaje de células T CD8 en una población celular. Como se ha demostrado que la administración de las composiciones de la invención aumenta el porcentaje de células T citotóxicas CD8, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en el número o porcentaje de células T citotóxicas CD8. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en el número o porcentaje de células T citotóxicas CD8. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando el número o porcentaje de células T citotóxicas CD8 en poblaciones celulares, en donde el aumento en el número o porcentaje de células T citotóxicas CD8 da como resultado una estimulación inmunitaria. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria aumentando el número o porcentaje de células T-citotóxicas CD8.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the percentage of CD8 cytotoxic T-cells (FIG. 6D) in PBMC. Therefore, administration of the compositions of the invention can lead to an increase in the percentage of CD8 T cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of CD8 cytotoxic T cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of CD8 cytotoxic T cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of CD8 cytotoxic T cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of CD8 cytotoxic T cells in cell populations, wherein increasing the number or percentage of CD8 cytotoxic T cells results in result in immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of CD8 cytotoxic T-cells.</span>
  </p>
  <p id="p0193" num="0193" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en el porcentaje de células CD8+ activadas (Figura 6E) en las PBMC. Por lo tanto, la administración de las composiciones de la invención puede llevar a un aumento del porcentaje de células CD8+ activadas en una población celular. Como se ha demostrado que la administración de las composiciones de la invención aumenta el porcentaje de células CD8+ activadas, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en el número o porcentaje de células CD8+ activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en el número o porcentaje de células CD8+ activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o la prevención de enfermedades aumentando el número o porcentaje de células CD8+ activadas en poblaciones celulares, en donde el aumento en el número o porcentaje de células CD8+ activadas da como resultado una estimulación inmunitaria. En una realización, las composiciones de la invención son para su uso en la estimulación de la respuesta inmunitaria aumentado el número o porcentaje de células CD8+ activadas.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the percentage of activated CD8+ cells (FIG. 6E) in PBMC. Therefore, the administration of the compositions of the invention can lead to an increase in the percentage of activated CD8+ cells in a cell population. Since administration of the compositions of the invention has been shown to increase the percentage of activated CD8+ cells, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the number or percentage of activated CD8+ cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the number or percentage of activated CD8+ cells. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the number or percentage of activated CD8+ cells in cell populations, wherein the increase in the number or percentage of activated CD8+ cells results in an immune stimulation. In one embodiment, the compositions of the invention are for use in stimulating the immune response by increasing the number or percentage of activated CD8+ cells.</span>
  </p>
  <p id="p0195" num="0195" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones para su uso de acuerdo con la invención puede llevar a un aumento en la expresión de moléculas proinflamatorias en las PBMC, como citoquinas proinflamatorias (Figura 7 y Figura 9). Los ejemplos de moléculas inmunoestimuladoras (por ejemplo, proinflamatorias) que mostraron un aumento en los niveles de expresión tras la administración de las composiciones de la invención incluyen IL-23, TNF-a, IL-1 p, MIP-3a, IL-8 e IL -6. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de moléculas inmunoestimuladoras (por ejemplo, proinflamatorias), las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de moléculas proinflamatorias, como las citoquinas proinflamatorias. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de moléculas proinflamatorias, en particular enfermedades caracterizadas por una disminución en la expresión y/o actividad de citoquinas proinflamatorias. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-8. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de CD11b. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y /o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-8. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o la actividad de CD11b. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y /o actividad de IL-23, TNF-a, IL-1 p, MIP-3a y/o IL-6. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de IL-8. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de CD11b.</span>The Examples show that administration of the compositions for use according to the invention can lead to an increase in the expression of proinflammatory molecules in PBMC, such as proinflammatory cytokines (Figure 7 and Figure 9). Examples of immunostimulatory (eg, proinflammatory) molecules that showed increased expression levels following administration of the compositions of the invention include IL-23, TNF-a, IL-1p, MIP-3a, IL-8 and IL-6. As administration of the compositions of the invention has been shown to increase the expression of immunostimulatory (eg, proinflammatory) molecules, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of proinflammatory molecules, such as proinflammatory cytokines. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of proinflammatory molecules, in particular diseases characterized by a decrease in the expression and/or activity of proinflammatory cytokines. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and /or IL-6. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-8. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in the treatment or prevention of diseases by increasing the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and/or IL-6. . In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-23, TNF-a, IL-1 p, MIP-3a and/or IL-6. . In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of CD11b.</span>
  </p>
  <p id="p0197" num="0197" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-1 p en las PBMC. IL-1 p es una citoquina proinflamatoria [21]. La producción y 
secreción de IL-1 p está regulada por el inflamasoma, un complejo proteico que está asociado con la activación de la respuesta inflamatoria [22]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-1 p, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de IL-1 p. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-1 p. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-1 p. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de IL-1 p. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es útil en el tratamiento de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-1 p. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es útil en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-1 p. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es útil en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de IL-1 p.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p in PBMC. IL-1p is a proinflammatory cytokine [21]. the production and  IL-1 p secretion is regulated by the inflammasome, a protein complex that is associated with the activation of the inflammatory response [22]. Since administration of the compositions of the invention has been shown to increase the expression of IL-1p, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-1p. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-1 p. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-1 p. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-1 p. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in the treatment of diseases characterized by decreased expression and/or activity of IL-1 p. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in treating or preventing disease by increasing the expression and/or activity of IL-1 p. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is useful in promoting the immune response by increasing the expression and/or activity of IL-1 p.</span>
  </p>
  <p id="p0199" num="0199" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-23. La IL-23 se ha relacionado con la inflamación [23,24] Las funciones propuestas de la IL-23 en la respuesta inmunitaria incluyen promover la proliferación de células T de memoria CD4+ y promover la secreción de IFN-<b class="style-scope patent-text"> <sup class="style-scope patent-text">y </sup> </b>por las células dendríticas (DC) [25]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-23, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución de la expresión de IL-23. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-23. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-23. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de IL-23. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-23. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-23. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de IL-23.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-23. IL-23 has been linked to inflammation [23,24] Proposed roles of IL-23 in the immune response include promoting proliferation of CD4+ memory T cells and promoting IFN <b class="style-scope patent-text"> <sup class="style-scope patent-text">-</sup> </b> γ secretion by dendritic cells ( DC) [25]. Since administration of the compositions of the invention has been shown to increase the expression of IL-23, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-23. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-23. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-23. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-23. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of IL-23. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of IL-23. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-23.</span>
  </p>
  <p id="p0201" num="0201" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de Proteína Inflamatoria de Macrófagos-3 (MIP3-a) o CCL20 en las PBMC. La MIP3-a es una quimiocina inflamatoria que se une al receptor CCR6 y funciona como quimioatrayente para las DC y las células T de memoria. La MIP3-a se asocia con el desencadenamiento de la respuesta inmunitaria adaptativa mediante el reclutamiento de DC inmaduras en el sitio de la inflamación [26]. La expresión desregulada de MIP3-a se ha asociado con enfermedades como la enfermedad inflamatoria intestinal [27]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de MIP3-a, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizado por una disminución en la expresión de MIP3-a. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de MIP3-a. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de MIP3-a. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de MIP3-a. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión y/o actividad de MIP3-a. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de MIP3-a. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de MIP3-a</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of Macrophage Inflammatory Protein-3 (MIP3-a) or CCL20 in PBMC. MIP3-a is an inflammatory chemokine that binds to the CCR6 receptor and functions as a chemoattractant for DC and memory T cells. MIP3-a is associated with the triggering of the adaptive immune response by recruiting immature DC to the site of inflammation [26]. Deregulated expression of MIP3-a has been associated with diseases such as inflammatory bowel disease [27]. As administration of the compositions of the invention has been shown to increase the expression of MIP3-a, the compositions of the invention may be useful in the treatment of diseases characterized by a decrease in the expression of MIP3-a. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of MIP3-a. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of MIP3-a. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of MIP3-a. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of MIP3-a. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of MIP3-a. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of MIP3-a</span>
  </p>
  <p id="p0203" num="0203" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión del Factor de Necrosis Tumoral alfa (TNF-a). El TNF-a es una citoquina proinflamatoria que se sabe que está implicada en varias vías de señalización para promover la muerte celular. TNF-a inicia la apoptosis al unirse a su receptor afín, TNFR-1, lo que lleva a una cascada de eventos de escisión en la vía apoptótica [28]. El TNF-a también puede desencadenar necrosis a través de un mecanismo dependiente de la quinasa RIP [29]. Como la administración de las composiciones de la invención muestra un aumento en la expresión de TNF-a, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades, en particular para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión de TNF-a. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de TNF-a. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de TNF-a. En una realización, las composiciones de la invención pueden ser útiles para tratar o prevenir enfermedades aumentando la expresión y/o actividad de TNF-a. En una realización, las composiciones de la 
invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de TNF-a. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión y/o actividad de TNF-a. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de TNF-a. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de TNF-a.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF-α is a proinflammatory cytokine that is known to be involved in various signaling pathways to promote cell death. TNF-α initiates apoptosis by binding to its cognate receptor, TNFR-1, leading to a cascade of cleavage events in the apoptotic pathway [28]. TNF-a can also trigger necrosis through a RIP kinase-dependent mechanism [29]. As the administration of the compositions of the invention shows an increase in the expression of TNF-a, the compositions of the invention may be useful in the treatment of diseases, in particular for use in the treatment or prevention of diseases characterized by a decrease in the expression of TNF-a. In one embodiment, the compositions of the invention are for use in the treatment of diseases characterized by decreased expression of TNF-α. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of TNF-a. In one embodiment, the compositions of the invention may be useful for treating or preventing disease by increasing the expression and/or activity of TNF-α. In one embodiment, the compositions of the  invention are for use in promoting the immune response by increasing the expression and/or activity of TNF-α. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of TNF-α. In one embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing disease by increasing the expression and/or activity of TNF-α. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of TNF-α.</span>
  </p>
  <p id="p0205" num="0205" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-6 en PBMC. La IL-6 es una citoquina proinflamatoria que se produce durante la inflamación y promueve la diferenciación de células T CD4+ inmaduras y la diferenciación de células T CD8+ en células T citotóxicas [30]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-6, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución de la expresión de IL-6. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-6. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-6. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de IL-6. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-6. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-6. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de IL-6.</span>The Examples also show that administration of the compositions of the invention can lead to increased expression of IL-6 in PBMC. IL-6 is a proinflammatory cytokine that is produced during inflammation and promotes the differentiation of immature CD4+ T cells and the differentiation of CD8+ T cells into cytotoxic T cells [30]. Since administration of the compositions of the invention has been shown to increase the expression of IL-6, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-6. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-6. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-6. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-6. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating diseases characterized by decreased expression and/or activity of IL-6. In one embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing disease by increasing IL-6 expression and/or activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-6.</span>
  </p>
  <p id="p0207" num="0207" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Bettelli et al. [31] informaron que la IL-6 inhibe la producción de Tregs. Como los Ejemplos muestran que las composiciones de la invención aumentan la expresión de IL-6, las composiciones de la invención pueden disminuir selectivamente el número o porcentaje de Tregs aumentando la expresión de IL-6. En una realización, las composiciones de la invención son para su uso en inmunoestimulación aumentando la expresión de IL-6. En otra realización, las composiciones de la invención son para su uso en inmunoestimulación disminuyendo el número o porcentaje de Tregs. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en inmunoestimulación aumentando la expresión de IL-6. En otra realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en inmunoestimulación disminuyendo el número o porcentaje de Tregs.</span>Bettelli et al. [31] reported that IL-6 inhibits the production of Tregs. As the Examples show that the compositions of the invention increase the expression of IL-6, the compositions of the invention can selectively decrease the number or percentage of Tregs by increasing the expression of IL-6. In one embodiment, the compositions of the invention are for use in immunostimulation by increasing the expression of IL-6. In another embodiment, the compositions of the invention are for use in immunostimulation by decreasing the number or percentage of Tregs. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in immunostimulation by increasing the expression of IL-6. In another embodiment, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in immunostimulation by decreasing the number or percentage of Tregs.</span>
  </p>
  <p id="p0209" num="0209" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-8 (ver Ejemplo 8). La IL-8 es una citoquina proinflamatoria secretada predominantemente por macrófagos con efectos inmunoestimuladores. Induce la quimiotaxis en las células objetivo, principalmente los neutrófilos pero también otros granulocitos, lo que hace que migren hacia el sitio de la infección. IL-8 también estimula la fagocitosis. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-8, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución de la expresión de IL-8. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de IL-8. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-8. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de IL-8. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de IL-8 y/o la actividad de IL-8. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de IL-8. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de IL-8.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the expression of IL-8 (see Example 8). IL-8 is a proinflammatory cytokine secreted predominantly by macrophages with immunostimulatory effects. It induces chemotaxis in target cells, mainly neutrophils but also other granulocytes, causing them to migrate towards the site of infection. IL-8 also stimulates phagocytosis. Since administration of the compositions of the invention has been shown to increase the expression of IL-8, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of IL-8. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of IL-8. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating diseases characterized by decreased IL-8 expression and/or IL-8 activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing the expression and/or activity of IL-8. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing the expression and/or activity of IL-8.</span>
  </p>
  <p id="p0211" num="0211" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de CD11b (ver Ejemplo 12). La CD11b es una citoquina proinflamatoria con efectos inmunoestimuladores. La CD11b se expresa en la superficie de muchos leucocitos implicados en el sistema inmunitario innato y media la inflamación regulando la adhesión y migración de leucocitos. CD11b se ha implicado en varios procesos inmunitarios, por ejemplo, fagocitosis, citotoxicidad mediada por células, quimiotaxis y activación celular. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de CD11b, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de CD11 b. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por una disminución en la expresión y/o actividad de CD11b. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de CD11b. En una realización, las composiciones de la invención son para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o actividad de CD11b. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera </i>
<i class="style-scope patent-text">massiliensis </i>es para su uso en el tratamiento de enfermedades caracterizadas por una disminución en la expresión de CD11b y/o la actividad de CD11b. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades aumentando la expresión y/o actividad de CD11b. En una realización, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la promoción de la respuesta inmunitaria aumentando la expresión y/o la actividad de CD11b.</span>The Examples also show that the administration of the compositions of the invention can lead to an increase in the expression of CD11b (see Example 12). CD11b is a proinflammatory cytokine with immunostimulatory effects. CD11b is expressed on the surface of many leukocytes involved in the innate immune system and mediates inflammation by regulating leukocyte adhesion and migration. CD11b has been implicated in various immune processes, eg, phagocytosis, cell-mediated cytotoxicity, chemotaxis, and cell activation. Since administration of the compositions of the invention has been shown to increase CD11b expression, the compositions of the invention may be useful in the treatment of diseases characterized by decreased expression of CD11b. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of diseases characterized by a decrease in the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in treating or preventing disease by increasing the expression and/or activity of CD11b. In one embodiment, the compositions of the invention are for use in promoting the immune response by increasing the expression and/or activity of CD11b. In certain embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera</i> species  <i class="style-scope patent-text">massiliensis</i> is for use in the treatment of diseases characterized by a decrease in CD11b expression and/or CD11b activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing disease by increasing CD11b expression and/or activity. In one embodiment, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in promoting the immune response by increasing CD11b expression and/or activity.</span>
  </p>
  <p id="p0213" num="0213" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invención pueden inducir la activación del promotor NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B—Ap1 (ver Figura 61). El NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B está implicado en la activación de la respuesta inmunitaria, en particular estimulando la expresión de mediadores de la inflamación y de citoquinas implicadas en la respuesta inmunitaria, por ejemplo, la IL-6. Como se ha descrito anteriormente, un aumento en la expresión de IL-6 ayuda a estimular el sistema inmunitario y, por lo tanto, la activación de la vía NF-<b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b>B tiene actividad inmunoestimuladora. Por consiguiente, en ciertas realizaciones, las composiciones de la invención activan la señalización de NF-kB y estimulan por tanto el sistema inmunitario. En ciertas realizaciones, las composiciones de la invención estimulan la expresión de mediadores de inflamación y citoquinas inmunoestimuladoras aumentando la activación del promotor NF-kB.</span>The Examples show that the compositions of the invention can induce activation of the NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">k</sup> </b> B-Ap1 promoter (see Figure 61). NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">kB</sup> </b> is involved in the activation of the immune response, in particular by stimulating the expression of inflammatory mediators and cytokines involved in the immune response, for example, IL-6. As described above, an increase in IL-6 expression helps to stimulate the immune system, and therefore activation of the NF- <b class="style-scope patent-text"> <sup class="style-scope patent-text">kB</sup> </b> pathway has immunostimulatory activity. Accordingly, in certain embodiments, the compositions of the invention activate NF-kB signaling and thereby stimulate the immune system. In certain embodiments, the compositions of the invention stimulate the expression of inflammatory mediators and immunostimulatory cytokines by increasing activation of the NF-kB promoter.</span>
  </p>
  <p id="p0215" num="0215" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cáncer</span>Cancer</span>
    </i>
  </p>
  <p id="p0217" num="0217" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de cerebro, en particular el neuroblastoma. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma, en particular el melanoma metastásico. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de cerebro. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del neuroblastoma. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma metastásico. En una realización más preferida, la composición de la invención comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y es para su uso en el tratamiento o prevención del cáncer de cerebro, en particular el neuroblastoma. En otra realización más preferida, la composición de la invención comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y es para su uso en el tratamiento o prevención del melanoma, en particular el melanoma metastásico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cancer. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of brain cancer, in particular neuroblastoma. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of melanoma, in particular metastatic melanoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of brain cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of neuroblastoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of melanoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma. In a more preferred embodiment, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and is for use in the treatment or prevention of brain cancer, in particular neuroblastoma. In another more preferred embodiment, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and is for use in the treatment or prevention of melanoma, in particular metastatic melanoma.</span>
  </p>
  <p id="p0219" num="0219" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos (Ejemplo 1) demuestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de tubulina beta de Clase III (Tubulina p3) en células de neuroblastoma no diferenciadas. La tubulina p3 es ampliamente conocida como marcador neuronal [32]. Los ejemplos también demuestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de la proteína 2 asociada a microtúbulos (MAP2) en células de neuroblastoma no diferenciadas. MAP2 se expresa predominantemente en las neuronas y funciona para estabilizar los microtúbulos, para promover el desarrollo de las dendritas y para el crecimiento de las neuritas [33]. MAP2 es conocido como un marcador de neuronas diferenciadas.</span>The Examples (Example 1) demonstrate that administration of the compositions of the invention can lead to an increase in the expression of Class III beta tubulin (Tubulin p3) in undifferentiated neuroblastoma cells. Tubulin p3 is widely known as a neuronal marker [32]. The examples also demonstrate that administration of the compositions of the invention can lead to increased expression of microtubule-associated protein 2 (MAP2) in undifferentiated neuroblastoma cells. MAP2 is predominantly expressed in neurons and functions to stabilize microtubules, to promote dendrite development and neurite outgrowth [33]. MAP2 is known as a marker of differentiated neurons.</span>
  </p>
  <p id="p0221" num="0221" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los agentes que provocan la diferenciación celular se han asociado con agentes terapéuticos contra el cáncer, ya que la administración de agentes de diferenciación celular se ha correlacionado con la inhibición del crecimiento tumoral [34]. Por lo tanto, las composiciones de la invención pueden ser útiles en el tratamiento del cáncer. En una realización particular, las composiciones de la invención son para su uso en el tratamiento de cánceres induciendo la diferenciación celular, en particular la diferenciación neuronal. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer de cerebro induciendo la diferenciación neuronal, en particular el tratamiento del neuroblastoma.</span>Agents that cause cell differentiation have been associated with anticancer therapeutics, as administration of cell differentiation agents has been correlated with inhibition of tumor growth [34]. Therefore, the compositions of the invention may be useful in the treatment of cancer. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers by inducing cell differentiation, in particular neuronal differentiation. In one embodiment, the compositions of the invention are for use in the treatment of brain cancer by inducing neuronal differentiation, in particular the treatment of neuroblastoma.</span>
  </p>
  <p id="p0223" num="0223" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, se ha descubierto que MAP2 se expresa en gran medida en los melanomas cutáneos primarios, pero tiene una expresión reducida en los melanomas metastásicos [35]. Se ha propuesto que la expresión aumentada de proteínas estabilizadoras de microtúbulos o el tratamiento con proteínas estabilizadoras de microtúbulos como MAP2 pueden interferir en la inestabilidad dinámica de los microtúbulos que se requiere durante la división celular. Por lo tanto, se cree que la regulación por incremento de MAP2 dificulta la división celular y retrasa el crecimiento tumoral en el cáncer [35]. Por lo tanto, las composiciones de la invención pueden ser útiles para tratar el cáncer, en particular los cánceres metastásicos. En una realización, las composiciones de la invención son para su uso en un método para tratar el cáncer. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres mediados por expresión disminuida de MAP2. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una expresión de MAP2 disminuida o ausente. En ciertas realizaciones, las composiciones de la invención son para su uso en el aumento de la expresión de MAP2 en el tratamiento del cáncer. En una realización preferida, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma. En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma metastásico. 
</span>Furthermore, MAP2 has been found to be highly expressed in primary cutaneous melanomas, but has reduced expression in metastatic melanomas [35]. It has been proposed that increased expression of microtubule-stabilizing proteins or treatment with microtubule-stabilizing proteins such as MAP2 may interfere with the dynamic instability of microtubules that is required during cell division. Therefore, upregulation of MAP2 is thought to hinder cell division and delay tumor growth in cancer [35]. Therefore, the compositions of the invention may be useful for treating cancer, particularly metastatic cancers. In one embodiment, the compositions of the invention are for use in a method of treating cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers mediated by decreased expression of MAP2. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent MAP2 expression. In certain embodiments, the compositions of the invention are for use in increasing MAP2 expression in the treatment of cancer. In a preferred embodiment, the compositions of the invention are for use in the treatment or prevention of melanoma. In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma. </span>
  </p>
  <p id="p0224" num="0224" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las combinaciones terapéuticas de la invención son para su uso en el tratamiento o prevención del melanoma. De acuerdo con algunas realizaciones, las combinaciones terapéuticas de la invención tienen un efecto sobre los melanocitos y pueden ser eficaces para tratar el melanoma. En ciertas realizaciones, las combinaciones terapéuticas de la invención son para su uso en la reducción del tamaño del tumor, reducir el crecimiento del tumor o reducir la angiogénesis en el tratamiento del melanoma.</span>In certain embodiments, the therapeutic combinations of the invention are for use in the treatment or prevention of melanoma. According to some embodiments, the therapeutic combinations of the invention have an effect on melanocytes and may be effective in treating melanoma. In certain embodiments, the therapeutic combinations of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma.</span>
  </p>
  <p id="p0226" num="0226" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En particular, los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de MAP2 en células de neuroblastoma no diferenciadas. Como MAP2 es ampliamente conocido como un marcador de neuronas diferenciadas y se ha demostrado que su expresión tiene implicaciones en el cáncer, las composiciones de la invención pueden ser particularmente útiles para tratar el cáncer de cerebro, como el neuroblastoma. En una realización, las composiciones de la invención son para su uso en un método para tratar el cáncer de cerebro. En una realización preferida, las composiciones de la invención son para su uso en un método para tratar el neuroblastoma.</span>In particular, the Examples show that administration of the compositions of the invention can lead to increased expression of MAP2 in undifferentiated neuroblastoma cells. As MAP2 is widely known as a marker of differentiated neurons and its expression has been shown to have implications in cancer, the compositions of the invention may be particularly useful for treating brain cancer, such as neuroblastoma. In one embodiment, the compositions of the invention are for use in a method of treating brain cancer. In a preferred embodiment, the compositions of the invention are for use in a method of treating neuroblastoma.</span>
  </p>
  <p id="p0228" num="0228" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a una disminución significativa en la expresión del Receptor de Dopamina D2 (DRD2) (ver el Ejemplo 2 y la Figura 3). El DRD2 es un receptor acoplado a proteína G (GPCR) y es parte de la familia de los receptores de dopamina. DRD2 está implicado en las vías de señalización que promueven la supervivencia celular y, por lo tanto, está asociado con el cáncer. La sobreexpresión o regulación por incremento de DRD2 se ha implicado en varios tipos de cáncer, ya que las células malignas muestran una expresión de DRD2 aumentada en comparación con las células normales [36]. Se ha demostrado que la inhibición de DRD2 a través de antagonistas específicos de DRD2 tiene efectos antitumorales. Se ha demostrado que los antagonistas de DRD2 tienen eficacia antitumoral en muchos tipos de cáncer, incluyendo el cáncer de mama [37][38], el glioblastoma [39][40][4l], el neuroblastoma [42], carcinoma hepatocelular [43], cáncer de pulmón, cáncer de próstata [44], cáncer de cuello uterino [45], cáncer de ovario [46], linfoma [47] y cáncer gástrico [48]. Por lo tanto, las composiciones que disminuyen el nivel de expresión de DRD2 pueden ser útiles para el tratamiento del cáncer. Como se ha demostrado que la administración de las composiciones de la invención disminuye la expresión de DRD2, las composiciones de la invención pueden ser útiles en el tratamiento del cáncer, en particular para su uso en el tratamiento o prevención de cánceres caracterizados por una expresión de DRD2 aumentada. En una realización, las composiciones de la invención pueden ser útiles en el tratamiento o prevención de cánceres caracterizados por una expresión y/o actividad de DRD2 aumentadas. En ciertas realizaciones, las composiciones de la invención son para su uso en la disminución de la expresión y/o actividad de DRD2 en el tratamiento del cáncer. En una realización, las composiciones de la invención pueden ser útiles para tratar el cáncer, en particular cáncer de mama, el cáncer de ovario, el cáncer de cuello uterino, el cáncer de cerebro, en particular el glioblastoma y el neuroblastoma, el carcinoma, en particular el carcinoma hepatocelular, el cáncer de pulmón, el cáncer de próstata, el linfoma y/o el cáncer gástrico. En una realización, las composiciones de la invención pueden ser útiles para tratar o prevenir el cáncer disminuyendo el nivel y/o la actividad de DRD2.</span>Furthermore, the Examples also show that administration of the compositions of the invention can lead to a significant decrease in Dopamine Receptor D2 (DRD2) expression (see Example 2 and Figure 3). DRD2 is a G protein-coupled receptor (GPCR) and is part of the dopamine receptor family. DRD2 is involved in signaling pathways that promote cell survival and is therefore associated with cancer. Overexpression or upregulation of DRD2 has been implicated in several types of cancer, as malignant cells show increased expression of DRD2 compared to normal cells [36]. Inhibition of DRD2 through specific DRD2 antagonists has been shown to have antitumor effects. DRD2 antagonists have been shown to have antitumor efficacy in many types of cancer, including breast cancer [37][38], glioblastoma [39][40][4l], neuroblastoma [42], hepatocellular carcinoma [ 43], lung cancer, prostate cancer [44], cervical cancer [45], ovarian cancer [46], lymphoma [47], and gastric cancer [48]. Therefore, compositions that decrease the expression level of DRD2 may be useful for the treatment of cancer. As administration of the compositions of the invention has been shown to decrease the expression of DRD2, the compositions of the invention may be useful in the treatment of cancer, in particular for use in the treatment or prevention of cancers characterized by an expression of increased DRD2. In one embodiment, the compositions of the invention may be useful in the treatment or prevention of cancers characterized by increased DRD2 expression and/or activity. In certain embodiments, the compositions of the invention are for use in decreasing the expression and/or activity of DRD2 in the treatment of cancer. In one embodiment, the compositions of the invention may be useful for treating cancer, particularly breast cancer, ovarian cancer, cervical cancer, brain cancer, particularly glioblastoma and neuroblastoma, carcinoma, in particular hepatocellular carcinoma, lung cancer, prostate cancer, lymphoma and/or gastric cancer. In one embodiment, the compositions of the invention may be useful for treating or preventing cancer by lowering the level and/or activity of DRD2.</span>
  </p>
  <p id="p0230" num="0230" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Prabhu et al. informaron que ONC201, un antagonista de DRD2, ha demostrado eficacia en la reducción de tumores en modelos de glioblastoma. La expresión de DRD2 está regulada por incremento en los tumores de glioblastoma y, por lo tanto, DRD2 es un objetivo atractivo para agentes terapéuticos contra el cáncer [49]. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del glioblastoma.</span>Prabhu et al. reported that ONC201, a DRD2 antagonist, has shown efficacy in shrinking tumors in glioblastoma models. DRD2 expression is upregulated in glioblastoma tumors and therefore DRD2 is an attractive target for anticancer therapeutics [49]. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of glioblastoma.</span>
  </p>
  <p id="p0232" num="0232" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de Caspasa 3 (Casp3) en células SH-SY5Y. Las caspasas son parte de la familia de las cisteínas proteasas y se sabe que promueven la apoptosis. Casp3 se conoce como una “caspasa ejecutora”, que desempeña un papel importante en la cascada de escisión de proteínas celulares en la vía apoptótica. La regulación por disminución de la expresión de Casp3 se ha demostrado previamente en cánceres de tejidos tumorales de mama, ovario y cuello uterino, y se cree que la disminución de la expresión de Casp3 promueve la supervivencia celular en el tejido canceroso [50]. Por lo tanto, las composiciones que aumentan el nivel de expresión de las caspasas ejecutoras, en particular Casp3, pueden ser útiles para el tratamiento del cáncer. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de Casp3, las composiciones de la invención pueden ser útiles en el tratamiento del cáncer, en particular para su uso en el tratamiento o prevención de cánceres mediados por la expresión de Casp3. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una expresión disminuida o ausente de Casp3. En una realización, las composiciones de la invención pueden ser útiles para tratar cánceres caracterizados por una expresión disminuida o ausente de la caspasa ejecutora. En una realización particular, las composiciones de la invención pueden ser útiles para tratar o prevenir cánceres caracterizados por una expresión disminuida o ausente de Casp3. En ciertas realizaciones, las composiciones de la invención son para su uso en el aumento de la expresión de Casp3 en el tratamiento del cáncer. En una realización, las composiciones de la invención pueden ser útiles para tratar el cáncer, en particular cáncer de mama, cáncer de ovario y/o cáncer de cuello uterino. En una realización, las composiciones de la invención pueden ser útiles para tratar el cáncer aumentando el nivel y/o la actividad de Casp3.</span>The Examples also show that administration of the compositions of the invention can lead to increased expression of Caspase 3 (Casp3) in SH-SY5Y cells. Caspases are part of the cysteine protease family and are known to promote apoptosis. Casp3 is known as an “executor caspase”, which plays an important role in the cellular protein cleavage cascade in the apoptotic pathway. Down-regulation of Casp3 expression has been previously shown in breast, ovarian, and cervical tumor tissue cancers, and downregulation of Casp3 expression is thought to promote cell survival in cancer tissue [50]. Therefore, compositions that increase the expression level of executor caspases, in particular Casp3, may be useful for the treatment of cancer. As administration of the compositions of the invention has been shown to increase the expression of Casp3, the compositions of the invention may be useful in the treatment of cancer, in particular for use in the treatment or prevention of cancers mediated by the expression of Casp3. Casp3. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent expression of Casp3. In one embodiment, the compositions of the invention may be useful for treating cancers characterized by decreased or absent expression of the executioner caspase. In a particular embodiment, the compositions of the invention may be useful for treating or preventing cancers characterized by decreased or absent expression of Casp3. In certain embodiments, the compositions of the invention are for use in increasing Casp3 expression in the treatment of cancer. In one embodiment, the compositions of the invention may be useful for treating cancer, particularly breast cancer, ovarian cancer, and/or cervical cancer. In one embodiment, the compositions of the invention may be useful for treating cancer by increasing the level and/or activity of Casp3.</span>
  </p>
  <p id="p0234" num="0234" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, se ha informado que las caspasas están implicadas en procesos distintos a la apoptosis, como la 
diferenciación celular [51]. Los Ejemplos (Ejemplo 1 y Ejemplo 3) demuestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de los marcadores neuronales Tubulina p3 y MAP2, y también aumentar la expresión de Casp3 en células de neuroblastoma indiferenciado. Como las composiciones de la invención pueden llevar a un aumento en la expresión de marcadores neuronales y proteínas que se sabe que desempeñan un papel en la diferenciación celular, las composiciones de la invención pueden ser útiles en la diferenciación de neuronas de células indiferenciadas.</span>Furthermore, caspases have been reported to be involved in processes other than apoptosis, such as  cell differentiation [51]. The Examples (Example 1 and Example 3) demonstrate that the administration of the compositions of the invention can lead to an increase in the expression of the neuronal markers Tubulin p3 and MAP2, and also increase the expression of Casp3 in undifferentiated neuroblastoma cells. As the compositions of the invention may lead to an increase in the expression of neuronal markers and proteins known to play a role in cell differentiation, the compositions of the invention may be useful in the differentiation of neurons from undifferentiated cells.</span>
  </p>
  <p id="p0236" num="0236" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a una disminución de la viabilidad celular en células de neuroblastoma no diferenciadas (Figura 5). En particular, los Ejemplos muestran que la administración de MRx0029 a una concentración del 5% o del 10% provoca una disminución significativa, dependiente de la dosis, en la viabilidad celular (Figura 5).</span>The Examples also show that administration of the compositions of the invention can lead to decreased cell viability in undifferentiated neuroblastoma cells (Figure 5). In particular, the Examples show that administration of MRx0029 at a concentration of 5% or 10% causes a significant, dose-dependent decrease in cell viability (Figure 5).</span>
  </p>
  <p id="p0238" num="0238" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sabe que una disminución de la viabilidad celular o un aumento de la muerte celular de las células cancerosas es un objetivo para el tratamiento del cáncer [52] Por lo tanto, las composiciones que disminuyen la viabilidad celular en líneas celulares de cáncer, como las líneas celulares de neuroblastoma, pueden ser útiles para el tratamiento del cáncer. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer disminuyendo la viabilidad celular. En otra realización, las composiciones de la invención son para su uso en el tratamiento del cáncer aumentando la muerte celular.</span>A decrease in cell viability or an increase in cell death of cancer cells is known to be a target for cancer treatment [52]. Therefore, compositions that decrease cell viability in cancer cell lines, such as neuroblastoma cell lines, may be useful for cancer treatment. In one embodiment, the compositions of the invention are for use in treating cancer by decreasing cell viability. In another embodiment, the compositions of the invention are for use in treating cancer by increasing cell death.</span>
  </p>
  <p id="p0240" num="0240" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, como los Ejemplos muestran que las composiciones de la invención aumentan tanto la expresión de Casp3 como disminuyen la viabilidad celular (Figura 4 y Figura 5), se propone que las composiciones de la invención disminuyan la viabilidad celular regulando por incremento la apoptosis. En una realización, las composiciones de la invención son para su uso en la regulación por incremento de la apoptosis. En otra realización, las composiciones de la invención son para su uso en el tratamiento del cáncer aumentando la muerte celular, en particular aumentando la apoptosis. En una realización, las composiciones de la invención son para su uso en el tratamiento de cánceres disminuyendo la viabilidad celular. En una realización, las composiciones de la invención son para su uso en el tratamiento de cánceres disminuyendo la viabilidad celular. En una realización, las composiciones de la invención son para su uso en el tratamiento de cánceres mediante la regulación por incremento de la apoptosis. En una realización particular, las composiciones de la invención son para su uso en el tratamiento de cánceres mediante la regulación por incremento de la apoptosis. En una realización particular, las composiciones de la invención son para su uso en el tratamiento de cánceres caracterizados por una expresión reducida o ausente de Casp3 mediante la regulación por incremento de la apoptosis. En ciertas realizaciones, las composiciones de la invención son para su uso en el aumento de la apoptosis en el tratamiento del cáncer. En ciertas realizaciones, las composiciones de la invención son para su uso en la disminución de la viabilidad celular en el tratamiento del cáncer.</span>Furthermore, as the Examples show that the compositions of the invention both increase Casp3 expression and decrease cell viability (Figure 4 and Figure 5), it is proposed that the compositions of the invention decrease cell viability by upregulating apoptosis. In one embodiment, the compositions of the invention are for use in upregulating apoptosis. In another embodiment, the compositions of the invention are for use in the treatment of cancer by increasing cell death, in particular by increasing apoptosis. In one embodiment, the compositions of the invention are for use in treating cancers by decreasing cell viability. In one embodiment, the compositions of the invention are for use in treating cancers by decreasing cell viability. In one embodiment, the compositions of the invention are for use in treating cancers by upregulating apoptosis. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers by upregulating apoptosis. In a particular embodiment, the compositions of the invention are for use in the treatment of cancers characterized by reduced or absent expression of Casp3 through upregulation of apoptosis. In certain embodiments, the compositions of the invention are for use in increasing apoptosis in the treatment of cancer. In certain embodiments, the compositions of the invention are for use in decreasing cell viability in the treatment of cancer.</span>
  </p>
  <p id="p0242" num="0242" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invención aumentan tanto la expresión de Casp3 como la de MAP2. Por lo tanto, la regulación por incremento de Casp3 y la regulación por incremento de MAP2 pueden estar relacionadas.</span>The Examples show that the compositions of the invention increase both Casp3 and MAP2 expression. Therefore, the upregulation of Casp3 and the upregulation of MAP2 may be related.</span>
  </p>
  <p id="p0244" num="0244" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La acetilación y desacetilación de histonas son importantes reguladores epigenéticos de la expresión génica. La regulación epigenética es una poderosa herramienta para regular todos los aspectos de la función celular. Las histonas deacetilasas (HDAC) reprimen la expresión génica eliminando los grupos acetilo de un aminoácido s-N-acetil lisina en una histona, permitiendo que las histonas envuelvan el ADN con más fuerza y dando como resultado la supresión transcripcional a través de la inaccesibilidad del nucleosoma. HDAC tiene 18 isoformas que se organizan en cuatro clases: Clase I, II, III y IV. Se han observado alteraciones en los niveles de HDAC en muchos tipos de enfermedades incluyendo, por ejemplo, cánceres, enfermedades infecciosas, enfermedades inflamatorias y enfermedades neurodegenerativas [53,54,55].</span>Histone acetylation and deacetylation are important epigenetic regulators of gene expression. Epigenetic regulation is a powerful tool for regulating all aspects of cell function. Histone deacetylases (HDACs) repress gene expression by removing the acetyl groups from an amino acid s-N-acetyl lysine on a histone, allowing histones to wrap DNA more tightly and resulting in transcriptional suppression through nucleosome inaccessibility. HDAC has 18 isoforms that are organized into four classes: Class I, II, III, and IV. Alterations in HDAC levels have been observed in many types of diseases including, for example, cancers, infectious diseases, inflammatory diseases, and neurodegenerative diseases [53,54,55].</span>
  </p>
  <p id="p0246" num="0246" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inhibidores de HDAC (HDACi) son una clase emergente de fármacos anticancerígenos prometedores que han demostrado que provocan la detención del crecimiento, la diferenciación, la apoptosis, la reducción de la angiogénesis y la modulación de la respuesta inmunitaria en una variedad de líneas celulares de cáncer [56,57,58,59]. Aunque el mecanismo preciso por el cual está mediada la actividad clínica de estos agentes sigue sin estar claro, actualmente se están investigando una amplia variedad de HDACi como posibles agentes anticancerígenos. Además, debido a la actividad anticancerígena demostrable en estudios tanto in vitro como in vivo, muchos HDACi han progresado rápidamente a través del desarrollo clínico, ya sea como monoterapias o en combinación con otros agentes anticancerígenos [60]. Entre ellos, el vorinostat (Zolinza™), la romidepsina (Istodax™) y el belinostat (Beleodaq™) han recibido la aprobación de la FDA de los Estados Unidos para el tratamiento del linfoma. El linfoma y otros tipos de cáncer de la sangre (también llamados cánceres hematológicos o enfermedades malignas hematológicas) son particularmente sensibles a los HDACi. El microbiota intestinal, con su inmensa diversidad y capacidad metabólica, representa un enorme depósito metabólico para la producción de una amplia variedad de moléculas con efectos potenciales sobre la actividad de HDAC. Pocos estudios han evaluado la actividad inhibidora de HDAC de metabolitos derivados de microbios distintos del butirato, que se ha demostrado que inhibe HDAC y se asocia con una mejora de la función motora en la enfermedad de Huntington [61].</span>HDAC inhibitors (HDACi) are an emerging class of promising anticancer drugs that have been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of cell lines from cancer [56,57,58,59]. Although the precise mechanism by which the clinical activity of these agents is mediated remains unclear, a wide variety of HDACi are currently being investigated as potential anticancer agents. Furthermore, due to demonstrable anticancer activity in both in vitro and in vivo studies, many HDACi have rapidly progressed through clinical development, either as monotherapies or in combination with other anticancer agents [60]. Among them, vorinostat (Zolinza™), romidepsin (Istodax™), and belinostat (Beleodaq™) have received US FDA approval for the treatment of lymphoma. Lymphoma and other blood cancers (also called hematologic cancers or hematologic malignancies) are particularly sensitive to HDACi. The gut microbiota, with its immense diversity and metabolic capacity, represents a huge metabolic reservoir for the production of a wide variety of molecules with potential effects on HDAC activity. Few studies have evaluated the HDAC inhibitory activity of microbially derived metabolites other than butyrate, which has been shown to inhibit HDAC and is associated with improved motor function in Huntington's disease [61].</span>
  </p>
  <p id="p0248" num="0248" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que las composiciones de la invención inhiben la actividad HDAC, en particular 
HDAC de Clase I, por ejemplo HDAC2 (Ejemplos 9 y 10). Por consiguiente, en ciertas realizaciones, las composiciones de la invención modulan la actividad de HDAC. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC. En ciertas realizaciones, las composiciones de la invención inhiben HDAC. En ciertas realizaciones, las composiciones de la invención son HDACi. En realizaciones preferidas, las composiciones de la invención reducen la actividad de HDAC Clase I. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC de Clase II. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC de Clase III. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC de Clase IV. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC1. En realizaciones preferidas, las composiciones de la invención reducen la actividad de HDAC2. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC3. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC a través de la producción de ácido valérico. En ciertas realizaciones, las composiciones de la invención reducen la actividad de HDAC a través de la producción de butirato de sodio. En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer reduciendo la actividad de HDAC. En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres asociados con HDAC. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, neuroblastoma, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer colorrectal, enfermedades malignas hematológicas y/o cáncer gástrico reduciendo la actividad de HDAC. En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades malignas hematológicas reduciendo la actividad de HDAC.</span>The Examples show that the compositions of the invention inhibit HDAC activity, in particular  Class I HDAC, for example HDAC2 (Examples 9 and 10). Accordingly, in certain embodiments, the compositions of the invention modulate HDAC activity. In certain embodiments, the compositions of the invention reduce HDAC activity. In certain embodiments, the compositions of the invention inhibit HDAC. In certain embodiments, the compositions of the invention are HDACi. In preferred embodiments, compositions of the invention reduce HDAC Class I activity. In certain embodiments, compositions of the invention reduce HDAC Class II activity. In certain embodiments, the compositions of the invention reduce Class III HDAC activity. In certain embodiments, the compositions of the invention reduce Class IV HDAC activity. In certain embodiments, the compositions of the invention reduce the activity of HDAC1. In preferred embodiments, the compositions of the invention reduce the activity of HDAC2. In certain embodiments, the compositions of the invention reduce the activity of HDAC3. In certain embodiments, the compositions of the invention reduce HDAC activity through the production of valeric acid. In certain embodiments, the compositions of the invention reduce HDAC activity through the production of sodium butyrate. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cancer by reducing HDAC activity. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of HDAC-associated cancers. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, cancer prostate, lymphoma, colorectal cancer, hematological malignancies and/or gastric cancer by reducing HDAC activity. In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of hematologic malignancies by reducing HDAC activity.</span>
  </p>
  <p id="p0250" num="0250" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la detención del crecimiento. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la detención del ciclo celular. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la diferenciación celular. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la apoptosis. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la reducción de la angiogénesis. En ciertas realizaciones, la actividad inhibidora de HDAC de las composiciones de la invención da como resultado la modulación de la respuesta inmunitaria. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción de la actividad de HDAC como monoterapia. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción de la actividad de HDAC como terapia de combinación. En ciertas realizaciones, las composiciones de la invención se utilizan en combinación con otro agente anticancerígeno. En ciertas realizaciones, las composiciones de la invención son para su uso en combinación con más de otro agente anticancerígeno. En ciertas realizaciones, las composiciones de la invención son para su uso en combinación con un agente quimioterapéutico. En ciertas realizaciones, las composiciones de la invención son para su uso en combinación con un inhibidor de proteasomas. En aspectos adicionales, las composiciones de la invención son reguladores epigenéticos. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades caracterizadas por aberraciones epigenéticas.</span>In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in growth arrest. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in cell cycle arrest. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in cell differentiation. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in apoptosis. In certain embodiments, the HDAC inhibitory activity of the compositions of the invention results in the reduction of angiogenesis. In certain embodiments, the HDAC inhibitory activity of compositions of the invention results in modulation of the immune response. In certain embodiments, the compositions of the invention are for use in reducing HDAC activity as monotherapy. In certain embodiments, the compositions of the invention are for use in reducing HDAC activity as combination therapy. In certain embodiments, the compositions of the invention are used in combination with another anticancer agent. In certain embodiments, the compositions of the invention are for use in combination with more than one other anticancer agent. In certain embodiments, the compositions of the invention are for use in combination with a chemotherapeutic agent. In certain embodiments, the compositions of the invention are for use in combination with a proteasome inhibitor. In additional aspects, the compositions of the invention are epigenetic regulators. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases characterized by epigenetic aberrations.</span>
  </p>
  <p id="p0252" num="0252" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>modula la actividad de HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>inhibe HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es una HDACi. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase I. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase II. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase III. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC de Clase IV. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC1. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC2. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC3. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC a través de la producción de ácido valérico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>reduce la actividad de HDAC a través de la producción de butirato de sodio. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer mediante la reducción de la actividad de HDAC. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de cánceres asociados con HDAC. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, neuroblastoma, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer colorrectal, enfermedades malignas hematológicas y/o cáncer gástrico reduciendo la actividad de HDAC. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades malignas hematológicas mediante la reducción de la actividad de HDAC. 
</span>In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> modulates HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> inhibits HDAC. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is an HDACi. In preferred embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera massiliensis</i> species reduces Class I HDAC activity. In certain embodiments, a bacterial strain of <i class="style-scope patent-text">Megasphaera massiliensis</i> species reduces Class II HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces Class III HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces Class IV HDAC activity. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC1. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC2. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces the activity of HDAC3. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity through the production of valeric acid. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> reduces HDAC activity through the production of sodium butyrate. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cancer by reducing HDAC activity. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of HDAC-associated cancers. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, glioblastoma, carcinoma, lung cancer, lymphocytic leukemia. chronic, prostate cancer, lymphoma, colorectal cancer, hematological malignancies and/or gastric cancer by reducing HDAC activity. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing hematological malignancies by reducing HDAC activity. </span>
  </p>
  <p id="p0253" num="0253" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la detención del crecimiento. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la detención del ciclo celular. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la diferenciación celular. En ciertas realizaciones, la actividad inhibidora de HDAC de la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la apoptosis. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado una reducción de la angiogénesis. En ciertas realizaciones, la actividad inhibidora de HDAC de una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>da como resultado la modulación de la respuesta inmunitaria. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción de la actividad de HDAC como monoterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción de la actividad de HDAC como terapia de combinación. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinación con otro agente anticancerígeno. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinación con más de otro agente anticancerígeno. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinación con un agente quimioterapéutico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en combinación con un inhibidor de proteasomas. En aspectos adicionales, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es un regulador epigenético. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades caracterizadas por aberraciones epigenéticas.</span>In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in growth arrest. In certain embodiments, the HDAC inhibitory activity of the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in cell cycle arrest. In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in cell differentiation. In certain embodiments, the HDAC inhibitory activity of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species bacterial strain results in apoptosis. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in reduced angiogenesis. In certain embodiments, HDAC inhibitory activity of a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> results in modulation of the immune response. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing HDAC activity as monotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing HDAC activity as a combination therapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in combination with another anticancer agent. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in combination with more than one other anticancer agent. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in combination with a chemotherapeutic agent. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in combination with a proteasome inhibitor. In additional aspects, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is an epigenetic regulator. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in treating or preventing diseases characterized by epigenetic aberrations.</span>
  </p>
  <p id="p0255" num="0255" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden regular la permeabilidad epitelial modificando la transducción de señales intracelulares implicadas en la expresión y localización de proteínas implicadas en la función de barrera intestinal. En particular, las composiciones de la invención mejoran la expresión de ARNm de ocludina, villina, proteína de unión estrecha 1 (TJP1) y proteína de unión estrecha 2 (TJP2). Por lo tanto, las composiciones de la invención funcionan para aumentar la función de barrera intestinal y reducir la permeabilidad intestinal (Ejemplo 11). En ciertas realizaciones, las composiciones de la invención son para su uso en el aumento de la función de barrera intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción de la permeabilidad intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de la reducción de la función de barrera intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del aumento de la permeabilidad intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades o condiciones que se caracterizan por la reducción de la función de barrera intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades o afecciones que se caracterizan por una permeabilidad intestinal aumentada. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o la prevención de la reducción de la función de barrera intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o la prevención del aumento de la permeabilidad intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de la caquexia aumentando la función de barrera intestinal. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención de la caquexia reduciendo la permeabilidad intestinal. En ciertas realizaciones, la caquexia es caquexia por cáncer.</span>The compositions of the invention can regulate epithelial permeability by modifying intracellular signal transduction involved in the expression and localization of proteins involved in intestinal barrier function. In particular, the compositions of the invention enhance the expression of occludin, villin, tight junction protein 1 (TJP1), and tight junction protein 2 (TJP2) mRNA. Therefore, the compositions of the invention function to increase intestinal barrier function and reduce intestinal permeability (Example 11). In certain embodiments, the compositions of the invention are for use in enhancing intestinal barrier function. In certain embodiments, the compositions of the invention are for use in reducing intestinal permeability. In certain embodiments, the compositions of the invention are for use in treating or preventing reduced intestinal barrier function. In certain embodiments, the compositions of the invention are for use in treating or preventing increased intestinal permeability. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases or conditions characterized by reduced intestinal barrier function. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of diseases or conditions that are characterized by increased intestinal permeability. In certain embodiments, the compositions of the invention are for use in treating or preventing reduced intestinal barrier function resulting from radiation therapy or chemotherapy. In certain embodiments, the compositions of the invention are for use in treating or preventing increased intestinal permeability resulting from radiation therapy or chemotherapy. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of cachexia by increasing intestinal barrier function. In certain embodiments, the compositions of the invention are for use in treating or preventing cachexia by reducing intestinal permeability. In certain embodiments, the cachexia is cancer cachexia.</span>
  </p>
  <p id="p0257" num="0257" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>espara su uso en el aumento de la función de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción de la permeabilidad intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de la reducción de la función de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del aumento de la permeabilidad intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades o afecciones que se caracterizan por la reducción de la función de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades o afecciones que se caracterizan por una permeabilidad intestinal aumentada. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de la reducción de la función de barrera intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del aumento de la permeabilidad intestinal resultante de radioterapia o quimioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de la caquexia aumentando la función de barrera intestinal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de la caquexia reduciendo la permeabilidad intestinal. En ciertas realizaciones, la caquexia es caquexia por cáncer.</span>In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in augmenting intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing reduced intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing increased intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of diseases or conditions characterized by reduced intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of diseases or conditions that are characterized by increased intestinal permeability. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing reduced intestinal barrier function resulting from radiation therapy or chemotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing increased intestinal permeability resulting from radiation therapy or chemotherapy. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cachexia by increasing intestinal barrier function. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating or preventing cachexia by reducing intestinal permeability. In certain embodiments, the cachexia is cancer cachexia.</span>
  </p>
  <p id="p0259" num="0259" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones son para tratar el cáncer en un paciente que se está sometiendo a radioterapia o quimioterapia. En tales realizaciones, la composición puede administrarse antes, 
durante o después de la radioterapia o la quimioterapia. A los pacientes sometidos a radioterapia o quimioterapia no se les debe administrar ningún agente que induzca un intestino permeable, pero la <i class="style-scope patent-text">Megasphaera massiliensis </i>promueve la función de barrera intestinal [62], por lo que las composiciones de la invención son particularmente adecuadas para tratar pacientes sometidos a radioterapia o quimioterapia. Se ha demostrado que la activación de TLR-5 mejora el daño epitelial inducido por la radiación in vivo [63]. Las composiciones de la invención también activan el sistema inmunitario. En algunas realizaciones, las composiciones de la invención son para su uso en el tratamiento del daño inducido por radioterapia. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento del daño inducido por radioterapia.</span>In preferred embodiments, the compositions are for treating cancer in a patient undergoing radiation therapy or chemotherapy. In such embodiments, the composition may be administered before,  during or after radiation therapy or chemotherapy. Patients undergoing radiotherapy or chemotherapy should not be given any agent that induces leaky gut, but <i class="style-scope patent-text">Megasphaera massiliensis</i> promotes intestinal barrier function [62], so the compositions of the invention are particularly suitable for treating patients undergoing to radiotherapy or chemotherapy. Activation of TLR-5 has been shown to ameliorate radiation-induced epithelial damage in vivo [63]. The compositions of the invention also activate the immune system. In some embodiments, the compositions of the invention are for use in the treatment of radiation therapy-induced damage. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating radiation-induced damage.</span>
  </p>
  <p id="p0261" num="0261" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las composiciones de la invención pueden llevar a una reducción del crecimiento tumoral.</span>In some embodiments, the compositions of the invention may lead to a reduction in tumor growth.</span>
  </p>
  <p id="p0263" num="0263" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, el tratamiento con las composiciones de la invención da como resultado una reducción del tamaño del tumor o una reducción del crecimiento del tumor. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor o reducción del crecimiento del tumor. Las composiciones de la invención pueden ser eficaces para reducir el tamaño o el crecimiento del tumor. En ciertas realizaciones, las composiciones de la invención son para su uso en pacientes con tumores sólidos. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción o prevención de la angiogénesis en el tratamiento del cáncer. Las composiciones de la invención pueden tener un efecto sobre los sistemas inmunitario o inflamatorio, que tienen funciones centrales en la angiogénesis. Las composiciones de la invención pueden tener actividad antimetastásica. Una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>puede tener actividad antimetastásica. En ciertas realizaciones, las composiciones de la invención son para su uso en la prevención de la metástasis. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la prevención de la metástasis.</span>In certain embodiments, treatment with the compositions of the invention results in a reduction in tumor size or a reduction in tumor growth. In certain embodiments, the compositions of the invention are for use in reducing tumor size or reducing tumor growth. The compositions of the invention may be effective in reducing tumor size or growth. In certain embodiments, the compositions of the invention are for use in patients with solid tumors. In certain embodiments, the compositions of the invention are for use in reducing or preventing angiogenesis in the treatment of cancer. The compositions of the invention may have an effect on the immune or inflammatory systems, which have central roles in angiogenesis. The compositions of the invention may have antimetastatic activity. A bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> may have antimetastatic activity. In certain embodiments, the compositions of the invention are for use in the prevention of metastasis. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in preventing metastasis.</span>
  </p>
  <p id="p0265" num="0265" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a una disminución del porcentaje de Tregs en las PBMC (Figura 6C). Las Tregs se han relacionado con el cáncer, y la infiltración de Tregs en el tejido tumoral se ha relacionado con un mal pronóstico [64]. Como se ha demostrado que la administración de las composiciones de la invención reduce selectivamente la población de Tregs (Figura 6C), las composiciones de la invención pueden ser útiles en el tratamiento del cáncer. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por un aumento en el porcentaje de Tregs en una población celular. En una realización, las composiciones de la invención pueden ser útiles para tratar o prevenir cánceres caracterizados por un aumento en el porcentaje de células CD4+CD25+CD127-en una población celular. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres disminuyendo el número o porcentaje de Tregs, en particular en tejido canceroso. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer mediante la reducción selectiva de Tregs.</span>The Examples show that the administration of the compositions of the invention can lead to a decrease in the percentage of Tregs in PBMC (Figure 6C). Tregs have been linked to cancer, and infiltration of Tregs into tumor tissue has been linked to poor prognosis [64]. As administration of the compositions of the invention has been shown to selectively reduce the population of Tregs (FIG. 6C), the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by an increase in the percentage of Tregs in a cell population. In one embodiment, the compositions of the invention may be useful for treating or preventing cancers characterized by an increase in the percentage of CD4+CD25+CD127- cells in a cell population. In one embodiment, the compositions of the invention are for use in treating or preventing cancers by decreasing the number or percentage of Tregs, in particular in cancerous tissue. In one embodiment, the compositions of the invention are for use in the treatment of cancer by the selective reduction of Tregs.</span>
  </p>
  <p id="p0267" num="0267" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha propuesto que reducir selectivamente el número de Tregs y activar las células T efectoras, como las células T CD8+, será una terapia eficaz contra el cáncer [64]. Los ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la proporción de células CD8 a células Tregs. Como se ha demostrado que la administración de las composiciones de la invención aumenta la proporción de tanto las células CD8/Tregs como las células CD8/Tregs activadas (Figura 6G y Figura 6H), las composiciones de la invención pueden ser útiles en el tratamiento del cáncer. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una disminución en la proporción de células CD8/Tregs y/o CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una disminución en la proporción de células CD8/Tregs. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una disminución en la proporción de células CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs. En otra realización, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer disminuyendo el porcentaje de Tregs en las poblaciones celulares, aumentando de este modo la proporción de células CD8/Tregs activadas. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer aumentando la proporción de células CD8/Tregs. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer aumentando la proporción de células CD8/Tregs activadas.</span>It has been proposed that selectively reducing the number of Tregs and activating effector T cells, such as CD8+ T cells, will be an effective cancer therapy [64]. The examples also show that administration of the compositions of the invention can lead to an increase in the ratio of CD8 cells to Treg cells. As administration of the compositions of the invention has been shown to increase the proportion of both CD8/Tregs cells and activated CD8/Tregs cells (Figure 6G and Figure 6H), the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the proportion of activated CD8/Tregs and/or CD8/Tregs cells. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the CD8/Tregs cell ratio. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by a decrease in the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating or preventing cancer by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of CD8 cells/Tregs. In another embodiment, the compositions of the invention are for use in the treatment or prevention of cancer by decreasing the percentage of Tregs in cell populations, thereby increasing the ratio of activated CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating cancer by increasing the ratio of CD8/Treg cells. In one embodiment, the compositions of the invention are for use in treating cancer by increasing the ratio of activated CD8/Treg cells.</span>
  </p>
  <p id="p0269" num="0269" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-1 p. En el cáncer asociado a la colitis, la disminución de la expresión de IL-1 p en los sitios tumorales se ha relacionado con síntomas como un resultado de la enfermedad y morbilidad aumentados [65]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-1 p, las composiciones de la invención pueden ser útiles en el tratamiento del cáncer. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención de cánceres caracterizados por una expresión disminuida o ausente de IL-1 p. En una realización, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer aumentando la expresión de IL-1 p. 
</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p. In colitis-associated cancer, decreased IL-1p expression at tumor sites has been associated with symptoms as a result of increased disease and morbidity [65]. Since administration of the compositions of the invention has been shown to increase the expression of IL-1 p, the compositions of the invention may be useful in the treatment of cancer. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancers characterized by decreased or absent expression of IL-1 p. In one embodiment, the compositions of the invention are for use in the treatment or prevention of cancer by increasing the expression of IL-1 p. </span>
  </p>
  <p id="p0270" num="0270" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión del Factor de Necrosis Tumoral alfa (TNF-a). El TNF-a es una citoquina proinflamatoria que se sabe que está implicada en varias vías de señalización para promover la muerte celular. TNF-a inicia la apoptosis uniéndose a su receptor afín, TNFR-1, lo que lleva a una cascada de eventos de escisión en la vía apoptótica. TNF-a también desencadena la necrosis a través de un mecanismo dependiente de quinasa RIP. Como muchos tipos de cáncer tienen vías apoptóticas y necróticas defectuosas, y se sabe que el TNF-a media en estas vías de muerte celular, el TNF-a es un objetivo potencial para la terapia contra el cáncer. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de TNF-a, las composiciones de la invención pueden ser útiles en el tratamiento del cáncer, en particular para su uso en el tratamiento o prevención de cánceres mediados por la expresión de TNF-a. En una realización, las composiciones de la invención pueden ser útiles para tratar cánceres mediados por la expresión de TNF-a, en particular cánceres con expresión y/o actividad disminuida de TNF-a. En una realización, las composiciones de la invención pueden ser útiles para tratar el cáncer. En una realización, las composiciones de la invención pueden ser útiles para tratar el cáncer aumentando el nivel y/o la actividad de TNF-a.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF-α is a proinflammatory cytokine that is known to be involved in various signaling pathways to promote cell death. TNF-α initiates apoptosis by binding to its cognate receptor, TNFR-1, leading to a cascade of cleavage events in the apoptotic pathway. TNF-a also triggers necrosis through a RIP kinase-dependent mechanism. As many types of cancer have defective apoptotic and necrotic pathways, and TNF-α is known to mediate these cell death pathways, TNF-α is a potential target for anticancer therapy. As administration of the compositions of the invention has been shown to increase the expression of TNF-α, the compositions of the invention may be useful in the treatment of cancer, particularly for use in the treatment or prevention of TNF-α mediated cancers. expression of TNF-a. In one embodiment, the compositions of the invention may be useful for treating cancers mediated by expression of TNF-α, in particular cancers with decreased expression and/or activity of TNF-α. In one embodiment, the compositions of the invention may be useful for treating cancer. In one embodiment, the compositions of the invention may be useful for treating cancer by increasing the level and/or activity of TNF-α.</span>
  </p>
  <p id="p0272" num="0272" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de mama. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de mama. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de mama. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de mama. En realizaciones preferidas, el cáncer es carcinoma mamario. En realizaciones preferidas, el cáncer es cáncer de mama en estadio IV.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of breast cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of breast cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments, the cancer is mammary carcinoma. In preferred embodiments, the cancer is stage IV breast cancer.</span>
  </p>
  <p id="p0274" num="0274" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de pulmón. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de pulmón. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de pulmón. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de pulmón. En realizaciones preferidas, el cáncer es carcinoma de pulmón.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of lung cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of lung cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. In preferred embodiments, the cancer is lung carcinoma.</span>
  </p>
  <p id="p0276" num="0276" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de hígado. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, la reducción del crecimiento del tumor o la reducción de la angiogénesis en el tratamiento del cáncer de hígado. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de hígado. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de hígado. En realizaciones preferidas, el cáncer es un hepatoma (carcinoma hepatocelular).</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of liver cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of liver cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of liver cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of liver cancer. In preferred embodiments, the cancer is a hepatoma (hepatocellular carcinoma).</span>
  </p>
  <p id="p0278" num="0278" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del melanoma. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del melanoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del melanoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del melanoma. En realizaciones preferidas, el melanoma es un melanoma metastásico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of melanoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of melanoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of melanoma. In preferred embodiments, the melanoma is a metastatic melanoma.</span>
  </p>
  <p id="p0280" num="0280" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de ovario. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de ovario. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de ovario. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de ovario.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of ovarian cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of ovarian cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of ovarian cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of ovarian cancer.</span>
  </p>
  <p id="p0282" num="0282" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de cuello uterino. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de cuello uterino. En realizaciones preferidas, una cepa bacteriana de la especie 
<i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de cuello uterino. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de cuello uterino.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of cervical cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of cervical cancer. In preferred embodiments, a bacterial strain of the species  <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of cervical cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of cervical cancer.</span>
  </p>
  <p id="p0284" num="0284" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del neuroblastoma. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del neuroblastoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del neuroblastoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del neuroblastoma.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of neuroblastoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of neuroblastoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of neuroblastoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of neuroblastoma.</span>
  </p>
  <p id="p0286" num="0286" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del glioblastoma. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento tumoral, o reducción de la angiogénesis en el tratamiento del glioblastoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del glioblastoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del glioblastoma.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of glioblastoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of glioblastoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of glioblastoma. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of glioblastoma.</span>
  </p>
  <p id="p0288" num="0288" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de próstata. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de próstata. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de próstata. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de próstata.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of prostate cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of prostate cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of prostate cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of prostate cancer.</span>
  </p>
  <p id="p0290" num="0290" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades malignas hematológicas. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento de enfermedades malignas hematológicas. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de enfermedades malignas hematológicas. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento de enfermedades malignas hematológicas. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia aguda. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia crónica. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia mielógena aguda. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia mielógena crónica. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia linfocítica aguda. En ciertas realizaciones, la enfermedad maligna hematológica es leucemia linfocítica crónica. En ciertas realizaciones, la enfermedad maligna hematológica es linfoma. En ciertas realizaciones, la enfermedad maligna hematológica es mieloma múltiple. En ciertas realizaciones, la enfermedad maligna hematológica es un síndrome mielodisplásico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of hematological malignancies. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of hematologic malignancies. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of hematological malignancies. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of hematologic malignancies. In certain embodiments, the hematologic malignancy is acute leukemia. In certain embodiments, the hematologic malignancy is chronic leukemia. In certain embodiments, the hematologic malignancy is acute myelogenous leukemia. In certain embodiments, the hematologic malignancy is chronic myelogenous leukemia. In certain embodiments, the hematologic malignancy is acute lymphocytic leukemia. In certain embodiments, the hematologic malignancy is chronic lymphocytic leukemia. In certain embodiments, the hematologic malignancy is lymphoma. In certain embodiments, the hematologic malignancy is multiple myeloma. In certain embodiments, the hematologic malignancy is a myelodysplastic syndrome.</span>
  </p>
  <p id="p0292" num="0292" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención de la leucemia linfocítica crónica. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento de la leucemia linfocítica crónica. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención de la leucemia linfocítica crónica. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento de la leucemia linfocítica crónica.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of chronic lymphocytic leukemia. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of chronic lymphocytic leukemia. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of chronic lymphocytic leukemia. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of chronic lymphocytic leukemia.</span>
  </p>
  <p id="p0294" num="0294" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del linfoma. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del linfoma. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del linfoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del linfoma. En ciertas realizaciones, el linfoma es linfoma de Hodgkin. En ciertas realizaciones, el linfoma es un linfoma no Hodgkin.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of lymphoma. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lymphoma. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of lymphoma. In certain embodiments, a bacterial strain of the <i class="style-scope patent-text">Megasphaera massiliensis</i> species is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lymphoma. In certain embodiments, the lymphoma is Hodgkin's lymphoma. In certain embodiments, the lymphoma is non-Hodgkin's lymphoma.</span>
  </p>
  <p id="p0296" num="0296" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer gástrico. En ciertas realizaciones, las composiciones de la invención son para su uso en la 
reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer gástrico. En realizaciones preferidas, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer gástrico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer gástrico.</span>In preferred embodiments, the compositions of the invention are for use in the treatment or prevention of gastric cancer. In certain embodiments, the compositions of the invention are for use in the  reduction of tumor size, reduction of tumor growth or reduction of angiogenesis in the treatment of gastric cancer. In preferred embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of gastric cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of gastric cancer.</span>
  </p>
  <p id="p0298" num="0298" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer de colon. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer colorrectal. Las composiciones de la invención pueden tener un efecto sobre las células de cáncer de colon y pueden ser eficaces para tratar el cáncer de colon. Las composiciones de la invención pueden tener un efecto sobre las células de cáncer de colon y pueden ser eficaces para tratar el cáncer colorrectal. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de colon. En ciertas realizaciones, las composiciones de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer colorrectal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de colon. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer colorrectal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer de colon. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer colorrectal. En realizaciones preferidas, el cáncer es adenocarcinoma colorrectal.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of colon cancer. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of colorectal cancer. The compositions of the invention may have an effect on colon cancer cells and may be effective in treating colon cancer. The compositions of the invention may have an effect on colon cancer cells and may be effective in treating colorectal cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colon cancer. In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colorectal cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of colon cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of colorectal cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colon cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of colorectal cancer. In preferred embodiments, the cancer is colorectal adenocarcinoma.</span>
  </p>
  <p id="p0300" num="0300" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las combinaciones terapéuticas de la invención son para su uso en el tratamiento o prevención del cáncer de riñón (también denominado en la presente cáncer renal). En ciertas realizaciones, las combinaciones terapéuticas de la invención son para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer renal. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer de riñón (también denominado en la presente cáncer renal). En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la reducción del tamaño del tumor, reducción del crecimiento del tumor o reducción de la angiogénesis en el tratamiento del cáncer renal. Los Ejemplos demuestran que las combinaciones terapéuticas de la invención tienen un efecto sobre las células de cáncer renal y pueden ser eficaces para tratar el cáncer renal. En realizaciones preferidas, el cáncer es carcinoma de células renales o carcinoma de células de transición. En algunas realizaciones, el cáncer es del intestino. En algunas realizaciones, el cáncer es de una parte del cuerpo que no es el intestino. En algunas realizaciones, el cáncer no es cáncer del intestino. En algunas realizaciones, el cáncer no es cáncer colorrectal. En algunas realizaciones, el cáncer no es cáncer del intestino delgado. En algunas realizaciones, el tratamiento o la prevención se produce en un sitio distinto del intestino. En algunas realizaciones, el tratamiento o la prevención se produce en el intestino y también en un sitio distinto del intestino.</span>In certain embodiments, the therapeutic combinations of the invention are for use in the treatment or prevention of kidney cancer (also referred to herein as renal cancer). In certain embodiments, the therapeutic combinations of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of kidney cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of kidney cancer (also referred to herein as kidney cancer). In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of kidney cancer. The Examples demonstrate that the therapeutic combinations of the invention have an effect on kidney cancer cells and can be effective in treating kidney cancer. In preferred embodiments, the cancer is renal cell carcinoma or transitional cell carcinoma. In some embodiments, the cancer is of the intestine. In some embodiments, the cancer is from a part of the body other than the intestine. In some embodiments, the cancer is not cancer of the intestine. In some embodiments, the cancer is not colorectal cancer. In some embodiments, the cancer is not cancer of the small intestine. In some embodiments, the treatment or prevention occurs at a site other than the intestine. In some embodiments, the treatment or prevention occurs in the intestine and also at a site other than the intestine.</span>
  </p>
  <p id="p0302" num="0302" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del carcinoma. Las composiciones de la invención pueden ser eficaces para tratar numerosos tipos de carcinoma. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer no inmunogénico. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del carcinoma. Una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>puede ser eficaz para tratar numerosos tipos de carcinoma. En ciertas realizaciones, una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento o prevención del cáncer no inmunogénico. Los Ejemplos demuestran que las composiciones de la invención pueden ser eficaces para tratar cánceres no inmunogénicos.</span>In certain embodiments, the compositions of the invention are for use in the treatment or prevention of carcinoma. The compositions of the invention can be effective in treating numerous types of carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment or prevention of non-immunogenic cancer. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of carcinoma. A bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> may be effective in treating numerous types of carcinoma. In certain embodiments, a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in the treatment or prevention of non-immunogenic cancer. The Examples demonstrate that the compositions of the invention can be effective in treating non-immunogenic cancers.</span>
  </p>
  <p id="p0304" num="0304" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los efectos terapéuticos de las composiciones de la invención sobre el cáncer pueden estar mediados por un mecanismo proinflamatorio. La expresión de una serie de citoquinas proinflamatorias puede aumentar después de la administración de MRx0029. La inflamación puede tener un efecto supresor del cáncer [66] y las citoquinas proinflamatorias como la TNF-a se están investigando como terapias contra el cáncer [67]. La regulación por incremento de genes como el TNF-a que se muestra en los Ejemplos puede indicar que las composiciones de la invención pueden ser útiles para tratar el cáncer a través de un mecanismo similar. La regulación por incremento de un ligando de CXCR3 como CXCL9) puede indicar que las composiciones de la invención provocan una respuesta de tipo IPN<sup class="style-scope patent-text">y</sup>. IPN<sup class="style-scope patent-text">y </sup>es un potente factor activador de macrófagos que puede estimular la actividad tumoricida [68], y CXCL9, por ejemplo, también tiene efectos anticancerígenos [69-71] Los ejemplos demuestran que la expresión de una serie de citoquinas proinflamatorias puede aumentar después de la administración de MRx0029. Por lo tanto, en ciertas realizaciones, las composiciones de la invención son para su uso en la promoción de la inflamación en el tratamiento del cáncer. En realizaciones preferidas, las composiciones de la invención son para su uso en la promoción de la inflamación de Th1 en el tratamiento del cáncer. Las células Th1 producen IPNy y tienen potentes efectos anticancerígenos [66]. En ciertas realizaciones, las composiciones de la invención son para su uso en el 
tratamiento de un cáncer en estadio temprano, como un cáncer que no ha hecho metástasis, o un cáncer en estadio 0 o estadio 1. Promover la inflamación puede ser más eficaz contra los cánceres en estadio temprano [66]. En ciertas realizaciones, las composiciones de la invención son para potenciar el efecto de un segundo agente anticancerígeno. En ciertas realizaciones, las composiciones de la invención son para su uso en la promoción de la inflamación para mejorar el efecto de un segundo agente anticancerígeno. En ciertas realizaciones, el tratamiento o prevención del cáncer comprende aumentar el nivel de expresión de una o más citoquinas. En ciertas realizaciones, el tratamiento o la prevención del cáncer comprende aumentar el nivel de expresión de una o más citoquinas proinflamatorias. Por ejemplo, en ciertas realizaciones, el tratamiento o la prevención del cáncer comprende aumentar el nivel de expresión de uno o más de IL-1 p, IL-6, MIP-3a, CXCL9, IL-23, MCP-1, GMCSF y TNF-a. En ciertas realizaciones, el tratamiento o prevención del cáncer comprende aumentar el nivel de expresión de uno o más de IL-1 p y MIP-3a. Se sabe que los aumentos en los niveles de expresión de cualquiera de IL-1 p, IL-6 y TNF-a son indicativos de eficacia en el tratamiento contra el cáncer.</span>The therapeutic effects of the compositions of the invention on cancer may be mediated through a pro-inflammatory mechanism. The expression of a number of proinflammatory cytokines can be increased after administration of MRx0029. Inflammation may have a suppressive effect on cancer [66] and proinflammatory cytokines such as TNF-a are being investigated as anticancer therapies [67]. The upregulation of genes such as TNF-α shown in the Examples may indicate that the compositions of the invention may be useful in treating cancer through a similar mechanism. Upregulation of a CXCR3 ligand such as CXCL9) may indicate that the compositions of the invention elicit an IPN <sup class="style-scope patent-text">y</sup> -type response. IPN <sup class="style-scope patent-text">y</sup> is a potent macrophage activating factor that can stimulate tumoricidal activity [68], and CXCL9, for example, also has anticancer effects [69-71]. Examples demonstrate that the expression of a number of proinflammatory cytokines can be increased after the administration of MRx0029. Therefore, in certain embodiments, the compositions of the invention are for use in promoting inflammation in the treatment of cancer. In preferred embodiments, the compositions of the invention are for use in promoting Th1 inflammation in the treatment of cancer. Th1 cells produce IPNy and have potent anticancer effects [66]. In certain embodiments, the compositions of the invention are for use in the  treatment of early-stage cancer, such as cancer that has not metastasized, or stage 0 or stage 1 cancer. Promoting inflammation may be more effective against early-stage cancers [66]. In certain embodiments, the compositions of the invention are for enhancing the effect of a second anticancer agent. In certain embodiments, the compositions of the invention are for use in promoting inflammation to enhance the effect of a second anticancer agent. In certain embodiments, the treatment or prevention of cancer comprises increasing the expression level of one or more cytokines. In certain embodiments, treating or preventing cancer comprises increasing the expression level of one or more proinflammatory cytokines. For example, in certain embodiments, treating or preventing cancer comprises increasing the expression level of one or more of IL-1 p, IL-6, MIP-3a, CXCL9, IL-23, MCP-1, GMCSF, and TNF-a. In certain embodiments, the treatment or prevention of cancer comprises increasing the expression level of one or more of IL-1 p and MIP-3a. Increases in the expression levels of any of IL-1 p, IL-6 and TNF-a are known to be indicative of efficacy in treating cancer.</span>
  </p>
  <p id="p0305" num="0305" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuando se usa una cepa bacteriana como se describe en la presente en combinación con lipopolisacárido (LPS), puede haber un aumento sinérgico en IL-1 p. Se sabe que el LPS provoca un efecto proinflamatorio. Por tanto, en ciertas realizaciones, el tratamiento o la prevención comprende el uso de una cepa bacteriana como se describe en la presente en combinación con un agente que regula por incremento IL-1 p. En ciertas realizaciones, el tratamiento o la prevención comprende el uso de una cepa bacteriana como se describe en la presente en combinación con LPS. Por consiguiente, una composición de la invención puede comprender adicionalmente un agente que regula por incremento Il-1p. Por consiguiente, una composición de la invención puede comprender adicionalmente LPS.</span>When a bacterial strain as described herein is used in combination with lipopolysaccharide (LPS), there may be a synergistic increase in IL-1 p. LPS is known to cause a pro-inflammatory effect. Thus, in certain embodiments, the treatment or prevention comprises the use of a bacterial strain as described herein in combination with an agent that upregulates IL-1 p. In certain embodiments, the treatment or prevention comprises the use of a bacterial strain as described herein in combination with LPS. Accordingly, a composition of the invention may further comprise an Il-1p upregulating agent. Accordingly, a composition of the invention may additionally comprise LPS.</span>
  </p>
  <p id="p0306" num="0306" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de un paciente que ha recibido quimioterapia con anterioridad. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de un paciente que no ha tolerado un tratamiento de quimioterapia. Las composiciones de la invención pueden ser particularmente adecuadas para tales pacientes.</span>In certain embodiments, the compositions of the invention are for use in treating a patient who has previously received chemotherapy. In certain embodiments, the compositions of the invention are for use in treating a patient who has not tolerated chemotherapy treatment. The compositions of the invention may be particularly suitable for such patients.</span>
  </p>
  <p id="p0307" num="0307" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para prevenir la recaída. Las composiciones de la invención pueden ser adecuadas para la administración a largo plazo. En ciertas realizaciones, las composiciones de la invención son para su uso en la prevención de la progresión del cáncer.</span>In certain embodiments, the compositions of the invention are for preventing relapse. The compositions of the invention may be suitable for long-term administration. In certain embodiments, the compositions of the invention are for use in preventing the progression of cancer.</span>
  </p>
  <p id="p0308" num="0308" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de carcinoma de pulmón de células no pequeñas. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento del carcinoma de pulmón de células pequeñas. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento del carcinoma de células escamosas. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de adenocarcinoma. En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de tumores glandulares, tumores carcinoides o carcinomas indiferenciados.</span>In certain embodiments, the compositions of the invention are for use in the treatment of non-small cell lung carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of small cell lung carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of squamous cell carcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of adenocarcinoma. In certain embodiments, the compositions of the invention are for use in the treatment of glandular tumors, carcinoid tumors, or undifferentiated carcinomas.</span>
  </p>
  <p id="p0309" num="0309" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de hepatoblastoma, colangiocarcinoma, cistoadenocarcinoma colangiocelular o cáncer de hígado resultante de una infección viral.</span>In certain embodiments, the compositions of the invention are for use in the treatment of hepatoblastoma, cholangiocarcinoma, cholangiocellular cystadenocarcinoma, or liver cancer resulting from viral infection.</span>
  </p>
  <p id="p0310" num="0310" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención son para su uso en el tratamiento de carcinoma ductal invasivo, carcinoma ductal in situ o carcinoma lobular invasivo.</span>In certain embodiments, the compositions of the invention are for use in the treatment of invasive ductal carcinoma, ductal carcinoma in situ, or invasive lobular carcinoma.</span>
  </p>
  <p id="p0311" num="0311" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones adicionales, las composiciones de la invención son para su uso en el tratamiento o prevención de la leucemia linfoblástica aguda (ALL), leucemia mieloide aguda, carcinoma adrenocortical, carcinoma de células basales, cáncer de conducto biliar, cáncer de vejiga, tumor óseo, osteosarcoma/histiocitoma fibroso maligno, glioma del tronco encefálico, tumor cerebral, astrocitoma cerebeloso, astrocitoma cerebral/glioma maligno, ependimoma, meduloblastoma, tumores neuroectodérmicos primitivos supratentoriales, cáncer de mama, adenomas bronquiales/carcinoides, linfoma de Burkitt, tumor carcinoide, cáncer de cuello uterino, leucemia linfocítica crónica, leucemia mielógena crónica, trastornos mieloproliferativos crónicos, cáncer de colon, linfoma cutáneo de células T, cáncer de endometrio, ependimoma, cáncer de esófago, sarcoma de Ewing, melanoma intraocular, retinoblastoma, cáncer de vesícula biliar, cáncer gástrico, tumor carcinoide gastrointestinal, tumor del estroma gastrointestinal (GIST), tumor de células germinales, glioma, vía visual infantil e hipotalámico, linfoma de Hodgkin, melanoma, carcinoma de células de los islotes, sarcoma de Kaposi, cáncer de células renales, cáncer de laringe, leucemias, linfomas, mesotelioma, neuroblastoma, linfoma no Hodgkin, cáncer de orofaringe, osteosarcoma, cáncer de ovario, cáncer de páncreas, cáncer de paratiroides, cáncer de faringe, adenoma pituitario, neoplasia de células plasmáticas, cáncer de próstata, carcinoma de células renales, retinoblastoma, sarcoma, cáncer testicular, cáncer de tiroides o cáncer uterino. En realizaciones adicionales, las composiciones de la invención son para su uso en el tratamiento o prevención de enfermedades malignas hematológicas, mieloma múltiple, o síndromes mielodisplásicos.</span>In additional embodiments, the compositions of the invention are for use in the treatment or prevention of acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor , osteosarcoma/malignant fibrous histiocytoma, brain stem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cancer cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor stinal (GIST), germ cell tumor, glioma, childhood and hypothalamic visual pathway, Hodgkin lymphoma, melanoma, islet cell carcinoma, Kaposi's sarcoma, renal cell cancer, laryngeal cancer, leukemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin's lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, cancer testicular, thyroid cancer, or uterine cancer. In additional embodiments, the compositions of the invention are for use in the treatment or prevention of hematologic malignancies, multiple myeloma, or myelodysplastic syndromes.</span>
  </p>
  <p id="p0312" num="0312" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden ser particularmente eficaces cuando se usan en combinación con agentes terapéuticos adicionales. Los efectos inmunomoduladores de las composiciones de la invención pueden 
ser eficaces cuando se combinan con agentes anticancerígenos más directos. Por lo tanto, en ciertas realizaciones, la invención proporciona una composición que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>y un agente anticancerígeno. En ciertas realizaciones, la composición de la invención que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en la estimulación de un cáncer para mejorar su susceptibilidad al tratamiento con un segundo agente anticancerígeno. En ciertas realizaciones, la composición de la invención que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis </i>es para su uso en el tratamiento de un cáncer, como un cáncer de cerebro, aumentando su susceptibilidad al tratamiento con un segundo agente anticancerígeno. El segundo agente anticancerígeno puede administrarse concurrentemente, o puede administrarse después de la composición que comprende la cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>como por lo menos un día, una semana o un mes después.</span>The compositions of the invention can be particularly effective when used in combination with additional therapeutic agents. The immunomodulatory effects of the compositions of the invention can  be effective when combined with more direct anticancer agents. Therefore, in certain embodiments, the invention provides a composition comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> and an anticancer agent. In certain embodiments, the composition of the invention comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in stimulating a cancer to improve its susceptibility to treatment with a second anticancer agent. In certain embodiments, the composition of the invention comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> is for use in treating a cancer, such as brain cancer, by increasing its susceptibility to treatment with a second anticancer agent. The second anticancer agent may be administered concurrently, or may be administered after the composition comprising the bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> such as at least one day, one week or one month later.</span>
  </p>
  <p id="p0314" num="0314" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, el agente anticancerígeno es un inhibidor del punto de control inmunitario, una inmunoterapia con anticuerpos dirigidos, una terapia con células CAR-T, un virus oncolítico o un fármaco citostático. En realizaciones preferidas, la composición comprende un agente anticancerígeno seleccionado del grupo que consiste de: Yervoy (ipilimumab, b Ms ); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); B<sup class="style-scope patent-text">m </sup>S-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prima Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (NewLink Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women’s University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastina (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptina (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); AbT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab estafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); A<sup class="style-scope patent-text">l</sup>T-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/Med-Immune); MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansina (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); IMGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); Xmab5574 (Morphosys); BPC-1C (ensituximab, Precision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880 
(Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); Ma GE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); cAr-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunwaybio); DnX-2401 (DNAtrix); Vc N-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); ProstAtak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); <sup class="style-scope patent-text">h </sup>F10 (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-001 (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracilo, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax), Tivantinib (ArQule); Cytoxan (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); y TS-1 (Taiho Pharmaceuticals).</span>In preferred embodiments, the anticancer agent is an immune checkpoint inhibitor, a targeted antibody immunotherapy, a CAR-T cell therapy, an oncolytic virus, or a cytostatic drug. In preferred embodiments, the composition comprises an anticancer agent selected from the group consisting of: Yervoy (ipilimumab, b Ms ); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); BmS- <sup class="style-scope patent-text">986016</sup> (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prime Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immotherapeutics/AZ); NLG-919 (New Link Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women's University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); AbT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab stafenatox (Active Biotech); AFM13 (Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); <sup class="style-scope patent-text">AI T</sup> -801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen); AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/Med-Immune); MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingleheim); BI-836845 (Boehringer Ingleheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217(Eli Lilly); LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); IMGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirrin); KW-2871 (ecromeximab, Life Science); Sonepcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); Xmab5574 (Morphosys); PCB-1C (ensituximab, Precision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880  (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716 (Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantictumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); Xmab2512 (Xencor); Xmab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); Ma GE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellectis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTCK20 (Unum Therapeutics); cAr-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunway bio); DnX-2401 (DNAtrix); VcN-01 (VCN Biosciences); Colo-Adl (PsiOxus Therapeutics); Prostak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); <sup class="style-scope patent-text">hF10</sup> (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-001 (Neotropyx); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafinlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax ), Tivantinib (ArQule); Cytoxane (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexvar (Bayer); IMMU-132 (Immunomedics); E7449 (Eisai); Thermodox (Celsion); Cometriq (Exellxis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); and TS-1 (Taiho Pharmaceuticals).</span>
  </p>
  <p id="p0316" num="0316" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, la cepa bacteriana de <i class="style-scope patent-text">Megasphaera massiliensis </i>depositada con el número de registro NCIMB 42761 es el único agente terapéuticamente activo en una composición de la invención.</span>In some embodiments, the <i class="style-scope patent-text">Megasphaera massiliensis</i> bacterial strain deposited under accession number NCIMB 42761 is the sole therapeutically active agent in a composition of the invention.</span>
  </p>
  <p id="p0318" num="0318" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han identificado que las cepas bacterianas del género <i class="style-scope patent-text">Megasphaera </i>pueden ser particularmente eficaces para tratar o prevenir el cáncer que comprende la señalización de la quinasa relacionada con la señal extracelular (ERK) oncogénica. La quinasa relacionada con la señal extracelular (ERK) es un efector en sentido descendente en la vía de la quinasa de la proteína activada por mitógenos (MAP), una vía de transducción de señales altamente conservada que se encuentra en todos los eucariotas [72]. La vía de la MAP-quinasa regula procesos como la proliferación celular, la diferenciación, la supervivencia y la apoptosis, y la activación aberrante de la vía está estrechamente relacionada con la patogénesis del cáncer. Como se describe en los ejemplos, la administración de composiciones que comprenden cepas de <i class="style-scope patent-text">Megasphaera </i>puede inhibir la señalización de ERK en líneas celulares de cáncer; es decir, reduce los niveles celulares de ERK fosforilada con respecto a la proteína ERK total. Los inventores también han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede reducir la supervivencia clonogénica de líneas celulares de cáncer que comprenden señalización de ERK oncogénica, en particular en líneas celulares de melanoma y cáncer colorrectal. Los inventores también han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede inducir la expresión génica de la proteína 2 asociada a microtúbulos (MAP2), lo que indica una utilidad particular en el tratamiento de cánceres metastásicos.</span>The inventors have identified that bacterial strains of the genus <i class="style-scope patent-text">Megasphaera</i> may be particularly effective in treating or preventing cancer involving oncogenic extracellular signal-related kinase (ERK) signaling. Extracellular signal-related kinase (ERK) is a downstream effector in the mitogen-activated protein (MAP) kinase pathway, a highly conserved signal transduction pathway found in all eukaryotes [72] . The MAP-kinase pathway regulates processes such as cell proliferation, differentiation, survival, and apoptosis, and aberrant activation of the pathway is closely related to cancer pathogenesis. As described in the examples, administration of compositions comprising <i class="style-scope patent-text">Megasphaera</i> strains can inhibit ERK signaling in cancer cell lines; that is, it reduces cellular levels of phosphorylated ERK relative to total ERK protein. The inventors have also identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can reduce the clonogenic survival of cancer cell lines comprising oncogenic ERK signaling, particularly in melanoma and colorectal cancer cell lines. The inventors have also identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can induce microtubule-associated protein 2 (MAP2) gene expression, indicating particular utility in the treatment of metastatic cancers.</span>
  </p>
  <p id="p0320" num="0320" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, en ciertas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>para su uso en un método para tratar o prevenir el cáncer, en donde el cáncer comprende la señalización de ERK oncogénica.</span>Therefore, in certain embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in a method of treating or preventing cancer, wherein the cancer comprises oncogenic ERK signaling.</span>
  </p>
  <p id="p0322" num="0322" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se usa en la presente, "señalización de ERK oncogénica" se refiere al cáncer que comprende señalización celular desregulada, como la señalización independiente del estímulo, a través de la vía de la MAP quinasa, cuyo resultado es una señalización hiperactiva por parte de ERK (ya sea la isoforma ERK1 o ERK2, o ambas), que impulsa una proliferación y/o supervivencia aumentada de las células cancerosas. ERK1 está activo (es decir, señalización) cuando se fosforila en las posiciones Thr202 y Tyr204. ERK2 está activo (es decir, señalización) cuando se fosforila en las posiciones Thr173 y Tyr185. Por consiguiente, la "señalización de ERK oncogénica" puede ser el resultado de la presencia de mutaciones oncogénicas en (mutaciones de ganancia de función) o sobreexpresión de reguladores positivos de la vía de la MAP quinasa, o mutaciones oncogénicas en (mutaciones de pérdida de función) o expresión regulada por disminución de reguladores negativos de la vía de la MAP quinasa.</span>As used herein, "oncogenic ERK signaling" refers to cancer involving dysregulated cell signaling, such as stimulus-independent signaling, via the MAP kinase pathway, resulting in hyperactive ERK signaling. (either the ERK1 or ERK2 isoform, or both), which drives increased proliferation and/or survival of cancer cells. ERK1 is active (ie signaling) when it is phosphorylated at positions Thr202 and Tyr204. ERK2 is active (ie signaling) when phosphorylated at positions Thr173 and Tyr185. Therefore, "oncogenic ERK signaling" may be the result of the presence of oncogenic mutations in (gain-of-function mutations) or overexpression of positive regulators of the MAP kinase pathway, or oncogenic mutations in (loss-of-function mutations). function) or down-regulated expression of negative regulators of the MAP kinase pathway.</span>
  </p>
  <p id="p0324" num="0324" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El cáncer que comprende la señalización de ERK oncogénica puede definirse alternativamente como cáncer que “muestra” o “caracterizado por” la señalización de ERK oncogénica. El cáncer que comprende la señalización de ERK oncogénica puede definirse alternativamente como un cáncer en el que se "estimulan", "inducen" o "regulan por incremento" la proliferación y/o la supervivencia de las células malignas mediante la señalización de ERK. El cáncer que comprende ERK oncogénico puede definirse alternativamente como cáncer que 
comprende, muestra o se caracteriza por la señalización de ERK "independiente del estímulo".</span>Cancer that comprises oncogenic ERK signaling may alternatively be defined as cancer that "displays" or "characterized by" oncogenic ERK signaling. Cancer comprising oncogenic ERK signaling may alternatively be defined as a cancer in which the proliferation and/or survival of malignant cells are "stimulated", "induced" or "up-regulated" by ERK signaling. Cancer comprising oncogenic ERK can alternatively be defined as cancer that  comprises, displays, or is characterized by "stimulus-independent" ERK signaling.</span>
  </p>
  <p id="p0325" num="0325" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La "mutación oncogénica" abarca cualquier variación de aminoácidos en una proteína, con respecto a la proteína de tipo salvaje, que promueve la proliferación y/o supervivencia de células cancerosas incluyendo, pero no limitado a, sustituciones (incluyendo sustituciones de un solo aminoácido), inserciones y/o deleciones. Como se ha indicado anteriormente, las mutaciones oncogénicas pueden ser mutaciones de pérdida de función o de ganancia de función, dependiendo de la proteína y su función dentro de la vía de la MAP-quinasa. "Sobreexpresión" o "expresión regulada por disminución" se refieren respectivamente al aumento o disminución de la expresión de una proteína en una célula cancerosa con respecto a una célula no cancerosa.</span>"Oncogenic mutation" encompasses any amino acid variation in a protein, relative to the wild-type protein, that promotes cancer cell proliferation and/or survival including, but not limited to, substitutions (including single amino acid substitutions) , insertions and/or deletions. As noted above, oncogenic mutations can be loss-of-function or gain-of-function mutations, depending on the protein and its function within the MAP kinase pathway. "Over-expression" or "down-regulated expression" refer respectively to the increased or decreased expression of a protein in a cancer cell relative to a non-cancer cell.</span>
  </p>
  <p id="p0326" num="0326" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, los cánceres que comprenden la señalización de ERK oncogénica incluyen aquellos que comprenden una mutación oncogénica en, o sobreexpresión de, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, s Os , HRAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 o ERK2; como BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2. Estas proteínas son reguladores positivos de la vía de MAP quinasa (es decir, oncoproteínas) [72] Por ejemplo, el cáncer puede comprender una mutación oncogénica en BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>Accordingly, cancers that comprise oncogenic ERK signaling include those that comprise an oncogenic mutation in, or overexpression of, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, sOs, HRAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 or ERK2; such as BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2. These proteins are positive regulators of the MAP kinase pathway (i.e., oncoproteins) [72] For example, cancer may comprise an oncogenic mutation in BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2 , ERK1 or ERK2.</span>
  </p>
  <p id="p0327" num="0327" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cánceres que comprenden la señalización de ERK oncogénica también incluyen aquellos que comprenden (ya sea alternativamente o además de las mutaciones/sobreexpresiones oncogénicas anteriores) una mutación oncogénica o una expresión regulada por disminución de RSK, DUSP1, DUSP5, DUSP6 o SPRY. Estas proteínas son reguladores negativos de la vía MAP quinasa (es decir, proteínas supresoras de tumores) [72].</span>Cancers that comprise oncogenic ERK signaling also include those that comprise (either alternatively or in addition to the above oncogenic mutations/overexpressions) an oncogenic mutation or down-regulated expression of RSK, DUSP1, DUSP5, DUSP6, or SPRY. These proteins are negative regulators of the MAP kinase pathway (ie, tumor suppressor proteins) [72].</span>
  </p>
  <p id="p0328" num="0328" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquier cáncer que comprenda la señalización de ERK oncogénica puede tratarse o prevenirse usando composiciones de la invención, como tumores sólidos o enfermedades malignas hematológicas. Tales cánceres incluyen, pero no se limitan a, cáncer colorrectal, melanoma, leucemia linfoblástica aguda (ALL), leucemia mieloide aguda, carcinoma adrenocortical, carcinoma de células basales, cáncer de las vías biliares, cáncer de vejiga, tumor óseo, osteosarcoma/histiocitoma fibroso maligno, glioma del tronco encefálico, tumor cerebral, astrocitoma cerebeloso, astrocitoma cerebral/glioma maligno, ependimoma, meduloblastoma, tumores neuroectodérmicos primitivos supratentoriales, cáncer de mama, adenomas/carcinoides bronquiales, linfoma de Burkitt, tumor carcinoide, cáncer de cuello uterino, leucemia linfocítica crónica, leucemia mielógena crónica, trastornos mieloproliferativos crónicos, linfoma cutáneo de células T, cáncer de endometrio, ependimoma, cáncer de esófago, sarcoma de Ewing, melanoma intraocular, retinoblastoma, cáncer de vesícula biliar, cáncer gástrico, tumor carcinoide gastrointestinal, tumor del estroma gastrointestinal (GIST), tumor de células germinales, glioma, vía visual infantil e hipotalámico, linfoma de Hodgkin, carcinoma de células de los islotes, sarcoma de Kaposi, cáncer de células renales, cáncer de laringe, leucemias, linfomas, mesotelioma, neuroblastoma, linfoma no Hodgkin, cáncer de orofaringe, osteosarcoma, cáncer de ovario, cáncer de páncreas, cáncer de paratiroides, cáncer de faringe, adenoma hipofisario, neoplasia de células plasmáticas, cáncer de próstata, carcinoma de células renales, retinoblastoma, sarcoma, cáncer testicular, cáncer de tiroides o cáncer uterino.</span>Any cancer that comprises oncogenic ERK signaling can be treated or prevented using compositions of the invention, such as solid tumors or hematological malignancies. Such cancers include, but are not limited to, colorectal cancer, melanoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor, osteosarcoma/histiocytoma malignant fibrous tumor, brainstem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, tumor gastrointestinal stromal tumor (GIST), germ cell tumor, glioma, childhood visual and hypothalamic, Hodgkin's lymphoma, islet cell carcinoma, Kaposi's sarcoma, renal cell cancer, laryngeal cancer, leukemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin's lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer , pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasm, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, testicular cancer, thyroid cancer, or uterine cancer.</span>
  </p>
  <p id="p0329" num="0329" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cualquier cáncer que comprenda la señalización de ERK oncogénica puede tratarse o prevenirse mediante una composición que comprenda una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>y preferiblemente cáncer colorrectal, melanoma, cáncer de próstata, adenocarcinoma de pulmón como adenocarcinoma de pulmón de células no pequeñas, cáncer de páncreas, cáncer de vejiga, leucemia como leucemia de células pilosas o leucemia mieloide aguda, glioma, astrocitoma pilocítico, cáncer de ovario, cáncer de tiroides papilar o folicular, seminoma, cáncer de hígado, síndrome mielodisplásico, cáncer de riñón o enfermedad de Hodgkin.</span>Any cancer comprising oncogenic ERK signaling can be treated or prevented by a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> and preferably colorectal cancer, melanoma, prostate cancer, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreas, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, or Hodgkin's disease.</span>
  </p>
  <p id="p0330" num="0330" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>para su uso en un método para tratar o prevenir el cáncer que comprende una mutación oncogénica en BRAF, opcionalmente en donde el cáncer comprende además la sobreexpresión de BRAF. Los inventores han identificado que el tratamiento con cepas de <i class="style-scope patent-text">Megasphaera </i>puede inhibir la supervivencia clonogénica, inhibir la señalización de ERK y regular por incremento la expresión del gen MAP2 en líneas celulares de cáncer que comprenden mutaciones de BRAF oncogénicas, en particular la mutación oncogénica BRAF V600E en líneas celulares de cáncer colorrectal y melanoma. Por lo tanto, en realizaciones preferidas, la invención también proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>para su uso en un método de tratamiento o prevención del cáncer que comprende una mutación oncogénica en la posición 600 de BRAF, preferiblemente BRAF V600E. En realizaciones especialmente preferidas, el cáncer es cáncer colorrectal o melanoma.</span>In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> for use in a method of treating or preventing cancer comprising an oncogenic mutation in BRAF, optionally wherein the cancer further comprises overexpression of BRAF. The inventors have identified that treatment with <i class="style-scope patent-text">Megasphaera</i> strains can inhibit clonogenic survival, inhibit ERK signaling, and upregulate MAP2 gene expression in cancer cell lines comprising oncogenic BRAF mutations, in particular the BRAF V600E oncogenic mutation. in colorectal cancer and melanoma cell lines. Therefore, in preferred embodiments, the invention also provides a composition comprising a bacterial strain of the <i class="style-scope patent-text">Megasphaera genus,</i> for use in a method of treating or preventing cancer comprising an oncogenic mutation at position 600 of BRAF, preferably BRAF V600E . In especially preferred embodiments, the cancer is colorectal cancer or melanoma.</span>
  </p>
  <p id="p0331" num="0331" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además de, o en lugar de, una mutación oncogénica en la posición 600 de BRAF (como V600E), el cáncer puede comprender una mutación oncogénica seleccionada de BRAF K601E, G469A, G469V, L597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A o G469E; opcionalmente en donde el cáncer es cáncer colorrectal. En otra realización, además de, o en lugar de, la mutación V600E, el cáncer puede comprender una mutación oncogénica seleccionada de BRAF V600K, V600R o V600D; opcionalmente en donde el cáncer es melanoma.</span>In addition to, or instead of, an oncogenic mutation at position 600 of BRAF (such as V600E), the cancer may comprise a selected oncogenic mutation of BRAF K601E, G469A, G469V, L597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A or G469E; optionally wherein the cancer is colorectal cancer. In another embodiment, in addition to, or instead of, the V600E mutation, the cancer may comprise a selected oncogenic mutation of BRAF V600K, V600R, or V600D; optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0332" num="0332" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invención también proporciona una composición que comprende una cepa 
bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un método para tratar el cáncer colorrectal, como el cáncer colorrectal metastásico. Como se muestra en los ejemplos, los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>pueden inhibir la supervivencia clonogénica y la señalización de ERK en líneas celulares de cáncer colorrectal.</span>In a further aspect, the invention also provides a composition comprising a strain  bacteria of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating colorectal cancer, such as metastatic colorectal cancer. As shown in the examples, the inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains can inhibit clonogenic survival and ERK signaling in colorectal cancer cell lines.</span>
  </p>
  <p id="p0333" num="0333" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invención también proporciona una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis</i>, para su uso en un método para tratar el melanoma, como el melanoma metastásico. Como se muestra en los ejemplos, los inventores han descubierto que las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>pueden inhibir la supervivencia clonogénica y la señalización de ERK en líneas celulares de melanoma. Además, la capacidad de las cepas de <i class="style-scope patent-text">Megasphaera massiliensis </i>para inducir la expresión del gen MAP2 en líneas celulares de melanoma indica una eficacia particular contra el melanoma metastásico.</span>In a further aspect, the invention also provides a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis</i> , for use in a method of treating melanoma, such as metastatic melanoma. As shown in the examples, the inventors have discovered that <i class="style-scope patent-text">Megasphaera massiliensis</i> strains can inhibit clonogenic survival and ERK signaling in melanoma cell lines. Furthermore, the ability of <i class="style-scope patent-text">Megasphaera massiliensis</i> strains to induce MAP2 gene expression in melanoma cell lines indicates particular efficacy against metastatic melanoma.</span>
  </p>
  <p id="p0334" num="0334" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, un inhibidor de BRAF se administra simultáneamente, por separado o secuencialmente, con respecto a la administración de la composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el inhibidor de BRAF es un inhibidor selectivo de BRAFV600E, preferiblemente seleccionado de Vemurafenib, Dabrafinib o Encorafenib. Más preferiblemente, el inhibidor de BRAF es Vemurafenib.</span>In preferred embodiments, a BRAF inhibitor is administered simultaneously, separately or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the BRAF inhibitor is a selective BRAFV600E inhibitor, preferably selected from Vemurafenib, Dabrafinib or Encorafenib. More preferably, the BRAF inhibitor is Vemurafenib.</span>
  </p>
  <p id="p0335" num="0335" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional de la invención, la invención también proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>y un inhibidor de BRAF, preferiblemente los definidos anteriormente, para su uso simultáneo, separado o secuencial en el tratamiento o prevención del cáncer.</span>In a further aspect of the invention, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a BRAF inhibitor, preferably those defined above, for simultaneous, separate or sequential use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0336" num="0336" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones preferidas, un análogo de citidina se administra simultáneamente, por separado o secuencialmente, con respecto a la administración de la composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el análogo de citidina se selecciona de Azacitidina-c, Decitabina o Zebularina. Más preferiblemente, el análogo de citidina es Azacitidina-c.</span>In other preferred embodiments, a cytidine analog is administered simultaneously, separately or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the cytidine analog is selected from Azacitidine-c, Decitabine or Zebularin. More preferably, the cytidine analog is Azacitidine-c.</span>
  </p>
  <p id="p0337" num="0337" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invención también proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>y un análogo de citidina, preferiblemente los definidos anteriormente, para su uso simultáneo, separado o secuencial en el tratamiento o prevención del cáncer.</span>In an additional aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a cytidine analog, preferably those defined above, for simultaneous, separate or sequential use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0338" num="0338" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otras realizaciones preferidas, un inhibidor de la polimerización de tubulina o un inhibidor de la despolimerización de tubulina se administran simultáneamente, por separado o secuencialmente, con respecto a la administración de la composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera. </i>Preferiblemente, el inhibidor de la polimerización de tubulina o el inhibidor de la despolimerización de tubulina se selecciona de Paclitaxel, Abraxane, Docetaxel, Epotilona, (+-)-Discodermolida, Colchicina, Combretastatina, 2-Metoxiestradiol, E7010, Vincristina, Vinblastina, Vinorelbina o Vinflunina; más preferiblemente Paclitaxel.</span>In other preferred embodiments, a tubulin polymerization inhibitor or a tubulin depolymerization inhibitor is administered simultaneously, separately, or sequentially, with respect to the administration of the composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera.</i> Preferably, the tubulin polymerization inhibitor or tubulin depolymerization inhibitor is selected from Paclitaxel, Abraxane, Docetaxel, Epothilone, (+-)-Discodermolide, Colchicine, Combretastatin, 2-Methoxyestradiol, E7010, Vincristine, Vinblastine, Vinorelbine or Vinflunine; more preferably Paclitaxel.</span>
  </p>
  <p id="p0339" num="0339" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, la invención también proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>y un inhibidor de la polimerización de tubulina o inhibidor de la despolimerización de tubulina, preferiblemente los definidos anteriormente, para su uso simultáneo, separado o secuencial en el tratamiento o prevención del cáncer. En un aspecto adicional, la invención también proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, para su uso en la terapia contra el cáncer aumentando la susceptibilidad del cáncer a un inhibidor de la polimerización o despolimerización de la tubulina, preferiblemente los definidos anteriormente.</span>In a further aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> and a tubulin polymerization inhibitor or tubulin depolymerization inhibitor, preferably those defined above, for simultaneous, separate or sequential use in the cancer treatment or prevention. In an additional aspect, the invention also provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , for use in cancer therapy by increasing the susceptibility of cancer to a tubulin polymerization or depolymerization inhibitor, preferably those defined above. .</span>
  </p>
  <p id="p0340" num="0340" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En tales realizaciones adicionales, la invención proporciona:</span>In such additional embodiments, the invention provides:</span>
  </p>
  <p id="p0341" num="0341" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana tiene una secuencia del gel de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1, para su uso en un método de tratamiento o prevención del cáncer, en particular, en donde el cáncer comprende la señalización oncogénica de ERK.</span>1. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain has a 16s rRNA gel sequence that is at least 95% identical to SEQ ID NO: 1, for use in a method of treating or preventing cancer, in particular, wherein the cancer comprises ERK oncogenic signaling.</span>
  </p>
  <p id="p0342" num="0342" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Una composición para su uso de acuerdo con la realización 1, en donde el cáncer comprende una mutación oncogénica en, o sobreexpresión de, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, F1RAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 o ERK2.</span>2. A composition for use according to embodiment 1, wherein the cancer comprises an oncogenic mutation in, or overexpression of, BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, F1RAS, KRAS4A, KRAS4B, MEK1, MEK2, ERK1 or ERK2.</span>
  </p>
  <p id="p0343" num="0343" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. Una composición para su uso de acuerdo con cualquier realización anterior, en donde el cáncer comprende una mutación oncogénica o una expresión regulada a la baja de RSK, DUSP1, DUSP5, DUSP6 o SPRY.</span>3. A composition for use according to any preceding embodiment, wherein the cancer comprises an oncogenic mutation or down-regulated expression of RSK, DUSP1, DUSP5, DUSP6, or SPRY.</span>
  </p>
  <p id="p0344" num="0344" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. Una composición para su uso de acuerdo con la realización 2, en donde el cáncer comprende una mutación oncogénica o sobreexpresión de BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>4. A composition for use according to embodiment 2, wherein the cancer comprises an oncogenic mutation or overexpression of BRAF, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2.</span>
  </p>
  <p id="p0345" num="0345" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. Una composición para su uso de acuerdo con la realización 2, en donde el cáncer comprende una mutación oncogénica en BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1 o ERK2.</span>5. A composition for use according to embodiment 2, wherein the cancer comprises an oncogenic mutation in BRAF, NRAS, ARAF, CRAF, EGFR, GRB2, SOS, HRAS, MEK1, MEK2, ERK1, or ERK2.</span>
  </p>
  <p id="p0346" num="0346" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composición para su uso de acuerdo con cualquier realización anterior, en donde el cáncer comprende una mutación oncogénica en BRAF o NRAS, opcionalmente en donde el cáncer comprende además la sobreexpresión de BRAF o NRAS.</span>6. The composition for use according to any preceding embodiment, wherein the cancer comprises an oncogenic mutation in BRAF or NRAS, optionally wherein the cancer further comprises overexpression of BRAF or NRAS.</span>
  </p>
  <p id="p0347" num="0347" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composición para su uso de acuerdo con la realización 6, en donde el cáncer comprende una mutación oncogénica en BRAF, opcionalmente en donde el cáncer comprende además la sobreexpresión de BRAF. 
</span>7. The composition for use according to embodiment 6, wherein the cancer comprises an oncogenic mutation in BRAF, optionally wherein the cancer further comprises BRAF overexpression. </span>
  </p>
  <p id="p0348" num="0348" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composición para su uso de acuerdo con la realización 7, en donde el cáncer comprende una mutación oncogénica en la posición 600 de BRAF.</span>8. The composition for use according to embodiment 7, wherein the cancer comprises an oncogenic mutation at position 600 of BRAF.</span>
  </p>
  <p id="p0349" num="0349" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composición para su uso de acuerdo con cualquiera de las realizaciones 6-8, en donde el cáncer comprende una mutación oncogénica seleccionada de BRAF V600E, K601E, G469A, G469V, L597R, K601N, G464V, N581S, L597Q, A598V, G464R, G466A o G469E; opcionalmente en donde el cáncer es cáncer colorrectal.</span>9. The composition for use according to any of embodiments 6-8, wherein the cancer comprises a selected oncogenic mutation of BRAF V600E, K601E, G469A, G469V, L597R, K601N, G464V, N581S, L597Q, A598V, G464R , G466A or G469E; optionally wherein the cancer is colorectal cancer.</span>
  </p>
  <p id="p0350" num="0350" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composición para su uso de acuerdo con cualquiera de las realizaciones 6-8, en donde el cáncer comprende una mutación oncogénica seleccionada de BRAF V600E, V600K, V600R o V600D; opcionalmente en donde el cáncer es melanoma.</span>10. The composition for use according to any of embodiments 6-8, wherein the cancer comprises a selected oncogenic mutation of BRAF V600E, V600K, V600R or V600D; optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0351" num="0351" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composición para su uso de acuerdo con cualquiera de las realizaciones 6-10, en donde el cáncer comprende la mutación oncogénica BRAF V600E.</span>11. The composition for use according to any of embodiments 6-10, wherein the cancer comprises the BRAF V600E oncogenic mutation.</span>
  </p>
  <p id="p0352" num="0352" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. La composición para su uso de acuerdo con cualquiera de las realizaciones 6-11, en donde el cáncer comprende la mutación oncogénica NRAS Q61R, opcionalmente en donde el cáncer es melanoma.</span>12. The composition for use according to any of embodiments 6-11, wherein the cancer comprises the NRAS Q61R oncogenic mutation, optionally wherein the cancer is melanoma.</span>
  </p>
  <p id="p0353" num="0353" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. La composición para su uso de acuerdo con cualquier realización anterior, en donde el cáncer se selecciona de cáncer colorrectal, melanoma, cáncer de próstata, adenocarcinoma de pulmón como adenocarcinoma de pulmón de células no pequeñas, cáncer de páncreas, cáncer de vejiga, leucemia como leucemia de células pilosas o leucemia mieloide aguda, glioma, astrocitoma pilocítico, cáncer de ovario, cáncer de tiroides papilar o folicular, seminoma, cáncer de hígado, síndrome mielodisplásico, cáncer de riñón o enfermedad de Hodgkin. 14. La composición para su uso de acuerdo con cualquier realización anterior, en donde el cáncer es cáncer colorrectal.</span>13. The composition for use according to any previous embodiment, wherein the cancer is selected from colorectal cancer, melanoma, prostate cancer, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreatic cancer, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, or Hodgkin's disease. 14. The composition for use according to any preceding embodiment, wherein the cancer is colorectal cancer.</span>
  </p>
  <p id="p0354" num="0354" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. La composición para su uso de acuerdo con cualquiera de las realizaciones 1-13, en donde el cáncer es melanoma.</span>15. The composition for use according to any of embodiments 1-13, wherein the cancer is melanoma.</span>
  </p>
  <p id="p0355" num="0355" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. La composición para su uso de acuerdo con cualquier realización anterior, en donde la cepa bacteriana es de la especie <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>16. The composition for use according to any previous embodiment, wherein the bacterial strain is of the species <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0356" num="0356" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">17. La composición para su uso de acuerdo con cualquier realización anterior, en un método para inhibir la señalización de ERK1 y/o ERK2 en el tratamiento o prevención del cáncer.</span>17. The composition for use according to any preceding embodiment, in a method of inhibiting ERK1 and/or ERK2 signaling in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0357" num="0357" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">18. La composición para su uso de acuerdo con cualquier realización anterior, en un método para inhibir la fosforilación de ERK1 y/o ERK2 en el tratamiento o prevención del cáncer.</span>18. The composition for use according to any previous embodiment, in a method of inhibiting the phosphorylation of ERK1 and/or ERK2 in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0358" num="0358" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">19. La composición para su uso de acuerdo con cualquier realización anterior, en un método para inducir la expresión del gen MAP2 en el tratamiento o prevención del cáncer.</span>19. The composition for use according to any previous embodiment, in a method of inducing the expression of the MAP2 gene in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0359" num="0359" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">20. La composición para su uso de acuerdo con cualquier realización anterior, en un método para reducir el tamaño del tumor, el crecimiento del tumor, prevenir o inhibir la metástasis o prevenir la angiogénesis en el tratamiento o la prevención del cáncer.</span>20. The composition for use according to any preceding embodiment, in a method of reducing tumor size, tumor growth, preventing or inhibiting metastasis, or preventing angiogenesis in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0360" num="0360" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">21. La composición para su uso de acuerdo con cualquier realización anterior, en un método para inhibir la metástasis en el tratamiento del cáncer.</span>21. The composition for use according to any preceding embodiment, in a method of inhibiting metastasis in the treatment of cancer.</span>
  </p>
  <p id="p0361" num="0361" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">22. La composición para su uso de acuerdo con cualquier realización anterior, en donde el método comprende la administración simultánea, separada o secuencial de un inhibidor de BRAF, con respecto a la administración de la composición.</span>22. The composition for use according to any preceding embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a BRAF inhibitor, with respect to the administration of the composition.</span>
  </p>
  <p id="p0362" num="0362" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">23. La composición para su uso de acuerdo con la realización 22, en donde BRAF inhibe selectivamente BRAFv600E, preferiblemente en donde el inhibidor de BRAF se selecciona de Vemurafenib, Dabrafinib o Encorafenib.</span>23. The composition for use according to embodiment 22, wherein BRAF selectively inhibits BRAFv600E, preferably wherein the BRAF inhibitor is selected from Vemurafenib, Dabrafinib or Encorafenib.</span>
  </p>
  <p id="p0363" num="0363" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">24. La composición para su uso de acuerdo con la realización 23, en donde el inhibidor de BRAF es Vemurafenib.</span>24. The composition for use according to embodiment 23, wherein the BRAF inhibitor is Vemurafenib.</span>
  </p>
  <p id="p0364" num="0364" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">25. La composición para su uso de acuerdo con cualquier realización anterior, en donde el método comprende la administración simultánea, separada o secuencial de un análogo de citidina, con respecto a la administración de la composición.</span>25. The composition for use according to any preceding embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a cytidine analog, relative to the administration of the composition.</span>
  </p>
  <p id="p0365" num="0365" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">26. La composición para su uso de acuerdo con la realización 25, en donde el análogo de citidina se selecciona de Azacitidina-c, Decitabina o Zebularina.</span>26. The composition for use according to embodiment 25, wherein the cytidine analog is selected from Azacitidine-c, Decitabine or Zebularin.</span>
  </p>
  <p id="p0366" num="0366" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">27. La composición para su uso de acuerdo con la realización 26, en donde el análogo de citidina es Aazacitidina-c.</span>27. The composition for use according to embodiment 26, wherein the cytidine analog is Aazacytidine-c.</span>
  </p>
  <p id="p0367" num="0367" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">28. La composición para su uso de acuerdo con cualquier realización anterior, en donde el método comprende la administración simultánea, separada o secuencial de un inhibidor de la polimerización de tubulina o un inhibidor de la despolimerización de tubulina, con respecto a la administración de la composición.</span>28. The composition for use according to any previous embodiment, wherein the method comprises the simultaneous, separate or sequential administration of a tubulin polymerization inhibitor or a tubulin depolymerization inhibitor, with respect to the administration of the composition.</span>
  </p>
  <p id="p0368" num="0368" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">29. La composición para su uso de acuerdo con la realización 28, en donde el inhibidor de la polimerización de tubulina o el inhibidor de la despolimerización de tubulina se selecciona de Paclitaxel, Abraxane, Docetaxel, Epotilona, (+)-Discodermolida, Colchicina, Combretastatina, 2-Metoxiestradiol, E7010, Vincristina, Vinblastina, Vinorelbina o Vinflunina.</span>29. The composition for use according to embodiment 28, wherein the tubulin polymerization inhibitor or tubulin depolymerization inhibitor is selected from Paclitaxel, Abraxane, Docetaxel, Epothilone, (+)-Discodermolide, Colchicine, Combretastatin, 2-Methoxyestradiol, E7010, Vincristine, Vinblastine, Vinorelbine or Vinflunine.</span>
  </p>
  <p id="p0370" num="0370" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, los cánceres que comprenden señalización de ERK oncogénica que pueden tratarse o prevenirse usando composiciones de la invención (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>incluyen, pero no se limitan a, cáncer colorrectal, melanoma, cáncer de próstata, adenocarcinoma de pulmón como adenocarcinoma de pulmón de células no pequeñas, cáncer de páncreas, cáncer de vejiga, leucemia como leucemia de células pilosas o leucemia mieloide aguda, glioma, astrocitoma pilocítico, cáncer de ovario, cáncer de tiroides papilar o folicular, seminoma, cáncer de hígado, síndrome mielodisplásico, cáncer de riñón y enfermedad de Hodgkin. Se ha informado que tales cánceres comprenden una vía 
de MAP-quinasa hiperactiva (es decir, señalización ERK oncogénica) [72].</span>Preferably, cancers comprising oncogenic ERK signaling that can be treated or prevented using compositions of the invention (in particular, those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> include, but are not limited to, colorectal cancer, melanoma, cancer prostate, lung adenocarcinoma such as non-small cell lung adenocarcinoma, pancreatic cancer, bladder cancer, leukemia such as hairy cell leukemia or acute myeloid leukemia, glioma, pilocytic astrocytoma, ovarian cancer, papillary or follicular thyroid cancer, seminoma, liver cancer, myelodysplastic syndrome, kidney cancer, and Hodgkin's disease. Such cancers have been reported to comprise a pathway  of overactive MAP-kinase (ie, oncogenic ERK signaling) [72].</span>
  </p>
  <p id="p0371" num="0371" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realización particular, las composiciones de la invención son para su uso en el tratamiento o prevención del cáncer que comprende una mutación oncogénica en BRAF o NRAS, opcionalmente en donde el cáncer comprende además la sobreexpresión de BRAF o NRAS. Preferiblemente, las composiciones de la invención (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevención del cáncer que comprende una mutación oncogénica en BRAF y la sobreexpresión opcional de BRAF.</span>In a particular embodiment, the compositions of the invention are for use in the treatment or prevention of cancer comprising an oncogenic mutation in BRAF or NRAS, optionally where the cancer further comprises overexpression of BRAF or NRAS. Preferably, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of cancer comprising an oncogenic mutation in BRAF and optional overexpression of BRAF.</span>
  </p>
  <p id="p0372" num="0372" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las mutaciones oncogénicas en BRAF incluyen V600E, K601E, G469A, G469V, F597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A o G469E, que se han identificado en cánceres colorrectales [73], y las composiciones de las composiciones de la invención (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>pueden usarse para tratar o prevenir tales cánceres. Otras mutaciones oncogénicas en BRAF incluyen V600E, V600K, V600R o V600D, que se han identificado en melanomas [74], y las composiciones de las composiciones de la invención (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>pueden usarse para tratar o prevenir tales cánceres. Los aminoácidos en BRAF se numeran de acuerdo con la entrada P15056 de UniProt [75] (BRAF de tipo salvaje).</span>Oncogenic mutations in BRAF include V600E, K601E, G469A, G469V, F597R, K601N, G464V, N581S, F597Q, A598V, G464R, G466A, or G469E, which have been identified in colorectal cancers [73], and the compositions of the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> can be used to treat or prevent such cancers. Other oncogenic mutations in BRAF include V600E, V600K, V600R or V600D, which have been identified in melanomas [74], and the compositions of the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> can used to treat or prevent such cancers. The amino acids in BRAF are numbered according to UniProt entry P15056 [75] (wild-type BRAF).</span>
  </p>
  <p id="p0373" num="0373" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realización especialmente preferida, las composiciones de la invención (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevención del cáncer que comprende la mutación BRAF V600E. Las líneas celulares de cáncer SKMEF28, 451Lu y HT29 comprenden esta mutación en BRAF, y se descubrió que una cepa de <i class="style-scope patent-text">Megasphaera </i>de los Ejemplos inhibía la supervivencia clonogénica, inhibía la señalización de ERK e inducía la expresión del gen MAP2 en dichas líneas celulares. El cáncer puede comprender además la mutación oncogénica NRAS Q61R. La línea celular de cáncer SKMEL2 comprende esta mutación en NRAS, y se descubrió que una cepa de <i class="style-scope patent-text">Megasphaera </i>de los Ejemplos inducía la expresión del gen MAP2 en esta línea celular.</span>In an especially preferred embodiment, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of cancer comprising the BRAF V600E mutation. Cancer cell lines SKMEF28, 451Lu, and HT29 comprise this mutation in BRAF, and a <i class="style-scope patent-text">Megasphaera</i> strain of Examples was found to inhibit clonogenic survival, inhibit ERK signaling, and induce MAP2 gene expression in these cell lines. The cancer may further comprise the NRAS Q61R oncogenic mutation. The cancer cell line SKMEL2 comprises this mutation in NRAS, and a <i class="style-scope patent-text">Megasphaera</i> strain of the Examples was found to induce expression of the MAP2 gene in this cell line.</span>
  </p>
  <p id="p0374" num="0374" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La línea celular HT29 usada en los Ejemplos es una línea celular de cáncer colorrectal, y se descubrió que una cepa de <i class="style-scope patent-text">Megasphaera </i>inhibía la supervivencia clonogénica e inhibía la señalización de ERK en esta línea celular. Por lo tanto, en realizaciones especialmente preferidas, las composiciones de la invención (en particular, las que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>son para su uso en el tratamiento o prevención del cáncer colorrectal, como el cáncer colorrectal que comprende la mutación BRAF V600E.</span>The HT29 cell line used in the Examples is a colorectal cancer cell line, and a Megasphaera strain was found to inhibit <i class="style-scope patent-text">clonogenic</i> survival and inhibit ERK signaling in this cell line. Therefore, in especially preferred embodiments, the compositions of the invention (in particular, those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are for use in the treatment or prevention of colorectal cancer, such as colorectal cancer comprising the BRAF V600E mutation.</span>
  </p>
  <p id="p0375" num="0375" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las líneas celulares SKMEL2 y SKMEL28 y 451Lu usadas en los Ejemplos son líneas celulares de melanoma, y se descubrió que una cepa de <i class="style-scope patent-text">Megasphaera </i>inhibía la supervivencia clonogénica, inhibía la señalización de ERK e inducía la expresión del gen MAP2 en dichas líneas celulares. Por lo tanto, en realizaciones especialmente preferidas, las composiciones de la invención (en particular, aquellas que comprenden una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>se usan para tratar o prevenir el melanoma, como el melanoma que comprende la mutación BRAF V600E.</span>The SKMEL2 and SKMEL28 and 451Lu cell lines used in the Examples are melanoma cell lines, and a Megasphaera strain was found to inhibit <i class="style-scope patent-text">clonogenic</i> survival, inhibit ERK signaling and induce MAP2 gene expression in these cell lines. Therefore, in especially preferred embodiments, the compositions of the invention (particularly those comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> are used to treat or prevent melanoma, such as melanoma comprising the BRAF V600E mutation.</span>
  </p>
  <p id="p0376" num="0376" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En otro aspecto, la composición de la invención comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un método de tratamiento del cáncer colorrectal. En otro aspecto, la composición de la invención comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>para su uso en un método de tratamiento del melanoma.</span>In another aspect, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating colorectal cancer. In another aspect, the composition of the invention comprises a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> for use in a method of treating melanoma.</span>
  </p>
  <p id="p0377" num="0377" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En cualquiera de los aspectos y realizaciones detallados anteriormente, la composición de la invención (en particular, una composición que comprende una cepa bacteriana de la especie <i class="style-scope patent-text">Megasphaera massiliensis) </i>es preferiblemente para su uso en el tratamiento de un cáncer metastásico. Como se informa en los Ejemplos, se descubrió que una cepa de <i class="style-scope patent-text">Megasphaera </i>regulaba por incremento la expresión del gen MAP2. Se ha descubierto que MAP2 se expresa en gran medida en los melanomas cutáneos primarios, pero tiene una expresión reducida en los melanomas metastásicos [76]. Se ha propuesto que la expresión aumentada de proteínas estabilizadoras de microtúbulos o el tratamiento con proteínas estabilizadoras de microtúbulos como MAP2 pueden interferir con la inestabilidad dinámica de los microtúbulos que se requiere durante la división celular. Por lo tanto, se cree que la regulación por incremento de MAP2 dificulta la división celular y retrasa el crecimiento tumoral en el cáncer [76], lo que indica que las composiciones de la invención pueden tener un uso particular en el tratamiento de cánceres metastásicos.</span>In any of the aspects and embodiments detailed above, the composition of the invention (in particular, a composition comprising a bacterial strain of the species <i class="style-scope patent-text">Megasphaera massiliensis)</i> is preferably for use in the treatment of metastatic cancer. As reported in the Examples, one strain of <i class="style-scope patent-text">Megasphaera</i> was found to up-regulate the expression of the MAP2 gene. MAP2 has been found to be highly expressed in primary cutaneous melanomas, but has reduced expression in metastatic melanomas [76]. It has been proposed that increased expression of microtubule-stabilizing proteins or treatment with microtubule-stabilizing proteins such as MAP2 may interfere with the dynamic instability of microtubules that is required during cell division. Thus, upregulation of MAP2 is believed to impair cell division and retard tumor growth in cancer [76], indicating that the compositions of the invention may have particular use in the treatment of metastatic cancers.</span>
  </p>
  <p id="p0378" num="0378" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se demuestra en los Ejemplos, las composiciones de la invención que comprenden una cepa de <i class="style-scope patent-text">Megasphaera </i>tienen los efectos de inducir la expresión del gen MAP2 e inhibir la señalización de ERK en líneas celulares de melanoma y cáncer colorrectal. Por lo tanto, las composiciones de la invención son útiles en métodos para inhibir la señalización de ERK, como la señalización de ERK1 y/o ERK2, en el tratamiento o prevención de cánceres que comprenden la señalización de ERK oncogénica, como se ha definido anteriormente. Las composiciones de la invención también son útiles en métodos para inhibir la fosforilación de ERK, como la fosforilación de ERK1 y/o ERK2, en el tratamiento o prevención de tales cánceres. Las composiciones de la invención también son útiles en métodos para inducir la expresión del gen MAP2 en el tratamiento o prevención de 
tales cánceres. La expresión del gen MAP2 se ha asociado con una sensibilidad aumentada del cáncer a compuestos dirigidos a microtúbulos como Paclitaxel [77]. Por lo tanto, las composiciones de la invención pueden usarse para aumentar la susceptibilidad de tales cánceres a un inhibidor de la polimerización o despolimerización de tubulina, en particular Paclitaxel. Las composiciones de la invención también son útiles en métodos para reducir el tamaño del tumor, reducir el crecimiento del tumor, prevenir o inhibir la metástasis o prevenir la angiogénesis en el tratamiento o la prevención de cánceres que comprenden la señalización de ERK oncogénica. Debido a los efectos sobre la expresión del gen MAP2 demostrados en los Ejemplos, las composiciones de la invención son preferiblemente para su uso en métodos de inhibición de metástasis en el tratamiento de tales cánceres.</span>As demonstrated in the Examples, compositions of the invention comprising a <i class="style-scope patent-text">Megasphaera</i> strain have the effects of inducing MAP2 gene expression and inhibiting ERK signaling in melanoma and colorectal cancer cell lines. Therefore, the compositions of the invention are useful in methods of inhibiting ERK signaling, such as ERK1 and/or ERK2 signaling, in the treatment or prevention of cancers that comprise oncogenic ERK signaling, as defined above. . The compositions of the invention are also useful in methods of inhibiting ERK phosphorylation, such as ERK1 and/or ERK2 phosphorylation, in the treatment or prevention of such cancers. The compositions of the invention are also useful in methods of inducing MAP2 gene expression in the treatment or prevention of  such cancers. MAP2 gene expression has been associated with increased sensitivity of cancer to microtubule-targeted compounds such as Paclitaxel [77]. Therefore, the compositions of the invention can be used to increase the susceptibility of such cancers to an inhibitor of tubulin polymerization or depolymerization, in particular Paclitaxel. The compositions of the invention are also useful in methods of reducing tumor size, reducing tumor growth, preventing or inhibiting metastasis, or preventing angiogenesis in the treatment or prevention of cancers that comprise oncogenic ERK signaling. Due to the effects on MAP2 gene expression demonstrated in the Examples, the compositions of the invention are preferably for use in methods of inhibiting metastasis in the treatment of such cancers.</span>
  </p>
  <p id="p0379" num="0379" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En un aspecto adicional, una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>es para su uso en un método para inhibir la señalización de ERK1 y/o ERK2 en el tratamiento o la prevención del cáncer. En un aspecto adicional, una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>es para su uso en un método para inhibir la fosforilación de ERK1 y/o ERK2 en el tratamiento o prevención del cáncer. En un aspecto adicional, una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>es para su uso en un método para inducir la expresión del gen MAP2 en el tratamiento o prevención del cáncer. En dichos aspectos adicionales, preferiblemente los cánceres se caracterizan como se ha detallado anteriormente ("Cánceres y características de los mismos").</span>In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inhibiting ERK1 and/or ERK2 signaling in the treatment or prevention of cancer. In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inhibiting ERK1 and/or ERK2 phosphorylation in the treatment or prevention of cancer. In a further aspect, a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is for use in a method of inducing MAP2 gene expression in the treatment or prevention of cancer. In such additional aspects, cancers are preferably characterized as detailed above ("Cancers and characteristics thereof").</span>
  </p>
  <p id="p0380" num="0380" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención es para su uso en el tratamiento del cáncer de intestino delgado, como el adenocarcinoma de intestino delgado. La línea celular HT29 tratada con metotrexato usada en los ejemplos tiene un fenotipo que se asemeja a las células epiteliales del intestino delgado y se demostró que las composiciones de la invención tienen un efecto útil sobre tales células. En ciertas realizaciones, las composiciones de la invención se usan para promover la apoptosis en el tratamiento o prevención del cáncer, en particular del cáncer de intestino delgado.</span>In certain embodiments, the composition of the invention is for use in the treatment of cancer of the small intestine, such as adenocarcinoma of the small intestine. The methotrexate-treated cell line HT29 used in the examples has a phenotype resembling epithelial cells of the small intestine and the compositions of the invention were shown to have a useful effect on such cells. In certain embodiments, the compositions of the invention are used to promote apoptosis in the treatment or prevention of cancer, particularly cancer of the small intestine.</span>
  </p>
  <p id="p0381" num="0381" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención es para su uso en un método para inducir la expresión del gen GPR109a en el tratamiento o la prevención del cáncer.</span>In certain embodiments, the composition of the invention is for use in a method of inducing GPR109a gene expression in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0382" num="0382" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención es para su uso en un método para aumentar los niveles de IL-8 en el tratamiento o la prevención del cáncer.</span>In certain embodiments, the composition of the invention is for use in a method of increasing IL-8 levels in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0383" num="0383" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención es para su uso en el tratamiento del cáncer colorrectal, como el adenocarcinoma colorrectal. La línea celular Caco-2 utilizada en los ejemplos es una línea celular de adenocarcinoma colorrectal y se demostró que las composiciones de la invención tienen un efecto útil sobre tales células.</span>In certain embodiments, the composition of the invention is for use in the treatment of colorectal cancer, such as colorectal adenocarcinoma. The Caco-2 cell line used in the examples is a colorectal adenocarcinoma cell line and the compositions of the invention were shown to have a useful effect on such cells.</span>
  </p>
  <p id="p0384" num="0384" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones son para su uso en el tratamiento o prevención del melanoma metastásico, el cáncer de pulmón de células pequeñas o el carcinoma de pulmón adenoescamoso. El efecto sobre NSE que se muestra en los ejemplos sugiere que las composiciones de la invención pueden ser especialmente eficaces contra estos cánceres.</span>In certain embodiments, the compositions are for use in the treatment or prevention of metastatic melanoma, small cell lung cancer, or adenosquamous lung carcinoma. The effect on NSE shown in the examples suggests that the compositions of the invention may be especially effective against these cancers.</span>
  </p>
  <p id="p0385" num="0385" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención no es para su uso en el tratamiento del cáncer. En ciertas realizaciones, la composición de la invención es para su uso en el tratamiento de una enfermedad o trastorno que no es cáncer.</span>In certain embodiments, the composition of the invention is not for use in the treatment of cancer. In certain embodiments, the composition of the invention is for use in the treatment of a disease or disorder that is not cancer.</span>
  </p>
  <p id="p0386" num="0386" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Uso como adyuvante de vacunas</span>Use as a vaccine adjuvant</span>
    </i>
  </p>
  <p id="p0387" num="0387" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión del Factor de Necrosis Tumoral alfa (TNF-a). Se sabe que el TNF-a es importante para las respuestas a las vacunas. Por ejemplo, se ha demostrado que se requiere el TNF-a para una respuesta vacunal eficaz en la vacunación contra la gripe de la población de edad avanzada [78]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de TNF-a, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvantes de vacunas aumentando el nivel y/o la actividad de TNF-a. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas en la terapia contra la gripe. En ciertas realizaciones, las composiciones de la invención son para su uso en la potenciación de una respuesta inmunitaria contra un antígeno. En ciertas realizaciones, la invención proporciona una composición para administrar en combinación con un antígeno. En ciertas realizaciones, las composiciones de la invención son para su administración a un paciente poco antes o después de la vacunación.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of Tumor Necrosis Factor alpha (TNF-a). TNF-α is known to be important for responses to vaccines. For example, TNF-α has been shown to be required for an effective vaccine response in influenza vaccination of the elderly population [78]. Since administration of the compositions of the invention has been shown to increase the expression of TNF-α, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the level and/or activity of TNF-α. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in influenza therapy. In certain embodiments, the compositions of the invention are for use in enhancing an immune response against an antigen. In certain embodiments, the invention provides a composition for administration in combination with an antigen. In certain embodiments, the compositions of the invention are for administration to a patient shortly before or after vaccination.</span>
  </p>
  <p id="p0388" num="0388" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-6. La expresión de IL-6 aumentada se ha asociado con respuestas a vacunas para muchas enfermedades. Por ejemplo, los monocitos inflamatorios CD14+CD16- produjeron IL-6 después de que se administrase una vacuna contra la gripe a adultos [79], y los niveles más altos de IL-6 se asociaron con el logro de 
una respuesta vacunal a una vacuna contra la gripe [80]. Además, se produjo IL-6 después de la inyección del sistema adyuvante AS03 [81] y se demostró que la regulación por disminución de IL-6 en ratones reduce la respuesta de las células T auxiliares después de la administración de una vacuna contra la tuberculosis [82]. Como se demostró que la administración de las composiciones de la invención aumenta la expresión de IL-6, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas aumentando el nivel y/o la actividad de IL-6. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas en la terapia contra la tuberculosis.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in IL-6 expression. Increased IL-6 expression has been associated with responses to vaccines for many diseases. For example, inflammatory monocytes CD14+CD16- produced IL-6 after an influenza vaccine was administered to adults [79], and higher levels of IL-6 were associated with achievement of  a vaccinal response to an influenza vaccine [80]. In addition, IL-6 was produced after injection of the AS03 adjuvant system [81] and down-regulation of IL-6 in mice was shown to reduce the T helper cell response after administration of a tuberculosis vaccine. [82]. Since administration of the compositions of the invention was shown to increase IL-6 expression, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant by increasing the level and/or activity of IL-6. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in tuberculosis therapy.</span>
  </p>
  <p id="p0390" num="0390" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, se ha demostrado que la expresión de IL-6 y TNF-a se correlaciona con la eficacia de una vacuna terapéutica contra el VIH [Huang et al], una vacuna contra la tuberculosis y una vacuna contra la clamidia [83]. Su et al. [84] demostraron que la coinoculación de IL-6 o TNF-a con la vacuna de ADN contra el FMDV dio como resultado un aumento de la expresión de IFN-<sup class="style-scope patent-text">y </sup>por las células T CD4+ y CD8+, una mayor expresión de IL-4 en las células T CD4+ y una mayor expresión de la respuesta citotóxica específica del antígeno. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-6 y TNF-a, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. En una realización, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas aumentando el nivel y/o la actividad de TNF-a. En una realización, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas aumentando el nivel y/o la actividad de IL-6. En una realización particular, las composiciones de la invención pueden ser útiles como adyuvante de vacunas aumentando el nivel y/o actividad de TNF-a e IL-6. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas en la terapia del VIH. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas en la terapia de clamidia.</span>Furthermore, the expression of IL-6 and TNF-α has been shown to correlate with the efficacy of a therapeutic HIV vaccine [Huang et al], a tuberculosis vaccine, and a chlamydia vaccine [83]. His et al. [84] showed that co-inoculation of IL-6 or TNF-α with FMDV DNA vaccine resulted in increased expression of IFN-α <sup class="style-scope patent-text">and</sup> , by CD4+ and CD8+ T cells, increased expression of IL-4 on CD4+ T cells and increased expression of the antigen-specific cytotoxic response. Since administration of the compositions of the invention has been shown to increase the expression of IL-6 and TNF-α, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention may be useful as vaccine adjuvants by increasing the level and/or activity of TNF-α. In one embodiment, the compositions of the invention may be useful as vaccine adjuvants by increasing the level and/or activity of IL-6. In a particular embodiment, the compositions of the invention may be useful as a vaccine adjuvant by increasing the level and/or activity of TNF-a and IL-6. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in HIV therapy. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in the therapy of chlamydia.</span>
  </p>
  <p id="p0392" num="0392" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de MIP-3a. Se ha demostrado que MIP-3a aumenta la respuesta a una vacuna contra el VIH [85]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de MIP-3a, las composiciones de la invención pueden ser útiles como adyuvante de vacunas.</span>The Examples show that the administration of the compositions of the invention can lead to an increase in the expression of MIP-3a. MIP-3a has been shown to increase the response to an HIV vaccine [85]. Since administration of the compositions of the invention has been shown to increase the expression of MIP-3a, the compositions of the invention may be useful as a vaccine adjuvant.</span>
  </p>
  <p id="p0394" num="0394" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-1 p. Li et al. [86] demostraron que el adyuvante hidróxido de aluminio activaba la secreción de IL-1 p y sugirieron que la propia IL-1 p puede actuar como adyuvante. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-1 p, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. Los ejemplos muestran que la administración de las composiciones de la invención puede aumentar la proporción de células T CD8+ a Tregs. Se ha demostrado que los adyuvantes estimulan las células T CD8+ [87] y como se ha demostrado que la administración de las composiciones de la invención aumenta la proporción de células T CD8+ a Tregs, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvantes de vacunas aumentando la proporción de células T CD8+ a Tregs.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-1 p. Li et al. [86] showed that aluminum hydroxide adjuvant activated IL-1p secretion and suggested that IL-1p itself may act as an adjuvant. Since administration of the compositions of the invention has been shown to increase IL-1 p expression, the compositions of the invention may be useful as vaccine adjuvants. The examples show that administration of the compositions of the invention can increase the ratio of CD8+ T cells to Tregs. Adjuvants have been shown to stimulate CD8+ T cells [87] and since administration of the compositions of the invention has been shown to increase the ratio of CD8+ T cells to Tregs, the compositions of the invention may be useful as vaccine adjuvants. . In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the ratio of CD8+ T cells to Tregs.</span>
  </p>
  <p id="p0396" num="0396" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-8. El aumento de la expresión de 11-8 se ha asociado con respuestas a vacunas para muchas enfermedades. Por ejemplo, los niveles más altos de IL-8 se asociaron con el logro de una respuesta vacunal a una vacuna contra la gripe aviar [88]. Además, la IL-8 sirve como adyuvante molecular en un modelo de vacunación con ADN [89]. Por lo tanto, la IL-8 puede usarse como inmunoestimulante para potenciar la eficacia inmunitaria de, por ejemplo, una vacuna contra la gripe aviar. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-8, las composiciones de la invención pueden ser útiles como adyuvantes de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvantes de vacunas aumentando el nivel y/o la actividad de IL-8. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas. En una realización, las composiciones de la invención son para su uso como adyuvante de vacunas en la terapia contra la gripe. En algunas realizaciones, cuando se usan como adyuvantes de vacunas, las composiciones de la invención se administrarán por sí solas para proporcionar un efecto adyuvante para un antígeno que se ha administrado por separado al paciente. En ciertas realizaciones, la composición de la invención se administra por vía oral, mientras que el antígeno se inyecta por vía parenteral.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in the expression of IL-8. Increased expression of 11-8 has been associated with responses to vaccines for many diseases. For example, higher levels of IL-8 were associated with achieving a vaccine response to an avian influenza vaccine [88]. In addition, IL-8 serves as a molecular adjuvant in a DNA vaccination model [89]. Therefore, IL-8 can be used as an immunostimulant to enhance the immune efficacy of, for example, an avian influenza vaccine. Since administration of the compositions of the invention has been shown to increase IL-8 expression, the compositions of the invention may be useful as vaccine adjuvants. In one embodiment, the compositions of the invention are for use as vaccine adjuvants by increasing the level and/or activity of IL-8. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant. In one embodiment, the compositions of the invention are for use as a vaccine adjuvant in influenza therapy. In some embodiments, when used as vaccine adjuvants, the compositions of the invention will be administered alone to provide an adjuvant effect for an antigen that has been separately administered to the patient. In certain embodiments, the composition of the invention is administered orally, while the antigen is injected parenterally.</span>
  </p>
  <p id="p0398" num="0398" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden usarse para potenciar una respuesta inmunitaria a cualquier antígeno útil. Ejemplos de antígenos para su uso con la invención incluyen: antígenos virales, como proteínas de superficie virales; antígenos bacterianos, como antígenos proteicos y/o sacáridos; antígenos fúngicos; antígenos de parásitos; y antígenos tumorales. La invención es particularmente útil para vacunas contra el virus de la gripe, VIH, anquilostomiasis, virus de la hepatitis B, virus del herpes simple, rabia, virus respiratorio sincitial, citomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus, </i>clamidia, coronavirus del SARS, virus de la varicela zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis, </i>virus de Epstein Barr, virus del papiloma humano, etc. Antígenos adicionales para su uso con la invención incluyen antígenos de glicoproteína y lipoglicano, antígenos de arqueas, antígeno de melanoma E (MAGE), antígeno carcinoembrionario (CEA), MUC-1, HER2, sialilTn (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antígeno prostático específico (PSA), antígenos del virus de Epstein-Barr, neoantígenos, oncoproteínas, amiloide-beta, Tau, PCSK9 y sustancias que crean hábito, por ejemplo, nicotina, alcohol u opiáceos.</span>The compositions of the invention can be used to enhance an immune response to any useful antigen. Examples of antigens for use with the invention include: viral antigens, such as viral surface proteins; bacterial antigens, such as protein and/or saccharide antigens; fungal antigens; parasite antigens; and tumor antigens. The invention is particularly useful for vaccines against influenza virus, HIV, hookworm, hepatitis B virus, herpes simplex virus, rabies, respiratory syncytial virus, cytomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus,</i> chlamydia, SARS coronavirus, varicella virus zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis,</i> Epstein Barr virus, human papilloma virus, etc. Additional antigens for use with the invention include glycoprotein and lipoglycan antigens, archaeal antigens, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2,  sialylTn (STn), human telomerase reverse transcriptase (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and habit-forming substances, for example, nicotine, alcohol, or opiates.</span>
  </p>
  <p id="p0399" num="0399" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los antígenos preferidos para su uso con la invención incluyen antígenos patógenos y antígenos tumorales. Un antígeno provocará una respuesta inmunitaria específica para el antígeno que será eficaz para proteger contra la infección por el patógeno o atacar el tumor. Los antígenos pueden ser, por ejemplo, péptidos o polisacáridos.</span>Preferred antigens for use with the invention include pathogen antigens and tumor antigens. An antigen will elicit an antigen-specific immune response that will be effective in protecting against infection by the pathogen or attacking the tumor. The antigens can be, for example, peptides or polysaccharides.</span>
  </p>
  <p id="p0400" num="0400" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención también proporciona el uso de: (i) una preparación acuosa de un antígeno; y (ii) una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>preferiblemente la especie <i class="style-scope patent-text">Megasphaera massiliensis, </i>en la fabricación de un medicamento para obtener una respuesta inmunitaria en un paciente.</span>The invention also provides the use of: (i) an aqueous preparation of an antigen; and (ii) a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> preferably the species <i class="style-scope patent-text">Megasphaera massiliensis,</i> in the manufacture of a medicament for eliciting an immune response in a patient.</span>
  </p>
  <p id="p0401" num="0401" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La respuesta inmunitaria provocada por estos métodos y usos incluirá generalmente una respuesta de anticuerpos, preferiblemente una respuesta de anticuerpos protectores.</span>The immune response elicited by these methods and uses will generally include an antibody response, preferably a protective antibody response.</span>
  </p>
  <p id="p0402" num="0402" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, se manipula una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>para que presente un antígeno. La presentación de un antígeno en la cepa bacteriana de la invención puede maximizar las actividades inmunoestimuladoras y potenciar adicionalmente la respuesta inmunitaria protectora generada contra el antígeno. Además, la fabricación y el suministro de productos terapéuticos que comprenden un antígeno y una bacteria de la invención pueden ser más eficientes y eficaces de esta manera que cuando cada antígeno y la composición que comprende la cepa bacteriana se fabrican y suministran por separado. Por tanto, en algunas realizaciones, la invención proporciona una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>que presenta un antígeno, por ejemplo, en su superficie celular. En algunas realizaciones, la composición que comprende la cepa bacteriana que presenta un antígeno es para su uso como antígeno vacunal. En algunas realizaciones, el antígeno se deriva de VIH, anquilostomiasis, virus de la hepatitis B, virus del herpes simple, rabia, virus respiratorio sincitial, citomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus, </i>clamidia, coronavirus del SARS, virus de la varicela zoster, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis, </i>virus de Epstein Barr o virus del papiloma humano. En algunas realizaciones, el antígeno es un antígeno de glicoproteína, antígeno de lipoglicano, antígeno de arqueas, antígeno de melanoma E (MAGE), antígeno carcinoembrionario (CEA), MUC-1, HER2, sialil-T n (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antígeno prostático específico (PSA), antígenos del virus de Epstein-Barr, neoantígenos, oncoproteínas, amiloide-beta, Tau, PCSK9 y sustancias que crean hábito, por ejemplo, nicotina, alcohol u opiáceos y similares.</span>In some embodiments, a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> is manipulated to present an antigen. Presentation of an antigen in the bacterial strain of the invention can maximize immunostimulatory activities and further enhance the protective immune response generated against the antigen. Furthermore, the manufacture and supply of therapeutics comprising an antigen and a bacteria of the invention can be more efficient and effective in this manner than when each antigen and the composition comprising the bacterial strain are manufactured and supplied separately. Thus, in some embodiments, the invention provides a composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that presents an antigen, for example, on its cell surface. In some embodiments, the composition comprising the antigen presenting bacterial strain is for use as a vaccine antigen. In some embodiments, the antigen is derived from HIV, hookworm, hepatitis B virus, herpes simplex virus, rabies, respiratory syncytial virus, cytomegalovirus, <i class="style-scope patent-text">Staphylococcus aureus,</i> chlamydia, SARS coronavirus, varicella zoster virus, <i class="style-scope patent-text">Streptococcus pneumoniae, Neisseria meningitidis, Mycobacterium tuberculosis, Bacillus anthracis,</i> Epstein Barr virus, or human papillomavirus. In some embodiments, the antigen is a glycoprotein antigen, lipoglycan antigen, archaeal antigen, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2, sialyl-T n (STn), reverse transcriptase human telomerase (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and substances that create habit, for example, nicotine, alcohol or opiates and the like.</span>
  </p>
  <p id="p0403" num="0403" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunas realizaciones, las bacterias de la invención expresan uno o más antígenos. Generalmente, el antígeno se expresará de manera recombinante y será heterólogo para las bacterias de la invención. Por lo tanto, la invención proporciona una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>que expresa un antígeno heterólogo. El antígeno puede ser parte de un polipéptido de fusión expresado con uno o más polipéptidos homólogos a las bacterias. En algunas realizaciones, las bacterias expresan el antígeno como un polipéptido no de fusión. En algunas realizaciones, la invención proporciona una composición que comprende una célula de una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera, </i>en donde la célula expresa un antígeno heterólogo. En algunas realizaciones, la composición es para su uso como vacuna. En algunas realizaciones, la invención proporciona una célula de una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, en donde la célula expresa un antígeno heterólogo. En algunas realizaciones, la célula se usa como una vacuna.</span>In some embodiments, the bacteria of the invention express one or more antigens. Generally, the antigen will be expressed recombinantly and will be heterologous to the bacteria of the invention. Therefore, the invention provides a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> that expresses a heterologous antigen. The antigen may be part of an expressed fusion polypeptide with one or more bacterially homologous polypeptides. In some embodiments, the bacteria express the antigen as a non-fusion polypeptide. In some embodiments, the invention provides a composition comprising a cell of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera,</i> wherein the cell expresses a heterologous antigen. In some embodiments, the composition is for use as a vaccine. In some embodiments, the invention provides a cell of a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the cell expresses a heterologous antigen. In some embodiments, the cell is used as a vaccine.</span>
  </p>
  <p id="p0404" num="0404" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los antígenos ejemplares para su uso con la invención incluyen: antígenos virales, como proteínas de superficie viral; antígenos bacterianos, como antígenos proteicos y/o sacáridos; antígenos fúngicos; antígenos de parásitos; y antígenos tumorales. Antígenos adicionales para expresar en una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera </i>incluyen antígenos de glicoproteína y lipoglicano, antígenos de arqueas, antígeno de melanoma E (MAGE), antígeno carcinoembrionario (CEA), MUC-1, HER2, sialil-Tn (STn), transcriptasa inversa de telomerasa humana (hTERT), gen del tumor de Wilms (WT1), CA-125, antígeno prostático específico (PSA), antígenos del virus de Epstein-Barr, neoantígenos, oncoproteínas, amiloide-beta, Tau, PCSK9 y sustancias que crean hábito, por ejemplo, nicotina, alcohol, opiáceos o similares.</span>Exemplary antigens for use with the invention include: viral antigens, such as viral surface proteins; bacterial antigens, such as protein and/or saccharide antigens; fungal antigens; parasite antigens; and tumor antigens. Additional antigens to express on a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> include glycoprotein and lipoglycan antigens, archaeal antigens, melanoma antigen E (MAGE), carcinoembryonic antigen (CEA), MUC-1, HER2, sialyl-Tn (STn), transcriptase telomerase inverse enzyme (hTERT), Wilms tumor gene (WT1), CA-125, prostate-specific antigen (PSA), Epstein-Barr virus antigens, neoantigens, oncoproteins, amyloid-beta, Tau, PCSK9, and substances that are habit forming, for example, nicotine, alcohol, opiates or the like.</span>
  </p>
  <p id="p0405" num="0405" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención también puede ser útil para potenciar la respuesta a las vacunas contra enfermedades no transmisibles como la enfermedad de Alzheimer y otros trastornos neurodegenerativos, en cuyo caso el antígeno para su uso con la invención puede ser amiloide-beta o Tau. Otros antígenos de este tipo para enfermedades no transmisibles incluyen PCSK9 (para el tratamiento del colesterol elevado).</span>The invention may also be useful for enhancing the response to vaccines against non-communicable diseases such as Alzheimer's disease and other neurodegenerative disorders, in which case the antigen for use with the invention may be amyloid-beta or Tau. Other such antigens for non-communicable diseases include PCSK9 (for the treatment of high cholesterol).</span>
  </p>
  <p id="p0406" num="0406" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La invención también puede ser útil para potenciar la respuesta a las vacunas contra las sustancias que crean hábito, por ejemplo, nicotina, alcohol u opiáceos.</span>The invention may also be useful for enhancing the response to vaccinations against habit-forming substances, eg, nicotine, alcohol, or opiates.</span>
  </p>
  <p id="p0407" num="0407" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapias celulares</span>cell therapies</span>
    </i>
  </p>
  <p id="p0408" num="0408" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Terapia de células T con receptores de antígenos quiméricos </i>(<i class="style-scope patent-text">CAR-T) </i> </span> <i class="style-scope patent-text">Chimeric Antigen Receptor T-Cell Therapy</i> ( <i class="style-scope patent-text">CAR-T)</i> </span>
  </p>
  <p id="p0409" num="0409" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede llevar a un aumento en la expresión de IL-6. El aumento de la expresión de IL-6 se ha correlacionado con la respuesta a la terapia con CD19 CAR-T de la leucemia linfocítica crónica. Un aumento en la IL-6 en suero se ha asociado con la expansión de las células CAR-T, mientras que la inhibición de la IL-6 se ha asociado con la inhibición de la proliferación de las células CAR-T [90]. Como se ha demostrado que la administración de las composiciones de la invención aumenta la expresión de IL-6, las composiciones de la invención pueden ser útiles en terapia celular, en particular en terapia celular CAR-T. En una realización, las composiciones de la invención son para su uso en terapia celular. En una realización, las composiciones de la invención son para su uso en terapia celular CAR-T. En una realización, las composiciones de la invención son para su uso en el tratamiento de leucemia linfocítica crónica.</span>The Examples also show that administration of the compositions of the invention can lead to an increase in IL-6 expression. Increased IL-6 expression has been correlated with response to CD19 CAR-T therapy of chronic lymphocytic leukemia. An increase in serum IL-6 has been associated with expansion of CAR-T cells, while inhibition of IL-6 has been associated with inhibition of CAR-T cell proliferation [90]. As administration of the compositions of the invention has been shown to increase IL-6 expression, the compositions of the invention may be useful in cell therapy, in particular CAR-T cell therapy. In one embodiment, the compositions of the invention are for use in cell therapy. In one embodiment, the compositions of the invention are for use in CAR-T cell therapy. In one embodiment, the compositions of the invention are for use in the treatment of chronic lymphocytic leukemia.</span>
  </p>
  <p id="p0411" num="0411" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Sorprendentemente, los Ejemplos también muestran que la administración de las composiciones de la invención redujo selectivamente el porcentaje de Tregs en una población de PBMC (Figura 6C). Se ha demostrado que el agotamiento selectivo de Tregs mejora la eficacia de los linfocitos citotóxicos [91]. Las células CAR-T son un subconjunto de linfocitos citotóxicos y, por lo tanto, se cree que el agotamiento selectivo de Tregs es eficaz en la terapia con células CAR-T. Como se ha demostrado que la administración de las composiciones de la invención agota las Tregs, las composiciones de la invención pueden ser útiles en terapia celular, en particular en terapia con células CAR-T.</span>Surprisingly, the Examples also show that administration of the compositions of the invention selectively reduced the percentage of Tregs in a population of PBMC (Figure 6C). Selective depletion of Tregs has been shown to enhance the efficacy of cytotoxic lymphocytes [91]. CAR-T cells are a subset of cytotoxic lymphocytes and therefore selective depletion of Tregs is believed to be effective in CAR-T cell therapy. As administration of the compositions of the invention have been shown to deplete Tregs, the compositions of the invention may be useful in cell therapy, particularly CAR-T cell therapy.</span>
  </p>
  <p id="p0413" num="0413" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, las composiciones de la invención pueden ser útiles en la terapia celular, en particular para potenciar la respuesta a una terapia celular.</span>Therefore, the compositions of the invention may be useful in cell therapy, in particular for enhancing response to cell therapy.</span>
  </p>
  <p id="p0415" num="0415" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Terapia con células madre mesenquimales </i>(<i class="style-scope patent-text">MSC)</i> </span> <i class="style-scope patent-text">Mesenchymal stem cell</i> ( <i class="style-scope patent-text">MSC)</i> therapy</span>
  </p>
  <p id="p0417" num="0417" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha informado que la terapia con células madre mesenquimales (MSC) tiene propiedades inmunoestimuladoras. Cuando las MSC se tratan con LPS, regulan por incremento las citoquinas proinflamatorias IL-6 e IL-8, lo que provoca una mayor proliferación de células B [92]. Por lo tanto, como se ha demostrado que las composiciones de la invención aumentan la expresión de IL-6, pueden ser útiles en combinación con la terapia celular con MSC.</span>Mesenchymal stem cell (MSC) therapy has been reported to have immunostimulatory properties. When MSCs are treated with LPS, they upregulate the proinflammatory cytokines IL-6 and IL-8, leading to increased B-cell proliferation [92]. Therefore, as the compositions of the invention have been shown to increase IL-6 expression, they may be useful in combination with MSC cell therapy.</span>
  </p>
  <p id="p0419" num="0419" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Terapia de trasplante de células madre</span>stem cell transplant therapy</span>
    </i>
  </p>
  <p id="p0421" num="0421" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha informado que, en lugar de usar células madre no diferenciadas en la terapia de trasplante de células madre, puede ser beneficioso diferenciar las células madre hasta cierto punto antes del trasplante. Por ejemplo, Heng et al. [93] informaron que la diferenciación cardiomiogénica de las células madre puede ser beneficiosa ya que tiene una mayor eficiencia de injerto, una regeneración de los miocitos mejorada y una restauración aumentada de la función cardíaca. Como la administración de las composiciones de la invención inició la diferenciación neuronal en células de neuroblastoma no diferenciadas, las composiciones de la invención pueden ser útiles para la diferenciación de células madre en la terapia de trasplante de células madre.</span>It has been reported that instead of using undifferentiated stem cells in stem cell transplant therapy, it may be beneficial to differentiate the stem cells to some extent before transplantation. For example, Heng et al. [93] reported that cardiomyogenic stem cell differentiation may be beneficial as it has higher graft efficiency, enhanced myocyte regeneration, and increased restoration of cardiac function. Since administration of the compositions of the invention initiated neuronal differentiation into undifferentiated neuroblastoma cells, the compositions of the invention may be useful for stem cell differentiation in stem cell transplantation therapy.</span>
  </p>
  <p id="p0423" num="0423" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunosenescencia</span>immunosenescence</span>
    </i>
  </p>
  <p id="p0425" num="0425" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los Ejemplos también muestran que la administración de las composiciones de la invención puede agotar selectivamente las Tregs y aumentar el número de células B (Figura 6C y Figura 6F). Fulop et al. [94] identificaron que un aumento en el número de células Tregs y una disminución en el número de células B están asociados con el envejecimiento en el sistema inmunitario adaptativo. Por lo tanto, las composiciones de la invención pueden usarse para prevenir o retrasar la inmunosenescencia. En una realización, las composiciones de la invención son para su uso en la prevención de la inmunosenescencia. En otra realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia caracterizada por un aumento en el número de células Tregs. En otra realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia caracterizada por una disminución en el número de células B. En otra realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia caracterizada por un aumento en el número de células Tregs y una disminución en el número de células B. En una realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia disminuyendo el número de células Tregs. En una realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia aumentando el número de células B. En otra realización, las composiciones de la invención son para su uso en el retraso de la inmunosenescencia disminuyendo el número de células Tregs y aumentando el número de células B. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades provocadas por inmunosenescencia. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades relacionadas con el envejecimiento retrasando y/o previniendo la inmunosenescencia.</span>The Examples also show that administration of the compositions of the invention can selectively deplete Tregs and increase the number of B cells (Figure 6C and Figure 6F). Fulop et al. [94] identified that an increase in the number of Treg cells and a decrease in the number of B cells are associated with aging in the adaptive immune system. Therefore, the compositions of the invention can be used to prevent or delay immunosenescence. In one embodiment, the compositions of the invention are for use in the prevention of immunosenescence. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by an increase in the number of Treg cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by a decrease in the number of B cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence characterized by a decrease in the number of B cells. by an increase in the number of Treg cells and a decrease in the number of B cells. In one embodiment, the compositions of the invention are for use in delaying immunosenescence by decreasing the number of Treg cells. In one embodiment, the compositions of the invention are for use in delaying immunosenescence by increasing the number of B cells. In another embodiment, the compositions of the invention are for use in delaying immunosenescence by decreasing the number of B cells. Tregs and increasing the number of B cells. In one embodiment, the compositions of the invention are for use in the treatment of diseases caused by immunosenescence. In one embodiment, the compositions of the invention are for use in treating age-related diseases by delaying and/or preventing immunosenescence.</span>
  </p>
  <p id="p0427" num="0427" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además, se ha propuesto que los adyuvantes de las vacunas pueden superar la inmunosenescencia [95]. Como las composiciones de la invención son adecuadas para su uso como adyuvante de vacunas, las composiciones de la invención pueden ser útiles para prevenir o retrasar la inmunosenescencia. En otra realización, las composiciones de la invención son para su uso en el retraso y/o prevención de la inmunosenescencia como 
adyuvante de vacunas. En otra realización, las composiciones de la invención son para su uso como adyuvantes de vacunas, en donde las composiciones retrasan y/o previenen la inmunosenescencia.</span>In addition, it has been proposed that vaccine adjuvants can overcome immunosenescence [95]. As the compositions of the invention are suitable for use as a vaccine adjuvant, the compositions of the invention may be useful in preventing or delaying immunosenescence. In another embodiment, the compositions of the invention are for use in delaying and/or preventing immunosenescence as  vaccine adjuvant. In another embodiment, the compositions of the invention are for use as vaccine adjuvants, wherein the compositions delay and/or prevent immunosenescence.</span>
  </p>
  <p id="p0428" num="0428" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las enfermedades que están asociadas con la inmunosenescencia incluyen enfermedades cardiovasculares, enfermedades neurodegenerativas, como la enfermedad de Alzheimer y la enfermedad de Parkinson, cáncer, diabetes mellitus tipo 2 [96] y trastornos autoinmunes [97] En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades cardiovasculares. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades cardiovasculares al retrasar y/o prevenir la inmunosenescencia. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades neurodegenerativas. En una realización, las composiciones de la invención son para su uso en el tratamiento de enfermedades neurodegenerativas, en particular la enfermedad de Alzheimer y la enfermedad de Parkinson, al retrasar y/o prevenir la inmunosenescencia. En una realización, las composiciones de la invención son para su uso en el tratamiento del cáncer al retrasar y/o prevenir la inmunosenescencia. En una realización, las composiciones de la invención son para su uso en el tratamiento de la diabetes mellitus tipo 2. En una realización, las composiciones de la invención son para su uso en el tratamiento de la diabetes mellitus tipo 2 al retrasar y/o prevenir la inmunosenescencia. En una realización, las composiciones de la invención son para su uso en el tratamiento de trastornos autoinmunes. En una realización, las composiciones de la invención son para su uso en el tratamiento de trastornos autoinmunes al retrasar y/o prevenir la inmunosenescencia.</span>Diseases that are associated with immunosenescence include cardiovascular diseases, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, cancer, type 2 diabetes mellitus [96], and autoimmune disorders [97]. In one embodiment, the compositions of the invention are for use in the treatment of cardiovascular diseases. In one embodiment, the compositions of the invention are for use in the treatment of cardiovascular diseases by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of neurodegenerative diseases. In one embodiment, the compositions of the invention are for use in the treatment of neurodegenerative diseases, in particular Alzheimer's disease and Parkinson's disease, by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of cancer by delaying and/or preventing immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of type 2 diabetes mellitus. In one embodiment, the compositions of the invention are for use in the treatment of type 2 diabetes mellitus by delaying and/or prevent immunosenescence. In one embodiment, the compositions of the invention are for use in the treatment of autoimmune disorders. In one embodiment, the compositions of the invention are for use in the treatment of autoimmune disorders by delaying and/or preventing immunosenescence.</span>
  </p>
  <p id="p0429" num="0429" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Modos de administración</span>Administration modes</span>
      </i>
    </b>
  </p>
  <p id="p0430" num="0430" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, las composiciones de la invención son para su administración en el tracto gastrointestinal para permitir el suministro y/o la colonización parcial o total del intestino con la cepa bacteriana de la invención. Generalmente, las composiciones de la invención se administran por vía oral, pero pueden administrarse por vía rectal, intranasal o por vía bucal o sublingual.</span>Preferably, the compositions of the invention are for administration to the gastrointestinal tract to allow partial or total delivery and/or colonization of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but may be administered rectally, intranasally, or buccally or sublingually.</span>
  </p>
  <p id="p0431" num="0431" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención pueden administrarse como una espuma, un aerosol o un gel.</span>In certain embodiments, the compositions of the invention can be administered as a foam, an aerosol, or a gel.</span>
  </p>
  <p id="p0432" num="0432" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención pueden administrarse como un supositorio, como un supositorio rectal, por ejemplo en forma de aceite de teobroma (manteca de cacao), grasa dura sintética (por ejemplo, suppocire, witepsol), glicerogelatina, composición de polietilenglicol o glicerina de jabón.</span>In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of theobroma oil (cocoa butter), synthetic hard fat (eg suppocire, witepsol), glycerogelatin, composition of polyethylene glycol or soap glycerin.</span>
  </p>
  <p id="p0433" num="0433" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención se administra al tracto gastrointestinal a través de un tubo, como un tubo nasogástrico, un tubo orogástrico, un tubo gástrico, un tubo de yeyunostomía (tubo en J), una gastrostomía endoscópica percutánea (PEG) o un puerto, como como puerto de pared torácica que proporciona acceso al estómago, yeyuno y otros puertos de acceso adecuados.</span>In certain embodiments, the composition of the invention is administered to the gastrointestinal tract through a tube, such as a nasogastric tube, an orogastric tube, a gastric tube, a jejunostomy tube (J-tube), a percutaneous endoscopic gastrostomy (PEG) or a port, such as a chest wall port that provides access to the stomach, jejunum, and other suitable access ports.</span>
  </p>
  <p id="p0434" num="0434" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse una vez o pueden administrarse secuencialmente como parte de un régimen de tratamiento. En ciertas realizaciones, las composiciones de la invención son para su administración diaria.</span>The compositions of the invention may be administered once or may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention are for daily administration.</span>
  </p>
  <p id="p0435" num="0435" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones de la invención, el tratamiento de acuerdo con la invención va acompañado de una evaluación del microbiota intestinal del paciente. El tratamiento puede repetirse si no se logra el suministro y/o la colonización parcial o total con la cepa de la invención de tal manera que no se observa eficacia, o puede suspenderse el tratamiento si el suministro y/o la colonización parcial o total tiene éxito y se observa eficacia.</span>In certain embodiments of the invention, treatment according to the invention is accompanied by an assessment of the patient's gut microbiota. Treatment may be repeated if delivery and/or partial or total colonization with the strain of the invention is not achieved such that no efficacy is observed, or treatment may be discontinued if delivery and/or partial or total colonization has success and efficacy is observed.</span>
  </p>
  <p id="p0436" num="0436" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición de la invención puede administrarse a un animal preñado, por ejemplo, un mamífero como un humano, para reducir la probabilidad de que se desarrolle cáncer en su hijo <i class="style-scope patent-text">in utero </i>y/o después de su nacimiento.</span>In certain embodiments, the composition of the invention may be administered to a pregnant animal, eg, a mammal such as a human, to reduce the likelihood of cancer developing in her child <i class="style-scope patent-text">in utero</i> and/or after birth.</span>
  </p>
  <p id="p0437" num="0437" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse a un paciente al que se le ha diagnosticado una enfermedad o afección mediada por una actividad inmunitaria reducida, o que se ha identificado como en riesgo de una enfermedad o afección mediada por una actividad inmunitaria reducida. Las composiciones también pueden administrarse como medida profiláctica para prevenir el desarrollo de enfermedades o afecciones mediadas por una actividad inmunitaria reducida en un paciente sano.</span>The compositions of the invention may be administered to a patient who has been diagnosed as having a disease or condition mediated by reduced immune activity, or who has been identified as being at risk for a disease or condition mediated by reduced immune activity. The compositions may also be administered as a prophylactic measure to prevent the development of diseases or conditions mediated by reduced immune activity in a healthy patient.</span>
  </p>
  <p id="p0438" num="0438" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse a un paciente al que se le ha diagnosticado cáncer, o que se ha identificado que tiene riesgo de cáncer. Por ejemplo, el paciente puede tener una colonización reducida o ausente por <i class="style-scope patent-text">Megasphaera, </i>y en particular <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>The compositions of the invention may be administered to a patient who has been diagnosed with cancer, or who has been identified as being at risk for cancer. For example, the patient may have reduced or absent colonization by <i class="style-scope patent-text">Megasphaera,</i> and in particular <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
  </p>
  <p id="p0439" num="0439" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden administrarse como un producto alimenticio, como un suplemento nutricional.</span>The compositions of the invention can be administered as a food product, as a nutritional supplement.</span>
  </p>
  <p id="p0440" num="0440" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generalmente, las composiciones de la invención son para el tratamiento de humanos, aunque pueden 
usarse para tratar animales que incluyen mamíferos monogástricos como aves, cerdos, gatos, perros, caballos o conejos. Las composiciones de la invención pueden ser útiles para mejorar el crecimiento y el rendimiento de los animales. Si se administra a animales, puede usarse alimentación forzada oral.</span>Generally, the compositions of the invention are for the treatment of humans, although they may  be used to treat animals including monogastric mammals such as birds, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for improving the growth and performance of animals. If administered to animals, oral gavage can be used.</span>
  </p>
  <p id="p0441" num="0441" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Composiciones</span>compositions</span>
      </i>
    </b>
  </p>
  <p id="p0442" num="0442" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Generalmente, la composición de la invención comprende bacterias. En realizaciones preferidas de la invención, la composición se formula en forma secada por congelación. Por ejemplo, la composición de la invención puede comprender gránulos o cápsulas de gelatina, por ejemplo cápsulas de gelatina dura, que comprenden una cepa bacteriana de la invención.</span>Generally, the composition of the invention comprises bacteria. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise gelatin capsules or granules, eg hard gelatin capsules, comprising a bacterial strain of the invention.</span>
  </p>
  <p id="p0443" num="0443" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Preferiblemente, la composición de la invención comprende bacterias liofilizadas. La liofilización de bacterias es un procedimiento bien establecido y la orientación relevante está disponible, por ejemplo, en las referencias [98, 100].</span>Preferably, the composition of the invention comprises freeze-dried bacteria. Lyophilization of bacteria is a well-established procedure and relevant guidance is available, for example, in references [98, 100].</span>
  </p>
  <p id="p0444" num="0444" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Alternativamente, la composición de la invención puede comprender un cultivo bacteriano vivo activo.</span>Alternatively, the composition of the invention may comprise a live active bacterial culture.</span>
  </p>
  <p id="p0445" num="0445" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En realizaciones preferidas, la composición de la invención se encapsula para permitir la administración de la cepa bacteriana al intestino. La encapsulación protege la composición de la degradación hasta la administración en la localización objetivo mediante, por ejemplo, la ruptura con estímulos químicos o físicos como presión, actividad enzimática o disgregación física, que pueden desencadenarse por cambios en el pH. Puede usarse cualquier método de encapsulación apropiado. Las técnicas de encapsulación ejemplares incluyen atrapamiento dentro de una matriz porosa, unión o adsorción sobre superficies portadoras sólidas, autoagregación por floculación o con agentes de reticulación y contención mecánica detrás de una membrana microporosa o una microcápsula. La orientación sobre la encapsulación que puede ser útil para preparar composiciones de la invención está disponible en, por ejemplo, las referencias [101] y [102].</span>In preferred embodiments, the composition of the invention is encapsulated to allow administration of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery to the target location by, for example, breaking down with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which can be triggered by changes in pH. Any suitable encapsulation method can be used. Exemplary encapsulation techniques include entrapment within a porous matrix, binding or adsorption onto solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or microcapsule. Guidance on encapsulation that may be useful in preparing compositions of the invention is available in, for example, references [101] and [102].</span>
  </p>
  <p id="p0446" num="0446" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composición puede administrarse por vía oral y puede estar en forma de comprimido, cápsula o polvo. Se prefieren los productos encapsulados porque las <i class="style-scope patent-text">Megasphaera </i>son anaerobias. Pueden incluirse otros ingredientes (como la vitamina C, por ejemplo), como captadores de oxígeno y sustratos prebióticos para mejorar la administración y/o la colonización parcial o total y la supervivencia in vivo. Alternativamente, la composición probiótica de la invención puede administrarse por vía oral como un producto alimenticio o nutricional, como leche o producto lácteo fermentado a base de suero, o como un producto farmacéutico.</span>The composition can be administered orally and can be in the form of a tablet, capsule or powder. Encapsulated products are preferred because <i class="style-scope patent-text">Megasphaera</i> are anaerobes. Other ingredients (such as vitamin C, for example), such as oxygen scavengers and prebiotic substrates, may be included to improve delivery and/or partial or total colonization and survival in vivo. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey-based fermented milk product, or as a pharmaceutical.</span>
  </p>
  <p id="p0447" num="0447" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La composición puede formularse como un probiótico.</span>The composition can be formulated as a probiotic.</span>
  </p>
  <p id="p0448" num="0448" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición de la invención incluye una cantidad terapéuticamente eficaz de una cepa bacteriana de la invención. Una cantidad terapéuticamente eficaz de una cepa bacteriana es suficiente para ejercer un efecto beneficioso sobre un paciente. Una cantidad terapéuticamente eficaz de una cepa bacteriana puede ser suficiente para dar como resultado la administración y/o colonización parcial o total del intestino del paciente.</span>A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial effect on a patient. A therapeutically effective amount of a bacterial strain may be sufficient to result in administration and/or partial or total colonization of the patient's intestine.</span>
  </p>
  <p id="p0449" num="0449" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una dosis diaria adecuada de las bacterias, por ejemplo para un humano adulto, puede ser de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias (UFC); por ejemplo, de aproximadamente 1 x 107 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 106 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 107 a aproximadamente 1 x 1011 UFC; en otro ejemplo de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC; en otro ejemplo de aproximadamente 1 x 108 a aproximadamente 1 x 1011 UFC.</span>A suitable daily dose of the bacteria, for example for an adult human, may be from about 1 x 103 to about 1 x 1011 colony-forming units (CFUs); for example, from about 1 x 107 to about 1 x 1010 CFU; in another example from about 1 x 106 to about 1 x 1010 CFU; in another example from about 1 x 107 to about 1 x 1011 CFU; in another example from about 1 x 108 to about 1 x 1010 CFU; in another example from about 1 x 108 to about 1 x 1011 CFU.</span>
  </p>
  <p id="p0450" num="0450" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la dosis de la bacteria es de por lo menos 109 células al día, como por lo menos 1010, por lo menos 1011 o por lo menos 1012 células al día.</span>In certain embodiments, the dose of the bacteria is at least 109 cells per day, such as at least 1010, at least 1011, or at least 1012 cells per day.</span>
  </p>
  <p id="p0451" num="0451" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición contiene la cepa bacteriana en una cantidad de aproximadamente 1 x 106 a aproximadamente 1 x 1011 UFC/g, con respecto al peso de la composición; por ejemplo, de aproximadamente 1 x 108 a aproximadamente 1 x 1010 UFC/g. La dosis puede ser de, por ejemplo, 1 g, 3 g, 5 g y 10 g.</span>In certain embodiments, the composition contains the bacterial strain in an amount of from about 1 x 106 to about 1 x 1011 CFU/g, based on the weight of the composition; for example, from about 1 x 108 to about 1 x 1010 CFU/g. The dose can be, for example, 1 g, 3 g, 5 g and 10 g.</span>
  </p>
  <p id="p0452" num="0452" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde la cantidad de la cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composición.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0453" num="0453" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde la composición se administra a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg y 1000 mg. En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde las bacterias liofilizadas de la composición farmacéutica se administran a una dosis de entre 500 mg y 1000 mg, entre 600 mg y 900 mg, entre 700 mg y 800 mg, entre 500 mg y 750 mg o entre 750 mg 
y 1000 mg.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750mg and 1000mg. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the lyophilized bacteria of the pharmaceutical composition are administered at a dose of between 500 mg and 1000 mg, between 600 mg and 900 mg, between 700 mg and 800 mg, between 500 mg and 750 mg or between 750 mg  and 1000mg.</span>
  </p>
  <p id="p0454" num="0454" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Típicamente, un probiótico, como la composición de la invención, se combina opcionalmente con por lo menos un compuesto prebiótico adecuado. Un compuesto prebiótico es habitualmente un carbohidrato no digerible, como un oligo- o polisacárido, o un alcohol de azúcar, que no se degrada ni se absorbe en el tracto digestivo superior. Los prebióticos conocidos incluyen productos comerciales como inulina y transgalacto-oligosacáridos.</span>Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually an indigestible carbohydrate, such as an oligo- or polysaccharide, or a sugar alcohol, that is not broken down or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.</span>
  </p>
  <p id="p0455" num="0455" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la composición probiótica de la presente invención incluye un compuesto prebiótico en una cantidad de aproximadamente el 1 a aproximadamente el 30% en peso, con respecto a la composición en peso total (por ejemplo, del 5 al 20% en peso). Los carbohidratos pueden seleccionarse del grupo que consiste de: fructo-oligosacáridos (o FOS), fructo-oligosacáridos de cadena corta, inulina, isomaltoligosacáridos, pectinas, xilo-oligosacáridos (o XOS), quitosano-oligosacáridos (o COS), beta-glucanos, goma de almendra modificada y almidones resistentes, polidextrosa, D-tagatosa, fibras de acacia, algarroba, avena y fibras de cítricos. En un aspecto, los prebióticos son los fructo-oligosacáridos de cadena corta (por simplicidad mostrados a continuación como FOSs-c.c.); dichos FOSs-c.c. son carbohidratos no digeribles, obtenidos generalmente por la conversión de azúcar de remolacha y que incluyen una molécula de sacarosa a la que se unen tres moléculas de glucosa.</span>In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, based on the total weight of the composition (for example, from 5 to 20% by weight). . Carbohydrates may be selected from the group consisting of: fructo-oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomaltoligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans , modified almond gum and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats and citrus fibers. In one aspect, the prebiotics are short-chain fructo-oligosaccharides (for simplicity shown below as FOSs-c.c.); said FOSs-c.c. they are non-digestible carbohydrates, generally obtained by the conversion of beet sugar and that include a sucrose molecule to which three glucose molecules are attached.</span>
  </p>
  <p id="p0456" num="0456" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden comprender excipientes o portadores farmacéuticamente aceptables. Ejemplos de tales excipientes adecuados pueden encontrarse en la referencia [103]. Los portadores o diluyentes aceptables para uso terapéutico son bien conocidos en la técnica farmacéutica y se describen, por ejemplo, en la referencia [104]. Los ejemplos de portadores adecuados incluyen lactosa, almidón, glucosa, metilcelulosa, estearato de magnesio, manitol, sorbitol y similares. Ejemplos de diluyentes adecuados incluyen etanol, glicerol y agua. La elección del portador, excipiente o diluyente farmacéutico puede seleccionarse con respecto a la vía de administración pretendida y la práctica farmacéutica estándar. Las composiciones farmacéuticas pueden comprender como, o además del portador, excipiente o diluyente, cualquier aglutinante, lubricante, agente de suspensión, agente de recubrimiento, agente de solubilización adecuado. Los ejemplos de aglutinantes adecuados incluyen almidón, gelatina, azúcares naturales como glucosa, lactosa anhidra, lactosa de flujo libre, betalactosa, edulcorantes de maíz, gomas naturales y sintéticas como acacia, tragacanto o alginato de sodio, carboximetilcelulosa y polietilenglicol. Los ejemplos de lubricantes adecuados incluyen oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio, cloruro de sodio y similares. En la composición farmacéutica pueden proporcionarse conservantes, estabilizadores, colorantes e incluso agentes aromatizantes. Los ejemplos de conservantes incluyen benzoato de sodio, ácido sórbico y ésteres de ácido p-hidroxibenzoico. También pueden usarse antioxidantes y agentes de suspensión.</span>The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients can be found in reference [103]. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [104]. Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, and the like. Examples of suitable diluents include ethanol, glycerol, and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with respect to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions may comprise as or in addition to the carrier, excipient or diluent, any suitable binder, lubricant, suspending agent, coating agent, solubilizing agent. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, colorants and even flavoring agents can be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents can also be used.</span>
  </p>
  <p id="p0457" num="0457" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden formularse como un producto alimenticio. Por ejemplo, un producto alimenticio puede proporcionar un beneficio nutricional además del efecto terapéutico de la invención, como en un suplemento nutricional. De manera similar, un producto alimenticio puede formularse para mejorar el sabor de la composición de la invención o para hacer que la composición sea más atractiva para el consumo al ser más similar a un producto alimenticio común, que a una composición farmacéutica. En ciertas realizaciones, la composición de la invención se formula como un producto a base de leche. El término "producto a base de leche" significa cualquier producto a base de leche o suero líquido o semisólido que tenga un contenido variable de grasa. El producto a base de leche puede ser, por ejemplo, leche de vaca, leche de cabra, leche de oveja, leche desnatada, leche entera, leche recombinada a partir de leche en polvo y suero sin ningún procesamiento, o un producto procesado, como yogur, leche cuajada, cuajada, leche agria, leche entera agria, leche de mantequilla y otros productos de leche agria. Otro grupo importante incluye las bebidas lácteas, como las bebidas de suero, las leches fermentadas, las leches condensadas, las leches infantiles o para bebés; leches aromatizadas, helados; alimentos que contienen leche, como dulces.</span>The compositions of the invention can be formulated as a food product. For example, a food product may provide a nutritional benefit in addition to the therapeutic effect of the invention, as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive for consumption by being more similar to a common food product, rather than a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk or whey-based product having variable fat content. The milk-based product can be, for example, cow's milk, goat's milk, sheep's milk, skim milk, whole milk, milk recombined from milk powder and whey without any processing, or a processed product, such as yogurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk drinks, such as whey drinks, fermented milks, condensed milks, infant or baby milks; flavored milks, ice creams; foods that contain milk, such as sweets.</span>
  </p>
  <p id="p0458" num="0458" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, las composiciones de la invención contienen una única cepa o especie bacteriana y no contienen ninguna otra cepa o especie bacteriana. Tales composiciones pueden comprender solo cantidades mínimas o biológicamente irrelevantes de otras cepas o especies bacterianas. Tales composiciones pueden ser un cultivo que esté sustancialmente libre de otras especies de organismos.</span>In certain embodiments, the compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strain or species. Such compositions may comprise only minute or biologically irrelevant amounts of other bacterial strains or species. Such compositions can be a culture that is substantially free of other species of organisms.</span>
  </p>
  <p id="p0459" num="0459" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones para su uso de acuerdo con la invención pueden requerir o no aprobación de comercialización.</span>Compositions for use in accordance with the invention may or may not require marketing approval.</span>
  </p>
  <p id="p0460" num="0460" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En algunos casos, la cepa bacteriana liofilizada se reconstituye antes de la administración. En algunos casos, la reconstitución se realiza mediante el uso de un diluyente descrito en la presente.</span>In some cases, the lyophilized bacterial strain is reconstituted prior to administration. In some cases, reconstitution is accomplished by use of a diluent described herein.</span>
  </p>
  <p id="p0461" num="0461" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las composiciones de la invención pueden comprender excipientes, diluyentes o portadores farmacéuticamente aceptables.</span>The compositions of the invention may comprise pharmaceutically acceptable excipients, diluents or carriers.</span>
  </p>
  <p id="p0462" num="0462" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa 
bacteriana está en una cantidad suficiente para tratar un trastorno cuando se administra a un sujeto con necesidad de ello; y en donde el trastorno es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En una realización adicional, el cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; where the strain  bacterial is in an amount sufficient to treat a disorder when administered to a subject in need thereof; and wherein the disorder is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0463" num="0463" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por MAP2. En realizaciones preferidas, dicha enfermedad o afección es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En una realización adicional, el cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a MAP2-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0464" num="0464" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por tubulina p3. En realizaciones preferidas, dicha enfermedad o afección es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En una realización adicional, el cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a p3 tubulin-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0465" num="0465" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por DRD2. En realizaciones preferidas, dicha enfermedad o afección es cáncer como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En una realización adicional, el cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a DRD2-mediated disease or condition. In preferred embodiments, said disease or condition is cancer such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, the cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma, or hematologic malignancies.</span>
  </p>
  <p id="p0466" num="0466" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por HDAC. En realizaciones preferidas, dicha enfermedad o afección es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, linfocito crónico leucemia, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent an HDAC-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer or gastric cancer, ovarian cancer, cervical cancer , glioblastoma, carcinoma, chronic lymphocyte leukemia, lymphoma or hematological malignancies.</span>
  </p>
  <p id="p0467" num="0467" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por citoquinas proinflamatorias, como IL-1 p, TNF-a, MIP-3a, IL-23 o IL-6. En una realización preferida, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por TNF-a. En una realización preferida, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por IL-8. En una realización preferida, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por CD11b. En realizaciones preferidas, dicha enfermedad o afección es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico. En una realización adicional, dicho cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a disease or condition mediated by proinflammatory cytokines, such as IL-1 p, TNF-a, MIP-3a, IL-23, or IL-6. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a TNF-α mediated disease or condition. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent an IL-8 mediated disease or condition. In a preferred embodiment, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a CD11b-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer. In a further embodiment, said cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma or hematological malignancies.</span>
  </p>
  <p id="p0468" num="0468" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona una composición farmacéutica que comprende: una cepa bacteriana de la invención; y un excipiente, portador o diluyente farmacéuticamente aceptable; en donde la cepa bacteriana está en una cantidad suficiente para tratar o prevenir una enfermedad o afección mediada por Casp3. En realizaciones preferidas, dicha enfermedad o afección es cáncer, como neuroblastoma, cáncer de cerebro, melanoma, cáncer de próstata, cáncer colorrectal, cáncer de mama, cáncer de pulmón, cáncer de hígado o cáncer gástrico.</span>In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a Casp3-mediated disease or condition. In preferred embodiments, said disease or condition is cancer, such as neuroblastoma, brain cancer, melanoma, prostate cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, or gastric cancer.</span>
  </p>
  <p id="p0469" num="0469" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En una realización adicional, dicho cáncer es cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, leucemia linfocítica crónica, linfoma o enfermedades malignas hematológicas. 
</span>In a further embodiment, said cancer is ovarian cancer, cervical cancer, glioblastoma, carcinoma, chronic lymphocytic leukemia, lymphoma or hematological malignancies. </span>
  </p>
  <p id="p0470" num="0470" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde la cantidad de la cepa bacteriana es de aproximadamente 1 x 103 a aproximadamente 1 x 1011 unidades formadoras de colonias por gramo con respecto al peso de la composición.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about 1 x 103 to about 1 x 1011 colony-forming units per gram based on the weight of the composition.</span>
  </p>
  <p id="p0471" num="0471" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde la composición se administra a una dosis de 1 g, 3 g, 5 g o 10 g.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g, or 10 g.</span>
  </p>
  <p id="p0472" num="0472" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde la composición se administra mediante un método seleccionado del grupo que consiste de oral, rectal, subcutáneo, nasal, bucal y sublingual.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sublingual.</span>
  </p>
  <p id="p0473" num="0473" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un portador seleccionado del grupo que consiste de lactosa, almidón, glucosa, metilcelulosa, estearato de magnesio, manitol y sorbitol.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, and sorbitol.</span>
  </p>
  <p id="p0474" num="0474" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un diluyente seleccionado del grupo que consiste de etanol, glicerol y agua.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol, and water.</span>
  </p>
  <p id="p0475" num="0475" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un excipiente seleccionado del grupo que consiste de almidón, gelatina, glucosa, lactosa anhidra, lactosa de flujo libre, beta-lactosa, edulcorante de maíz, acacia, tragacanto, alginato de sodio, carboximetilcelulosa, polietilenglicol, oleato de sodio, estearato de sodio, estearato de magnesio, benzoato de sodio, acetato de sodio y cloruro de sodio.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, acacia, tragacanth, alginate sodium, carboxymethylcellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, and sodium chloride.</span>
  </p>
  <p id="p0476" num="0476" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende además por lo menos uno de un conservante, un antioxidante y un estabilizador.</span>In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant, and a stabilizer.</span>
  </p>
  <p id="p0477" num="0477" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, que comprende un conservante seleccionado del grupo que consiste de benzoato de sodio, ácido sórbico y ésteres de ácido phidroxibenzoico.</span>In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.</span>
  </p>
  <p id="p0478" num="0478" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde dicha cepa bacteriana está liofilizada.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilized.</span>
  </p>
  <p id="p0479" num="0479" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, la invención proporciona la composición farmacéutica anterior, en donde cuando la composición se almacena en un recipiente sellado a aproximadamente 4° C o aproximadamente 25° C y el recipiente se coloca en una atmósfera que tiene una humedad relativa del 50%, permanece por lo menos un 80% de la cepa bacteriana medida en unidades formadoras de colonias, después de un período de por lo menos aproximadamente: 1 mes, 3 meses, 6 meses, 1 año, 1,5 años, 2 años, 2,5 años o 3 años.</span>In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere having a relative humidity of 50%, At least 80% of the bacterial strain measured in colony-forming units remains after a period of at least approximately: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2, 5 years or 3 years.</span>
  </p>
  <p id="p0480" num="0480" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos de cultivo</span>cultivation methods</span>
      </i>
    </b>
  </p>
  <p id="p0481" num="0481" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas bacterianas para su uso en la presente invención pueden cultivarse usando técnicas estándar de microbiología como se detalla, por ejemplo, en las referencias [105,107].</span>Bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed, for example, in references [105,107].</span>
  </p>
  <p id="p0482" num="0482" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El medio sólido o líquido usado para el cultivo puede ser agar YCFA o medio YCFA. El medio YCFA puede incluir (por 100 ml, valores aproximados): casitona (1,0 g), extracto de levadura (0,25 g), NaHCÜ3 (0,4 g), cisteína (0,1 g), K2HPO4 (0,045 g), KH2PO4 (0,045 g), NaCl (0,09 g), (NH4)2SÜ4 (0,09 g), MgSÜ4 ■ 7H2O (0,009 g), CaCl2 (0,009 g), resazurina (0,1 mg), hemina (1 mg), biotina (1 pg), cobalamina (1 pg), ácido p-aminobenzoico (3 pg), ácido fólico (5 pg) y piridoxamina (15 pg).</span>The solid or liquid medium used for the culture may be YCFA agar or YCFA medium. YCFA medium may include (per 100 mL, approximate values): casitone (1.0 g), yeast extract (0.25 g), NaHCÜ3 (0.4 g), cysteine (0.1 g), K2HPO4 ( 0.045 g), KH2PO4 (0.045 g), NaCl (0.09 g), (NH4)2SÜ4 (0.09 g), MgSÜ4 ■ 7H2O (0.009 g), CaCl2 (0.009 g), Resazurin (0.1 mg) , hemin (1 mg), biotin (1 pg), cobalamin (1 pg), p-aminobenzoic acid (3 pg), folic acid (5 pg) and pyridoxamine (15 pg).</span>
  </p>
  <p id="p0483" num="0483" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas para su uso en composiciones de vacunas.</span>Bacterial strains for use in vaccine compositions.</span>
      </i>
    </b>
  </p>
  <p id="p0484" num="0484" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores han identificado que las cepas bacterianas de la invención son útiles para tratar o prevenir enfermedades o afecciones asociadas con una actividad inmunitaria reducida. Es probable que esto sea el resultado del efecto que las cepas bacterianas de la invención tienen sobre el sistema inmunitario del huésped. Por lo tanto, las composiciones de la invención también pueden ser útiles para prevenir enfermedades o afecciones como el cáncer, cuando se administran como composiciones de vacunas. En ciertas realizaciones de este tipo, las cepas bacterianas de la invención pueden estar muertas, inactivadas o atenuadas. En ciertas realizaciones de este tipo, las composiciones pueden comprender un adyuvante de vacuna. En ciertas realizaciones, las composiciones son para administración mediante inyección, como mediante inyección subcutánea.</span>The inventors have identified that the bacterial strains of the invention are useful for treating or preventing diseases or conditions associated with reduced immune activity. This is likely to be the result of the effect that the bacterial strains of the invention have on the host's immune system. Therefore, the compositions of the invention may also be useful in preventing diseases or conditions such as cancer, when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention may be killed, inactivated, or attenuated. In certain such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration by injection, such as by subcutaneous injection.</span>
  </p>
  <p id="p0485" num="0485" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En ciertas realizaciones, una cepa bacteriana de la especie Megasphaera massiliensis reduce los niveles de ácido fórmico. El ácido fórmico es la base conjugada del formiato que se ha implicado en la alteración del transporte de electrones mitocondrial y la producción de energía inhibiendo la actividad de la citocromo oxidasa, el 
aceptor de electrones terminal de la cadena de transporte de electrones. Por consiguiente, la reducción del ácido fórmico y, por tanto, del formiato, reduciría la incidencia de muerte celular o mediante la inhibición de la citocromo oxidasa o la acumulación de especies reactivas de oxígeno. Por consiguiente, en ciertas realizaciones, una cepa bacteriana de la especie Megasphaera massiliensis estimula el sistema inmunitario en el tratamiento de enfermedades reduciendo los niveles de ácido fórmico.</span>In certain embodiments, a bacterial strain of the species Megasphaera massiliensis reduces formic acid levels. Formic acid is the conjugate base of formate that has been implicated in the alteration of mitochondrial electron transport and energy production by inhibiting the activity of cytochrome oxidase, the  terminal electron acceptor of the electron transport chain. Therefore, reduction of formic acid, and thus formate, would reduce the incidence of cell death either by inhibiting cytochrome oxidase or the accumulation of reactive oxygen species. Accordingly, in certain embodiments, a bacterial strain of the species Megasphaera massiliensis stimulates the immune system in treating disease by reducing formic acid levels.</span>
  </p>
  <p id="p0486" num="0486" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">General</span>General</span>
      </i>
    </b>
  </p>
  <p id="p0487" num="0487" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La puesta en práctica de la presente invención empleará, a menos que se indique lo contrario, métodos convencionales de química, bioquímica, biología molecular, inmunología y farmacología, dentro de la experiencia de la técnica. Tales técnicas se explican completamente en la bibliografía. Ver, por ejemplo, las referencias [108] y [109,115], etc.</span>The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are fully explained in the literature. See, for example, references [108] and [109,115], etc.</span>
  </p>
  <p id="p0488" num="0488" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El término "que comprende" abarca "que incluye" así como "que consiste", por ejemplo, una composición "que comprende" X puede consistir exclusivamente de X o puede incluir algo adicional, por ejemplo, X  Y.</span>The term "comprising" encompasses "including" as well as "consisting", for example, a composition "comprising" X may consist exclusively of X or may include something additional, for example, X and Y.</span>
  </p>
  <p id="p0489" num="0489" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El término "aproximadamente" en relación a un valor numérico x es opcional y significa, por ejemplo, x ± 10%.</span>The term "approximately" in relation to a numerical value x is optional and means, for example, x ± 10%.</span>
  </p>
  <p id="p0490" num="0490" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La palabra "sustancialmente" no excluye "completamente", por ejemplo, una composición que está "sustancialmente libre" de Y puede estar completamente libre de Y. Cuando sea necesario, la palabra "sustancialmente" puede omitirse de la definición de la invención.</span>The word "substantially" does not exclude "completely", eg, a composition that is "substantially free" of Y may be completely free of Y. When necessary, the word "substantially" may be omitted from the definition of the invention.</span>
  </p>
  <p id="p0491" num="0491" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las referencias a un porcentaje de identidad de secuencia entre dos secuencias de nucleótidos significan que, cuando se alinean, ese porcentaje de nucleótidos es el mismo al comparar las dos secuencias. Esta alineación y el porcentaje de homología o identidad de secuencia pueden determinarse usando programas de software conocidos en la técnica, por ejemplo, los descritos en la sección 7.7.18 de la ref. [116]. El algoritmo de búsqueda de homología Smith-Waterman determina una alineación preferida usando una búsqueda de espacio afín con una penalización de espacio abierto de 12 y una penalización de extensión de espacio de 2, matriz BLOSUM de 62. El algoritmo de búsqueda de homología Smith-Waterman se describe en la ref. [117]</span>References to a percentage of sequence identity between two nucleotide sequences mean that, when aligned, that percentage of nucleotides is the same when comparing the two sequences. This alignment and percent sequence homology or identity can be determined using software programs known in the art, eg, those described in section 7.7.18 of ref. [116]. The Smith-Waterman homology search algorithm determines a preferred alignment using an affine space search with an open space penalty of 12 and a space extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm Waterman is described in ref. [117]</span>
  </p>
  <p id="p0492" num="0492" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A menos que se indique específicamente, un proceso o método que comprende numerosos pasos puede comprender pasos adicionales al principio o al final del método, o puede comprender pasos intermedios adicionales. Además, los pasos pueden combinarse, omitirse o realizarse en un orden alternativo, si es apropiado.</span>Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intermediate steps. Additionally, the steps may be combined, omitted, or performed in an alternate order, if appropriate.</span>
  </p>
  <p id="p0493" num="0493" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En la presente se describen varias realizaciones de la invención. Se apreciará que las características especificadas en cada realización pueden combinarse con otras características especificadas, para proporcionar realizaciones adicionales. En particular, las realizaciones resaltadas en la presente como adecuadas, típicas o preferidas pueden combinarse entre sí (excepto cuando sean mutuamente excluyentes).</span>Various embodiments of the invention are described herein. It will be appreciated that features specified in each embodiment may be combined with other features specified, to provide additional embodiments. In particular, embodiments highlighted herein as suitable, typical, or preferred may be combined with one another (except where mutually exclusive).</span>
  </p>
  <p id="p0494" num="0494" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MODOS DE LLEVAR A CABO LA INVENCIÓN</span>MODES OF CARRYING OUT THE INVENTION</span>
    </b>
  </p>
  <p id="p0495" num="0495" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 1 - MRx0029 induce un fenotipo maduro en células SH-SY5Y</span>Example 1 - MRx0029 induces a mature phenotype in SH-SY5Y cells</span>
      </i>
    </b>
  </p>
  <p id="p0496" num="0496" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0497" num="0497" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresión de marcadores de neurodiferenciación, tubulina p3 y MAP2 en células de neuroblastoma. La tubulina p3 es un marcador de prediferenciación en neuronas y MAP2 es un marcador de neuronas maduras (diferenciadas).</span>The inventors sought to identify the effect of MRx0029 on the expression of neurodifferentiation markers, tubulin p3 and MAP2 in neuroblastoma cells. Tubulin p3 is a marker of predidifferentiation in neurons and MAP2 is a marker of mature (differentiated) neurons.</span>
  </p>
  <p id="p0498" num="0498" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0499" num="0499" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0500" num="0500" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0501" num="0501" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Células SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0502" num="0502" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0503" num="0503" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">qPCR</span>qPCR</span>
    </i>
  </p>
  <p id="p0504" num="0504" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las SH-SY5Y se colocaron en placas petri de 10 cm con una densidad de 2 x 106 células. Después de 24 h, las células se trataron en medio de diferenciación (medio de crecimiento que contenía FBS al 1% sin RA) con sobrenadantes de bacterias al 10% o YCFA+, RA 10 uM, ácido hexanoico 200 uM o ácido valproico 200 uM, durante 
17 horas. Posteriormente, se tomaron imágenes representativas usando un microscopio central EVOS XL de contraste de fase con un aumento de 40X/0,65. Se recogieron las células y se aisló el ARN total de acuerdo con el protocolo del mini kit RNeasy (Qiagen). Los ADNc se elaboraron usando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems). La expresión génica se midió usando qPCR. Se usó GAPDH como control interno. El cambio de veces se calculó de acuerdo con el método 2(-ññct).</span>SH-SY5Y were plated in 10 cm petri dishes at a density of 2 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS without RA) with 10% bacteria supernatants or YCFA+, 10 uM RA, 200 uM hexanoic acid or 200 uM valproic acid, during  17 hours. Subsequently, representative images were taken using an EVOS XL phase contrast core microscope at 40X/0.65 magnification. Cells were harvested and total RNA isolated according to the RNeasy mini kit protocol (Qiagen). cDNAs were made using the High Throughput cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured using qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ññct) method.</span>
  </p>
  <p id="p0505" num="0505" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunomarcado e imagenología celular</span>Immunostaining and cell imaging</span>
    </i>
  </p>
  <p id="p0506" num="0506" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células se sembraron en portaobjetos de cámara de 8 pocillos (Marienfeld Laboratory Glassware) a 5 x 104 células/pocillo durante la noche y se trataron con sobrenadante bacteriano al 10% durante 24 h. Para la diferenciación, las células se trataron con RA 10 nM durante 5 días antes de tratarlas con sobrenadante bacteriano libre de células durante 24 h.</span>Cells were seeded on 8-well chamber slides (Marienfeld Laboratory Glassware) at 5 x 10 4 cells/well overnight and treated with 10% bacterial supernatant for 24 h. For differentiation, cells were treated with 10 nM RA for 5 days before being treated with cell-free bacterial supernatant for 24 h.</span>
  </p>
  <p id="p0507" num="0507" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Posteriormente, las células se fijaron con paraformaldehído al 4% en PBS durante 20 minutos a temperatura ambiente (TA). Las células fijadas se lavaron con PBS y se permeabilizaron con Triton X-100 al 1% en PBS durante 10 minutos. Después de lavarlos con PBS, los portaobjetos se incubaron con tampón de bloqueo (BSA/PBS al 4%) durante 1 h a TA antes de añadir el anticuerpo anti-MAP2 o tubulina p3 (sc-74421 y sc-80005 respectivamente, Santa Cruz Biotechnology Inc) diluidos en BSA/PBS al 1% durante 12 horas a 4° C. Luego se lavaron dos veces con PBS, seguido de incubación con anti-ratón conjugado con Alexa Flour 488 (Molecular Probes Inc) y faloidina conjugada con Alexa Flour 594 (ab176757, Abeam) durante 1 h a TA. Después de lavar 3X con PBS, los portaobjetos se tiñeron con DAPI y se montaron con Vectashield® (Vector Laboratories). Los portaobjetos se observaron usando un microscopio Axioskop 50 (Zeiss) equipado con un conjunto de objetivo 63x/1.2 W Korr y filtros adecuados para la detección de los fluorocromos usados. Los tiempos de exposición manual para la adquisición digital de imágenes inmunomarcadas con MAP-2 se mantuvieron constantes, lo que permitió la comparación entre diferentes pocillos y tratamientos. Los tiempos de exposición de faloidina (actina F) y DAPI variaron para adaptarse al campo de visión. Los campos de visión aleatorizados se adquirieron usando una cámara Qlmaging controlada por el software Image Pro Plus. Las imágenes se guardaron como archivos TIFF y se abrieron en Adobe Photoshop CC 2015.1.2. Las imágenes de MAP-2, DAPI y Faloidina se superpusieron y fusionaron. Se seleccionaron imágenes representativas para ilustrar las diferencias en abundancia y localización de las proteínas examinadas.</span>Subsequently, the cells were fixed with 4% paraformaldehyde in PBS for 20 minutes at room temperature (RT). Fixed cells were washed with PBS and permeabilized with 1% Triton X-100 in PBS for 10 minutes. After washing with PBS, slides were incubated with blocking buffer (4% BSA/PBS) for 1 h at RT before adding anti-MAP2 antibody or p3 tubulin (sc-74421 and sc-80005 respectively, Santa Cruz Biotechnology Inc) diluted in 1% BSA/PBS for 12 hours at 4°C. They were then washed twice with PBS, followed by incubation with Alexa Flour 488-conjugated anti-mouse (Molecular Probes Inc) and Alexa Flour 594-conjugated phalloidin. (ab176757, Abeam) for 1 h at RT. After washing 3X with PBS, slides were stained with DAPI and mounted with Vectashield® (Vector Laboratories). Slides were viewed using an Axioskop 50 microscope (Zeiss) equipped with a 63x/1.2 W Korr objective set and filters suitable for detection of the fluorochromes used. Manual exposure times for digital acquisition of MAP-2 immunolabeled images were kept constant, allowing comparison between different wells and treatments. Phalloidin (F-actin) and DAPI exposure times varied to suit the field of view. Randomized fields of view were acquired using a Qlmaging camera controlled by Image Pro Plus software. Images were saved as TIFF files and opened in Adobe Photoshop CC 2015.1.2. MAP-2, DAPI and Phalloidin images were superimposed and merged. Representative images were selected to illustrate the differences in abundance and localization of the proteins examined.</span>
  </p>
  <p id="p0508" num="0508" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunotransferencia</span>immunoblot</span>
    </i>
  </p>
  <p id="p0509" num="0509" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se trataron células SH-SY5Y cultivadas en las condiciones indicadas descritas anteriormente con MRx0029 durante 24 h y luego se lisaron en tampón RIPA que contenía un cóctel de inhibidores de proteasa (Roche Diagnostics, Reino Unido). La concentración de proteínas se estimó usando el kit de ensayo de proteínas BCA (Pierce Biotechnology, Rockford, IL), se separó mediante SDS-PAGE y se transfirió a una membrana de PVDF. Luego, las membranas se bloquearon con leche descremada en polvo al 5% o BSA al 5% y se incubaron durante la noche a 4° C con los anticuerpos primarios (respectivamente MAP2 y tubulina p3). Luego, las transferencias se incubaron con el anticuerpo secundario conjugado con peroxidasa de rábano picante (HRP) apropiado y las proteínas se detectaron mediante un kit de detección de quimioluminiscencia (Pierce Biotechnology, Rockford, IL). Tanto para MAP2 como para tubulina p3, la p-actina sirvió como control para monitorizar la variabilidad de la carga de proteínas entre las muestras.</span>SH-SY5Y cells grown under the conditions described above were treated with MRx0029 for 24 h and then lysed in RIPA buffer containing a cocktail of protease inhibitors (Roche Diagnostics, UK). Protein concentration was estimated using the BCA protein assay kit (Pierce Biotechnology, Rockford, IL), separated by SDS-PAGE, and blotted onto a PVDF membrane. Membranes were then blocked with 5% nonfat dry milk or 5% BSA and incubated overnight at 4°C with the primary antibodies (respectively MAP2 and tubulin p3). The blots were then incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody and proteins detected using a chemiluminescence detection kit (Pierce Biotechnology, Rockford, IL). For both MAP2 and p3 tubulin, p-actin served as a control to monitor protein loading variability between samples.</span>
  </p>
  <p id="p0510" num="0510" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0511" num="0511" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la expresión de tubulina p3 en células de neuroblastoma SH-SY5Y indiferenciadas. La Figura 1 muestra que el tratamiento con MRx0029 aumenta la expresión de tubulina p3 en comparación con las células SH-SY5Y no tratadas.</span>MRx0029 induces p3 tubulin expression in undifferentiated SH-SY5Y neuroblastoma cells. Figure 1 shows that MRx0029 treatment increases p3 tubulin expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0512" num="0512" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la expresión de MAP2 en células SH-SY5Y de neuroblastoma indiferenciadas. La Figura 2 muestra que el tratamiento con MRx0029 aumentó significativamente la expresión de MAP2 en comparación con las células SH-SY5Y no tratadas.</span>MRx0029 induces MAP2 expression in undifferentiated SH-SY5Y neuroblastoma cells. Figure 2 shows that MRx0029 treatment significantly increased MAP2 expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0513" num="0513" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0514" num="0514" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser una composición eficaz para promover la diferenciación, en particular la diferenciación neuronal. Además, los resultados muestran que MRx0029 puede ser una composición eficaz en el tratamiento de cáncer de cerebro, en particular neuroblastoma y melanoma, en particular, melanoma metastásico.</span>The results show that MRx0029 may be an effective composition for promoting differentiation, particularly neuronal differentiation. Furthermore, the results show that MRx0029 may be an effective composition in the treatment of brain cancer, in particular neuroblastoma and melanoma, in particular metastatic melanoma.</span>
  </p>
  <p id="p0515" num="0515" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 2: MRx0029 disminuye la expresión de DRD2 en células SH-SY5Y</span>Example 2: MRx0029 Downregulates DRD2 Expression in SH-SY5Y Cells</span>
      </i>
    </b>
  </p>
  <p id="p0516" num="0516" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0517" num="0517" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresión de DRD2 en células de 
neuroblastoma.</span>The inventors sought to identify the effect of MRx0029 on the expression of DRD2 in cells of  neuroblastoma.</span>
  </p>
  <p id="p0518" num="0518" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0519" num="0519" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0520" num="0520" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0521" num="0521" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Células SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0522" num="0522" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0523" num="0523" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores midieron el cambio en la expresión de DRD2 en células de neuroblastoma usando el mismo método que se describe en el Ejemplo 1.</span>The inventors measured the change in DRD2 expression in neuroblastoma cells using the same method as described in Example 1.</span>
  </p>
  <p id="p0524" num="0524" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0525" num="0525" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 disminuye la expresión de DRD2 en células de neuroblastoma SH-SY5Y. La Figura 3 muestra que el tratamiento con MRx0029 disminuyó significativamente la expresión de DRD2 en comparación con las células SH-SY5Y no tratadas.</span>MRx0029 downregulates DRD2 expression in SH-SY5Y neuroblastoma cells. Figure 3 shows that MRx0029 treatment significantly decreased DRD2 expression compared to untreated SH-SY5Y cells.</span>
  </p>
  <p id="p0526" num="0526" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0527" num="0527" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composición eficaz en el tratamiento del cáncer.</span>This shows that MRx0029 can be an effective composition in the treatment of cancer.</span>
  </p>
  <p id="p0528" num="0528" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 3 - MRx0029 induce la regulación por incremento de Caspasa 3 en células SH-SY5Y</span>Example 3 - MRx0029 Induces Caspase 3 Upregulation in SH-SY5Y Cells</span>
      </i>
    </b>
  </p>
  <p id="p0529" num="0529" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0530" num="0530" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la expresión de Caspasa 3 (Casp3) en células de neuroblastoma.</span>The inventors sought to identify the effect of MRx0029 on Caspase 3 (Casp3) expression in neuroblastoma cells.</span>
  </p>
  <p id="p0531" num="0531" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0532" num="0532" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0533" num="0533" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0534" num="0534" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Células SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0535" num="0535" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0536" num="0536" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores midieron el cambio en la expresión de Casp3 en células de neuroblastoma.</span>The inventors measured the change in Casp3 expression in neuroblastoma cells.</span>
  </p>
  <p id="p0537" num="0537" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0538" num="0538" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 induce la regulación por incremento de Casp3 en células SH-SY5Y de neuroblastoma indiferenciadas. La Figura 4 muestra que el tratamiento con MRx0029 aumenta la expresión de Casp3 en comparación con las células SH-SY5Y no tratadas. En particular, la Figura 4 muestra que la administración de MRx0029 aumentó tres veces la expresión de Casp3 en comparación con el control.</span>MRx0029 induces upregulation of Casp3 in SH-SY5Y undifferentiated neuroblastoma cells. Figure 4 shows that MRx0029 treatment increases Casp3 expression compared to untreated SH-SY5Y cells. In particular, Figure 4 shows that administration of MRx0029 increased Casp3 expression threefold compared to control.</span>
  </p>
  <p id="p0539" num="0539" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0540" num="0540" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En células SH-SY5Y no diferenciadas, el aumento de la expresión del gen Casp3 por parte de MRx0029 podría estar relacionado tanto con la diferenciación celular como con la inducción de muerte celular programada, como la apoptosis.</span>In undifferentiated SH-SY5Y cells, the increased expression of the Casp3 gene by MRx0029 could be related to both cell differentiation and the induction of programmed cell death, such as apoptosis.</span>
  </p>
  <p id="p0541" num="0541" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La caspasa 3 es una caspasa ejecutora y, por lo tanto, está asociada con la apoptosis. La apoptosis desregulada se ha implicado en los cánceres y, por lo tanto, los resultados muestran que MRx0029 puede ser una composición eficaz en el tratamiento del cáncer.</span>Caspase 3 is an executive caspase and is therefore associated with apoptosis. Dysregulated apoptosis has been implicated in cancers and therefore the results show that MRx0029 may be an effective composition in cancer treatment.</span>
  </p>
  <p id="p0542" num="0542" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha mostrado que las caspasas tienen funciones en la diferenciación celular. Por lo tanto, el aumento de la expresión de Casp3 después del tratamiento con MRx0029 muestra que MRx0029 puede ser una composición eficaz para aumentar la diferenciación celular. 
</span>Caspases have been shown to have roles in cell differentiation. Therefore, the increased expression of Casp3 after MRx0029 treatment shows that MRx0029 may be an effective composition for increasing cell differentiation. </span>
  </p>
  <p id="p0543" num="0543" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 4 - Ensayo MTT en células SH-SY5Y:</span>Example 4 - MTT assay in SH-SY5Y cells:</span>
      </i>
    </b>
  </p>
  <p id="p0544" num="0544" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0545" num="0545" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la viabilidad de las células de neuroblastoma, usando el ensayo MTT, que es un método ampliamente usado para evaluar la actividad metabólica celular que se refleja en el número de células viables.</span>The inventors sought to identify the effect of MRx0029 on the viability of neuroblastoma cells, using the MTT assay, which is a widely used method to assess cellular metabolic activity that is reflected in the number of viable cells.</span>
  </p>
  <p id="p0546" num="0546" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepas bacterianas</span>bacterial strains</span>
    </i>
  </p>
  <p id="p0547" num="0547" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0548" num="0548" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0549" num="0549" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Células SH-SY5Y</span>SH-SY5Y cells</span>
  </p>
  <p id="p0550" num="0550" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0551" num="0551" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo MTT</span>MTT test</span>
    </i>
  </p>
  <p id="p0552" num="0552" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células SH-SY5Y se sembraron en placas a una densidad de siembra de 10.000 células/pocillo, 24 horas después, las células se trataron en 100 ul de medio de crecimiento FBS al 1% con diferentes concentraciones (expresadas como porcentaje v/v) de sobrenadantes bacterianos libres de células de los cultivos de la fase estacionaria durante 22 h. Luego, se añadieron 10 |jl de solución de MTT y las células se incubaron en una incubadora de CO2 durante 4 h, al final de este tiempo se añadieron 100 j l de isopropanol con 0,04 HCl a cada pocillo. La absorbancia se midió a una longitud de onda de 560 nm y una longitud de onda de referencia de 655 nm. El kit de ensayo MTT se adquirió de Merck Millipore (N° de Cat. CT01).</span>SH-SY5Y cells were plated at a seeding density of 10,000 cells/well, 24 hours later, the cells were treated in 100 ul of 1% FBS growth medium with different concentrations (expressed as percentage v/v). of cell-free bacterial supernatants from stationary phase cultures for 22 h. Then, 10 µl of MTT solution was added and the cells were incubated in a CO2 incubator for 4 h, at the end of this time 100 µl of isopropanol with 0.04 HCl was added to each well. The absorbance was measured at a wavelength of 560 nm and a reference wavelength of 655 nm. The MTT assay kit was purchased from Merck Millipore (Cat. No. CT01).</span>
  </p>
  <p id="p0553" num="0553" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0554" num="0554" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 mostró efectos dependientes de la dosis sobre la viabilidad de las células de neuroblastoma, en donde MRx0029 al 10% redujo la viabilidad en aproximadamente un 70% en comparación con el control. El tratamiento con un 10% de sobrenadante bacteriano libre de células de MRx0029 mostró una disminución de la viabilidad celular. Los resultados de los experimentos se muestran en la Figura 5.</span>MRx0029 showed dose-dependent effects on neuroblastoma cell viability, with 10% MRx0029 reducing viability by approximately 70% compared to control. Treatment with 10% cell-free bacterial supernatant of MRx0029 showed decreased cell viability. The results of the experiments are shown in Figure 5.</span>
  </p>
  <p id="p0555" num="0555" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0556" num="0556" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composición eficaz para aumentar la muerte celular y, por lo tanto, MRx0029 puede ser una composición eficaz para su uso en el tratamiento del cáncer.</span>This shows that MRx0029 may be an effective composition for increasing cell death, and therefore MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0557" num="0557" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 5: -fenotipado celular básico en PBMC de donantes sanos</span>Example 5: Basic cell-phenotyping in PBMC from healthy donors</span>
      </i>
    </b>
  </p>
  <p id="p0558" num="0558" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0559" num="0559" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0560" num="0560" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0561" num="0561" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de PBMC</span>PBMC Treatment</span>
    </i>
  </p>
  <p id="p0562" num="0562" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se adquirieron PBMC humanas sanas congeladas de Stem Cells Technologies (Cambridge, Reino Unido). Brevemente, las células se descongelaron y se dejaron reposar durante la noche en medio de crecimiento completo (RPMI 1640 con FBS al 10%, glutamina 2 mM l, 2-mercapoetanol 55 jM y 100 U/ml de penicilina, 100 jg/ml estreptomicina) en una incubadora de CO2 a 37° C. Para el experimento, las células se sembraron en placas a una densidad de 750.000 células/pocillo en placas de 48 pocillos y se trataron en medio de crecimiento completo con sobrenadantes de bacterias al 10% en presencia o ausencia de 1 ng/ml de LPS. Se añadió medio de cultivo celular a los pocillos no tratados. Las células se dejaron reposar durante 72 h, posteriormente se recogieron los sobrenadantes libres de células y se centrifugaron durante 3 minutos a 10.000 g a 4° C. Las muestras se almacenaron a -80° C para el análisis de citoquinas.</span>Frozen healthy human PBMC were purchased from Stem Cells Technologies (Cambridge, UK). Briefly, cells were thawed and allowed to stand overnight in complete growth medium (RPMI 1640 with 10% FBS, 2 mM l glutamine, 55 jM 2-mercapoethanol, and 100 U/ml penicillin, 100 jg/ml streptomycin). ) in a 37°C CO2 incubator. For the experiment, cells were plated at a density of 750,000 cells/well in 48-well plates and treated in complete growth medium with 10% bacterial supernatants in presence or absence of 1 ng/ml of LPS. Cell culture medium was added to untreated wells. Cells were allowed to settle for 72 h, then cell-free supernatants were collected and centrifuged for 3 min at 10,000 g at 4°C. Samples were stored at -80°C for cytokine analysis.</span>
  </p>
  <p id="p0563" num="0563" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Inmunofenotipado</span>Immunophenotyping</span>
    </i>
  </p>
  <p id="p0564" num="0564" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se tiñeron 1,5 x 106 células por muestra con colorante de viabilidad fijable (Miltenyi) para discriminar entre células vivas y muertas durante 10 min a TA. Posteriormente, las células se tiñeron con el cóctel de anticuerpos enumerados a continuación (Miltenyi) para inmunofenotipado básico (CD3/CD4/CD8/CD25/CD127 y CD 19) y se 
incubaron durante 10 min a TA.</span>1.5 x 10 6 cells per sample were stained with fixable viability dye (Miltenyi) to discriminate between live and dead cells for 10 min at RT. Cells were subsequently stained with the antibody cocktail listed below (Miltenyi) for basic immunophenotyping (CD3/CD4/CD8/CD25/CD127 and CD19) and  incubated for 10 min at RT.</span>
  </p>
  <p id="p0565" num="0565" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se llevaron a cabo experimentos para medir el porcentaje de las siguientes poblaciones celulares:</span>Experiments were carried out to measure the percentage of the following cell populations:</span>
  </p>
  <p id="p0566" num="0566" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD4+ CD3+ (marcadores de células T auxiliares CD4)</span>• CD4+ CD3+ cells (CD4 helper T cell markers)</span>
  </p>
  <p id="p0567" num="0567" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD4+ CD25+ (marcadores de células CD4+ activadas)</span>• CD4+ CD25+ cells (markers of activated CD4+ cells)</span>
  </p>
  <p id="p0568" num="0568" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD25++ CD17- de la población de células CD4+ (marcadores de células T regs)</span>• CD25++ CD17- cells of the CD4+ cell population (T regs cell markers)</span>
  </p>
  <p id="p0569" num="0569" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD8+ CD3+ (marcadores de células T citotóxicas)</span>• CD8+ CD3+ cells (markers of cytotoxic T cells)</span>
  </p>
  <p id="p0570" num="0570" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD25+ CD8+ (marcadores de células CD8+ activadas)</span>• CD25+ CD8+ cells (markers of activated CD8+ cells)</span>
  </p>
  <p id="p0571" num="0571" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">• Células CD19+ CD3-(marcadores de células B).</span>• CD19+ CD3- cells (B cell markers).</span>
  </p>
  <p id="p0572" num="0572" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se determinó la proporción de células CD8+/Tregs y la proporción de CD8/Tregs activadas.</span>The ratio of CD8+ cells/Tregs and the ratio of activated CD8/Tregs were determined.</span>
  </p>
  <p id="p0573" num="0573" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Anticuerpos</span>Antibodies</span>
    </i>
  </p>
  <p id="p0575" num="0575" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="182" wi="606" file="imgf000047_0001.tif" img-format="tif" width="2424" height="728" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000047_0001" he="182" wi="606" file="imgf000047_0001.tif" img-format="tif" width="2424" height="728" alt="Figure imgf000047_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/12/2f/8e/b0a6acb101ae80/imgf000047_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0578" num="0578" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0579" num="0579" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos se muestran en la Figura 6.</span>The results of the experiments are shown in Figure 6.</span>
  </p>
  <p id="p0580" num="0580" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El resultado más sorprendente es el efecto del tratamiento con MRx0029 sobre el porcentaje de células CD25++ CD17-, que representan células Tregs (ver Figura 6C). MRx0029 redujo selectivamente el porcentaje de Tregs en la población de PBMC. El tratamiento con MRx0029 no cambió significativamente el porcentaje de células T auxiliares CD4, células CD4+ activadas, células T citotóxicas, células CD8+ activadas o células B.</span>The most surprising result is the effect of MRx0029 treatment on the percentage of CD25++ CD17- cells, which represent Tregs cells (see Figure 6C). MRx0029 selectively reduced the percentage of Tregs in the PBMC population. MRx0029 treatment did not significantly change the percentage of CD4 helper T cells, activated CD4+ cells, cytotoxic T cells, activated CD8+ cells, or B cells.</span>
  </p>
  <p id="p0581" num="0581" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 aumentó la proporción de CD8+/Tregs y la proporción de células CD8/Tregs activadas en comparación con las células no tratadas (ver la Figura 6G y la Figura 6H).</span>MRx0029 treatment increased the ratio of CD8+/Tregs and the ratio of activated CD8/Tregs cells compared to untreated cells (see Figure 6G and Figure 6H).</span>
  </p>
  <p id="p0582" num="0582" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0583" num="0583" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La observación de que el tratamiento con MRx0029 disminuyó selectivamente el porcentaje de Tregs, aumentando de este modo las proporciones de CD8/Tregs y CD8/Tregs activadas es sorprendente porque MRx0029 produce butirato, y la producción de butirato se ha asociado con aumentos en la población de Tregs.</span>The observation that treatment with MRx0029 selectively decreased the percentage of Tregs, thereby increasing the ratios of CD8/Tregs and activated CD8/Tregs is surprising because MRx0029 produces butyrate, and butyrate production has been associated with increases in population. of Tregs.</span>
  </p>
  <p id="p0584" num="0584" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El perfil de inmunofenotipado básico de MRx0029 en PBMC de donantes sanos sugiere que el tratamiento con MRx0029 disminuye el porcentaje relativo de Tregs en la población de linfocitos, lo que se refleja en una proporción creciente entre células CD8/Tregs.</span>The basic immunophenotyping profile of MRx0029 in PBMC from healthy donors suggests that treatment with MRx0029 decreases the relative percentage of Tregs in the lymphocyte population, which is reflected in an increasing CD8/Tregs cell ratio.</span>
  </p>
  <p id="p0585" num="0585" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 puede ser una composición eficaz para estimular la respuesta inmunitaria y disminuir la supresión inmunitaria por las Tregs. Los resultados también muestran que MRx0029 puede ser una composición eficaz para su uso en el tratamiento del cáncer.</span>This shows that MRx0029 can be an effective composition for stimulating the immune response and decreasing immune suppression by Tregs. The results also show that MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0586" num="0586" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 6 - Análisis de citoquinas de PBMC de donantes sanos</span>Example 6 - Cytokine analysis of PBMC from healthy donors</span>
      </i>
    </b>
  </p>
  <p id="p0587" num="0587" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0588" num="0588" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar adicionalmente las PBMC después de la incubación con MRx0029. Los inventores analizaron la expresión de citoquinas particulares de PBMC tras el tratamiento con MRx0029, incluyendo las citoquinas proinflamatorias TNF-a, IL-1 p e IL-23.</span>The inventors sought to further analyze PBMCs after incubation with MRx0029. The inventors analyzed the expression of particular cytokines from PBMC after treatment with MRx0029, including the pro-inflammatory cytokines TNF-α, IL-1p and IL-23.</span>
  </p>
  <p id="p0589" num="0589" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana </span>bacterial strain</span>
    </i>
    
  </p>
  <p id="p0590" num="0590" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0591" num="0591" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0592" num="0592" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de las PBMC</span>Treatment of PBMCs</span>
    </i>
  </p>
  <p id="p0593" num="0593" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las PBMC se trataron como se describe en el Ejemplo 5.</span>PBMCs were treated as described in Example 5.</span>
  </p>
  <p id="p0594" num="0594" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificación de citoquinas</span>Cytokine quantification</span>
    </i>
  </p>
  <p id="p0595" num="0595" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cuantificación de citoquinas se realizó usando un inmunoensayo multiplex ProcartaPlex siguiendo las recomendaciones del fabricante (Thermo Fischer Scientific). En resumen, se usaron 50 pl de sobrenadantes de cocultivo libres de células para la cuantificación de citoquinas usando un sistema MAGPIX® MILLIPLEX® (Merck) con el software xPONENT (Luminex, Austin, TX, USA). Los datos se analizaron usando el software analista MILLIPLEX® (Merck) usando una curva logística de 5 parámetros y sustracción de fondo para convertir la intensidad de fluorescencia media en valores de pg/ml.</span>Cytokine quantification was performed using a ProcartaPlex multiplex immunoassay following the manufacturer's recommendations (Thermo Fischer Scientific). Briefly, 50 μl of cell-free co-culture supernatants were used for cytokine quantitation using a MAGPIX® MILLIPLEX® system (Merck) with xPONENT software (Luminex, Austin, TX, USA). Data was analyzed using MILLIPLEX® Analyst Software (Merck) using a 5-parameter logistic curve and background subtraction to convert mean fluorescence intensity to pg/mL values.</span>
  </p>
  <p id="p0596" num="0596" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0597" num="0597" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados del análisis de citoquinas de MRx0029 en cultivo de PBMC de donantes sanos mostraron una firma inmunoestimuladora para MRx0029. En particular, el tratamiento con MRx0029 aumentó la expresión de TNF-a, IL-1 p e IL-23.</span>Results of cytokine analysis of MRx0029 in cultured PBMC from healthy donors showed an immunostimulatory signature for MRx0029. In particular, MRx0029 treatment increased the expression of TNF-α, IL-1p and IL-23.</span>
  </p>
  <p id="p0598" num="0598" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados también muestran que el tratamiento con MRx0029 aumentó la expresión de MIP-3a, IL-6 e IL-10. Los niveles de expresión de MCP-1, CXCL9 y GMCSF fueron similares a los de los controles.</span>The results also show that MRx0029 treatment increased the expression of MIP-3a, IL-6 and IL-10. Expression levels of MCP-1, CXCL9 and GMCSF were similar to controls.</span>
  </p>
  <p id="p0599" num="0599" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0600" num="0600" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Esto muestra que MRx0029 tiene propiedades inmunoestimuladoras y puede ser una composición eficaz para la inmunoestimulación. Los resultados también muestran que MRx0029 puede ser una composición eficaz en el tratamiento del cáncer.</span>This shows that MRx0029 has immunostimulatory properties and can be an effective composition for immunostimulation. The results also show that MRx0029 can be an effective composition in the treatment of cancer.</span>
  </p>
  <p id="p0601" num="0601" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 7 - Análisis de citometría de flujo de diferentes poblaciones celulares</span>Example 7 - Flow cytometry analysis of different cell populations</span>
      </i>
    </b>
  </p>
  <p id="p0602" num="0602" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0603" num="0603" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar adicionalmente las PBMC después de la incubación con MRx0029. Se usó análisis de citometría de flujo para determinar los porcentajes de células CD4 (CD4+ CD3+), Tregs (CD25++ CD127-), células CD8 (CD8+ CD3+) y células B (CD19+ CD3-).</span>The inventors sought to further analyze PBMCs after incubation with MRx0029. Flow cytometry analysis was used to determine the percentages of CD4 cells (CD4+ CD3+), Tregs (CD25++ CD127-), CD8 cells (CD8+ CD3+), and B cells (CD19+ CD3-).</span>
  </p>
  <p id="p0604" num="0604" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0605" num="0605" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Tratamiento de PBMC</span>PBMC Treatment</span>
    </i>
  </p>
  <p id="p0606" num="0606" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las PBMC se trataron como se describe en el Ejemplo 5.</span>PBMCs were treated as described in Example 5.</span>
  </p>
  <p id="p0607" num="0607" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis de citometría de flujo de diferentes poblaciones celulares</span>Flow cytometry analysis of different cell populations</span>
    </i>
  </p>
  <p id="p0608" num="0608" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se tiñeron 1,5 x 106 células por muestra con colorante de viabilidad fijable (Miltenyi) para discriminar entre células vivas y muertas durante 10 min a TA. Posteriormente, las células se tiñeron con el cóctel de anticuerpos enumerados a continuación (Miltenyi) para inmunofenotipado básico (CD3/CD4/CD8/CD25/CD127 y CD19) y se incubaron durante 10 min a TA. Luego, las células se lavaron y resuspendieron en PBS y se analizaron inmediatamente usando un FACS Aria II equipado con láseres azul (488 nm), rojo (633 nm) y violeta (405 nm). Se incluyeron FMO en todos los experimentos. Para el análisis se usó el software Flowjo versión 10.4.2 (FlowJo, LLC). <i class="style-scope patent-text">Resultados</i> </span>1.5 x 10 6 cells per sample were stained with fixable viability dye (Miltenyi) to discriminate between live and dead cells for 10 min at RT. Cells were subsequently stained with the antibody cocktail listed below (Miltenyi) for basic immunophenotyping (CD3/CD4/CD8/CD25/CD127 and CD19) and incubated for 10 min at RT. Cells were then washed and resuspended in PBS and immediately analyzed using a FACS Aria II equipped with blue (488nm), red (633nm), and violet (405nm) lasers. FMOs were included in all experiments. For the analysis, Flowjo software version 10.4.2 (FlowJo, LLC) was used. <i class="style-scope patent-text">Results</i> </span>
  </p>
  <p id="p0609" num="0609" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos de citometría de flujo se muestran en la Figura 8.</span>The results of the flow cytometry experiments are shown in Figure 8.</span>
  </p>
  <p id="p0610" num="0610" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 8A muestra que el 0,73% de las PBMC eran Tregs (CD25++ CD127-).</span>Figure 8A shows that 0.73% of the PBMCs were Tregs (CD25++ CD127-).</span>
  </p>
  <p id="p0611" num="0611" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0612" num="0612" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser útil para regular por diminución las Tregs. Además, los resultados muestran que MRx0029 puede ser una composición eficaz para estimular la respuesta inmunitaria y 
disminuir la supresión inmunitaria por las Tregs. Los resultados también muestran que MRx0029 puede ser una composición eficaz para su uso en el tratamiento del cáncer.</span>The results show that MRx0029 may be useful for down-regulating Tregs. Furthermore, the results show that MRx0029 can be an effective composition to stimulate the immune response and  decrease immune suppression by Tregs. The results also show that MRx0029 may be an effective composition for use in treating cancer.</span>
  </p>
  <p id="p0614" num="0614" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 8 - M R x0029 aum enta la secreción de IL -8 en células M G U373</span>Example 8 - MR x0029 increases IL-8 secretion in M G U373 cells</span>
      </i>
    </b>
  </p>
  <p id="p0615" num="0615" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0616" num="0616" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban identificar el efecto de MRx0029 sobre la secreción de IL-8 en células de neuroblastoma. Se trataron células de astrocitoma de glioblastoma de Fluman con composiciones que comprendían MRx0029 en combinación con LPS para observar su capacidad para modular los niveles de IL-8. La IL-8 es una citoquina proinflamatoria secretada predominantemente por macrófagos con efectos inmunoestimuladores.</span>The inventors sought to identify the effect of MRx0029 on IL-8 secretion in neuroblastoma cells. Fluman glioblastoma astrocytoma cells were treated with compositions comprising MRx0029 in combination with LPS to observe their ability to modulate IL-8 levels. IL-8 is a proinflammatory cytokine secreted predominantly by macrophages with immunostimulatory effects.</span>
  </p>
  <p id="p0617" num="0617" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0618" num="0618" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0619" num="0619" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0620" num="0620" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MG U373 es un astrocitoma de glioblastoma humano derivado de un tumor maligno y se adquirió de Sigma-Aldrich (N° de cat. 08061901 -1VL). Se cultivaron células de astrocitoma de glioblastoma humano MG U373 en MEM (Sigma Aldrich, N° de cat. M-2279) suplementado con FBS al 10%, Pen Strep al 1%, L-Glut 4 mM, solución de aminoácidos no esenciales MEM 1X y piruvato sódico 1X.</span>MG U373 is a human glioblastoma astrocytoma derived from a malignant tumor and was purchased from Sigma-Aldrich (Cat# 08061901-1VL). MG U373 human glioblastoma astrocytoma cells were cultured in MEM (Sigma Aldrich, Cat. No. M-2279) supplemented with 10% FBS, 1% Pen Strep, 4 mM L-Glut, MEM non-essential amino acid solution. 1X and 1X sodium pyruvate.</span>
  </p>
  <p id="p0621" num="0621" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0622" num="0622" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una vez cultivadas, las células MG U373 se sembraron en una placa de 24 pocillos a 100.000 células/pocillo. Las células se trataron con LPS (1ug/ml) solo o con un 10% de bacterias sobrenadantes de MRx0029 durante 24 h. El LPS es un estimulador conocido de citoquinas proinflamatorias como la IL-8. Posteriormente se recogieron los sobrenadantes libres de células, se centrifugaron a 10.000 g durante 3 min a 4° C. La IL-8 se midió usando el kit IL-8 ELISA humano de Peprotech (N° de cat. 900-K18) de acuerdo con las instrucciones del fabricante. <i class="style-scope patent-text">Resultados</i> </span>Once cultured, the MG U373 cells were seeded in a 24-well plate at 100,000 cells/well. Cells were treated with LPS (1ug/ml) alone or with 10% bacterial supernatants from MRx0029 for 24h. LPS is a known stimulator of proinflammatory cytokines such as IL-8. Cell-free supernatants were subsequently collected, centrifuged at 10,000 g for 3 min at 4°C. IL-8 was measured using the Peprotech human IL-8 ELISA kit (Cat. No. 900-K18) according to with the manufacturer's instructions. <i class="style-scope patent-text">Results</i> </span>
  </p>
  <p id="p0623" num="0623" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de estos experimentos se muestran en la Figura 9. El tratamiento de las células con las cepas bacterianas llevó a un aumento de la secreción de IL-8 independientemente de la presencia de LPS.</span>The results of these experiments are shown in Figure 9. Treatment of the cells with the bacterial strains led to an increase in IL-8 secretion regardless of the presence of LPS.</span>
  </p>
  <p id="p0624" num="0624" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0625" num="0625" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 puede ser útil para aumentar la secreción de IL-8. Por lo tanto, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por una activación inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada.</span>The results show that MRx0029 may be useful in increasing IL-8 secretion. Therefore, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by an increased immune response.</span>
  </p>
  <p id="p0626" num="0626" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 9 - MRx0029 reduce los niveles de <i class="style-scope patent-text">activ idad </i>de histona deacetilasa en células HT-29 </span>Example 9 - MRx0029 Reduces Histone <i class="style-scope patent-text">Deacetylase</i> Activity Levels in HT-29 Cells</span>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0627" num="0627" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó la capacidad de las composiciones que comprenden MRx0029 para alterar la actividad de histona deacetilasa. Se ha demostrado que HDACi provoca la detención del crecimiento, la diferenciación, la apoptosis, la reducción de la angiogénesis y la modulación de la respuesta inmunitaria en una variedad de líneas de células cancerosas.</span>The ability of compositions comprising MRx0029 to alter histone deacetylase activity was investigated. HDACi has been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of cancer cell lines.</span>
  </p>
  <p id="p0628" num="0628" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0629" num="0629" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0630" num="0630" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular</span>Cellphone line</span>
    </i>
  </p>
  <p id="p0631" num="0631" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se usó la línea celular HT-29 porque está presente la histona deacetilasa.</span>The HT-29 cell line was used because histone deacetylase is present.</span>
  </p>
  <p id="p0632" num="0632" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0633" num="0633" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los sobrenadantes libres de células de cultivos bacterianos en fase estacionaria se aislaron mediante centrifugación y filtración en un filtro de 0,22 uM. Las células HT-29 se usaron 3 días después de la confluencia y se redujeron en 1 ml de DTS 24 horas antes del comienzo del experimento. Las células HT-29 se desafiaron con 
sobrenadante libre de células al 10% diluido en DTS y se dejó incubar durante 48 horas. Luego, se extrajeron las proteínas de nucleasa usando el kit de extracción Sigma Aldrich Nuclease y las muestras se congelaron al instante antes de la medición de la actividad de HDAC. La actividad de HDAC se evaluó fluorométricamente usando el kit Sigma Aldrich (Reino Unido).</span>Cell-free supernatants from stationary phase bacterial cultures were isolated by centrifugation and filtration on a 0.22 uM filter. HT-29 cells were used 3 days after confluency and reduced in 1 ml DTS 24 hours before the start of the experiment. HT-29 cells were challenged with  10% cell-free supernatant diluted in DTS and allowed to incubate for 48 hours. Nuclease proteins were then extracted using the Sigma Aldrich Nuclease Extraction Kit and samples snap frozen prior to measurement of HDAC activity. HDAC activity was assessed fluorometrically using the Sigma Aldrich kit (UK).</span>
  </p>
  <p id="p0634" num="0634" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0635" num="0635" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados de los experimentos se muestran en la Figura 10. La Figura 109 muestra que MRx0029 es capaz de reducir los niveles de actividad de histona deacetilasa.</span>The results of the experiments are shown in Figure 10. Figure 109 shows that MRx0029 is capable of reducing histone deacetylase activity levels.</span>
  </p>
  <p id="p0636" num="0636" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
  </p>
  <p id="p0637" num="0637" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 es un candidato prometedor para su uso en el tratamiento o la prevención de enfermedades caracterizadas por aberraciones epigenéticas, mediante la inhibición de la actividad HDAC. El cáncer es una enfermedad caracterizada por aberraciones epigenéticas. Además, los inhibidores de HDAC (HDACi) son una clase emergente de fármacos anticancerígenos prometedores que han demostrado que provocan la detención del crecimiento, la diferenciación, la apoptosis, la reducción de la angiogénesis y la modulación de la respuesta inmunitaria en una variedad de líneas de células cancerosas. Por lo tanto, los resultados muestran que las composiciones de la invención pueden ser eficaces para su uso en el tratamiento o prevención del cáncer.</span>The results show that MRx0029 is a promising candidate for use in the treatment or prevention of diseases characterized by epigenetic aberrations, by inhibiting HDAC activity. Cancer is a disease characterized by epigenetic aberrations. In addition, HDAC inhibitors (HDACi) are an emerging class of promising anticancer drugs that have been shown to cause growth arrest, differentiation, apoptosis, reduced angiogenesis, and modulation of the immune response in a variety of lines. of cancer cells. Therefore, the results show that the compositions of the invention may be effective for use in the treatment or prevention of cancer.</span>
  </p>
  <p id="p0638" num="0638" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 10 - Análisis adicional del mecanismo de inhibición de la desacetilación de histonas </span>Example 10 - Further analysis of the mechanism of inhibition of histone deacetylation</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0639" num="0639" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El microbiota intestinal, con su inmensa diversidad y capacidad metabólica, representa un enorme depósito metabólico para la producción de una gran variedad de moléculas con potencial para influir en la actividad de HDAC. Por lo tanto, los inventores buscaban determinar qué metabolitos son responsables de la inhibición de HDAC y dilucidar adicionalmente los mecanismos mediante los cuales se logra la inhibición.</span>The gut microbiota, with its immense diversity and metabolic capacity, represents a huge metabolic reservoir for the production of a wide variety of molecules with the potential to influence HDAC activity. Therefore, the inventors sought to determine which metabolites are responsible for HDAC inhibition and to further elucidate the mechanisms by which inhibition is achieved.</span>
  </p>
  <p id="p0640" num="0640" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0641" num="0641" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0642" num="0642" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Método</span>Method</span>
    </i>
  </p>
  <p id="p0643" num="0643" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cultivo bacteriano y recogida de sobrenadante libre de células</span>Bacterial culture and collection of cell-free supernatant</span>
    </i>
  </p>
  <p id="p0644" num="0644" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cultivos puros de bacterias se cultivaron anaeróbicamente en caldo YCFA+ hasta que alcanzaron su fase de crecimiento estacionario. Los cultivos se centrifugaron a 5.000 x g durante 5 minutos y el sobrenadante libre de células (CFS) se filtró usando un filtro de 0,2 pM (Millipore, Reino Unido). Se almacenaron alícuotas de 1 ml de CFS a -80° C hasta su uso. El butirato de sodio, el ácido hexanoico y el valérico se obtuvieron de Sigma Aldrich (Reino Unido) y se prepararon suspensiones en caldo YCFA+.</span>Pure cultures of bacteria were grown anaerobically in YCFA+ broth until they reached their stationary growth phase. Cultures were centrifuged at 5,000 x g for 5 minutes and cell free supernatant (CFS) was filtered using a 0.2 pM filter (Millipore, UK). Aliquots of 1 ml of CFS were stored at -80°C until use. Sodium butyrate, hexanoic acid and valeric acid were obtained from Sigma Aldrich (UK) and suspensions were prepared in YCFA+ broth.</span>
  </p>
  <p id="p0645" num="0645" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificación de SCFA y MCFA de sobrenadantes bacterianos</span>SCFA and MCFA quantification of bacterial supernatants</span>
    </i>
  </p>
  <p id="p0646" num="0646" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizaron y cuantificaron los ácidos grasos de cadena corta (SCFA) y los ácidos grasos de cadena media (MCFA) de sobrenadantes bacterianos por MS Omics APS de la siguiente manera. Las muestras se acidificaron usando ácido clorhídrico y se añadieron estándares internos marcados con deuterio. Todas las muestras se analizaron en un orden aleatorio. El análisis se realizó usando una columna de alta polaridad (Zebron™ ZB-FFAP, GC Cap. de 30 m x 0,25 mm x 0,25 pm) instalada en un GC (7890B, Agilent) acoplada a un detector de cuadropolo (59977B, Agilent). El sistema fue controlado por ChemStation (Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos fueran importados y procesados en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito en [118].</span>Short chain fatty acids (SCFA) and medium chain fatty acids (MCFA) of bacterial supernatants were analyzed and quantified by MS Omics APS as follows. Samples were acidified using hydrochloric acid and deuterium-labelled internal standards were added. All samples were analyzed in a random order. Analysis was performed using a high polarity column (Zebron™ ZB-FFAP, GC Cap. 30 m x 0.25 mm x 0.25 pm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B , Agilent). The system was controlled by ChemStation (Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described in [118].</span>
  </p>
  <p id="p0647" num="0647" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis de actividad de HDAC específica</span>Specific HDAC activity analysis</span>
    </i>
  </p>
  <p id="p0648" num="0648" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizó la actividad de inhibición específica de HDAC para HDAC1,2, 3, 4, 5, 6, 9 usando kits de ensayo fluorogénico para cada tipo de HDAC (BPS Bioscience, CA). Los ensayos se realizaron de acuerdo con las instrucciones del fabricante y cada muestra se realizó por duplicado. Los sobrenadantes libres de células se diluyeron 1 en 10 y se expusieron a proteínas de HDAC específicas proporcionadas en el kit para mantener la consistencia entre los métodos.</span>Specific HDAC inhibition activity was assayed for HDAC1,2,3,4,5,6,9 using fluorogenic assay kits for each type of HDAC (BPS Bioscience, CA). Assays were performed according to the manufacturer's instructions and each sample was run in duplicate. Cell-free supernatants were diluted 1 in 10 and challenged with specific HDAC proteins provided in the kit to maintain consistency between methods.</span>
  </p>
  <p id="p0649" num="0649" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados </span>Results</span>
    </i>
    
  </p>
  <p id="p0650" num="0650" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Los metabolitos microbianos comensales intestinales que inhiben la histona deacetilasa son butirato y ácido valérico </i>MRx0029, cuyo sobrenadante mostró una fuerte inhibición de HDAC tanto en células enteras HT29 como en lisados de células HT29 (ver Figura 11 A), produjo ácido valérico y ácido hexanoico a concentraciones medias de 5,08 mM y 1,60 mM, respectivamente (ver Figura 11B).</span> <i class="style-scope patent-text">Intestinal commensal microbial metabolites that inhibit histone deacetylase are butyrate and valeric acid</i> MRx0029, whose supernatant showed strong HDAC inhibition in both whole HT29 cells and HT29 cell lysates (see Figure 11A), produced valeric acid and hexanoic acid at mean concentrations of 5.08 mM and 1.60 mM, respectively (see Figure 11B).</span>
  </p>
  <p id="p0651" num="0651" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para investigar qué metabolitos eran responsables de la inhibición de HDAC inducida por la cepa, se midieron diferentes concentraciones de ácido hexanoico, ácido valérico y butirato de sodio para determinar su inhibición de HDAC en células HT-29 completas y en lisado de células HT-29. Los resultados en la Figura 11C muestran una inhibición significativa (P&lt;0,05) de la actividad de HDAC por el butirato de sodio en células completas así como en el lisado celular, mientras que el ácido hexanoico no mostró una actividad inhibidora significativa. El ácido valérico también inhibió la actividad de HDAC en células enteras así como en el lisado celular (*(p&lt;0,05), **(p&lt;0,005), ***(P&lt;0,001), ****(p&lt;0,0001)).</span>To investigate which metabolites were responsible for strain-induced HDAC inhibition, different concentrations of hexanoic acid, valeric acid, and sodium butyrate were measured for their HDAC inhibition in whole HT-29 cells and in HT-29 cell lysate. . The results in Figure 11C show significant (P&lt;0.05) inhibition of HDAC activity by sodium butyrate in whole cells as well as in cell lysate, while hexanoic acid did not show significant inhibitory activity. Valeric acid also inhibited HDAC activity in whole cells as well as in cell lysate (*(p&lt;0.05), **(p&lt;0.005), ***(P&lt;0.001), ****( p&lt;0.0001)).</span>
  </p>
  <p id="p0652" num="0652" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los potentes inhibidores totales de HDAC investigados se dirigen a las HDAC de clase I.</span>The potent total HDAC inhibitors investigated target class I HDACs.</span>
    </i>
  </p>
  <p id="p0653" num="0653" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó el perfil de inhibición específico de HDAC de la cepa de bacterias de prueba. Se llevaron a cabo ensayos de inhibición específicos de HDAC (BPS Bioscience, CA) para HDAC de Clase I y Clase II. La capacidad de la cepa bacteriana para inhibir las enzimas de HDAC se comparó con butirato, ácido hexanoico y valérico. Nuestros resultados demuestran que MRx0029 es un inhibidor muy potente de las enzimas de HDAC de Clase 1 (HDAC1,2 y 3). La inhibición de las HDAC de clase II no fue tan significativa (datos no mostrados).</span>The HDAC-specific inhibition profile of the test bacteria strain was investigated. Specific HDAC inhibition assays (BPS Bioscience, CA) were performed for Class I and Class II HDACs. The ability of the bacterial strain to inhibit HDAC enzymes was compared with butyrate, hexanoic and valeric acid. Our results demonstrate that MRx0029 is a very potent inhibitor of HDAC Class 1 enzymes (HDAC1,2 and 3). Inhibition of class II HDACs was not as significant (data not shown).</span>
  </p>
  <p id="p0654" num="0654" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0655" num="0655" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa con actividad inhibidora de HDAC produjo cantidades significativas de ácido valérico y ácido hexanoico, así como cantidades significativas de butirato de sodio (Figura 11B). Cuando se probaron como sustancias puras, el ácido valérico y el butirato de sodio dieron como resultado una inhibición significativa de HDAC (p&lt;0,0001).</span>The strain with HDAC inhibitory activity produced significant amounts of valeric acid and hexanoic acid, as well as significant amounts of sodium butyrate (FIG. 11B). When tested as pure substances, valeric acid and sodium butyrate resulted in significant HDAC inhibition (p&lt;0.0001).</span>
  </p>
  <p id="p0656" num="0656" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Curiosamente, los resultados de la actividad específica de HDAC muestran que la cepa analizada es un potente inhibidor de las HDAC de clase I y, en particular, de HDAC2 (Figura 12 y Figura 13). Las HDAC de clase I (HDAC1,2, 3 y 8) residen en el núcleo y se expresan ubicuamente en varios tipos de células humanas. Las HDAC 1 -3 comparten más del 50% de homología, pero tienen estructuras y funciones celulares distintas [119]. Participan principalmente en la supervivencia, proliferación y diferenciación celular y, por lo tanto, su inhibición puede ser útil en una amplia variedad de enfermedades [120]; [121]; [122]; [123]; [124]. Por lo tanto, las composiciones de la invención pueden ser particularmente útiles para el tratamiento de enfermedades en las que la actividad de las HDAC de Clase I está regulada por incremento. En particular, las composiciones de la invención pueden ser particularmente útiles para el tratamiento de cánceres en los que la actividad de las HDAC de Clase I está regulada por incremento. Por ejemplo, las composiciones de la invención pueden ser particularmente útiles para el tratamiento de cánceres en los que la actividad de HDAC2 está regulada por incremento.</span>Interestingly, the results of the specific activity of HDAC show that the tested strain is a potent inhibitor of HDAC class I and, in particular, of HDAC2 (Figure 12 and Figure 13). Class I HDACs (HDAC1,2, 3, and 8) reside in the nucleus and are ubiquitously expressed in various human cell types. HDACs 1-3 share more than 50% homology, but have distinct cellular structures and functions [119]. They are mainly involved in cell survival, proliferation, and differentiation, and therefore their inhibition may be useful in a wide variety of diseases [120]; [121]; [122]; [123]; [124]. Therefore, the compositions of the invention may be particularly useful for the treatment of diseases in which the activity of Class I HDACs is upregulated. In particular, the compositions of the invention may be particularly useful for the treatment of cancers in which Class I HDAC activity is upregulated. For example, the compositions of the invention may be particularly useful for the treatment of cancers in which HDAC2 activity is upregulated.</span>
  </p>
  <p id="p0657" num="0657" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 11 - Modulación de la función de barrera intestinal y permeabilidad intestinal por MRx0029 </span>Example 11 - Modulation of intestinal barrier function and intestinal permeability by MRx0029</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0658" num="0658" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó la capacidad de MRx0029 para provocar cualquier disfunción de la barrera intestinal. Se usaron monocapas de células epiteliales productoras de mucina HT29-mtx [125] como modelo in vitro para evaluar la alteración de la barrera intestinal y la estimulación inmunitaria después del tratamiento con MRx0029.</span>The ability of MRx0029 to cause any intestinal barrier dysfunction was investigated. Monolayers of HT29-mtx mucin-producing epithelial cells [125] were used as an in vitro model to assess intestinal barrier disruption and immune stimulation after MRx0029 treatment.</span>
  </p>
  <p id="p0659" num="0659" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0660" num="0660" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0661" num="0661" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos</span>Methods</span>
    </i>
  </p>
  <p id="p0662" num="0662" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extracción de ARN y análisis qPCR</span>RNA extraction and qPCR analysis</span>
    </i>
  </p>
  <p id="p0663" num="0663" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ARN total se extrajo usando el mini kit RNeasy (Qiagen, Manchester, JUK) de acuerdo con las instrucciones del fabricante, y la concentración de ARN se determinó por absorbancia a 260/280nm usando un espectrofotómetro (nano-Drop ND-1000; Thermo Scientific, Wilmington, DE). Para el análisis de expresión de ARNm, se preparó ADNc a partir de ARN total usando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems, Reino Unido) de acuerdo con las instrucciones del fabricante. Las reacciones de transcripción inversa se realizaron en un termociclador (Biometra, Alemania) a 25° C durante 10 min, 37° C durante 120 min y 85° C durante 5 min, manteniendo a 4° C. El ADNc resultante se amplificó por duplicado mediante el ensayo de PCR SYBR-Green y los productos se detectaron en la máquina de PCR en tiempo real QuantStudio 6 flex (Applied 
Biosystems, Reino Unido) usando un perfil estandarizado (desnaturalización inicial de 95° C durante 10 minutos, seguido de 40 ciclos de 15 segundos de desnaturalización a 95° C y 60 segundos de apareamiento/extensión a 60/65° C, dependiendo de los cebadores. Se añadio una etapa de disociación después de 40 ciclos para generar una curva de fusión. El análisis se realizó usando el software de PCR en tiempo real Applied Biosystems QuantStudio v1.2.</span>Total RNA was extracted using the RNeasy mini kit (Qiagen, Manchester, JUK) according to the manufacturer's instructions, and RNA concentration was determined by absorbance at 260/280nm using a spectrophotometer (nano-Drop ND-1000; Thermo Scientific, Wilmington, DE). For mRNA expression analysis, cDNA was prepared from total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, UK) according to the manufacturer's instructions. Reverse transcription reactions were performed in a thermocycler (Biometra, Germany) at 25°C for 10 min, 37°C for 120 min, and 85°C for 5 min, keeping at 4°C. The resulting cDNA was amplified in duplicate. using the SYBR-Green PCR assay and the products were detected in the QuantStudio 6 flex real-time PCR machine (Applied  Biosystems, UK) using a standardized profile (initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 15 seconds denaturation at 95°C and 60 seconds annealing/extension at 60/65°C, depending on the primers.A cleavage step was added after 40 cycles to generate a melting curve.Analysis was performed using Applied Biosystems QuantStudio v1.2 real-time PCR software.</span>
  </p>
  <p id="p0664" num="0664" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0665" num="0665" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células HT29-mtx diferenciadas expuestas a forbol 12-miristato-13-acetato (PMA) secretaron una cantidad significativa de IL-8; por el contrario, el tratamiento durante 24 h con sobrenadantes bacterianos de MRx0029 indujo una secreción incluso más baja de IL-8 en comparación con las células no tratadas y las tratadas con YCFA+ (Figura 14A).</span>Differentiated HT29-mtx cells exposed to phorbol 12-myristate-13-acetate (PMA) secreted a significant amount of IL-8; in contrast, treatment for 24 h with bacterial supernatants from MRx0029 induced even lower secretion of IL-8 compared to untreated and YCFA+ treated cells (FIG. 14A).</span>
  </p>
  <p id="p0666" num="0666" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Luego se investigó la capacidad de MRx0029 para regular la permeabilidad epitelial mediante la modificación de la transducción de señales intracelulares implicadas en la expresión y localización de proteínas implicadas en la formación de la barrera intestinal.</span>The ability of MRx0029 to regulate epithelial permeability by modifying intracellular signal transduction involved in the expression and localization of proteins involved in intestinal barrier formation was then investigated.</span>
  </p>
  <p id="p0667" num="0667" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se aisló el ARN y se realizó un análisis de RT-PCR cuantitativa (qRT-PCR) para caracterizar los cambios en la expresión génica de las proteínas de unión estrecha durante la incubación con MRx0029. La administración de MRx0029 mejoró la expresión de ARNm de Ocludina, Vilina, Proteína de Unión Estrecha 1 y 2 (respectivamente TJP1 y TJP2) después de 2 horas de incubación (Figura 14B).</span>RNA was isolated and quantitative RT-PCR (qRT-PCR) analysis was performed to characterize changes in gene expression of tight junction proteins during incubation with MRx0029. Administration of MRx0029 enhanced the expression of Occludin, Vilin, Tight Junction Protein 1 and 2 (respectively TJP1 and TJP2) mRNA expression after 2 hours of incubation (FIG. 14B).</span>
  </p>
  <p id="p0668" num="0668" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados in vitro se compararon con los datos del análisis paralelo ex vivo en el intestino de ratones alimentados con MRx0029. La expresión génica de TJP1 y Ocludina se cuantificó en el colon y el íleon. Los datos ex vivo reflejan perfectamente los datos in vitro ya que MRx0029 fue capaz de regular significativamente TJP1 y Ocludina (p=0,073) en la región del colon del intestino murino (Figura 14C+14D). MRx0029 también pudo disminuir la función de permeabilidad en el colon de los mismos ratones (Figura 14F).</span>The in vitro results were compared with data from the parallel ex vivo analysis in the intestine of mice fed MRx0029. Gene expression of TJP1 and Ocludin was quantified in the colon and ileum. The ex vivo data perfectly mirrors the in vitro data as MRx0029 was able to significantly regulate TJP1 and Ocludin (p=0.073) in the colon region of the murine intestine (FIG. 14C+14D). MRx0029 was also able to decrease permeability function in the colon of the same mice (FIG. 14F).</span>
  </p>
  <p id="p0669" num="0669" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis</span>Analysis</span>
    </i>
  </p>
  <p id="p0670" num="0670" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los resultados muestran que MRx0029 es capaz de regular la permeabilidad epitelial modificando la transducción de señales intracelulares implicadas en la expresión y localización de proteínas implicaas en la función de barrera intestinal (por ejemplo, Ocludina, Vilina, TJP1 y TJP2). Por lo tanto, los resultados muestran que MRx0029 funciona para aumentar la función de barrera intestinal y reducir la permeabilidad intestinal. Por lo tanto, las composiciones de la invención son eficaces para el tratamiento o la prevención de enfermedades o afecciones que se caracterizan por la reducción de la función de barrera intestinal o el aumento de la permeabilidad intestinal.</span>The results show that MRx0029 is capable of regulating epithelial permeability by modifying the transduction of intracellular signals involved in the expression and localization of proteins involved in intestinal barrier function (for example, Ocludin, Vilin, TJP1 and TJP2). Therefore, the results show that MRx0029 works to increase intestinal barrier function and reduce intestinal permeability. Therefore, the compositions of the invention are effective for the treatment or prevention of diseases or conditions that are characterized by reduced intestinal barrier function or increased intestinal permeability.</span>
  </p>
  <p id="p0671" num="0671" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 12</span>Example 12</span>
      </i>
    </b>
  </p>
  <p id="p0672" num="0672" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0673" num="0673" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los inventores buscaban analizar la expresión de genes para marcadores inflamatorios en tejido cerebral del hipocampo, la amígdala y la corteza prefrontal de ratones alimentados con MRx0029. Los inventores también exploraron los efectos sobre la producción de citoquinas del bazo en los mismos ratones a los que se les administró MRx0029.</span>The inventors sought to analyze gene expression for inflammatory markers in brain tissue from the hippocampus, amygdala, and prefrontal cortex of mice fed MRx0029. The inventors also explored the effects on spleen cytokine production in the same mice administered MRx0029.</span>
  </p>
  <p id="p0674" num="0674" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cepa bacteriana</span>bacterial strain</span>
    </i>
  </p>
  <p id="p0675" num="0675" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Megasphaera massiliensis </i>MRx0029</span> <i class="style-scope patent-text">Megasphaera massiliensis</i> MRx0029</span>
  </p>
  <p id="p0676" num="0676" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos</span>Methods</span>
    </i>
  </p>
  <p id="p0677" num="0677" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Animales</span>Animals</span>
    </i>
  </p>
  <p id="p0678" num="0678" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se alojaron en grupo ratones macho adultos BALBc (Envigo, Reino Unido) bajo un ciclo de luz-oscuridad de 12 h; La comida estándar para roedores y el agua estaban disponibles a voluntad. Todos los experimentos se realizaron de acuerdo con las pautas europeas luego de la aprobación del Comité de Experimentación de Ética Animal del University College Cork. Los animales tenían 8 semanas de edad al comienzo del experimento.</span>Adult male BALBc mice (Envigo, UK) were group-housed under a 12-h light-dark cycle; Standard rodent food and water were available at will. All experiments were performed in accordance with European guidelines after approval by the University College Cork Animal Ethics Experimentation Committee. The animals were 8 weeks old at the beginning of the experiment.</span>
  </p>
  <p id="p0679" num="0679" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Diseño del estudio</span>Study design</span>
    </i>
  </p>
  <p id="p0680" num="0680" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se permitió que los animales se habituaran a su sala de espera durante una semana después de su llegada a la unidad de animales. Reciben alimentación forzada oral (dosis de 200 gl) de bioterapéuticos vivos a una dosis de 1 X 109 UFC durante 6 días consecutivos entre las 15:00 y las 17:00. El día 7, los animales son decapitados y se recogen los tejidos para experimentación. 
</span>Animals were allowed to habituate in their waiting room for one week after arrival at the animal unit. They receive oral force feeding (200 gl dose) of live biotherapeutics at a dose of 1 X 109 CFU for 6 consecutive days between 15:00 and 17:00. On day 7, the animals are decapitated and the tissues are collected for experimentation. </span>
  </p>
  <p id="p0681" num="0681" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Recogida de Tejidos</span>Tissue Collection</span>
    </i>
  </p>
  <p id="p0682" num="0682" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los animales se sacrificaron de manera aleatoria según el tratamiento y las condiciones de prueba; el muestreo se realizó entre las 9:00 am y las 2:30 pm. Se recogió sangre del tronco en tubos con EDTA de potasio (ácido etilendiaminotetraacético) y se centrifugó durante 15 min a 4000 g. El plasma se aisló y almacenó a -80° C para su análisis posterior. El cerebro se extirpó rápidamente, se diseccionó y cada región del cerebro se congeló al instante en hielo seco y se almacenó a -80° C para su análisis posterior. Se extrajo el bazo, se recogió en 5 ml de medio RPMI (con L-glutamina y bicarbonato de sodio, R8758 Sigma  FBS al 10% (F7524, Sigma)  Pen/Strep al 1% (P4333, Sigma)) y se procesó inmediatamente después de los sacrificios para la estimulación inmune ex-vivo. Se montó tejido intestinal (se extirparon 2 segmentos de 3 cm de íleon y colon más cercanos al ciego, y se usaron los 1cm 2cm más alejados del ciego) en las cámaras de Ussing para el ensayo de permeabilidad intestinal. Se extrajo el ciego, se pesó y se almacenó a -80° C para el análisis de SCFA.</span>Animals were randomly sacrificed according to treatment and test conditions; Sampling was carried out between 9:00 am and 2:30 pm. Trunk blood was collected in potassium EDTA (ethylenediaminetetraacetic acid) tubes and centrifuged for 15 min at 4000 g. Plasma was isolated and stored at -80°C for later analysis. The brain was rapidly excised, dissected, and each brain region snap-frozen on dry ice and stored at -80°C for later analysis. The spleen was removed, collected in 5 mL RPMI medium (with L-glutamine and sodium bicarbonate, R8758 Sigma 10% FBS (F7524, Sigma) 1% Pen/Strep (P4333, Sigma)) and processed immediately. after sacrifices for ex-vivo immune stimulation. Intestinal tissue (2 3-cm segments of ileum and colon closest to the cecum were excised, and the furthest 1cm 2cm from the cecum used) was mounted in Ussing chambers for intestinal permeability testing. The cecum was removed, weighed and stored at -80°C for SCFA analysis.</span>
  </p>
  <p id="p0683" num="0683" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo de citoquinas del bazo</span>Spleen cytokine assay</span>
    </i>
  </p>
  <p id="p0684" num="0684" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los bazos se recogieron inmediatamente en 5 ml de medio RPMI después del sacrificio y se cultivaron inmediatamente. Primero se homogeneizaron las células de bazo en este medio RPMI, seguido de 5 min de incubación con 1 ml de tampón de lisis de RBC (11814389001 ROCHE, Sigma). Se añadieron 10 ml adicionales de medio RPMI, seguido de centrifugación a 200G durante 5 min. Luego, el sobrenadante se filtró a través de un filtro de 40 um. Las células se contaron y sembraron (4.000.000/ml de medio). Después de 2,5 h de adaptación, las células se estimularon con lipopolisacárido (LPS-2 gg/ml) o concanavalina A (ConA-2,5 gg/ml) durante 24 h. Después de la estimulación, se recogieron los sobrenadantes para evaluar la liberación de citoquinas usando el kit V-<sup class="style-scope patent-text">p</sup>L<sup class="style-scope patent-text">e</sup>X (Meso Scale Discovery, Maryland, USA) del Panel 1 (ratón) proinflamatorio para TNF-a, IL-10, IL-1 p, Interferón <sup class="style-scope patent-text">y</sup>, CXCL2 e IL6. Los análisis se realizaron usando MESO QuickPlex SQ 120, SECTOR Imager 2400, SECTOR Imager 6000, SECTOR S 600.</span>Spleens were immediately harvested in 5 ml RPMI medium after sacrifice and cultured immediately. Spleen cells were first homogenized in this RPMI medium, followed by 5 min incubation with 1 ml RBC lysis buffer (11814389001 ROCHE, Sigma). An additional 10 ml of RPMI medium was added, followed by centrifugation at 200G for 5 min. The supernatant was then filtered through a 40 um filter. Cells were counted and seeded (4,000,000/ml medium). After 2.5 h adaptation, cells were stimulated with lipopolysaccharide (LPS-2 gg/ml) or concanavalin A (ConA-2.5 gg/ml) for 24 h. After stimulation, supernatants were collected to assess cytokine release using the proinflammatory Panel 1 (mouse) V- <sup class="style-scope patent-text">p</sup> L <sup class="style-scope patent-text">e</sup> X kit (Meso Scale Discovery, Maryland, USA) for TNF-a, IL-10, IL -1 p, Interferon <sup class="style-scope patent-text">and</sup> , CXCL2 and IL6. Analyzes were performed using MESO QuickPlex SQ 120, SECTOR Imager 2400, SECTOR Imager 6000, SECTOR S 600.</span>
  </p>
  <p id="p0685" num="0685" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis de expresión génica</span>Gene expression analysis</span>
    </i>
  </p>
  <p id="p0686" num="0686" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ARN total se extrajo con el kit de aislamiento de ARNmi mirVana™ (Ambion/Llife technologies, Paisley, Reino Unido) y se trató con DNasa (Turbo DNA-free, Ambion/life technologies) de acuerdo con las recomendaciones del fabricante. El ARN se cuantificó usando el espectrofotómetro NanoDrop™ (Thermo Fisher Scientific Inc., Wilmington, Delaware, USA) de acuerdo con las instrucciones del fabricante. La calidad del ARN se evaluó usando el Agilent Bioanalyzer (Agilent, Stockport, Reino Unido) de acuerdo con el procedimiento del fabricante y se calculó un número de integridad del ARN (RIN). Se usó ARN con un valor RIN&gt;7 para experimentos posteriores. El ARN se transcribió inversamente a ADNc usando el kit de ADNc de capacidad de vuelo de Applied Biosystems (Applied Biosystems, Warrington, Reino Unido) de acuerdo con las instrucciones del fabricante. Brevemente, Se añadió transcriptasa inversa Multiscribe (50 U/gl) (1 )(2)(1 )(10) como parte de la mezcla maestra de RT, se incubó a 25° C durante 10 min, 37° C durante 2 h, 85° C durante 5 min y se almacenó a 4°C. La PCR cuantitativa se llevó a cabo usando sondas (6 carboxifluoresceína-FAM) diseñadas por Applied Biosystems para genes objetivo específicos de ratón, mientras se usaba p-actina como control endógeno. Las reacciones de amplificación contenían 1 gl de ADNc, 5 gl de la mezcla maestra de PCR 2X (Roche), 900 nM de cada cebador y se llevaron a un total de 10 gl mediante la adición de agua libre de RNasa. Todas las reacciones se realizaron por triplicado usando placas de 96 pocillos en el sistema LightCycler®480. Las condiciones de los ciclado térmico fueron las recomendadas por el fabricante (Roche) para 55 ciclos. Para verificar la contaminación por amplicones, cada serie no contenía controles de plantilla por triplicado para cada sonda uszada. Se registraron los valores de umbral de ciclo (Ct). Los datos se normalizaron usando p-actina y se transformaron usando el método 2-AACT y se presentaron como un cambio de veces frente al grupo de control.</span>Total RNA was extracted with the mirVana™ miRNA isolation kit (Ambion/Llife technologies, Paisley, UK) and treated with DNase (Turbo DNA-free, Ambion/life technologies) according to the manufacturer's recommendations. RNA was quantified using the NanoDrop™ spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, Delaware, USA) according to the manufacturer's instructions. RNA quality was assessed using the Agilent Bioanalyzer (Agilent, Stockport, UK) according to the manufacturer's procedure and an RNA integrity number (RIN) was calculated. RNA with an RIN value &gt;7 was used for further experiments. RNA was reverse transcribed to cDNA using the Applied Biosystems Flightability cDNA Kit (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions. Briefly, Multiscribe reverse transcriptase (50 U/gl) (1)(2)(1)(10) was added as part of the RT master mix, incubated at 25°C for 10 min, 37°C for 2 h , 85°C for 5 min and stored at 4°C. Quantitative PCR was carried out using probes (6 carboxyfluorescein-FAM) designed by Applied Biosystems for mouse-specific target genes, while using p-actin as an endogenous control. Amplification reactions contained 1 μl of cDNA, 5 μl of 2X PCR master mix (Roche), 900 nM of each primer and brought to a total of 10 μl by the addition of RNase-free water. All reactions were performed in triplicate using 96-well plates on the LightCycler®480 system. Thermal cycling conditions were those recommended by the manufacturer (Roche) for 55 cycles. To check for amplicon contamination, each run did not contain triplicate template controls for each probe used. Cycle threshold (Ct) values were recorded. Data was normalized using p-actin and transformed using the 2-AACT method and presented as fold change versus control group.</span>
  </p>
  <p id="p0687" num="0687" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis estadístico</span>Statistic analysis</span>
    </i>
  </p>
  <p id="p0688" num="0688" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media ± SEM; Los conjuntos de datos no paramétricos se presentan como mediana con rango intercuartílico. Se aplicó la prueba t de dos colas no pareadas para analizar los datos paramétricos y la prueba de Mann-Whitney para los no paramétricos. Se empleó el coeficiente de correlación de rangos de Spearman para el análisis de correlación en los conjuntos de datos agrupados. Un valor de p&lt;0,05 se consideró significativo en todos los casos.</span>Normally distributed data are presented as mean ± SEM; Nonparametric data sets are presented as median with interquartile range. The unpaired two-tailed t-test was applied to analyze parametric data and the Mann-Whitney test for non-parametric data. Spearman's rank correlation coefficient was used for correlation analysis on pooled data sets. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0689" num="0689" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados - Expresión génica</span>Results - Gene Expression</span>
    </i>
  </p>
  <p id="p0690" num="0690" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizó la expresión de genes para marcadores inflamatorios [IL-1 p, IL6, CD11b, TNF-a y TLR-4] en tejido cerebral del hipocampo, la amígdala y la corteza prefrontal. Las Figuras 15-25 muestran los cambios en la expresión génica después del tratamiento con MRx0029 en el hipocampo, la amígdala y la corteza prefrontal. El tratamiento con MRx0029 aumentó significativamente la expresión de TLR-4 en la amígdala (Figura 20). El tratamiento con MRx0029 también aumentó la expresión de CD11b en la amígdala (Figura 21). 
</span>Gene expression for inflammatory markers [IL-1p, IL6, CD11b, TNF-a, and TLR-4] was analyzed in brain tissue from the hippocampus, amygdala, and prefrontal cortex. Figures 15-25 show changes in gene expression after MRx0029 treatment in the hippocampus, amygdala, and prefrontal cortex. MRx0029 treatment significantly increased TLR-4 expression in amygdala (FIG. 20). MRx0029 treatment also increased CD11b expression in tonsil (FIG. 21). </span>
  </p>
  <p id="p0691" num="0691" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados - Efecto sobre la expresión de citoquinas de los esplenocíticos</span>Results - Effect on splenocytic cytokine expression</span>
    </i>
  </p>
  <p id="p0692" num="0692" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El ensayo de esplenocitos ex vivo implica desafiar los esplenocitos (células aisladas del bazo, un órgano principal implicado en la defensa inmunitaria), con un desafío mimético bacteriológico o viral.</span>The ex vivo splenocyte assay involves challenging splenocytes (cells isolated from the spleen, a major organ involved in immune defense), with a bacteriological or viral mimetic challenge.</span>
  </p>
  <p id="p0693" num="0693" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 llevó a una reducción de interferón-Y, iinterleucina-1 p e interleucina-6 después de un desafío con LPS (Figuras 26, 27 y 28, respectivamente).</span>MRx0029 treatment led to a reduction in interferon-Y, interleukin-1p and interleukin-6 after LPS challenge (Figures 26, 27 and 28, respectively).</span>
  </p>
  <p id="p0694" num="0694" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 llevó a un aumento en los niveles del quimioatrayente CXCL1 (Figura 30). <i class="style-scope patent-text">Análisis</i> </span>Treatment with MRx0029 led to an increase in the levels of the chemoattractant CXCL1 (FIG. 30). <i class="style-scope patent-text">Analysis</i> </span>
  </p>
  <p id="p0695" num="0695" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El tratamiento con MRx0029 aumentó significativamente la expresión de las citoquinas proinflamatorias TLR-4 y CD11b en la amígdala. Por lo tanto, las composiciones de la invención pueden ser útiles en el tratamiento de enfermedades, en particular enfermedades caracterizadas por una activación inmunitaria reducida y enfermedades que pueden tratarse por una respuesta inmunitaria aumentada.</span>MRx0029 treatment significantly increased the expression of the proinflammatory cytokines TLR-4 and CD11b in the tonsil. Therefore, the compositions of the invention may be useful in the treatment of diseases, in particular diseases characterized by reduced immune activation and diseases that can be treated by an increased immune response.</span>
  </p>
  <p id="p0696" num="0696" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 13 - Prueba de estabilidad</span>Example 13 - Stability test</span>
      </i>
    </b>
  </p>
  <p id="p0697" num="0697" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Una composición descrita en la presente que contiene por lo menos una cepa bacteriana descrita en la presente se almacena en un recipiente sellado a 25° C o 4° C y el recipiente se coloca en una atmósfera que tiene un 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% o 95% de humedad relativa. Después de 1 mes, 2 meses, 3 meses, 6 meses, 1 año, 1,5 años, 2 años, 2,5 años o 3 años, deberá quedar por lo menos el 50%, 60%, 70%, 80% o 90% de la cepa bacteriana medida en unidades formadoras de colonias determinadas por protocolos estándar.</span>A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25°C or 4°C and the container is placed in an atmosphere that is 30%, 40%, 50% %, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, there must be at least 50%, 60%, 70%, 80% left or 90% of the bacterial strain measured in colony forming units determined by standard protocols.</span>
  </p>
  <p id="p0698" num="0698" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14 - análisis del efecto de M. massiliensis sobre la vía de señalización de ERK</span>Example 14 - Analysis of the effect of M. massiliensis on the ERK signaling pathway</span>
      </i>
    </b>
  </p>
  <p id="p0699" num="0699" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0700" num="0700" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extracción de ARN y análisis MAP2 qPCR</span>RNA extraction and MAP2 qPCR analysis</span>
    </i>
  </p>
  <p id="p0701" num="0701" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células se sembraron en placas de 12 pocillos a una densidad de 2 x 105 células/pocillo. Después de 24 h, las células se trataron o con DMSO o con Vemurafenib (662005; EMD Millipore; VEMU; SKMEL28, SKMEL31, 451Lu, HT29 (1 pM) SKMEL2 (10 pM) o Azacitidina-C (A3656; Sigma Aldrich; AzaC; 5 pg/ml) o ambos fármacos (VEMU+Aza) juntos, en presencia de 10% de sobrenadantes de bacterias o ausencia de ellas (YCFA+). El ARN total se extrajo usando el mini kit RNeasy (Qiagen, Manchester, Reino Unido) de acuerdo con las instrucciones del fabricante, y la concentración de ARN se determinó mediante espectrofotómetro a 260/280 nm (NanoDrop ND-1000; Thermo Fisher Scientific, Loughborough). Para el análisis de expresión de ARNm, se preparó ADNc a partir de 2000 ng de ARN total usando el kit de transcripción inversa de ADNc de alta capacidad (Thermo Fisher, Loughborough) de acuerdo con las instrucciones del fabricante. Las reacciones de transcripción inversa se realizaron en un termociclador (Biometra, Alemania) a 25° C durante 10 min, 37° C durante 120 min y 85° C durante 5 min. El ADNc resultante se amplificó por duplicado mediante el ensayo de PCR SYBR-Green y los productos se detectaron en la máquina de PCR en tiempo real QuantStudio 6 flex (Applied Biosystems, Reino Unido) usando un perfil estandarizado (desnaturalización inicial de 95° C durante 10 minutos, seguido de 40 ciclos de 10 segundos de desnaturalización a 95° C y 30 segundos de apareamiento/extensión a 65° C). Se añadió una etapa de disociación después de los 40 ciclos para generar una curva de fusión. El análisis se realizó usando el software de PCR en tiempo real QuantStudio v1.2 de Applied Biosystems. Las secuencias de los cebadores para GAPDH y MAP2 se muestran a continuación.</span>Cells were seeded in 12-well plates at a density of 2 x 10 5 cells/well. After 24 h, cells were treated with either DMSO or Vemurafenib (662005; EMD Millipore; VEMU; SKMEL28, SKMEL31, 451Lu, HT29 (1 pM) SKMEL2 (10 pM) or Azacitidine-C (A3656; Sigma Aldrich; AzaC ; 5 pg/ml) or both drugs (VEMU+Aza) together, in the presence of 10% bacterial supernatants or absence of bacteria (YCFA+).Total RNA was extracted using the RNeasy mini kit (Qiagen, Manchester, UK). ) according to the manufacturer's instructions, and the RNA concentration was determined by spectrophotometer at 260/280 nm (NanoDrop ND-1000; Thermo Fisher Scientific, Loughborough).For mRNA expression analysis, cDNA was prepared from 2000 ng of total RNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Loughborough) according to the manufacturer's instructions Reverse transcription reactions were performed in a thermocycler (Biometra, Germany) at 25°C for 10 min, 37°C for 120 min and 85°C for 5 min.The res cDNA The ultant was amplified in duplicate by the SYBR-Green PCR assay and the products were detected in the QuantStudio 6 flex real-time PCR machine (Applied Biosystems, UK) using a standardized profile (initial denaturation at 95°C for 10 minutes). , followed by 40 cycles of 10 seconds denaturation at 95°C and 30 seconds annealing/extension at 65°C). A dissociation step was added after 40 cycles to generate a melting curve. Analysis was performed using QuantStudio v1.2 real-time PCR software from Applied Biosystems. The primer sequences for GAPDH and MAP2 are shown below.</span>
  </p>
  <p id="p0702" num="0702" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis de Transferencia Western</span>Western Blot Analysis</span>
    </i>
  </p>
  <p id="p0703" num="0703" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Después de 24 horas de tratamiento con los fármacos apropiados en presencia o ausencia de sobrenadante bacteriano al 10% (YCFA+), se obtuvieron extractos de proteína lisando las células en tampón RIPA (R0278; Sigma Aldrich) suplementado con inhibidores de proteasa (cOmplete Protease Inhibitor Cocktail Tablets; Roche, Suiza) y ortovanadato de sodio 1 mM/l, PMSF 0,5 mM/l. La cuantificación de proteínas se realizó mediante el ensayo de proteínas BCA. Luego, se separaron cantidades iguales de proteína total (20 pg/filal) mediante SDS-PAGE en gel con gradiente del 4-15% (BioRad) y se transfirieron a membranas de difluoruro de polivinilideno (PVDF) (Thermo Fisher Scientific, Loughborough). Después de bloquear con BSA al 5% o leche en polvo desnatada en TBST (Tris 10 mM, pH 7,5, NaCl 150 mM, Tween 20 al 0,5%) durante 60 min, las membranas se probaron con anticuerpos primarios contra fosfo-ERK (9101S, 1:1000, Cell Signalling; New England Biolabs (Reino Unido)) o ERK total (4696S, 1:1000, Cell signalling; New England Biolabs (Reino Unido)).</span>After 24 hours of treatment with the appropriate drugs in the presence or absence of 10% bacterial supernatant (YCFA+), protein extracts were obtained by lysing cells in RIPA buffer (R0278; Sigma Aldrich) supplemented with protease inhibitors (complete Protease Inhibitor Cocktail Tablets; Roche, Switzerland) and sodium orthovanadate 1 mM/l, PMSF 0.5 mM/l. Protein quantification was performed using the BCA protein assay. Equal amounts of total protein (20 pg/filal) were then separated by 4-15% gradient gel SDS-PAGE (BioRad) and transferred to polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Scientific, Loughborough). . After blocking with 5% BSA or nonfat dry milk in TBST (10 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Tween 20) for 60 min, membranes were probed with primary antibodies against phospho -ERK (9101S, 1:1000, Cell Signaling; New England Biolabs (UK)) or total ERK (4696S, 1:1000, Cell signaling; New England Biolabs (UK)).</span>
  </p>
  <p id="p0704" num="0704" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las proteínas de interés se detectaron con el anticuerpo secundario conjugado con HRP adecuado (1: 10.000, Thermo Fisher Scientific, Loughborough), desarrollado con el sustrato de transferencia Western ECL Super Signal PicoPlus (34577; Thermo Fisher Scientific, Loughborough) y se visualizaron en Chemidoc XRS Imager 
(BioRad).</span>Proteins of interest were detected with the appropriate HRP-conjugated secondary antibody (1:10,000, Thermo Fisher Scientific, Loughborough), developed with ECL Super Signal PicoPlus Western blot substrate (34577; Thermo Fisher Scientific, Loughborough) and visualized on Chemidoc XRS Imager  (BioRad).</span>
  </p>
  <p id="p0705" num="0705" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Crecimiento independiente de anclaje </i>(<i class="style-scope patent-text">ensayo de crecimiento de agar suave) en placas de 96 pocilios</i> </span> <i class="style-scope patent-text">Anchorage-independent growth</i> ( <i class="style-scope patent-text">soft agar growth assay) in 96-well plates</i> </span>
  </p>
  <p id="p0706" num="0706" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sembraron en placas una mezcla de 25 pl precalentada (37° C) 2x de medio de crecimiento apropiado (EMEM para líneas celulares de melanoma; DMEM alto en glucosa para HT29) que contenía FBS al 20%, L-Glu 4 mM, 2x NEAA, bicarbonato de sodio al 0,6%, 200 U/ml de penicilina/estreptomicina (Invitrogen) y 25 pl de agar noble al 1,2% precalentado (47° C) (A5431; Sigma Aldrich) en cada pocillo de una microplaca de 96 pocillos para servir como capa previa para el ensayo. Se mezclaron diez microlitros de suspensiones celulares que contenían 0-2 x 103 células con 25 pl de medio de cultivo 2x y 35 pl de agar noble al 0,8% en una microplaca de polipropileno de fondo redondo de 96 pocillos y se transfirieron a la microplaca de 96 pocillos que contenía las capas previas solidificadas. Se permitió que las células crecieran durante 2 días y luego se alimentaron con medios que contenían fármacos en presencia de sobrenadantes bacterianos al 10% o YCFA+ cada tres días. Se dejaron crecer en la incubadora humidificada a 37° C con CO2 al 5% durante 1 o 2 semanas antes de puntuar el crecimiento en agar blando usando el ensayo de transformación de células de 96 pocillos CytoSelect (CBA-130; Cell Biolabs) de acuerdo con el protocolo del fabricante. El crecimiento celular se midió usando un lector de placas de múltiples pocillos Tecan Infinite F200 Pro Series (Tecan Biosystems), con excitación a 485 nm y emisión a 530 nm.</span>A 25 pl prewarmed (37°C) 2x mixture of appropriate growth medium (EMEM for melanoma cell lines; high glucose DMEM for HT29) containing 20% FBS, 4 mM L-Glu, 2x NEAA, 0.6% sodium bicarbonate, 200 U/ml penicillin/streptomycin (Invitrogen), and 25 µl prewarmed (47°C) 1.2% noble agar (A5431; Sigma Aldrich) in each well of a 96-well microplate to serve as a prelayer for the assay. Ten microliters of cell suspensions containing 0-2 x 10 3 cells were mixed with 25 μl of 2x culture medium and 35 μl of 0.8% noble agar in a 96-well round bottom polypropylene microplate and transferred to the microplate. 96-well microplate containing solidified previous layers. Cells were allowed to grow for 2 days and then fed drug-containing media in the presence of 10% bacterial supernatants or YCFA+ every three days. They were allowed to grow in the humidified incubator at 37°C with 5% CO2 for 1 or 2 weeks before scoring growth in soft agar using the CytoSelect 96-well cell transformation assay (CBA-130; Cell Biolabs) according to with the manufacturer's protocol. Cell growth was measured using a Tecan Infinite F200 Pro Series multiwell plate reader (Tecan Biosystems), with excitation at 485nm and emission at 530nm.</span>
  </p>
  <p id="p0707" num="0707" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">Crecimiento independiente del anclaje </i>(<i class="style-scope patent-text">ensayo de crecimiento de asar suave) en una placa de 32 mm</i> </span> <i class="style-scope patent-text">Anchorage-independent growth</i> ( <i class="style-scope patent-text">gentle roast growth assay) in a 32 mm plate</i> </span>
  </p>
  <p id="p0708" num="0708" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se mezcló una mezcla de 1 ml de medio de cultivo 2x apropiado precalentado (37° C) (EMEM para líneas celulares de melanoma; DMEM alto en glucosa para HT29) y 1 ml de agar noble al 0,8% precalentado (47° C) por placa (agar final al 0,4%) con 1 ml de suspensión celular y se sembraron sobre una precapa de agar/crecimiento celular al 0,6% (2 ml) en una placa de 6 pocillos. Se permitió que las células crecieran en la incubadora humidificada a 37° C con CO2 al 5% durante 21-28 días. Se alimentaron con fármacos en ausencia (YCFA+) o presencia de sobrenadante bacteriano al 10% cada tres días. Las colonias se fotografiaron usando un microscopio Evos XL Core (Thermo Fisher Scientific, Loughborough).</span>A mixture of 1 mL of prewarmed (37°C) appropriate 2x culture medium (EMEM for melanoma cell lines; DMEM high glucose for HT29) and 1 mL of prewarmed (47°C) 0.8% noble agar was mixed. ) per plate (0.4% final agar) with 1 mL cell suspension and plated onto a 0.6% cell growth/agar prelayer (2 mL) in a 6-well plate. Cells were allowed to grow in the 37°C humidified incubator with 5% CO2 for 21-28 days. They were fed drugs in the absence (YCFA+) or presence of 10% bacterial supernatant every three days. Colonies were photographed using an Evos XL Core microscope (Thermo Fisher Scientific, Loughborough).</span>
  </p>
  <p id="p0709" num="0709" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ensayo clonogénico</span>Clonogenic assay</span>
    </i>
  </p>
  <p id="p0710" num="0710" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células se tripsinizaron y se sembraron 200 células/pocillo en placas de 12 pocillos. Después de 48 h, las células se trataron con los fármacos apropiados en ausencia (YCFA+) o presencia de sobrenadante bacteriano al 10% y se realimentaron cada tres días. El día 21 después de la siembra, las células se fijaron en metanol enfriado con hielo y se tiñeron con azul cristal violeta. Se contaron las colonias (0,50 células) y se calculó la fracción de supervivencia como el número de colonias dividido por el número de células sembradas (eficacia de sembrado) de las tratadas dividido por la eficacia de sembrado del control.</span>Cells were trypsinized and plated at 200 cells/well in 12-well plates. After 48 h, cells were treated with the appropriate drugs in the absence (YCFA+) or presence of 10% bacterial supernatant and re-fed every three days. On day 21 after seeding, cells were fixed in ice-cold methanol and stained with crystal blue violet. Colonies (0.50 cells) were counted and the survival fraction was calculated as the number of colonies divided by the number of cells seeded (seeding efficiency) of the treated divided by the seeding efficiency of the control.</span>
  </p>
  <p id="p0711" num="0711" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14A - Línea celular de melanoma SKMEL2</span>Example 14A - Melanoma cell line SKMEL2</span>
      </i>
    </b>
  </p>
  <p id="p0712" num="0712" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la línea celular de melanoma SKMEL2 (WT BRAF; mutación oncogénica N61R en Nras): (1) MRX0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRX029; (4) azacitidina-C (Aza-c) en medio Y<sup class="style-scope patent-text">f</sup>C<sup class="style-scope patent-text">a </sup>+; (5) Aza-c y MRX029; (6) VEMU, Aza-c y MRX0029.</span>The effects of the following treatments on the melanoma cell line SKMEL2 (WT BRAF; N61R oncogenic mutation in Nras) were evaluated: (1) MRX0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRX029; (4) azacitidine-C (Aza-c) in medium Y <sup class="style-scope patent-text">f</sup> C <sup class="style-scope patent-text">a</sup> +; (5) Aza-c and MRX029; (6) VEMU, Aza-c and MRX0029.</span>
  </p>
  <p id="p0713" num="0713" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresión del gen MAP2 en la línea celular SKMEL2 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 31. Todos los tratamientos con MRX029 (solo o en combinación con VEMU y/o Aza-c) aumentaron la expresión del gen MAP2 con respecto a ambos controles negativos (línea celular solamente y YCFA+). La supervivencia clonogénica de la línea celular SKMEL2 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 32. El crecimiento en agar blando de la línea celular SKMEL2 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 33. VEMU+Aza-c mejoró la inhibición del crecimiento en agar blando por MRX029. La señalización de ERK en la línea celular SKMEL2 se evaluó usando el protocolo en Materiales y Métodos, y los resultados se muestran en la Figura 34 (no se evaluaron VEMU, Aza-c y MRX029).</span>MAP2 gene expression in the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 31. All MRX029 treatments (alone or in combination with VEMU and/or Aza-c) increased MAP2 gene expression relative to both negative controls (cell line only and YCFA+). The clonogenic survival of the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 32. The soft agar growth of the SKMEL2 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 32. results are shown in Figure 33. VEMU+Aza-c enhanced growth inhibition in soft agar by MRX029. ERK signaling in the SKMEL2 cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 34 (VEMU, Aza-c and MRX029 were not evaluated).</span>
  </p>
  <p id="p0714" num="0714" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRX0029 solo o en combinación con Vemurafenib y/o Azacitidina-C puede tener los efectos de inducir la expresión del gen MAP2 en una línea celular de melanoma (SKMEL2). Además, Vemurafenib+Azacitidina-C mejoró la inhibición del crecimiento en agar blando por MRX0029. Sobre esta base, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de varios cánceres, en particular cánceres metastásicos, en particular melanoma metastásico.</span>These results indicate that MRX0029 alone or in combination with Vemurafenib and/or Azacitidine-C may have the effects of inducing MAP2 gene expression in a melanoma cell line (SKMEL2). In addition, Vemurafenib+Azacitidine-C improved growth inhibition in soft agar by MRX0029. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of various cancers, in particular metastatic cancers, in particular metastatic melanoma.</span>
  </p>
  <p id="p0715" num="0715" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14B - Línea celular de melanoma SKMEL28</span>Example 14B - Melanoma cell line SKMEL28</span>
      </i>
    </b>
  </p>
  <p id="p0716" num="0716" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la línea celular de melanoma SKMEL28 (mutación oncogénica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YCFA+; (3) VEMU y MRx0029; (4) azacitidina-C (Aza-c) en medio YCFA+; (5) Aza-c y MRX0029; (6) VEMU, Aza-c y MRx0029. 
</span>The effects of the following treatments on the melanoma cell line SKMEL28 (BRAF V600E oncogenic mutation) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YCFA+ medium; (3) VEMU and MRx0029; (4) azacitidine-C (Aza-c) in YCFA+ medium; (5) Aza-c and MRX0029; (6) VEMU, Aza-c and MRx0029. </span>
  </p>
  <p id="p0717" num="0717" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresión del gen MAP2 en la línea celular SKMEL28 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 35. La supervivencia clonogénica de la línea celular SKMEL28 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 36. MRx0029 en combinación con VEMU y/o Aza-c disminuyó la supervivencia clonogénica con respecto a ambos controles negativos (YCFA+ y línea celular solamente). El crecimiento en agar blando de la línea celular SKMEE28 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 37. La señalización de ERK en la línea celular SKMEL28 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 38 (VEMU, Aza-c y MRx0029 no fueron evaluados). Todos los tratamientos con MRx0029 (solo o en combinación con VEMU o Aza-c) redujeron la señalización de ERK con respecto al control negativo (YFCA+).</span>The expression of the MAP2 gene in the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 35. The clonogenic survival of the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results results are shown in Figure 36. MRx0029 in combination with VEMU and/or Aza-c decreased clonogenic survival relative to both negative controls (YCFA+ and cell line only). Growth of the SKMEE28 cell line in soft agar was evaluated using the Materials and Methods protocol, and the results are shown in Figure 37. ERK signaling in the SKMEL28 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 38 (VEMU, Aza-c and MRx0029 were not evaluated). All MRx0029 treatments (alone or in combination with VEMU or Aza-c) reduced ERK signaling relative to the negative control (YFCA+).</span>
  </p>
  <p id="p0718" num="0718" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinación con Vemurafenib y/o Azacitidina-C puede tener los efectos de inhibir la señalización de ERK y disminuir la supervivencia clonogénica de una línea celular de melanoma que comprende la mutación BRAF V600E (SKMEL28). Sobre esta base, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de cánceres, en particular aquellos que comprenden señalización de ERK oncogénica, especialmente melanomas. En particular, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de tales cánceres que comprenden una mutación oncogénica en BRAF, en particular en la posición 600, y especialmente la mutación BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C may have the effects of inhibiting ERK signaling and decreasing clonogenic survival of a melanoma cell line comprising the BRAF V600E (SKMEL28) mutation. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially melanomas. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0719" num="0719" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14C - Línea celular de melanoma SKMEL31</span>Example 14C - Melanoma cell line SKMEL31</span>
      </i>
    </b>
  </p>
  <p id="p0720" num="0720" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos en la línea celular de melanoma SKMEL31 (heterocigota para BRAF V600E): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio <sup class="style-scope patent-text">y </sup>F<sup class="style-scope patent-text">c</sup>A+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the melanoma cell line SKMEL31 (heterozygous for BRAF V600E) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in medium <sup class="style-scope patent-text">and</sup> F <sup class="style-scope patent-text">c</sup> A+; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0721" num="0721" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresión del gen MAP2 en la línea celular SKMEL31 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 39. La supervivencia clonogénica de la línea celular SKMEL31 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 40. El crecimiento en agar blando de la línea celular SKMEL31 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 41. VEMU, Aza-c y VEMU+Aza-c mejoraron el crecimiento en agar blando y la inhibición de la supervivencia clonogénica mediante MRx0029. La señalización de ERK en la línea celular SKMEL31 se evaluó usando el protocolo en Materiales y Métodos, y los resultados se muestran en la Figura 42 (VEMU, Aza-c y MRx0029 en combinación no se evaluaron). Todos los tratamientos con MRx0029 (solo o en combinación con VEMU o Aza-c) redujeron la señalización de ERK con respecto al control negativo (YFCA+).</span>The expression of the MAP2 gene in the SKMEL31 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 39. The clonogenic survival of the SKMEL31 cell line was evaluated using the Materials and Methods protocol, and the results The results are shown in Figure 40. Growth of the SKMEL31 cell line in soft agar was evaluated using the Materials and Methods protocol, and the results are shown in Figure 41. VEMU, Aza-c, and VEMU+Aza-c improved growth in soft agar and inhibition of clonogenic survival by MRx0029. ERK signaling in the SKMEL31 cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 42 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). All MRx0029 treatments (alone or in combination with VEMU or Aza-c) reduced ERK signaling relative to the negative control (YFCA+).</span>
  </p>
  <p id="p0722" num="0722" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14D - Linea celular de melanoma 451Lu</span>Example 14D - Melanoma cell line 451Lu</span>
      </i>
    </b>
  </p>
  <p id="p0723" num="0723" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos en la línea celular de melanoma 451Lu (mutación oncogénica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio YFCA+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the 451Lu melanoma cell line (BRAF V600E oncogenic mutation) were evaluated: (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in YFCA+ medium; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0724" num="0724" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresión del gen MAP2 en la línea celular 451Lu se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 43. Todos los tratamientos con MRx0029 (solo o en combinación con VEMU y/o Aza-c) aumentaron la expresión del gen MAP2 con respecto a la línea celular sólo con control negativo. La supervivencia clonogénica de la línea celular 451Lu se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 44. Todos los tratamientos con MRx0029 (solo o en combinación con VEMU y/o Aza-c) redujeron la supervivencia clonogénica con respecto a ambos controles negativos (línea celular solamente y YCFA+ DMSO). El crecimiento en agar blando de la línea celular 451Lu se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 45. La azacitidina C mejoró la inhibición del crecimiento en agar blando por MRx0029. La señalización de ERK en la línea celular 451Lu se evaluó usando el protocolo en Materiales y Métodos, y los resultados se muestran en la Figura 46 (VEMU, Aza-c y MRx0029 en combinación no se evaluaron). MRx0029 en combinación con VEMU o Aza-c redujo la señalización de ERK con respecto al control negativo (YFCA+ DMSO).</span>MAP2 gene expression in the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 43. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) increased the expression of the MAP2 gene with respect to the cell line only with negative control. The clonogenic survival of the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 44. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) reduced survival. clonogenic relative to both negative controls (cell line only and YCFA+ DMSO). Soft agar growth of the 451Lu cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 45. Azacitidine C enhanced soft agar growth inhibition by MRx0029. ERK signaling in the 451Lu cell line was evaluated using the protocol in Materials and Methods, and the results are shown in Figure 46 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). MRx0029 in combination with VEMU or Aza-c reduced ERK signaling relative to the negative control (YFCA+ DMSO).</span>
  </p>
  <p id="p0725" num="0725" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinación con Vemurafenib y/o Azacitidina-C tiene los efectos de inducir la expresión del gen MAP2 y disminuir la supervivencia clonogénica y el crecimiento de una línea celular de melanoma portadora de una mutación oncogénica BRAF V600E (451Lu). Sobre esta base, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de cánceres, en particular aquellos que comprenden señalización de ERK oncogénica, especialmente melanomas como melanomas metastásicos. En particular, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de dichos cánceres que comprenden una mutación oncogénica en BRAF, en particular en la posición 600, y especialmente la mutación BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C has the effects of inducing MAP2 gene expression and decreasing clonogenic survival and growth of a melanoma cell line carrying an oncogenic mutation BRAF V600E (451Lu ). On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially melanomas such as metastatic melanomas. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0726" num="0726" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 14E - Línea celular de cáncer colorrectal HT29</span>Example 14E - Colorectal cancer cell line HT29</span>
      </i>
    </b>
  </p>
  <p id="p0727" num="0727" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se evaluaron los efectos de los siguientes tratamientos sobre la línea celular de cáncer colorrectal HT29 
(mutación oncogénica V600E en BRAF): (1) MRx0029; (2) Vemurafenib (VEMU) en medio YFCA+; (3) VEMU y MRx0029; (4) Azacitidina-C (Aza-c) en medio YCFA+; (5) Aza-c y MRx0029; (6) VEMU, Aza-c y MRx0029.</span>The effects of the following treatments on the HT29 colorectal cancer cell line were evaluated.  (BRAF V600E oncogenic mutation): (1) MRx0029; (2) Vemurafenib (VEMU) in YFCA+ medium; (3) VEMU and MRx0029; (4) Azacitidine-C (Aza-c) in YCFA+ medium; (5) Aza-c and MRx0029; (6) VEMU, Aza-c and MRx0029.</span>
  </p>
  <p id="p0729" num="0729" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La expresión del gen MAP2 en la línea celular HT29 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 47. MRx0029 en combinación con VEMU y/o Aza-c aumentó la expresión del gen MAP2 con respecto a ambos controles negativos (línea celular solamente e YCFA+). La supervivencia clonogénica de la línea celular HT29 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 48. Todos los tratamientos con MRx0029 (solo o en combinación con VEMU y/o Aza-c) disminuyeron la supervivencia clonogénica con respecto a ambos controles negativos (línea celular solamente y YCFA+ DMSO). Aza-c mejoró los efectos de MRx0029 en la inhibición de la supervivencia clonogénica. El crecimiento en agar blando de la línea celular HT29 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 49a y b. La señalización de ERK en la línea celular HT29 se evaluó usando el protocolo de Materiales y Métodos, y los resultados se muestran en la Figura 50 (VEMU, Aza-c y MRx0029 en combinación no se evaluaron). MRx0029 solo señalización de ERK con respecto al control negativo (YFCA+ DMSO).</span>MAP2 gene expression in the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 47. MRx0029 in combination with VEMU and/or Aza-c increased MAP2 gene expression relative to both negative controls (cell line only and YCFA+). Clonogenic survival of the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 48. All MRx0029 treatments (alone or in combination with VEMU and/or Aza-c) decreased survival. clonogenic relative to both negative controls (cell line only and YCFA+ DMSO). Aza-c enhanced the effects of MRx0029 in inhibiting clonogenic survival. Soft agar growth of the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 49a and b. ERK signaling in the HT29 cell line was evaluated using the Materials and Methods protocol, and the results are shown in Figure 50 (VEMU, Aza-c, and MRx0029 in combination were not evaluated). MRx0029 only ERK signaling relative to the negative control (YFCA+ DMSO).</span>
  </p>
  <p id="p0731" num="0731" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Estos resultados indican que MRx0029 solo o en combinación con Vemurafenib y/o Azacitidina-C tiene los efectos de inducir la expresión del gen MAP2, disminuir la supervivencia clonogénica e inhibir la señalización de ERK en una línea celular portadora de la mutación oncogénica V600E (EEG29). Sobre esta base, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de cánceres, en particular aquellos que comprenden señalización de ERK oncogénica, especialmente cánceres colorrectales como cáncer colorrectal metastásico. En particular, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de dichos cánceres que comprenden una mutación oncogénica en BRAF, en particular en la posición 600, y especialmente la mutación BRAF V600E.</span>These results indicate that MRx0029 alone or in combination with Vemurafenib and/or Azacitidine-C has the effects of inducing MAP2 gene expression, decreasing clonogenic survival and inhibiting ERK signaling in a cell line carrying the V600E oncogenic mutation (EEG29). ). On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of cancers, in particular those that comprise oncogenic ERK signaling, especially colorectal cancers such as metastatic colorectal cancer. In particular, the compositions of the invention are expected to be useful in the treatment or prevention of such cancers that comprise an oncogenic mutation in BRAF, particularly at position 600, and especially the BRAF V600E mutation.</span>
  </p>
  <p id="p0733" num="0733" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 15 - Expresión de ARN de GPR109a en células Caco-2 diferenciadas</span>Example 15 - Expression of GPR109a RNA in Differentiated Caco-2 Cells</span>
      </i>
    </b>
  </p>
  <p id="p0735" num="0735" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GPR109a es un receptor acoplado a proteína G expresado en la membrana apical orientada hacia el lumen de las células epiteliales intestinales y colónicas. El silenciamiento de la expresión de GPR109a se encuentra en líneas celulares de cáncer de colon, y se ha informado que la inducción de su expresión induce la apoptosis de las células tumorales en presencia de productos de fermentación bacteriana como el butirato [126].</span>GPR109a is a G protein-coupled receptor expressed on the lumen-facing apical membrane of intestinal and colonic epithelial cells. Silencing of GPR109a expression is found in colon cancer cell lines, and induction of its expression has been reported to induce apoptosis of tumor cells in the presence of bacterial fermentation products such as butyrate [126].</span>
  </p>
  <p id="p0737" num="0737" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sembraron células HT29mtx sembradas en placas de 12 pocillos y se diferenciaron durante 10 días; luego se privaron de suero durante 12 horas y posteriormente se expusieron a sobrenadante al 10% derivado de bacterias en fase estacionaria durante 24 horas. Se recogieron las células y se aisló el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se preparó usando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems). La expresión génica se midió por qPCR. Se usó p-actina como control interno. Se calcularon las veces de cambio de acuerdo con el método 2A(-AAct) [127]. Las secuencias de los cebadores directo e inverso usados se proporcionan como las SEQ ID NO: 6 y 7, respectivamente.</span>Seed HT29mtx cells were plated in 12-well plates and differentiated for 10 days; they were then serum starved for 12 hours and subsequently exposed to 10% supernatant derived from bacteria in stationary phase for 24 hours. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. p-actin was used as internal control. The fold change was calculated according to the 2A(-AAct) method [127]. The sequences of the forward and reverse primers used are provided as SEQ ID NOs: 6 and 7, respectively.</span>
  </p>
  <p id="p0739" num="0739" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las Caco-2 diferenciadas forman membranas apicales/mucosas y basolaterales/serosas polarizadas que son impermeables y estructural y funcionalmente similares a las células epiteliales del intestino delgado. El tratamiento de células Caco-2 con MRx0029 provocó un aumento de la expresión de GPR109a (Figura 52A). Además, las Caco-2 tratadas con sobrenadante de forbol-12-miristato-13-acetato (PMA) mostraron una mayor expresión de ARN de GPR109a que el tratamiento con PMA solo (o PMA en medio YCFA+) - ver la Figura 52B. Por lo tanto, estos datos sugieren que las composiciones de la invención pueden ser útiles en el tratamiento de cánceres, especialmente cánceres metastásicos, en particular cáncer colorrectal metastásico o cáncer de intestino delgado como adenocarcinoma de intestino delgado, y en particular aquellos que comprenden señalización de ERK oncogénica. Estos datos también sugieren que las composiciones de la invención pueden efectuar tal tratamiento a través del mecanismo de inducción de apoptosis, como resultado de la expresión de GPR109a.</span>Differentiated Caco-2 form polarized apical/mucosal and basolateral/serous membranes that are impermeable and structurally and functionally similar to epithelial cells of the small intestine. Treatment of Caco-2 cells with MRx0029 caused an increase in the expression of GPR109a (FIG. 52A). In addition, Caco-2 treated with phorbol-12-myristate-13-acetate (PMA) supernatant showed higher GPR109a RNA expression than treatment with PMA alone (or PMA in YCFA+ medium) - see Figure 52B. Therefore, these data suggest that the compositions of the invention may be useful in the treatment of cancers, especially metastatic cancers, in particular metastatic colorectal cancer or cancer of the small intestine such as adenocarcinoma of the small intestine, and in particular those that comprise signaling of oncogenic ERK. These data also suggest that the compositions of the invention may effect such treatment through the mechanism of induction of apoptosis, as a result of the expression of GPR109a.</span>
  </p>
  <p id="p0741" num="0741" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 16 - Efecto de MRx0029 sobre la secreción de IL-8 por la linea celular HT29</span>Example 16 - Effect of MRx0029 on IL-8 secretion by the HT29 cell line</span>
      </i>
    </b>
  </p>
  <p id="p0743" num="0743" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células HT29 diferenciadas forman membranas apicales/mucosas y basolaterales/serosas polarizadas que son impermeables y son estructural y funcionalmente similares a las células epiteliales del intestino delgado. Las células HT29 se sembraron en placas de 12 pocillos a una densidad de 200.000 células/pocillo. Las células se diferenciaron durante 10 días (cambio de medio cada 2 días). El día del experimento las células se colocaron en la campana anaeróbica y se lavaron con solución de HANKs equilibrada anaeróbica. Luego se añadieron a las células 900 ul de medio de cultivo (sin FBS ni antibióticos). Las células bacterianas se volvieron a suspender en medio de crecimiento (sin FBS ni antibióticos) y luego se añadieron a 10A7 UFC en total en 100ul. Las células se coincubaron con bacterias durante 2 h en una campana anaeróbica. Posteriormente, las células se lavaron en medios de crecimiento sin FBS pero que contenían antibióticos. Las células se dejaron reposar en 1 ml de medio de acondicionamiento de THP1 durante 24 h. Después de 24 h de incubación, se recogió el sobrenadante y se centrifugó a 10.000 g durante 3 min y 4° C. Las muestras se congelaron a -80°C hasta su uso posterior. 
</span>Differentiated HT29 cells form polarized apical/mucosal and basolateral/serous membranes that are impermeable and are structurally and functionally similar to epithelial cells of the small intestine. HT29 cells were seeded in 12-well plates at a density of 200,000 cells/well. Cells were differentiated for 10 days (medium change every 2 days). On the day of the experiment the cells were placed in the anaerobic hood and washed with anaerobic balanced HANKs solution. Then 900 ul of culture medium (without FBS and antibiotics) was added to the cells. Bacterial cells were resuspended in growth medium (without FBS or antibiotics) and then added to 10A7 CFU in total in 100ul. Cells were coincubated with bacteria for 2 h in an anaerobic hood. Cells were subsequently washed in growth media without FBS but containing antibiotics. Cells were allowed to stand in 1 ml of THP1 conditioning medium for 24 h. After 24 h of incubation, the supernatant was collected and centrifuged at 10,000 g for 3 min and 4°C. Samples were frozen at -80°C until further use. </span>
  </p>
  <p id="p0744" num="0744" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Medios de acondicionamiento de THP1: se sembraron THp1 en un matraz T25 a una densidad de 4310A6/matraz. Las células se trataron en medio RPMI (que contenía L-glutamina 2 mM sin FBS) con LPS 1ug/ml o LPS  ATP 5 mM (ATP añadido 3 horas después de LPS). Las células se dejaron reposar durante 24 horas. Posteriormente, se recogió el Medio de Acondicionamiento (CM) centrifugando las células a 250 g durante 5 min y a TA. Se usaron diferentes CM para tratar las células HT29. Se congeló una pequeña alícuota a 80° C para ELISA.</span>THP1 Conditioning Media: THp1 was seeded into a T25 flask at a density of 4310A6/flask. Cells were treated in RPMI medium (containing 2mM L-glutamine without FBS) with 1ug/ml LPS or 5mM LPS ATP (ATP added 3 hours after LPS). The cells were allowed to settle for 24 hours. Subsequently, the Conditioning Medium (CM) was collected by centrifuging the cells at 250 g for 5 min and at RT. Different CMs were used to treat HT29 cells. A small aliquot was frozen at 80°C for ELISA.</span>
  </p>
  <p id="p0745" num="0745" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se recogieron los sobrenadantes de las diferentes muestras y se realizó el análisis de citoquinas de acuerdo con las instrucciones del fabricante usando un kit ELISA de IL-8 humana de Peprotech. Se usó GraphPad Prism7 para trazar y analizar los datos.</span>Supernatants from the different samples were collected and cytokine analysis was performed according to the manufacturer's instructions using a human IL-8 ELISA kit from Peprotech. GraphPad Prism7 was used to plot and analyze the data.</span>
  </p>
  <p id="p0746" num="0746" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">MRx0029 aumentó la secreción de IL-8, que es una citoquina potente inmunoestimuladora (Figura 53). Estos datos demuestran la actividad inmunoestimuladora de MRx0029.</span>MRx0029 increased the secretion of IL-8, which is a potent immunostimulatory cytokine (FIG. 53). These data demonstrate the immunostimulatory activity of MRx0029.</span>
  </p>
  <p id="p0747" num="0747" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se ha indicado anteriormente, la secreción de IL-8 aumenta la proliferación de células B. Las células B se han implicado en la modulación de la respuesta inmunitaria a los tumores. De hecho, la secreción de anticuerpos antitumorales por parte de las células B es un potente mecanismo de control tumoral. Es bien sabido que la producción de anticuerpos específicos de tumores puede desencadenar que las células asesinas naturales se unan al dominio constante de los anticuerpos, lo que da como resultado la lisis de las células tumorales a través de la citotoxicidad mediada por células dependiente de anticuerpos (ADCC). Por lo tanto, las composiciones de la invención pueden efectuar el tratamiento del cáncer a través de la modulación apropiada de la respuesta de las células B asegurando respuestas inmunitarias antitumorales aumentadas.</span>As noted above, IL-8 secretion increases B cell proliferation. B cells have been implicated in modulating the immune response to tumors. In fact, the secretion of antitumor antibodies by B cells is a powerful mechanism of tumor control. It is well known that the production of tumor-specific antibodies can trigger natural killer cells to bind to the constant domain of antibodies, resulting in lysis of tumor cells through antibody-dependent cell-mediated cytotoxicity ( ADCC). Therefore, the compositions of the invention can effect the treatment of cancer through the appropriate modulation of the B cell response ensuring increased anti-tumor immune responses.</span>
  </p>
  <p id="p0748" num="0748" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">En base al hecho de que el mecanismo patológico de la mayoría de los cánceres implica la evasión de la vigilancia por parte del sistema inmunitario del huésped, cualquier mecanismo implicado en la estimulación de la respuesta inmunitaria tendría un impacto terapéutico beneficioso. Por lo tanto, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de varios tipos de cáncer.</span>Based on the fact that the pathological mechanism of most cancers involves evasion of vigilance by the host's immune system, any mechanism involved in stimulating the immune response would have a beneficial therapeutic impact. Therefore, the compositions of the invention are expected to be useful in the treatment or prevention of various types of cancer.</span>
  </p>
  <p id="p0749" num="0749" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 17 - Análisis de metabolitos</span>Example 17 - Analysis of metabolites</span>
      </i>
    </b>
  </p>
  <p id="p0750" num="0750" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0751" num="0751" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El microbiota intestinal, con su inmensa diversidad y capacidad metabólica, representa un enorme depósito metabólico para la producción de una gran variedad de moléculas. Los inventores buscaban determinar qué ácidos grasos de cadena corta y ácidos grasos de cadena media son producidos y consumidos por la cepa NCIMB 42787 de <i class="style-scope patent-text">M.massiliensis </i>y otras cepas de <i class="style-scope patent-text">M.massiliensis </i>identificadas en la presente como Ref 1, Ref 2 y Ref 3.</span>The gut microbiota, with its immense diversity and metabolic capacity, represents an enormous metabolic reservoir for the production of a wide variety of molecules. The inventors sought to determine which short chain fatty acids and medium chain fatty acids are produced and consumed by M.massiliensis strain NCIMB <i class="style-scope patent-text">42787</i> and other <i class="style-scope patent-text">M.massiliensis</i> strains identified herein as Ref 1, Ref 2 and Ref 3.</span>
  </p>
  <p id="p0752" num="0752" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Material y métodos</span>Material and methods</span>
    </i>
  </p>
  <p id="p0753" num="0753" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cultivo bacteriano y recogida de sobrenadante libre de células</span>Bacterial culture and collection of cell-free supernatant</span>
    </i>
  </p>
  <p id="p0754" num="0754" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los cultivos puros de bacterias se cultivaron anaeróbicamente en caldo YCFA+ hasta que alcanzaron su fase de crecimiento estacionario. Los cultivos se centrifugaron a 5000 x g durante 5 minutos y el sobrenadante libre de células (CFS) se filtró usando un filtro de 0,2 pM (Millipore, Reino Unido). Se almacenaron alícuotas de 1 ml de CFS a -80° C hasta su uso. El butirato de sodio, el ácido hexanoico y el valérico se obtuvieron de Sigma Aldrich (Reino Unido) y se prepararon suspensiones en caldo YCFA+.</span>Pure cultures of bacteria were grown anaerobically in YCFA+ broth until they reached their stationary growth phase. Cultures were centrifuged at 5000 x g for 5 minutes and cell free supernatant (CFS) was filtered using a 0.2 pM filter (Millipore, UK). Aliquots of 1 ml of CFS were stored at -80°C until use. Sodium butyrate, hexanoic acid and valeric acid were obtained from Sigma Aldrich (UK) and suspensions were prepared in YCFA+ broth.</span>
  </p>
  <p id="p0755" num="0755" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cuantificación de SCFA y MCFA de sobrenadantes bacterianos</span>SCFA and MCFA quantification of bacterial supernatants</span>
    </i>
  </p>
  <p id="p0756" num="0756" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se analizaron y cuantificaron los ácidos grasos de cadena corta (SCFA) y los ácidos grasos de cadena media (MCFA) de sobrenadantes bacterianos mediante MS Omics APS de la siguiente manera. Las muestras se acidificaron usando ácido clorhídrico y se añadieron estándares internos marcados con deuterio. Todas las muestras se analizaron en un orden aleatorio. El análisis se realizó usando una columna de alta polaridad (Zebron™ ZB-FFAP, GC Cap. 30 m x 0,25 mm x 0,25 pm) instalada en un GC (7890B, Agilent) acoplado a un detector de cuadropolo (59977B, Agilent). El sistema fue controlado por ChemStation (Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos fueran importados y procesados en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito en [128].</span>Short chain fatty acids (SCFA) and medium chain fatty acids (MCFA) of bacterial supernatants were analyzed and quantified by MS Omics APS as follows. Samples were acidified using hydrochloric acid and deuterium-labelled internal standards were added. All samples were analyzed in a random order. Analysis was performed using a high polarity column (Zebron™ ZB-FFAP, GC Cap. 30 m x 0.25 mm x 0.25 pm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B, Agilent). The system was controlled by ChemStation (Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described in [128].</span>
  </p>
  <p id="p0757" num="0757" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0758" num="0758" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Como se muestra en las Figuras 54-56, la cepa 42787 produce ácido valérico, butirato y ácido hexanoico y consume propionato y acetato. Los inventores también descubrieron otras cepas de la especie <i class="style-scope patent-text">M. massiliensis </i>que producen niveles comparables de ácido valérico, ácido hexanoico y butirato y que consumen cantidades similares de acetato y propionato.</span>As shown in Figures 54-56, strain 42787 produces valeric acid, butyrate, and hexanoic acid and consumes propionate and acetate. The inventors also discovered other strains of the <i class="style-scope patent-text">M. massiliensis</i> species that produce comparable levels of valeric acid, hexanoic acid, and butyrate and that consume similar amounts of acetate and propionate.</span>
  </p>
  <p id="p0759" num="0759" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 18 - Supresión de enolasa 2 </span>Example 18 - Deletion of enolase 2</span>
      </i>
    </b>
    
  </p>
  <p id="p0760" num="0760" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 57 demuestra que MRx0029 tiene un efecto estadísticamente significativo que suprime la enolasa específica de neuronas (NSE)/enolasa 2. Se cree que la NSE respalda las demandas metabólicas de las células tumorales aumentadas, protege a las células tumorales de condiciones estresantes y promueve su invasión y migración [129]. También está implicado en la progresión del melanoma metastásico [130], la supervivencia y la progresión en el cáncer de pulmón de células pequeñas [131 ] y el pronóstico del carcinoma de pulmón adenoescamoso [132]. Por lo tanto, se espera que las composiciones de la invención sean eficaces para tratar y prevenir el cáncer, en particular, melanoma metastásico, cáncer de pulmón de células pequeñas y carcinoma de pulmón adenoescamoso.</span>Figure 57 demonstrates that MRx0029 has a statistically significant effect in suppressing neuron-specific enolase (NSE)/enolase 2. NSE is believed to support increased tumor cell metabolic demands, protect tumor cells from stressful conditions, and promote their invasion and migration [129]. It is also implicated in metastatic melanoma progression [130], survival and progression in small cell lung cancer [131], and adenosquamous lung carcinoma prognosis [132]. Therefore, the compositions of the invention are expected to be effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer, and adenosquamous lung carcinoma.</span>
  </p>
  <p id="p0761" num="0761" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 19 - Análisis de metabolitos</span>Example 19 - Analysis of metabolites</span>
      </i>
    </b>
  </p>
  <p id="p0762" num="0762" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Además de los datos proporcionados en el Ejemplo 17, la Figura 58 demuestra qué otros ácidos grasos de cadena corta son producidos y consumidos por la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>y otras cepas depositadas con los números de registro NCIMB 43385, Nc IMB 43388 y NCIMB 43389.</span>In addition to the data provided in Example 17, Figure 58 demonstrates what other short chain fatty acids are produced and consumed by <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 and other strains deposited under accession numbers NCIMB 43385, Nc IMB 43388 and NCIMB 43389.</span>
  </p>
  <p id="p0763" num="0763" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La cepa de <i class="style-scope patent-text">M. massiliensis </i>NCIMB 42787 reduce el ácido fórmico a la vez que aumenta los niveles de ácido 2-metil-propanoico y ácido 3-metil-butanoico (Figura 58). Por lo tanto, la cepa NCIMB 42787 produce ácido 2-metil-propanoico y ácido 3-metil-butanoico y consume ácido fórmico. Los inventores también descubrieron que otras de las cepas depositadas producen niveles comparables de ácido 2-metil-propanoico y ácido 3-metil-butanoico y consumen cantidades similares de ácido fórmico.</span> <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 reduces formic acid while increasing levels of 2-methyl-propanoic acid and 3-methyl-butanoic acid (Figure 58). Therefore, the NCIMB 42787 strain produces 2-methyl-propanoic acid and 3-methyl-butanoic acid and consumes formic acid. The inventors also discovered that other of the deposited strains produce comparable levels of 2-methyl-propanoic acid and 3-methyl-butanoic acid and consume similar amounts of formic acid.</span>
  </p>
  <p id="p0764" num="0764" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 20 - Regulación por incremento de IL-6</span>Example 20 - Upregulation of IL-6</span>
      </i>
    </b>
  </p>
  <p id="p0765" num="0765" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0766" num="0766" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se investigó la capacidad de las cepas bacterianas para desencadenar un aumento en la secreción de IL-6 por la línea celular de astrocitoma U373.</span>The ability of bacterial strains to trigger an increase in IL-6 secretion by the astrocytoma cell line U373 was investigated.</span>
  </p>
  <p id="p0767" num="0767" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0768" num="0768" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Línea celular de astrocitoma de glioblastoma humana (U373), se mantuvieron en 25 ml de MEME 4,5 g/l de D-glucosa suplementada con 10% de FBS inactivado por calor, 4 mM de L-glutamina, 100 U/ml de penicilina, 100 gg/ml de estreptomicina y 5 gg/ml de ml de plasmocina, 1% de aminoácidos no esenciales, 1% de piruvato de sodio (denominado medio de crecimiento completo).</span>Human glioblastoma astrocytoma cell line (U373), maintained in 25 ml MEME 4.5 g/l D-glucose supplemented with 10% heat-inactivated FBS, 4 mM L-glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin and 5 gg/ml plasmocin, 1% non-essential amino acids, 1% sodium pyruvate (referred to as complete growth medium).</span>
  </p>
  <p id="p0769" num="0769" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células se sembraron en placas de 24 pocillos a una densidad de 100.000 células/pocillo en 1ml de medio de cultivo completo y se dejaron reposar a 37°C/5% de CO2 durante 72 h. El día del tratamiento, se retiró el medio de cada pocillo, las células se enjuagaron con 0,5 ml de medio de lavado (MEME libre de suero), 0,9 ml de medio de estimulación (medio MEME que contenía FBS al 2%). Después de una preincubación de 1 h, las células se retiraron de la incubadora de CO2 y se trataron con 100 gl de sobrenadante de bacterias. Se usó medio YCFA+ como control. Luego, las células se incubaron durante 24 h adicionales a 37° C/5% de CO2, después de lo cual se recogieron los sobrenadantes libres de células y se centrifugaron a 10.000 g a 4° C durante 3 min. Las muestras se dividieron en alícuotas en microtubos de 1,5 ml y se almacenaron a -80° C para hIL-6 ELISA.</span>Cells were seeded in 24-well plates at a density of 100,000 cells/well in 1 ml of complete culture medium and left to stand at 37°C/5% CO2 for 72 h. On the day of treatment, medium was removed from each well, cells were rinsed with 0.5 mL wash medium (MEME serum-free), 0.9 mL stimulation medium (MEME medium containing 2% FBS ). After a 1 h preincubation, cells were removed from the CO2 incubator and treated with 100 gl of bacterial supernatant. YCFA+ medium was used as a control. Cells were then incubated for an additional 24 h at 37°C/5% CO2, after which cell-free supernatants were collected and centrifuged at 10,000 g at 4°C for 3 min. Samples were aliquoted into 1.5 ml microtubes and stored at -80°C for hIL-6 ELISA.</span>
  </p>
  <p id="p0770" num="0770" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados y conclusiones</span>Results and conclusions</span>
    </i>
  </p>
  <p id="p0771" num="0771" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 59 demuestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>regula por incremento la secreción de IL-6 en células U373 en comparación con los controles de YCFA+ y sin tratar. Otras cepas depositadas, en particular la NCIMB 43389, también aumentaron la secreción de IL-6. Las cepas depositadas adicionales son NCIMB 43385, NCIMB 43388, NCIMB 43386 y NCIMB 43387.</span>Figure 59 demonstrates that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 up-regulates IL-6 secretion in U373 cells compared to YCFA+ and untreated controls. Other deposited strains, notably NCIMB 43389, also increased IL-6 secretion. Additional deposited strains are NCIMB 43385, NCIMB 43388, NCIMB 43386, and NCIMB 43387.</span>
  </p>
  <p id="p0772" num="0772" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La secreción de IL-6 aumenta la proliferación de células B. Como se ha descrito anteriormente, la proliferación de células B aumentada puede actuar como un potente mecanismo para mejorar la respuesta inmunitaria contra un cáncer (por ejemplo, a través de la producción de anticuerpos y la activación de ADCC).</span>IL-6 secretion increases B-cell proliferation. As described above, increased B-cell proliferation may act as a potent mechanism to enhance the immune response against cancer (for example, through the production of antibodies). and ADCC activation).</span>
  </p>
  <p id="p0773" num="0773" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">De hecho, la actividad inmunoestimuladora se demuestra, no sólo por la cepa depositada, sino también por las cepas depositadas relacionadas. Por lo tanto, se espera que las composiciones de la invención que comprenden cepas del género <i class="style-scope patent-text">Megasphaera, </i>o biotipos de las mismas, sean útiles en el tratamiento o prevención de varios cánceres.</span>In fact, the immunostimulatory activity is demonstrated, not only by the deposited strain, but also by the related deposited strains. Therefore, compositions of the invention comprising strains of the genus <i class="style-scope patent-text">Megasphaera,</i> or biotypes thereof, are expected to be useful in the treatment or prevention of various cancers.</span>
  </p>
  <p id="p0774" num="0774" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 21 - Supresión de enolasa 2</span>Example 21 - Deletion of enolase 2</span>
      </i>
    </b>
  </p>
  <p id="p0775" num="0775" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos </span>Materials and methods</span>
    </i>
    
  </p>
  <p id="p0776" num="0776" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivó la línea celular de neuroblastoma SH-SY5Y en medio MEM al 50% y mezcla de nutrientes F-12 Ham al 50% suplementado con L-glutamina 2 mM, FBS inactivado por calor al 10%, 100 U/ml de penicilina y 100 |jg/ml de estreptomicina. Las SH-SY5Y se sembraron en placas de 6 pocillos a una densidad de 0,5 x 106 células. Después de 24 h, las células se trataron en medio de diferenciación (medio de crecimiento que contenía FBS al 1%) con sobrenadantes bacterianos al 10% o YCFA+ durante 17 h. Se recogieron las células y se aisló el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se elaboró usando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems). La expresión génica se midió por qPCR. Se usó GAPDH como control interno. El cambio de veces se calculó de acuerdo con el método 2(-ññct). Los conjuntos de cebadores usados se enumeran como las SEQ ID NO: 2, 3, 13 y 14.</span>Neuroblastoma cell line SH-SY5Y was grown in 50% MEM medium and 50% F-12 Ham nutrient mix supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin and 100 |jg/ml of streptomycin. SH-SY5Ys were plated in 6-well plates at a density of 0.5 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS) with 10% bacterial supernatants or YCFA+ for 17 h. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. The cDNA was made using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ññct) method. The primer sets used are listed as SEQ ID NOs: 2, 3, 13 and 14.</span>
  </p>
  <p id="p0777" num="0777" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0778" num="0778" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 60 demuestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>tiene un efecto estadísticamente significativo de supresión de la enolasa específica de las neuronas (NSE)/enolasa 2. Además, los inventores también descubrieron que las cepas de referencia depositadas desencadenan una reducción estadísticamente significativa de la enolasa 2 en comparación con el control de cultivo de YCFA+. En particular, las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43388, NCIMB 43389, NCI<sup class="style-scope patent-text">m </sup>B 43386 y NCI<sup class="style-scope patent-text">m </sup>B 43387 provocaron una supresión significativa de la enolasa 2.</span>Figure 60 demonstrates that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 has a statistically significant effect of suppressing neuron-specific enolase (NSE)/enolase 2. In addition, the inventors also found that the deposited reference strains elicit a statistically significant reduction. significant increase in enolase 2 compared to the YCFA+ culture control. In particular, strains deposited under accession numbers NCIMB 43385, NCIMB 43388, NCIMB 43389, NCI <sup class="style-scope patent-text">m</sup> B 43386, and NCI <sup class="style-scope patent-text">m</sup> B 43387 caused significant suppression of enolase 2.</span>
  </p>
  <p id="p0779" num="0779" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Conclusión</span>conclusion</span>
    </i>
  </p>
  <p id="p0780" num="0780" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, de acuerdo con los comentarios del Ejemplo 18 anterior, se espera que las composiciones de la invención, en ciertas realizaciones que comprenden las cepas de referencia ejemplares, sean eficaces para tratar y prevenir el cáncer, en particular, el melanoma metastásico, el cáncer de pulmón de células pequeñas y el cáncer de pulmón adenoescamoso.</span>Accordingly, based on the discussion of Example 18 above, the compositions of the invention, in certain embodiments comprising the exemplary reference strains, are expected to be effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer and adenosquamous lung cancer.</span>
  </p>
  <p id="p0781" num="0781" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 22 - Regulación por incremento de MAP2</span>Example 22 - Upregulation of MAP2</span>
      </i>
    </b>
  </p>
  <p id="p0782" num="0782" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0783" num="0783" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La línea celular de neuroblastoma SH-SY5Y se cultivó en medio MEM al 50% y mezcla de nutrientes F-12 Ham al 50% suplementado con L-glutamina 2 mM, FBS inactivado por calor al 10%, 100 U/ml de penicilina y 100 jg/ml de estreptomicina. Las SH-SY5Y se sembraron en placas de 6 pocillos a una densidad de 0,5 x 106 células. Después de 24 h, las células se trataron en medio de diferenciación (medio de crecimiento que contenía FBS al 1%) con sobrenadantes bacterianos al 10% o YCFA+ durante 17 h. Se recogieron las células y se aisló el ARN total de acuerdo con el protocolo del RNeasy mini kit (Qiagen). El ADNc se elaboró usando el kit de transcripción inversa de ADNc de alta capacidad (Applied Biosystems). La expresión génica se midió por qPCR. Se usó GAPDH como control interno. El cambio de veces se calculó de acuerdo con el método 2(-ññct). Los conjuntos de cebadores usados se enumeran como las SEQ ID NO: 2, 3, 4 y 5.</span>The SH-SY5Y neuroblastoma cell line was grown in 50% MEM medium and 50% F-12 Ham nutrient mix supplemented with 2 mM L-glutamine, 10% heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml of streptomycin. SH-SY5Ys were plated in 6-well plates at a density of 0.5 x 10 6 cells. After 24 h, cells were treated in differentiation medium (growth medium containing 1% FBS) with 10% bacterial supernatants or YCFA+ for 17 h. Cells were harvested and total RNA isolated according to the RNeasy mini kit (Qiagen) protocol. The cDNA was made using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was measured by qPCR. GAPDH was used as an internal control. The fold change was calculated according to the 2(-ññct) method. The primer sets used are listed as SEQ ID NOs: 2, 3, 4 and 5.</span>
  </p>
  <p id="p0784" num="0784" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0785" num="0785" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 61 A muestra que la cepa NCIMB 42787 de <i class="style-scope patent-text">M. massiliensis </i>y otras cepas depositadas desencadenan un aumento estadísticamente significativo de la expresión de MAP2 en comparación con los controles (es decir, control negativo y control de medios). En particular, las cepas depositadas con los números de registro NCIMB 43385, NCIMB 43388, NCIMB 43389, NCiMb 43386 y NCIMB 43387 provocaron un aumento significativo en la expresión de MAP2. Sobre esta base, se espera que las composiciones de la invención sean útiles en el tratamiento o prevención de varios tipos de cáncer, en particular cánceres metastásicos, en particular melanoma metastásico.</span>Figure 61A shows that <i class="style-scope patent-text">M. massiliensis</i> strain NCIMB 42787 and other deposited strains elicit a statistically significant increase in MAP2 expression compared to controls (ie, negative control and media control). In particular, strains deposited under accession numbers NCIMB 43385, NCIMB 43388, NCIMB 43389, NCiMb 43386, and NCIMB 43387 caused a significant increase in MAP2 expression. On this basis, the compositions of the invention are expected to be useful in the treatment or prevention of various types of cancer, in particular metastatic cancers, in particular metastatic melanoma.</span>
  </p>
  <p id="p0786" num="0786" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 23 - Modulación de la secreción de citoquinas en células HMC3 expuestas a TNFa tras el tratamiento con la cepa NCIMB 42787 de M. massiliensis</span>Example 23 - Modulation of cytokine secretion in HMC3 cells exposed to TNFa after treatment with M. massiliensis strain NCIMB 42787</span>
      </i>
    </b>
  </p>
  <p id="p0787" num="0787" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0788" num="0788" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células HMC3 se trataron con TNFa y se midió la secreción de IL-8 tras el tratamiento con sobrenadantes libres de células del cultivo en fase estacionaria de NCIMB 42787.</span>HMC3 cells were treated with TNFa and IL-8 secretion was measured after treatment with cell-free supernatants from the stationary phase culture of NCIMB 42787.</span>
  </p>
  <p id="p0789" num="0789" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0790" num="0790" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivaron células HMC3 de microglía humana en medio EMEM suplementado con glutamina que contenía FBS inactivado por calor al 15% y 100 |ug/ml de penicilina y 100 |ug/ml de estreptomicina. Las células HMC3 se sembraron en placas de 24 pocillos a una densidad de 50.000 células/pocillo. Las células se dejaron en una incubadora de CO2 en reposo durante 48 horas. Luego, las células se lavaron en EMEM en blanco y se pretrataron en medio de cultivo FBS al 2% con 10 ng/ml de TNF-a durante 1 h. Posteriormente, se añadieron sobrenadantes 
bacterianos libres de células al 10% para cultivos de crecimiento estacionarios de NCIMB 42787 (aislados como se ha descrito anteriormente) a pocillos tratados y no tratados con TNF-a y se incubaron en incubadora con CO2 a 37° C durante 24 h. Los sobrenadantes libres de células se recogieron y centrifugaron a 10.000 x g durante 3 minutos y 4° C. Las muestras se dividieron en alícuotas en microtubos de 1,5 ml y se almacenaron a -80° C para hIL-8 ELISA.</span>Human microglia HMC3 cells were cultured in glutamine-supplemented EMEM medium containing 15% heat-inactivated FBS and 100 µg/ml penicillin and 100 µg/ml streptomycin. HMC3 cells were seeded in 24-well plates at a density of 50,000 cells/well. Cells were left in a CO2 incubator at rest for 48 hours. Cells were then washed in blank EMEM and pretreated in 2% FBS culture medium with 10 ng/ml TNF-α for 1 h. Subsequently, supernatants were added  10% cell-free bacterial cells for stationary growth cultures of NCIMB 42787 (isolated as described above) were added to TNF-a treated and untreated wells and incubated in a 37°C CO 2 incubator for 24 h. Cell-free supernatants were collected and centrifuged at 10,000 xg for 3 minutes and 4°C. Samples were aliquoted into 1.5 ml microtubes and stored at -80°C for hIL-8 ELISA.</span>
  </p>
  <p id="p0791" num="0791" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La secreción de IL-8 se analizó usando kits de ELISA estándar de hIL-8, de acuerdo con el protocolo del fabricante en los sobrenadantes libres de células de células HMC3 tratadas como se ha descrito anteriormente. Las muestras se midieron a 405 nm con una longitud de onda de corrección establecida a 655 nm en un lector de microplacas (iMark, Bio-Rad). Los datos sin procesar se trazaron y analizaron utilizando el software GraphPad Prism 7.</span>IL-8 secretion was assayed using standard hIL-8 ELISA kits according to the manufacturer's protocol on cell-free supernatants from HMC3 cells treated as described above. Samples were measured at 405nm with a correction wavelength set to 655nm in a microplate reader (iMark, Bio-Rad). Raw data was plotted and analyzed using GraphPad Prism 7 software.</span>
  </p>
  <p id="p0792" num="0792" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis estadístico</span>Statistic analysis</span>
  </p>
  <p id="p0793" num="0793" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media ± SEM; Se usó Anova unidireccional (prueba de comparación múltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consideró significativo en todos los casos.</span>Normally distributed data are presented as mean ± SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0794" num="0794" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0795" num="0795" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NCIMB 42787 induce la secreción de IL-8 en ausencia de estimulación (Figura 61B). Como se ha indicado anteriormente, la IL-8 está implicada en la activación del sistema inmunitario, en particular mediante la estimulación de la proliferación de células B.</span>NCIMB 42787 induces IL-8 secretion in the absence of stimulation (FIG. 61B). As indicated above, IL-8 is involved in the activation of the immune system, in particular by stimulating the proliferation of B cells.</span>
  </p>
  <p id="p0796" num="0796" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 24 - Activación del promotor de NF-</span>Example 24 - Activation of the NF-promoter</span>
      </i>
    </b>
    <sup class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">k </span>k</span>
    </sup>
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">B en células HEK-TLR4 por M. massiliensis NCIMB 42787 </span>B in HEK-TLR4 cells by M. massiliensis NCIMB 42787</span>
      </i>
    </b>
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0797" num="0797" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para verificar si el tratamiento con NCIMB 42787 induciría la actividad del promotor NF-KB-Ap1 inducida por la participación de TLR4, se trataron células F1EK-TLR4 con sobrenadantes bacterianos sin células para NCIMB 42787 solo o en combinación con LPS.</span>To verify whether NCIMB 42787 treatment would induce TLR4-induced NF-KB-Ap1 promoter activity, F1EK-TLR4 cells were treated with cell-free bacterial supernatants for NCIMB 42787 alone or in combination with LPS.</span>
  </p>
  <p id="p0798" num="0798" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0799" num="0799" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se cultivaron células informadoras FlEK293-Blue que expresan de manera estable TLR4 humano (HEK-TLR4) de acuerdo con las instrucciones del fabricante. Brevemente, las células HEK-TLR4 se mantuvieron en DMEM 4,5 g/l de D-glucosa suplementada con FBS inactivado por calor al 10% (v/v), L-glutamina 4 mM, 100 U/ml de penicilina, 100 pg/ml de estreptomicina, 100 pg/ml de ml de normocina, medio de selección HEK-Blue 1X.</span>FlEK293-Blue reporter cells stably expressing human TLR4 (HEK-TLR4) were cultured according to the manufacturer's instructions. Briefly, HEK-TLR4 cells were maintained in DMEM with 4.5 g/l D-glucose supplemented with 10% (v/v) heat-inactivated FBS, 4 mM L-glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 100 pg/ml normocin ml, HEK-Blue 1X selection medium.</span>
  </p>
  <p id="p0800" num="0800" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Brevemente, las células se lavaron con PBS, se disociaron en PBS y se recogieron en medios de cultivo. Las células se sembraron en placas de 96 pocillos a una densidad de 25.000 células/pocillo. Para evaluar el efecto de las cepas bacterianas sobre el LPS que induce la activación del promotor de NF-<sup class="style-scope patent-text">k</sup>B, las células se trataron con 10 ng/ml de LPS en presencia o ausencia de sobrenadantes al 10% (aislados como se ha descrito anteriormente) y se incubaron en una incubadora de CO2. Los tratamientos continuaron durante 22 h a 37° C y 5% de CO, después de lo cual se realizó la detección de la actividad de la fosfatasa alcalina embrionaria secretada (SEAP) del sobrenadante del cultivo celular usando la solución QUANTI-blue de acuerdo con las instrucciones del fabricante. Brevemente, se recogieron 20 pl de sobrenadante libre de células y se analizó la presencia de SEAP mezclándolo con 200 pl de medio de detección QUANTI-Blue filtrado estéril. Después de 2 h de incubación a 37° C, se midió la densidad óptica a 655 nm en un lector de microplacas (microplaca iMark, Bio-Rad).</span>Briefly, cells were washed with PBS, dissociated in PBS and collected in culture media. Cells were seeded in 96-well plates at a density of 25,000 cells/well. To assess the effect of bacterial strains on LPS inducing NF- <sup class="style-scope patent-text">kB</sup> promoter activation, cells were treated with 10 ng/mL LPS in the presence or absence of 10% supernatants (isolated as described above). ) and incubated in a CO2 incubator. Treatments continued for 22 h at 37°C and 5% CO, after which secreted embryonic alkaline phosphatase (SEAP) activity detection of cell culture supernatant was performed using QUANTI-blue solution according to the manufacturer's instructions. Briefly, 20 μl of cell-free supernatant was collected and tested for the presence of SEAP by mixing with 200 μl of sterile filtered QUANTI-Blue detection medium. After 2 h of incubation at 37°C, the optical density at 655 nm was measured in a microplate reader (iMark microplate, Bio-Rad).</span>
  </p>
  <p id="p0801" num="0801" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis estadístico</span>Statistic analysis</span>
  </p>
  <p id="p0802" num="0802" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media ± SEM; Se usó Anova unidireccional (prueba de comparación múltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consideró significativo en todos los casos.</span>Normally distributed data are presented as mean ± SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0803" num="0803" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0804" num="0804" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">NCIMB 42787 indujo la activación del promotor NF-KB-Ap1 por sí mismo (Figura 61C).</span>NCIMB 42787 induced activation of the NF-KB-Ap1 promoter by itself (FIG. 61C).</span>
  </p>
  <p id="p0805" num="0805" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El NF-<sup class="style-scope patent-text">k</sup>B está implicado en la activación de la respuesta inmunitaria, en particular estimulando la expresión de mediadores de la inflamación y de citoquinas implicadas en la respuesta inmunitaria, por ejemplo, la IL-6. Como se ha indicado anteriormente, un aumento en la expresión de IL-6 ayuda a estimular el sistema inmunitario y, por lo tanto, la activación de la vía de NF-<sup class="style-scope patent-text">k</sup>B tiene actividad inmunoestimuladora. Por consiguiente, en ciertas realizaciones, las composiciones de la invención activan la señalización de NF-kB y, por tanto, estimulan el sistema inmunitario. 
</span>NF- <sup class="style-scope patent-text">kB</sup> is involved in the activation of the immune response, in particular by stimulating the expression of inflammatory mediators and cytokines involved in the immune response, for example, IL-6. As noted above, an increase in IL-6 expression helps to stimulate the immune system, and thus activation of the NF- <sup class="style-scope patent-text">kB</sup> pathway has immunostimulatory activity. Accordingly, in certain embodiments, the compositions of the invention activate NF-kB signaling and thus stimulate the immune system. </span>
  </p>
  <p id="p0806" num="0806" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 25 - Las cepas de M. massiliensis producen ácido butírico, valérico y hexanoico</span>Example 25 - M. massiliensis strains produce butyric, valeric and hexanoic acid</span>
      </i>
    </b>
  </p>
  <p id="p0807" num="0807" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Materiales y Métodos</span>Materials and methods</span>
    </i>
  </p>
  <p id="p0808" num="0808" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La extracción de SCFA de YCFA+, YCFA+ enriquecidos con una mezcla estándar de SCFA (ácido acético 40 mM y ácido fórmico 20 mM, ácido propiónico, ácido butírico, ácido valérico y ácido hexanoico) se realizó de acuerdo con el método de De Baere et al.133.</span>SCFA extraction of YCFA+, YCFA+ spiked with SCFA standard mixture (40 mM acetic acid and 20 mM formic acid, propionic acid, butyric acid, valeric acid and hexanoic acid) was performed according to the method of De Baere et al. .133.</span>
  </p>
  <p id="p0809" num="0809" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis HPLC de SCFA</span>SCFA HPLC analysis</span>
  </p>
  <p id="p0810" num="0810" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La detección y cuantificación de SCFA por HPLC se realizó de acuerdo con el método de De Baere et al. 133 con ligeras modificaciones. Brevemente, el análisis HPLC se realizó usando un sistema Waters e2695 HPLC equipado con un detector Waters Photodiode Array (PDA) 2998 (Waters Limited, Elstree, Reino Unido). El análisis HPLC de los estándares de SCFA, SCFA extraídos de los extractos de MRx0005 y MRx0029 BCFS y MRx0005 y MRx0029 hexano, éter dietílico, acetato de etilo, acetonitrilo y metanol se realizaron usando una columna LC Xselect® HSS T33,5 qm 4,6 x 150 mm (Waters Limited, Elstree, Reino Unido).). El análisis LC se realizó usando el conjunto de detectores de matriz de fotodiodos (PDA) para analizar longitudes de onda de 200-800 nm. La detección y cuantificación de SCFA se realizó a 210 nm. La fase móvil consistía de tampón de fosfato de sodio 25 mM en agua HPLC (pH ajustado a 3,0 usando ácido fosfórico (A) y acetonitrilo (B). El método de LC para la detección y cuantificación de SCFA se llevó a cabo usando el sistema de solventes con el siguiente gradiente: t0'A=95%, B=5%; t10' A=95%, B=5%; t30' A=30%, B=70%; t31' A=0%, B=100%; t36' A=0%, B=100%; t38' A=5%, B=95%; t60' A=5%, B=95%; caudal=lml/min.</span>Detection and quantification of SCFA by HPLC was performed according to the method of De Baere et al. 133 with slight modifications. Briefly, HPLC analysis was performed using a Waters e2695 HPLC system equipped with a Waters Photodiode Array (PDA) 2998 detector (Waters Limited, Elstree, UK). HPLC analysis of SCFA standards, SCFA extracted from MRx0005 and MRx0029 BCFS extracts and MRx0005 and MRx0029 hexane, diethyl ether, ethyl acetate, acetonitrile and methanol were performed using an Xselect® HSS T33.5 qm 4 LC column, 6 x 150 mm (Waters Limited, Elstree, UK). LC analysis was performed using the photodiode array (PDA) detector array to analyze wavelengths of 200-800 nm. Detection and quantification of SCFA was performed at 210 nm. The mobile phase consisted of 25 mM sodium phosphate buffer in HPLC water (pH adjusted to 3.0 using phosphoric acid (A) and acetonitrile (B). The LC method for the detection and quantification of SCFA was carried out using the solvent system with the following gradient: t0'A=95%, B=5%; t10' A=95%, B=5%; t30' A=30%, B=70%; t31' A=0 %, B=100%, t36' A=0%, B=100%, t38' A=5%, B=95%, t60' A=5%, B=95%, flow rate=lml/min.</span>
  </p>
  <p id="p0811" num="0811" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se preparó una curva de calibración de siete puntos para cada SCFA inyectando 20 |ul de una dilución en serie doble de un SCFA (ácido acético 40 mM y ácido fórmico 20 mM, ácido propiónico, ácido butírico, ácido valérico y ácido hexanoico). La eficiencia de cuantificación-extracción se calculó mediante la siguiente fórmula:</span>A seven-point calibration curve was prepared for each SCFA by injecting 20 µl of a two-fold serial dilution of an SCFA (40 mM acetic acid and 20 mM formic acid, propionic acid, butyric acid, valeric acid, and hexanoic acid). The quantification-extraction efficiency was calculated using the following formula:</span>
  </p>
  <p id="p0812" num="0812" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[SCFA en YCFA+ enriquecido y extraído]/[SCFA en YCFA+ enriquecido no extraído]</span>[SCFA in YCFA+ enriched and extracted]/[SCFA in YCFA+ enriched non-extracted]</span>
  </p>
  <p id="p0813" num="0813" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se usó la eficiencia de extracción para determinar las concentraciones de SCFA individuales en cada muestra. La producción de SCFA específicos se calculó restando la cantidad de SCFA correspondiente presente en el control de medios no enriquecidos.</span>Extraction efficiency was used to determine individual SCFA concentrations in each sample. Specific SCFA production was calculated by subtracting the amount of corresponding SCFA present in the non-enriched media control.</span>
  </p>
  <p id="p0814" num="0814" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Metabolómica dirigida: metabolitos bacterianos y análisis de ácidos grasos</span>Targeted Metabolomics: Bacterial Metabolites and Fatty Acid Analysis</span>
  </p>
  <p id="p0815" num="0815" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El análisis de las muestras se realizó por MS-Omics (Copenhague, Dinamarca). Se creó una muestra agrupada mixta (muestra QC) tomando una alícuota de cada muestra. Esta muestra se analizó con intervalos regulares a lo largo de la secuencia. Se probaron los efectos de la matriz para los compuestos cuantificados enriqueciendo la muestra QC en un mínimo de dos niveles.</span>Sample analysis was performed by MS-Omics (Copenhagen, Denmark). A mixed pooled sample (QC sample) was created by taking an aliquot of each sample. This sample was analyzed at regular intervals throughout the sequence. Matrix effects for quantified compounds were tested by spiking the QC sample by a minimum of two levels.</span>
  </p>
  <p id="p0816" num="0816" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el análisis de metabolitos de GC, las muestras se derivatizaron con cloroformiato de metilo usando una versión ligeramente modificada del protocolo descrito por Smart et al.134. Todas las muestras se analizaron en un orden aleatorio. El análisis se realizó usando GC (7890B, Agilent) acoplado con un detector de cuadrupolo (59977B, Agilent). Los datos sin procesar se convirtieron al formato netCDF usando Chemstation (Agilent), antes de que los datos se importaran y procesaran en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito por Johnsen et al.135.</span>For GC metabolite analysis, samples were derivatized with methyl chloroformate using a slightly modified version of the protocol described by Smart et al.134. All samples were analyzed in a random order. Analysis was performed using GC (7890B, Agilent) coupled with a quadrupole detector (59977B, Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described by Johnsen et al.135.</span>
  </p>
  <p id="p0817" num="0817" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para el análisis SCFA, las muestras se acidificaron usando ácido clorhídrico y se añadieron estándares internos marcados con deuterio. El análisis se realizó usando una columna de alta polaridad (Columna Zebron™ ZB-FFAP, GC Cap. 30mx0,25mmx0,25qm) instalada en un GC (7890B, Agilent) acoplado a un detector de cuadrupolo (59977B, Agilent). Los datos sin procesar se convirtieron a formato netCDF usando Chemstation (Agilent), antes de que los datos se importaran y procesaran en Matlab R2014b (Mathworks, Inc.) usando el software PARADISe descrito por Johnsen et al.135.</span>For SCFA analysis, samples were acidified using hydrochloric acid and deuterium-labeled internal standards were added. Analysis was performed using a high polarity column (Zebron™ ZB-FFAP Column, GC Cap. 30mx0.25mmx0.25qm) installed on a GC (7890B, Agilent) coupled to a quadrupole detector (59977B, Agilent). Raw data was converted to netCDF format using Chemstation (Agilent), before data was imported and processed in Matlab R2014b (Mathworks, Inc.) using PARADISe software described by Johnsen et al.135.</span>
  </p>
  <p id="p0818" num="0818" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0819" num="0819" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El análisis de ácidos grasos, usando metabolómica dirigida, demostró que NCIMB 42787 produce ácido butanoico (butírico), pentanoico (valérico) y hexanoico (caproico), tanto en forma lineal como ramificada (C4-C6) (Figura 62A). Además, la proporción de ácido 4-hidroxi-fenilacético:medio aumentó en el sobrenadante libre de células NCIMB 42787. Se usó análisis HPLC de sobrenadantes libres de células para monitorizar la producción de ácido fórmico, acético, propiónico, butírico, valérico y hexanoico (en base al tiempo de retención y el espectro de absorbancia de SCFA relevantes) por NCIMB 42787. En la Figura 62C se informa de cromatogramas representativos para estándares de SCFA superpuestos a sobrenadantes libres de células NCIMB 42787 extraídos para SCFA. El análisis HPLC confirmó la producción de ácido butírico, valérico y hexanoico por NCIMB 42787. 
</span>Fatty acid analysis, using directed metabolomics, showed that NCIMB 42787 produces butanoic (butyric), pentanoic (valeric), and hexanoic (caproic) acids, both in linear and branched (C4-C6) forms (FIG. 62A). In addition, the ratio of 4-hydroxy-phenylacetic acid:medium was increased in the NCIMB 42787 cell-free supernatant. HPLC analysis of cell-free supernatants was used to monitor the production of formic, acetic, propionic, butyric, valeric, and hexanoic acid ( based on relevant SCFA retention time and absorbance spectrum) by NCIMB 42787. Representative chromatograms for SCFA standards overlaid on extracted NCIMB 42787 cell-free supernatants for SCFA are reported in Figure 62C. HPLC analysis confirmed the production of butyric, valeric and hexanoic acid per NCIMB 42787. </span>
  </p>
  <p id="p0820" num="0820" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 26 - Las fracciones metanólicas de M. massiliensis que contienen butirato y valerato muestran actividad inmunoestimuladora en células U373</span>Example 26 - M. massiliensis Methanolic Fractions Containing Butyrate and Valerate Show Immunostimulatory Activity in U373 Cells</span>
      </i>
    </b>
  </p>
  <p id="p0821" num="0821" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para investigar la función de los SCFA en la reducción de la secreción de IL-8, se trataron células U373 con concentraciones crecientes de butirato de sodio (SB), valerato de sodio (SV) y ácido hexanoico (HA).</span>To investigate the role of SCFAs in reducing IL-8 secretion, U373 cells were treated with increasing concentrations of sodium butyrate (SB), sodium valerate (SV), and hexanoic acid (HA).</span>
  </p>
  <p id="p0822" num="0822" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos</span>Methods</span>
    </i>
  </p>
  <p id="p0823" num="0823" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células U373 se prepararon como se ha descrito anteriormente. Las células se pretrataron durante 1 h con 1 gg/ml de LPS indicado anteriormente y se incubaron a 37° C y CO2 al 5%. Después de una preincubación de 1 h, las células se retiraron de la incubadora con CO2 y se trataron con una concentración creciente de butirato de sodio (SB), valerato de sodio (SV) y ácido hexanoico (HA) recién preparados.</span>U373 cells were prepared as described above. Cells were pretreated for 1 h with 1 gg/ml LPS indicated above and incubated at 37°C and 5% CO2. After a 1 h preincubation, cells were removed from the CO 2 incubator and treated with increasing concentrations of freshly prepared sodium butyrate (SB), sodium valerate (SV), and hexanoic acid (HA).</span>
  </p>
  <p id="p0824" num="0824" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis estadístico</span>Statistic analysis</span>
  </p>
  <p id="p0825" num="0825" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media ± SEM; Se usó Anova unidireccional (prueba de comparación múltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consideró significativo en todos los casos.</span>Normally distributed data are presented as mean ± SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0826" num="0826" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados y conclusiones</span>Results and conclusions</span>
    </i>
  </p>
  <p id="p0827" num="0827" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las concentraciones probadas cubrieron el intervalo de concentraciones medidas en los sobrenadantes libres de células para los diferentes ácidos grasos y tuvieron en cuenta el hecho de que solo se usó el 10% de los sobrenadantes mencionados anteriormente en los ensayos basados en células. Tanto SB como SV aumentaron la secreción de IL-8 inducida por LPS en las mismas células (Figura 63), lo que sugiere que la presencia de ambos SCFA probablemente contribuyó a la inducción de IL-8 cuando se añade NCIMB 42787 al cultivo. HA no inhibía la secreción de IL-8 después del desafío con LPS. Ninguno de los SFCA probados indujo per se la secreción de IL-8 por encima del nivel de referencia (control de células sin tratar). La mezcla reconstituida de los tres SCFA reprodujo la actividad biológica del sobrenadante libre de células NCIMB 42787, tanto en presencia como en ausencia de LPS.</span>The concentrations tested covered the range of concentrations measured in the cell-free supernatants for the different fatty acids and took into account the fact that only 10% of the aforementioned supernatants were used in the cell-based assays. Both SB and SV increased LPS-induced IL-8 secretion in the same cells (FIG. 63), suggesting that the presence of both SCFAs likely contributed to IL-8 induction when NCIMB 42787 is added to culture. HA did not inhibit IL-8 secretion after LPS challenge. None of the SFCAs tested per se induced IL-8 secretion above the baseline level (untreated cell control). The reconstituted mixture of the three SCFAs reproduced the biological activity of the NCIMB 42787 cell-free supernatant, both in the presence and absence of LPS.</span>
  </p>
  <p id="p0828" num="0828" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, en ciertas realizaciones, el ácido butírico y/o valérico están implicados en la generación de IL-8 y, por lo tanto, son importantes para estimular el sistema inmunitario, por ejemplo mediante la proliferación de células B. Por lo tanto, en ciertas realizaciones, las cepas bacterianas de la invención estimulan el sistema inmunitario a través de la producción de ácido butírico y/o valérico.</span>Accordingly, in certain embodiments, butyric and/or valeric acid are involved in the generation of IL-8 and thus are important in stimulating the immune system, for example, by proliferation of B cells. Therefore, In certain embodiments, the bacterial strains of the invention stimulate the immune system through the production of butyric and/or valeric acid.</span>
  </p>
  <p id="p0829" num="0829" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 27 - Los SCFA generados por NCIMB 42787 son por lo menos parcialmente responsables de la actividad inmunoestimuladora</span>Example 27 - SCFAs generated by NCIMB 42787 are at least partially responsible for immunostimulatory activity</span>
      </i>
    </b>
  </p>
  <p id="p0830" num="0830" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Introducción</span>Introduction</span>
    </i>
  </p>
  <p id="p0831" num="0831" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Para confirmar aún más si la actividad de NCIMB 42787 se debía por lo menos en parte a los SCFA, se fraccionó el sobrenadante bacteriano libre de células con diferentes solventes de polaridad creciente. Se realizó un análisis HPLC de los extractos brutos desproteinizados (hexano, F5; éter dietílico, F4; acetato de etilo, F3; acetonitrilo, F4; metanol, F1) de los sobrenadantes de esta cepa para analizar la complejidad bioquímica de los sobrenadantes de fase estacionaria libres de células de NCIMB 42787, así como para subfraccionar compuestos en base a la polaridad y la solubilidad.</span>To further confirm whether the activity of NCIMB 42787 was at least in part due to SCFAs, cell-free bacterial supernatant was fractionated with different solvents of increasing polarity. HPLC analysis of the crude deproteinized extracts (hexane, F5; diethyl ether, F4; ethyl acetate, F3; acetonitrile, F4; methanol, F1) of the supernatants of this strain was performed to analyze the biochemical complexity of phase supernatants. cell-free stationary enzyme of NCIMB 42787, as well as to subfractionate compounds based on polarity and solubility.</span>
  </p>
  <p id="p0832" num="0832" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Métodos</span>Methods</span>
    </i>
  </p>
  <p id="p0833" num="0833" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Extracciones secuenciales con solventes - preparación de extractos brutos</span>Sequential solvent extractions - preparation of crude extracts</span>
    </i>
  </p>
  <p id="p0834" num="0834" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se extrajeron tres réplicas biológicas de BCFS de la cepa NCIMB 42787 y YCFA+ (control de medio) secuencialmente con hexano de grado HPLC (HEX), éter dietílico (DE), acetato de etilo (EtOAc), acetonitrilo (ACN) y metanol (MeOFl). Brevemente, se colocaron 20 ml de BCFS en viales de vidrio y se extrajeron a temperatura ambiente (TA) en 20 ml de HEX en un agitador rotatorio (70 rpm) durante 30 min. Se realizaron un total de tres extracciones en cada BCFS y control de medio YCFA+. Luego, las capas acuosas restantes se extrajeron a TA en 20 ml de DE, EtOAc en un agitador rotatorio MX-RD-Pro (70 rpm) durante 30 min un total de tres veces. Los extractos combinados de cada muestra se secaron a presión reducida en un evaporador rotatorio R-300 equipado con una bomba de vacío V-300 (Büchi, Flawil, Suiza) a una temperatura que no excedía los 30° C. Los extractos resultantes se volvieron a solubilizar en 2 ml del solvente correspondiente y se dividieron en alícuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno correspondiente a 5 ml de muestra original). Luego, las capas acuosas restantes se extrajeron a TA en 20 ml de DE, EtOAc en un agitador rotatorio MX-RD-Pro (70 rpm) durante 30 min un total de tres veces. Los extractos combinados de cada muestra se secaron a presión reducida en un evaporador rotatorio R-300 equipado con una bomba de vacío V-300 (Büchi, Flawil, Suiza) a una temperatura que no excedía los 
30° C. Los extractos resultantes se volvieron a solubilizar en 2 ml del solvente correspondiente y se dividieron en alícuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno correspondiente a 5 ml de muestra original).</span>Three biological replicates of BCFS from strain NCIMB 42787 and YCFA+ (medium control) were extracted sequentially with HPLC-grade hexane (HEX), diethyl ether (DE), ethyl acetate (EtOAc), acetonitrile (ACN), and methanol (MeOFl). ). Briefly, 20 ml BCFS was placed in glass vials and extracted at room temperature (RT) into 20 ml HEX on a rotary shaker (70 rpm) for 30 min. A total of three extractions were performed on each BCFS and YCFA+ medium control. The remaining aqueous layers were then extracted at RT into 20 mL DE, EtOAc on MX-RD-Pro rotary shaker (70 rpm) for 30 min for a total of three times. The combined extracts of each sample were dried under reduced pressure in an R-300 rotary evaporator equipped with a V-300 vacuum pump (Büchi, Flawil, Switzerland) at a temperature not exceeding 30°C. The resulting extracts were turned to be solubilized in 2 ml of the corresponding solvent and divided into aliquots in four 1.5 ml Eppendorf tubes (500 ml each corresponding to 5 ml of original sample). The remaining aqueous layers were then extracted at RT into 20 mL DE, EtOAc on MX-RD-Pro rotary shaker (70 rpm) for 30 min for a total of three times. The combined extracts of each sample were dried under reduced pressure in an R-300 rotary evaporator equipped with a V-300 vacuum pump (Büchi, Flawil, Switzerland) at a temperature not exceeding  30°C. The resulting extracts were resolubilized in 2 ml of the corresponding solvent and aliquoted into four 1.5 ml Eppendorf tubes (500 ml each corresponding to 5 ml of original sample).</span>
  </p>
  <p id="p0835" num="0835" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las capas acuosas restantes se evaporaron hasta la sequedad usando un evaporador rotatorio R-300. Los extractos secos resultantes se extrajeron durante 30 min en 20 ml de ACN un total de tres veces. Los extractos de ACN se combinaron, se evaporaron hasta la sequedad usando un evaporador rotatorio, se volvieron a solubilizar en 2 ml de ACN y se dividieron en alícuotas en cuatro tubos Eppendorf de 1,5 ml (500 pl cada uno). Los extractos secos restantes (porción insoluble en ACN de los extractos) se extrajeron luego durante 30 min en 20 ml de MeOH un total de tres veces. Los extractos de MeOH se combinaron, se evaporaron hasta la sequedad usando un evaporador rotatorio R-300, se volvieron a solubilizar en 2 ml de MeOH y se dividieron en alícuotas en cuatro tubos Eppendorf de 1,5 ml (500 ml cada uno).</span>The remaining aqueous layers were evaporated to dryness using an R-300 rotary evaporator. The resulting dry extracts were extracted for 30 min into 20 ml ACN a total of three times. The ACN extracts were combined, evaporated to dryness using a rotary evaporator, resolubilized in 2 ml ACN and aliquoted into four 1.5 ml Eppendorf tubes (500 μl each). The remaining dry extracts (ACN-insoluble portion of the extracts) were then extracted for 30 min into 20 mL MeOH a total of three times. The MeOH extracts were combined, evaporated to dryness using an R-300 rotary evaporator, resolubilized in 2 mL MeOH, and aliquoted into four 1.5 mL Eppendorf tubes (500 mL each).</span>
  </p>
  <p id="p0836" num="0836" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se mantuvieron alícuotas de los extractos brutos durante la noche a -20° C induciendo la precipitación de los componentes proteicos. Después de la precipitación durante la noche, cada alícuota se centrifugó a 10.000 xg durante 6 min y se transfirió a un tubo nuevo de 2 ml. La precipitación durante la noche se repitió tres veces, después de lo cual los extractos se secaron en un RVC 2-18 CDPlus speedvac (Christ, Osterode am Harz, Alemania) y se pesaron. Todas las alícuotas secas de cada extracto se almacenaron a -80° C hasta su uso posterior. Tratamiento</span>Aliquots of crude extracts were kept overnight at -20°C inducing precipitation of protein components. After overnight precipitation, each aliquot was centrifuged at 10,000 xg for 6 min and transferred to a fresh 2 ml tube. The overnight precipitation was repeated three times, after which the extracts were dried on a RVC 2-18 CDPlus speedvac (Christ, Osterode am Harz, Germany) and weighed. All dry aliquots of each extract were stored at -80°C until further use. Treatment</span>
  </p>
  <p id="p0837" num="0837" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las células U373 se prepararon como se ha descrito anteriormente. Las células se pretrataron durante 1 h con 1 pg/ml de LPS como se ha indicado anteriormente. Posteriormente, las células se retiraron de la incubadora de CO2 y se trataron con 100 ml de las diferentes fracciones. Las fracciones de los medios se usaron como controles. Los sobrenadantes libres de células se recogieron 24 horas después del tratamiento y se analizaron mediante ELISA para determinar la secreción de IL-8 (como se ha descrito anteriormente).</span>U373 cells were prepared as described above. Cells were pretreated for 1 h with 1 pg/ml LPS as above. Subsequently, the cells were removed from the CO2 incubator and treated with 100 ml of the different fractions. Media fractions were used as controls. Cell-free supernatants were collected 24 hours after treatment and analyzed by ELISA for IL-8 secretion (as described above).</span>
  </p>
  <p id="p0838" num="0838" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Análisis estadístico</span>Statistic analysis</span>
  </p>
  <p id="p0839" num="0839" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Los datos normalmente distribuidos se presentan como media ± SEM; Se usó Anova unidireccional (prueba de comparación múltiple de Sidak) para analizar los datos presentados en la presente. Un valor de p&lt;0,05 se consideró significativo en todos los casos.</span>Normally distributed data are presented as mean ± SEM; One-way Anova (Sidak multiple comparison test) was used to analyze the data presented here. A value of p&lt;0.05 was considered significant in all cases.</span>
  </p>
  <p id="p0840" num="0840" class="style-scope patent-text">
    <i class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Resultados</span>Results</span>
    </i>
  </p>
  <p id="p0841" num="0841" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">El análisis por HPLC confirmó la extracción selectiva y el fraccionamiento bruto de los compuestos presentes en los sobrenadantes desproteinizados. El NCIMB 42787 no fraccionado indujo la secreción de IL-8 en células U373 tanto en presencia como en ausencia de LPS, y la misma actividad fue producida por la fracción metanólica F1, reiterando por tanto la importante función de los ácidos butírico y valérico en la producción de IL-8 por estos tipos de células (Figura 64A y B).</span>HPLC analysis confirmed the selective extraction and crude fractionation of compounds present in the deproteinized supernatants. Unfractionated NCIMB 42787 induced IL-8 secretion in U373 cells both in the presence and absence of LPS, and the same activity was produced by the F1 methanolic moiety, thus reiterating the important role of butyric and valeric acids in the IL-8 production by these cell types (FIG. 64A and B).</span>
  </p>
  <p id="p0842" num="0842" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por lo tanto, como se ha descrito anteriormente, en ciertas realizaciones, la producción de ácido butírico y/o valérico estimuló el sistema inmunitario. Por consiguiente, en ciertas realizaciones, las cepas bacterianas de la invención estimulan el sistema inmunitario a través de la producción de ácido butírico y/o valérico.</span>Therefore, as described above, in certain embodiments, the production of butyric and/or valeric acid stimulated the immune system. Accordingly, in certain embodiments, the bacterial strains of the invention stimulate the immune system through the production of butyric and/or valeric acid.</span>
  </p>
  <p id="p0843" num="0843" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejemplo 28 - La cepa de referencia de Megasphaera NCIMB 43387 reduce significativamente la expresión de ARNm de IDO-1 colónico en ratones BALB/c</span>Example 28 - Megasphaera Reference Strain NCIMB 43387 Significantly Reduces Colonic IDO-1 mRNA Expression in BALB/c Mice</span>
      </i>
    </b>
  </p>
  <p id="p0844" num="0844" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 65 demuestra que NCIMB 43387 provoca una reducción significativa (cuantificada por qPCR normalizada a p-actina) en la expresión de ARNm de IDO-1 en el colon de ratones BALB/c en comparación con el control del vehículo.</span>Figure 65 demonstrates that NCIMB 43387 causes a significant reduction (measured by qPCR normalized to p-actin) in IDO-1 mRNA expression in the colon of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0845" num="0845" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se ha implicado a IDO-1 en la promoción de la inmunosupresión en respuesta a la inflamación o infección. Por consiguiente, impulsar una disminución en la expresión de IDO-1 está asociada con la inmunoestimulación. Además, las reducciones en IDO-1 reducen la capacidad proliferativa y migratoria de las células cancerosas y mejoran la vigilancia inmunitaria contra los tumores. Por lo tanto, en ciertas realizaciones, las cepas bacterianas de la invención sirven para reducir la expresión de IDO-1. En ciertas realizaciones, la inmunoestimulación está asociada con la reducción de la expresión de IDO-1. Además, en ciertas realizaciones, las composiciones de la presente invención previenen el crecimiento del cáncer metastásico. En ciertas realizaciones, las composiciones de la presente invención son eficaces para tratar y prevenir el cáncer, en particular, el melanoma metastásico, cáncer de pulmón de células pequeñas y carcinoma de pulmón adenoescamoso a la luz de su actividad contra la metástasis <b class="style-scope patent-text"> <i class="style-scope patent-text">Ejemplo 29 - Las cepas de Megasphaera depositadas con los números de registro NCIMB 43385 y NCIMB 43387 reducen la expresión del ARNm de Tph-1 colónico en ratones BALB/c</i> </b> </span>IDO-1 has been implicated in promoting immunosuppression in response to inflammation or infection. Therefore, driving a decrease in IDO-1 expression is associated with immunostimulation. In addition, reductions in IDO-1 reduce the proliferative and migratory capacity of cancer cells and improve immune surveillance against tumors. Therefore, in certain embodiments, the bacterial strains of the invention serve to reduce the expression of IDO-1. In certain embodiments, the immunostimulation is associated with the reduction of IDO-1 expression. Furthermore, in certain embodiments, the compositions of the present invention prevent the growth of metastatic cancer. In certain embodiments, the compositions of the present invention are effective in treating and preventing cancer, in particular, metastatic melanoma, small cell lung cancer, and adenosquamous lung carcinoma in light of their anti-metastatic activity. <b class="style-scope patent-text"> <i class="style-scope patent-text">Example 29 - The Megasphaera strains deposited under accession numbers NCIMB 43385 and NCIMB 43387 reduce colonic Tph-1 mRNA expression in BALB/c mice</i> </b> </span>
  </p>
  <p id="p0846" num="0846" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones BALB/c se les administró bioterapéutico vivo y los tejidos se aislaron para el análisis de la 
expresión génica usando qPCR.</span>BALB/c mice were administered live biotherapeutic and tissues were isolated for analysis of the  gene expression using qPCR.</span>
  </p>
  <p id="p0847" num="0847" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 66 demuestra la capacidad de las composiciones de la invención para reducir la expresión de ARNm de Tph-1 (usando la cuantificación por qPCR normalizada a p-actina) en comparación con el control del vehículo.</span>Figure 66 demonstrates the ability of compositions of the invention to reduce Tph-1 mRNA expression (using qPCR quantification normalized to p-actin) compared to vehicle control.</span>
  </p>
  <p id="p0848" num="0848" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Se sabe que las disminuciones en Tph-1 están asociadas con una mayor resistencia al cáncer y un crecimiento reducido de células cancerosas. Además, una disminución en la actividad de Tph-1 estimula el sistema inmunitario proporcionando niveles suficientes del aminoácido esencial triptófano para que los mastocitos impulsen la inmunidad antitumoral. Por consiguiente, en ciertas realizaciones, las composiciones de la invención disminuyen los niveles de expresión de Tph-1. En ciertas realizaciones, las composiciones de la invención desencadenan la inmunoestimulación y tratan y/o previenen las enfermedades divulgadas en el presente reduciendo los niveles de Tph-1.</span>Decreases in Tph-1 are known to be associated with increased cancer resistance and reduced cancer cell growth. Additionally, a decrease in Tph-1 activity stimulates the immune system by providing sufficient levels of the essential amino acid tryptophan for mast cells to boost antitumor immunity. Accordingly, in certain embodiments, the compositions of the invention decrease the expression levels of Tph-1. In certain embodiments, the compositions of the invention trigger immunostimulation and treat and/or prevent the diseases disclosed herein by reducing Tph-1 levels.</span>
  </p>
  <p id="p0850" num="0850" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejem plo 30 - La cepa M egasphaera depositada con e l núm ero de registro N C IM B 43385 aum enta la producción de IF N <sup class="style-scope patent-text">y </sup>e IL -6 tras la estim ulación con ConA de esplenocitos de ratones BALB/c</span>Example 30 - Strain M egasphaera deposited under NC registry number IM B 43385 increases IFNγ <sup class="style-scope patent-text">and</sup> IL-6 production after ConA stimulation of splenocytes from BALB/c mice</span>
      </i>
    </b>
  </p>
  <p id="p0851" num="0851" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Las cepas bioterapéuticas vivas se seleccionaron ex vivo en cuanto a la eficacia de la producción de marcadores inmunitarios en esplenocitos aislados de ratones BALB/c y estimulados con ConA.</span>Live biotherapeutic strains were screened ex vivo for the efficacy of production of immune markers in splenocytes isolated from BALB/c and ConA-stimulated mice.</span>
  </p>
  <p id="p0852" num="0852" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 67 muestra la capacidad de las composiciones de la invención para aumentar significativamente la producción de las citoquinas proinflamatorias IFNy e IL-6. Como se ha descrito anteriormente, ambas citoquinas están implicadas en la estimulación de la respuesta inmunitaria. Además, IFNy tiene actividad tumoricida significativa.</span>Figure 67 shows the ability of the compositions of the invention to significantly increase the production of the proinflammatory cytokines IFNγ and IL-6. As described above, both cytokines are involved in the stimulation of the immune response. In addition, IFNγ has significant tumoricidal activity.</span>
  </p>
  <p id="p0853" num="0853" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, como se ha descrito anteriormente, en ciertas realizaciones, las composiciones de la invención aumentan la producción de y/o IL-6 y, por lo tanto, impulsan la estimulación de la respuesta inmunitaria. Por consiguiente, en ciertas realizaciones, el beneficio terapéutico de las composiciones de la presente invención está relacionado con un aumento en la producción de IFNy y/o IL-6.</span>Accordingly, as described above, in certain embodiments, the compositions of the invention increase the production of and/or IL-6 and thereby drive the stimulation of the immune response. Accordingly, in certain embodiments, the therapeutic benefit of the compositions of the present invention is related to an increase in IFN[gamma] and/or IL-6 production.</span>
  </p>
  <p id="p0855" num="0855" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Ejem plo 30 - La cepa de referencia de M egasphaera depositada con e l núm ero de registro N C IM B 43385 aum enta s ignificativam ente la expresión de IL -6 y CD11b</span>Example 30 - Reference strain of Megasphaera deposited under registry number NCIM B 43385 significantly increases the expression of IL-6 and CD11b</span>
      </i>
    </b>
  </p>
  <p id="p0856" num="0856" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones B ALB/c se les administró bioterapéutico vivo y los tejidos se aislaron para el análisis de la expresión génica usando qPCR.</span>B ALB/c mice were administered live biotherapeutic and tissues were isolated for gene expression analysis using qPCR.</span>
  </p>
  <p id="p0857" num="0857" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 68 demuestra la capacidad de NCIMB 43385 para aumentar significativamente la expresión de IL-6 y CD11b en el hipocampo de ratones BALB/c en comparación con el control del vehículo.</span>Figure 68 demonstrates the ability of NCIMB 43385 to significantly increase IL-6 and CD11b expression in the hippocampus of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0858" num="0858" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Por consiguiente, como se ha descrito anteriormente, las composiciones de la presente invención, en ciertas realizaciones, aumentan la expresión de citoquinas proinflamatorias implicadas en la estimulación de la respuesta inmunitaria, en particular IL-6 y CD11b. En ciertas realizaciones, las composiciones de la invención son terapéuticamente eficaces a la luz del aumento en la expresión de IL-6 y CD11b.</span>Accordingly, as described above, the compositions of the present invention, in certain embodiments, increase the expression of proinflammatory cytokines involved in the stimulation of the immune response, in particular IL-6 and CD11b. In certain embodiments, the compositions of the invention are therapeutically effective in light of increased expression of IL-6 and CD11b.</span>
  </p>
  <p id="p0860" num="0860" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <i class="style-scope patent-text">
        <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">E jem plo 31 - N C IM B 42787 aum enta la expresión de TLR4</span>Example 31 - N CIM B 42787 increases the expression of TLR4</span>
      </i>
    </b>
  </p>
  <p id="p0861" num="0861" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">A los ratones BALB/c se les administró bioterapéutico vivo y los tejidos se aislaron para el análisis de la expresión génica usando qPCR.</span>BALB/c mice were administered live biotherapeutic and tissues were isolated for gene expression analysis using qPCR.</span>
  </p>
  <p id="p0862" num="0862" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">La Figura 69 demuestra la capacidad de NCIMB 42787 para aumentar significativamente la expresión de TLR4 en la amígdala de ratones BALB/c en comparación con el control del vehículo.</span>Figure 69 demonstrates the ability of NCIMB 42787 to significantly increase TLR4 expression in the amygdala of BALB/c mice compared to vehicle control.</span>
  </p>
  <p id="p0863" num="0863" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TLR4 está asociado con la activación de la respuesta inmunitaria. Por consiguiente, aumentar la expresión de TLR4 mejorará la inmunoestimulación. En ciertas realizaciones, las composiciones de la invención aumentan la expresión de TLR4. En ciertas realizaciones, el aumento de la expresión de TLR4 aumenta la respuesta inmunitaria. En ciertas realizaciones, las composiciones de la presente invención aumentan la respuesta inmunitaria y tienen un efecto terapéutico en el tratamiento de las enfermedades divulgadas en la presente a través del aumento de la expresión de TLR4.</span>TLR4 is associated with the activation of the immune response. Therefore, increasing the expression of TLR4 will improve immunostimulation. In certain embodiments, the compositions of the invention increase the expression of TLR4. In certain embodiments, increased expression of TLR4 enhances the immune response. In certain embodiments, the compositions of the present invention enhance the immune response and have a therapeutic effect in the treatment of the diseases disclosed herein through increased expression of TLR4.</span>
  </p>
  <p id="p0864" num="0864" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Secuencias</span>sequences</span>
    </b>
  </p>
  <p id="p0865" num="0865" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 1 (secuencia de ARNr 16S de consenso para la cepa MRx0029 de <i class="style-scope patent-text">Megasphaera massiliensis) </i>
TGAGAAGCTTGCTTCTTATCGATTCTAGTGGCAAACGGGTGAGTAACGCGTAAGCAACC TGCCCTTCAGATGGGGACAACAGCTGGAAACGGCTGCTAATACCGAATACGTTCTTTCC GCCGCATGACGGGAAGAAGAAAGGGAGGCCTTCGGGCTTTCGCTGGAGGAGGGGCTTG CGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGTC TGAGAGGATGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA GCAGTGGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAACGA T GAC GGC C TTCGGGTT GT A AAGTTCTGTT AT AT GGGAC GA AC AGGAC AT C GGTT AAT AC CCGGTGTCTTTGACGGTACCGTAAGAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGC GGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCGCGCAGGC GGCATCGCAAGTCGGTCTTAAAAGTGCGGGGCTTAACCCCGTGAGGGGACCGAAACTGT GA AGCTC GAGT GT C GGAGAGGA AAGC GG A ATT C CT AGT GT AGC GGT GA AAT GC GT AGA TATTAGGAGGAACACCAGTGGCGAAAGCGGCTTTCTGGACGACAACTGACGCTGAGGC GCGAAAGCCAGGGGAGCAAACGGGATTAGATACCCCGGTAGTCCTGGCCGTAAACGAT GGATACTAGGTGTAGGAGGTATCGACTCCTTCTGTGCCGGAGTTAACGCAATAAGTATC CCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGTATGTGGTTTAATTCGACGCAACGCGAAGAACCTTACCAAGCCTTGAC ATTGATTGCTACGGAAAGAGATTTCCGGTTCTTCTTCGGAAGACAAGAAAACAGGTGGT GCACGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA CCCCTATCTTCTGTTGCCAGCACCTCGGGTGGGGACTCAGAAGAGACTGCCGCAGACAA TGCGGAGGAAGGCGGGGATGACGTCAAGTCATCATGCCCCTTATGGCTTGGGCTACACA CGTACTACAATGGCTCTTAATAGAGGGAAGCGAAGGAGCGATCCGGAGCAAACCCCAA AAACAGAGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCAGGAATCGCT AGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCACGAAAGTCATTCACACCCGAAGCCGGTGAGGCAACCGCAAG</span>SEQ ID NO: 1 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera massiliensis strain MRx0029)</i>  TGAGAAGCTTGCTTCTTATCGATTCTAGTGGCAAACGGGTGAGTAACGCGTAAGCAACC TGCCCTTCAGATGGGGACAACAGCTGGAAACGGCTGCTAATACCGAATACGTTCTTTCC GCCGCATGACGGGAAGAAGAAAGGGAGGCCTTCGGGCTTTCGCTGGAGGAGGGGCTTG CGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGTC TGAGAGGATGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCA GCAGTGGGGAATCTTCCGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAACGA T GAC GGC C TTCGGGTT GT A AAGTTCTGTT AT AT GGGAC GA AC AGGAC AT C GGTT AAT AC CCGGTGTCTTTGACGGTACCGTAAGAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGC GGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCGCGCAGGC GGCATCGCAAGTCGGTCTTAAAAGTGCGGGGCTTAACCCCGTGAGGGGACCGAAACTGT GA AGCTC GAGT GT C GGAGAGGA AAGC GG A ATT C CT AGT GT AGC GGT GA AAT GC GT AGA TATTAGGAGGAACACCAGTGGCGAAAGCGGCTTTCTGGACGACAACTGACGCTGAGGC GCGAAAGCCAGGGGAGCAAACGGGATTAGATACCCCGGTAGTCCTGGCCGTAAACGAT GGATACTAGGTGTAGGAGGTATCGACTCCTTCTGTGCCGGAGTTAACGCAATAAGTATC CCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGTATGTGGTTTAATTCGACGCAACGCGAAGAACCTTACCAAGCCTTGAC ATTGATTGCT ACGGAAAGAGATTTCCGGTTCTTCTTCGGAAGACAAGAAAACAGGTGGT GCACGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAA CCCCTATCTTCTGTTGCCAGCACCTCGGGTGGGGACTCAGAAGAGACTGCCGCAGACAA TGCGGAGGAAGGCGGGGATGACGTCAAGTCATCATGCCCCTTATGGCTTGGGCTACACA CGTACTACAATGGCTCTTAATAGAGGGAAGCGAAGGAGCGATCCGGAGCAAACCCCAA AAACAGAGTCCCAGTTCGGATTGCAGGCTGCAACTCGCCTGCATGAAGCAGGAATCGCT AGTAATCGCAGGTCAGCATACTGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCACGAAAGTCATTCACACCCGAAGCCGGTGAGGCAACCGCAAG</span>
  </p>
  <p id="p0866" num="0866" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cebadores usados para qPCR</span>Primers used for qPCR</span>
  </p>
  <p id="p0868" num="0868" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000066_0001" he="104" wi="1954" file="imgf000066_0001.tif" img-format="tif" width="7816" height="416" alt="Figure imgf000066_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000066_0001" he="104" wi="1954" file="imgf000066_0001.tif" img-format="tif" width="7816" height="416" alt="Figure imgf000066_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/c3/c9/69/b121d1365133f7/imgf000066_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0870" num="0870" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 8 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB43385) </span>SEQ ID NO: 8 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB43385)</span>
  </p>
  <p id="p0871" num="0871" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC 
TGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC C T GTTTT C TTGTCTTC C G A A G A A G A A C C GG A A A TC TC TTTC C GT A GC A AT C A A TGT CA A G GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG TTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCA GCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTT TGCCACTCGAATTGATAAGAAGCAAGCTTCTCATC </span>GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC  TGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CT GTTTT C TTGTCTTC CGAAGAAGAACC GG AAA TC TC TTTC C GT A GC A AT CAA TGT CA AG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG TTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCT CCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCA GCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTT TGCCACTCGAATTGATAAGAAGCAAGCTTCTCATC</span>
  </p>
  <p id="p0872" num="0872" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">SEQ ID NO: 9 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB43388) GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC TGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTCAAG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG 
TTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGTCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCAG CCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTTT GCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCT SEQ ID NO: 10 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera massilliensis </i>depositada con el número de registro NCIMB43389) CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGT TGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCA CCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGT CAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTG CGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATAC TTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTT TACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGC GTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATT TCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTC CCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCT TTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCAC GTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGCC CTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTT GCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCT GGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGC CTTGGTGGGCCGTTACCCCTCCAACCAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAA AGCCCGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTA GCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCC GTTTGCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCTCGTTCGACTTGCAT SEQ ID NO: 11 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB43386) 
</span>SEQ ID NO: 9 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera</i> depositada con el número de registro NCIMB43388) GGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGTGACG GGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATTACTA GCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTGTTTTT GGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACGTGTG TAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCATTGTC TGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGTTGCG CTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCACCAC CTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTCAAG GCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGCGGG CCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACTTAT TGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTTACG GCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCGTCA GTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTTCAC CGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCCCCT CACGGGGTTAAGCCCCGCACTTTT AAGACCGACTTGCGATGCCGCCTGCGCGCCCTTTAC GCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAG  TTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGTCCTGT TCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTGCTC CGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGC CGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCCTTG GTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAAGCC CGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAGCAG CCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCGTTT GCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCT SEQ ID NO: 10 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera massilliensis</i> depositada con el número de registro NCIMB43389) CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCGAGGTGCTGGCAACAGAAGATAGGGGT TGCGCTCGTTGCGGGACTTAACCCAACAT CTCACGACACGAGCTGACGACAGCCGTGCA CCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGT CAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTG CGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATAC TTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTT TACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGC GTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATT TCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTC CCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCT TTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCAC GTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAAAGACACCGGGTATTAACCGATGCC CTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTT GCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCT GGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGC CTTGGTGGGCCGTTACCCCTCCAACCAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAA AGCCCGAAGGCCTCCCTTTCTTCTTCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTA GCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTC ACCC GTTTGCCACTAGAATCGATAAGAAGCAAGCTTCTCATGTCTTCTCGTTCGACTTGCAT SEQ ID NO: 11 (consensus 16S rRNA sequence for <i class="style-scope patent-text">Megasphaera</i> strain deposited under accession number NCIMB43386) </span>
  </p>
  <p id="p0873" num="0873" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTT GCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCAC CACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTC AAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGC GGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACT TATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTT ACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCG TCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTT CACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCC CCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTT TACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACG TAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTATCC TGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTG CTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTG GGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCC TTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAA GCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAG CAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCG TTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTGCA SEQ ID NO: 12 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera </i>depositada con el número de registro NCIMB43387) TCGAACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGT GTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGA TTACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCT GTTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTAC GTGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGC ATTGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGG GTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTG CACCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAAT GTCAAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTG TGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGAT ACTTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCG 
TTTACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCA </span>CGACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGTGT GACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGATT ACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCTG TTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTACG TGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGCAT TGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGGGTT GCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCGTGCAC CACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAATGTC AAGGCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAACCACATACTCCACCGCTTGTGC GGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGATACT TATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCGTTT ACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCAGCG TCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCATTT CACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGGTCC CCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCCCTT TACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACG TAGTTAGCCGTGGCTTTCTCTTACGGT ACCGTCAGGGATAACGGGTATTGACCGCTATCC TGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGTTG CTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTCTG GGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCGCC TTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGAAA GCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATTAG CAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACCCG TTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTGCA SEQ ID NO: 12 (secuencia de ARNr 16S de consenso para la cepa de <i class="style-scope patent-text">Megasphaera</i> depositada con el número de registro NCIMB43387) TCGAACGGCTGGTTCCTTGCGGTTGCCTCACCGGCTTCGGGTGTGAATGACTTTCGTGGT GTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGTATGCTGACCTGCGA TTACTAGCGATTCCTGCTTCATGCAGGCGAGTTGCAGCCTGCAATCCGAACTGGGACTCT GTTTTTGGGGTTTGCTCCGGATCGCTCCTTCGCTTCCCTCTATTAAGAGCCATTGTAGTAC GTGTGTAGCCCAAGCCATAAGGGGCATGATGACTTGACGTCATCCCCGCCTTCCTCCGC ATTGTCTGCGGCAGTCTCTTCTGAGTCCCCACCCTTAGTGCTGGCAACAGAAGATAGGG GTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGC CGTG CACCACCTGTTTTCTTGTCTTCCGAAGAAGAACCGGAAATCTCTTTCCGTAGCAATCAAT GTCAAGGCTTGGTAAGGTTCTTCGTTGCGTCGAATTAAACCACATACTCCACCGCTTG TGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGGAAT ACTTATTGCGTTAACTCCGGCACAGAAGGAGTCGATACCTCCTACACCTAGTATCCATCG  TTTACGGCCAGGACTACCGGGGTATCTAATCCCGTTTGCTCCCCTGGCTTTCGCGCCTCA</span>
  </p>
  <p id="p0874" num="0874" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">GCGTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCA </span>GGCGTCAGTTGTCGTCCAGAAAGCCGCTTTCGCCACTGGTGTTCCTCCTAATATCTACGCA</span>
  </p>
  <p id="p0875" num="0875" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TTTCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGG </span>TTTCACCGCTACACTAGGAATTCCGCTTTCCTCTCCGACACTCGAGCTTCACAGTTTCGG</span>
  </p>
  <p id="p0876" num="0876" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TCCCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCC </span>TCCCCTCACGGGGTTAAGCCCCGCACTTTTAAGACCGACTTGCGATGCCGCCTGCGCGCC</span>
  </p>
  <p id="p0877" num="0877" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CTTTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCA </span>CTTTAGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGCGTGCTGGCA</span>
  </p>
  <p id="p0878" num="0878" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTAT </span>CGTAGTTAGCCGTGGCTTTCTCTTACGGTACCGTCAGGGATAACGGGTATTGACCGCTAT</span>
  </p>
  <p id="p0879" num="0879" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CCTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGT </span>CCTGTTCGTCCCATATAACAGAACTTTACAACCCGAAGGCCGTCATCGTTCACGCGGCGT</span>
  </p>
  <p id="p0880" num="0880" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TGCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTC </span>TGCTCCGTCAGACTTTCGTCCATTGCGGAAGATTCCCCACTGCTGCCTCCCGTAGGAGTC</span>
  </p>
  <p id="p0881" num="0881" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">TGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCG </span>TGGGCCGTGTCTCAGTCCCAATGTGGCCGTTCATCCTCTCAGACCGGCTACTGATCGTCG</span>
  </p>
  <p id="p0882" num="0882" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CCTTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGA </span>CCTTGGTGGGCCGTTACCCCTCCAACTAGCTAATCAGACGCAAGCCCCTCCTCCAGCGA</span>
  </p>
  <p id="p0883" num="0883" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AAGCCCGAAGGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATT </span>AAGCCCGAAGCCTCCCTTTCTTCATCCCGTCATGCGGCGGAAAGAACGTATTCGGTATT</span>
  </p>
  <p id="p0884" num="0884" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">AGCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACC </span>AGCAGCCGTTTCCAGCTGTTGTCCCCATCTGAAGGGCAGGTTGCTTACGCGTTACTCACC</span>
  </p>
  <p id="p0885" num="0885" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">CGTTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTTGCA</span>CGTTTGCCACTCGAATTGATAAGAAGCAAGCTTCTCATCTCTTCTCGTTCGACTTGCA</span>
  </p>
  <p id="p0887" num="0887" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">Cebadores usados para qPCR de endolasa</span>Primers used for endolase qPCR</span>
  </p>
  <p id="p0889" num="0889" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text">
      <span class="google-src-text style-scope patent-text">
        </span></span></p><div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000070_0001" he="52" wi="1954" file="imgf000070_0001.tif" img-format="tif" width="7816" height="208" alt="Figure imgf000070_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png"></a></div>
      
      <div class="patent-image style-scope patent-text"><a href="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png" class="style-scope patent-text"><img img-content="table" inline="no" id="imgf000070_0001" he="52" wi="1954" file="imgf000070_0001.tif" img-format="tif" width="7816" height="208" alt="Figure imgf000070_0001" class="patent-full-image style-scope patent-text" src="https://patentimages.storage.googleapis.com/ef/fe/31/b66f8c9edd93d2/imgf000070_0001.png"></a></div>
    
  <p class="style-scope patent-text"></p>
  <p id="p0892" num="0892" class="style-scope patent-text">
    <b class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REFERENCIAS</span>REFERENCES</span>
    </b>
  </p>
  <p id="p0894" num="0894" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[1] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.</span>[1] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.</span>
  </p>
  <p id="p0895" num="0895" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[2] Eckburg et al. (2005) Science. 10;308(5728):1635-8.</span>[2] Eckburg et al. (2005) Science. 10;308(5728):1635-8.</span>
  </p>
  <p id="p0896" num="0896" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[3] Macpherson et al. (2001) Microbes Infect. 3(12):1021-35</span>[3] Macpherson et al. (2001) Microbes Infect. 3(12):1021-35</span>
  </p>
  <p id="p0897" num="0897" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[4] Macpherson et al. (2002) Cell Mol Life Sci. 59(12):2088-96.</span>[4] Macpherson et al. (2002) Cell Mol Life Sci. 59(12):2088-96.</span>
  </p>
  <p id="p0898" num="0898" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[5] Mazmanian et al. (2005) Cell 15;122(1 ):107-18.</span>[5] Mazmanian et al. (2005) Cell 15;122(1):107-18.</span>
  </p>
  <p id="p0899" num="0899" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[6] Frank et al. (2007) PNAS 104(34):13780-5.</span>[6] Frank et al. (2007) PNAS 104(34):13780-5.</span>
  </p>
  <p id="p0900" num="0900" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[7] Scanlan et al. (2006) J Clin Microbiol. 44(11 ):3980-8.</span>[7] Scanlan et al. (2006) J Clin Microbiol. 44(11):3980-8.</span>
  </p>
  <p id="p0901" num="0901" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[8] Kang et al. (2010) Inflamm Bowel Dis. 16(12):2034-42.</span>[8] Kang et al. (2010) Inflamm Bowel Dis. 16(12):2034-42.</span>
  </p>
  <p id="p0902" num="0902" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[9] Machiels et al. (2013) Gut. 63(8):1275-83.</span>[9] Machiels et al. (2013) Gut. 63(8):1275-83.</span>
  </p>
  <p id="p0903" num="0903" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[10] WO 2013/050792</span>[10] WO 2013/050792</span>
  </p>
  <p id="p0904" num="0904" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[11 ] WO 03/046580</span>[11] WO 03/046580</span>
  </p>
  <p id="p0905" num="0905" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[12] WO 2013/008039</span>[12] WO 2013/008039</span>
  </p>
  <p id="p0906" num="0906" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[13] WO 2014/167338</span>[13] WO 2014/167338</span>
  </p>
  <p id="p0907" num="0907" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[14] Goldin and Gorbach (2008) Clin Infect Dis. 46 Suppl 2:S96-100.</span>[14] Goldin and Gorbach (2008) Clin Infect Dis. 46 Suppl 2:S96-100.</span>
  </p>
  <p id="p0908" num="0908" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[15] Azad et al. (2013) BMJ. 347:f6471.</span>[15] Azad et al. (2013) BMJ. 347:f6471.</span>
  </p>
  <p id="p0909" num="0909" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[16] Padmanabhan et al. (2013) Standards in Genomic Sciences 8:525-538</span>[16] Padmanabhan et al. (2013) Standards in Genomic Sciences 8:525-538</span>
  </p>
  <p id="p0910" num="0910" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[17] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563.</span>[17] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563.</span>
  </p>
  <p id="p0911" num="0911" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[18] Srutková et al. (2011) J. Microbiol. Methods, 87(1):10-6.</span>[18] Srutková et al. (2011) J. Microbiol. Methods, 87(1):10-6.</span>
  </p>
  <p id="p0912" num="0912" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[19] Kondelková et al. (2010) Acta Medica (Hradec Kralove).;53(2):73-7.</span>[19] Kondelková et al. (2010) Acta Medica (Hradec Kralove).;53(2):73-7.</span>
  </p>
  <p id="p0913" num="0913" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[20] Zhang et al. (2016) BMC Gastroenterol.; 16: 84.</span>[20] Zhang et al. (2016). BMC Gastroenterol.; 16:84.</span>
  </p>
  <p id="p0914" num="0914" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[21] Ren and Torres (2009) Brain Res Rev.;60(1):57-64</span>[21] Ren and Torres (2009) Brain Res Rev.;60(1):57-64</span>
  </p>
  <p id="p0915" num="0915" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[22] Martinon et al. (2002) Mol Cell.;10(2):417-26.</span>[22] Martinon et al. (2002) MolCell.;10(2):417-26.</span>
  </p>
  <p id="p0916" num="0916" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[23] Murphy et al. (2003) J Exp Med. 2003; 198(12): 1951-1957.</span>[23] Murphy et al. (2003) J Exp Med. 2003; 198(12): 1951-1957.</span>
  </p>
  <p id="p0917" num="0917" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[24] Chan et al. (2006) J Exp Med.; 203(12): 2577-2587.</span>[24] Chan et al. (2006) J Exp Med.; 203(12): 2577-2587.</span>
  </p>
  <p id="p0918" num="0918" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text"> <i class="style-scope patent-text">[25] </i>The Immune Response Basic and Clinical Principles, 1a Edición (2006)</span> <i class="style-scope patent-text">[25]</i> The Immune Response Basic and Clinical Principles, 1st Edition (2006)</span>
  </p>
  <p id="p0919" num="0919" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[26] Hoover et al. (2002) J Biol Chem. 277(40):37647-54.</span>[26] Hoover et al. (2002) J Biol Chem. 277(40):37647-54.</span>
  </p>
  <p id="p0920" num="0920" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[27] Kaser et al. (2004) J Clin Immunol.;24(1):74-85.</span>[27] Kaser et al. (2004) J Clin Immunol.;24(1):74-85.</span>
  </p>
  <p id="p0921" num="0921" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[28] Gaur and Aggarwal (2003). Biochem Pharmacol.;66(8):1403-8.</span>[28] Gaur and Aggarwal (2003). Biochem Pharmacol.;66(8):1403-8.</span>
  </p>
  <p id="p0922" num="0922" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[29] Wang and Lin (2008) Acta Pharmacol Sin.; 29(11): 1275-1288.</span>[29] Wang and Lin (2008) Acta Pharmacol Sin.; 29(11): 1275-1288.</span>
  </p>
  <p id="p0923" num="0923" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[30] Tanaka et al. (2014) Cold Spring Harb Perspect Biol.; 6(10): a016295.</span>[30] Tanaka et al. (2014) Cold Spring Harb Perspective Biol.; 6(10): a016295.</span>
  </p>
  <p id="p0924" num="0924" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[31] Bettelli et al. (2006) Nature 441:235-238</span>[31] Bettelli et al. (2006) Nature 441:235-238</span>
  </p>
  <p id="p0925" num="0925" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[32] Menezes and Luskin (1994) Journal of Neuroscience, 14 (9) 5399-5416;</span>[32] Menezes and Luskin (1994) Journal of Neuroscience, 14 (9) 5399-5416;</span>
  </p>
  <p id="p0926" num="0926" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[33] Bhat et al. (2006) Nucleic Acids Res.;34(13):3819-32. 
</span>[33] Bhat et al. (2006) Nucleic Acids Res.;34(13):3819-32. </span>
  </p>
  <p id="p0927" num="0927" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[34] Andreeff et al. (2003), Holland-Frei Cáncer Medicine. 6a edición.</span>[34] Andreeff et al. (2003), Holland-Frei Cancer Medicine. 6th edition.</span>
  </p>
  <p id="p0928" num="0928" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[35] Soltani MH et al, (2005) Am J Pathol;166:1841 -50</span>[35] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>
  </p>
  <p id="p0929" num="0929" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[36] Jandaghi et al. (2016) Gastroenterology;151 (6):1218-1231.</span>[36] Jandaghi et al. (2016) Gastroenterology;151(6):1218-1231.</span>
  </p>
  <p id="p0930" num="0930" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[37] Pornour et al. (2015) Recent Pat Anticancer Drug Discov.;10(2):214-23.</span>[37] Pornour et al. (2015) Recent Pat Anticancer Drug Disc.;10(2):214-23.</span>
  </p>
  <p id="p0931" num="0931" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[38] Sachlos et al. (2012) Cell.;149(6):1284-97</span>[38] Sachlos et al. (2012) Cell.;149(6):1284-97</span>
  </p>
  <p id="p0932" num="0932" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[39] Li et al. (2014), Oncotarget.;5(4):882-93.</span>[39] Li et al. (2014), Oncotarget.;5(4):882-93.</span>
  </p>
  <p id="p0933" num="0933" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[40] Visnyei et al. (2011) Mol Cancer Ther.;10(10):1818-28.</span>[40] Visnyei et al. (2011) Mol Cancer Ther.;10(10):1818-28.</span>
  </p>
  <p id="p0934" num="0934" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[41] Cheng et al. (2015) Cell Death Dis.;6:e1753</span>[41] Cheng et al. (2015) Cell Death Dis.;6:e1753</span>
  </p>
  <p id="p0935" num="0935" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[42] Shin et al. (2012) Biol Pharm Bull. ;35(7):1069-75.</span>[42] Shin et al. (2012) BiolPharm Bull. ;35(7):1069-75.</span>
  </p>
  <p id="p0936" num="0936" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[43] Chen et al. (2011) PLoS One.;6(11):e27186</span>[43] Chen et al. (2011) PLoS One.;6(11):e27186</span>
  </p>
  <p id="p0937" num="0937" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[44] Arvigo et al. (2010) J Endocrinol. ;207(3):309-17.</span>[44] Arvigo et al. (2010) J Endocrinol. ;207(3):309-17.</span>
  </p>
  <p id="p0938" num="0938" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[45] Mao et al. (2015) J Obstet Gynaecol Res.;41(8):1240-5</span>[45] Mao et al. (2015) J Obstet Gynaecol Res.;41(8):1240-5</span>
  </p>
  <p id="p0939" num="0939" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[46] Park et al. (2014) Oncotarget.;5(13):4929-34.</span>[46] Park et al. (2014) Oncotarget.;5(13):4929-34.</span>
  </p>
  <p id="p0940" num="0940" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[47] Spengler et al. (2011) Anticancer Res.;31(12):4201-5.</span>[47] Spengler et al. (2011) Anticancer Res.;31(12):4201-5.</span>
  </p>
  <p id="p0941" num="0941" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[48] Mu et al. (2014) Oncol Rep.;31(5):2107-14.</span>[48] Mu et al. (2014) Oncol Rep.;31(5):2107-14.</span>
  </p>
  <p id="p0942" num="0942" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[49] Prabhu et al. (2017) Neuro-Oncology, 19(6) vi60</span>[49] Prabhu et al. (2017) Neuro-Oncology, 19(6) vi60</span>
  </p>
  <p id="p0943" num="0943" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[50] Devarajan et al. (2002) Oncogene. 12;21(57):8843-51.</span>[50] Devarajan et al. (2002) Oncogene. 12;21(57):8843-51.</span>
  </p>
  <p id="p0944" num="0944" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[51] Bell and Megeney (2017) Cell Death Differ. ;24(8):1359-1368.</span>[51] Bell and Megeney (2017) Cell Death Differ. ;24(8):1359-1368.</span>
  </p>
  <p id="p0945" num="0945" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[52] Gerl and Vaux (2005) Carcinogenesis. 2005 Feb;26(2):263-70.</span>[52] Gerl and Vaux (2005) Carcinogenesis. 2005 Feb;26(2):263-70.</span>
  </p>
  <p id="p0946" num="0946" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[53] Barnes et al. (2005) Eur Respir J. 25:552-563.</span>[53] Barnes et al. (2005) Eur Respir J. 25:552-563.</span>
  </p>
  <p id="p0947" num="0947" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[54] Gray SG, Dangond F. (2006) Epigenetics. 1:67-75.</span>[54] Gray SG, Dangond F. (2006) Epigenetics. 1:67-75.</span>
  </p>
  <p id="p0948" num="0948" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[55] Grabiec et al. (2008) Arthritis Res Ther. 10:226.</span>[55] Grabiec et al. (2008) Arthritis Res Ther. 10:226.</span>
  </p>
  <p id="p0949" num="0949" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[56] Saito et al. (1999) Proc Natl Acad Sci USA. 96:4592-4597.</span>[56] Saito et al. (1999) Proc Natl Acad Sci USA. 96:4592-4597.</span>
  </p>
  <p id="p0950" num="0950" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[57] Butler et al. (2000) Cancer Res. 60:5165-5170.</span>[57] Butler et al. (2000) Cancer Res. 60:5165-5170.</span>
  </p>
  <p id="p0951" num="0951" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[58] Mwakwari et al. (2010) Curr Top Med Chem. 10 (14): 1423-40.</span>[58] Mwakwari et al. (2010) Curr Top Med Chem. 10(14): 1423-40.</span>
  </p>
  <p id="p0952" num="0952" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[59] Monneret C. (2007) Anti-Cancer Drugs. 18 (4): 363-70.</span>[59] Monneret C. (2007) Anti-Cancer Drugs. 18 (4): 363-70.</span>
  </p>
  <p id="p0953" num="0953" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[60] Chun, (2015) Arch Pharm Res. 38(6):933-49.</span>[60] Chun, (2015) Arch Pharm Res. 38(6):933-49.</span>
  </p>
  <p id="p0954" num="0954" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[61] Abel and Zukin (2008) Curr Opin Pharmacol, 2008. 8(1): 57-64.</span>[61] Abel and Zukin (2008) Curr Opin Pharmacol, 2008. 8(1): 57-64.</span>
  </p>
  <p id="p0955" num="0955" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[62] PCT/EP2018/065858</span>[62] PCT/EP2018/065858</span>
  </p>
  <p id="p0956" num="0956" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[63] Toshkov et al. (2017) Radiat Res. 187(5):570-580</span>[63] Toshkov et al. (2017) Radiat Res. 187(5):570-580</span>
  </p>
  <p id="p0957" num="0957" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[64] Tanaka and Sakaguchi (2017) Cell Res.;27(1):109-118.</span>[64] Tanaka and Sakaguchi (2017) Cell Res.;27(1):109-118.</span>
  </p>
  <p id="p0958" num="0958" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[65] Allen et al. (2010) J Exp Med.;207(5):1045-56.</span>[65] Allen et al. (2010) J Exp Med.;207(5):1045-56.</span>
  </p>
  <p id="p0959" num="0959" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[66] Haabeth et al. (2012) Oncolmmunology 1 (1):1146-1152.</span>[66] Haabeth et al. (2012) Oncolmmunology 1(1):1146-1152.</span>
  </p>
  <p id="p0960" num="0960" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[67] Lejeune et al. (2006) Cancer Immun. 6:6</span>[67] Lejeune et al. (2006) Cancer Immun. 6:6</span>
  </p>
  <p id="p0961" num="0961" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[68] Pace et al. (1983) PNAS. 80:8782-6.</span>[68] Pace et al. (1983) PNAS. 80:8782-6.</span>
  </p>
  <p id="p0962" num="0962" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[69] Sgadari et al. (1996) PNAS. 93:13791-6.</span>[69] Sgadari et al. (1996) PNAS. 93:13791-6.</span>
  </p>
  <p id="p0963" num="0963" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[70] Arenberg et al. (1996) J. Exp. Med. 184:981-92.</span>[70] Arenberg et al. (1996) J. Exp. Med. 184:981-92.</span>
  </p>
  <p id="p0964" num="0964" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[71] Sgadari et al. (1997) Blood. 89:2635-43.</span>[71] Sgadari et al. (1997) Blood. 89:2635-43.</span>
  </p>
  <p id="p0965" num="0965" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[72] Liu et al., (2018) Acta Pharmaceutica Sinica B; 8, 4; 552-562</span>[72] Liu et al., (2018) Acta Pharmaceutica Sinica B; 8, 4; 552-562</span>
  </p>
  <p id="p0966" num="0966" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[73] Jones et al. (2017). J Clin Oncol. 2017 Aug 10; 35(23): 2624-2630</span>[73] Jones et al. (2017). J Clin Oncol. 2017 Aug 10; 35(23): 2624-2630</span>
  </p>
  <p id="p0967" num="0967" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[74] Ascierto et al. (2012) Journal of Translational Medicine. 10, 85</span>[74] Ascerto et al. (2012) Journal of Translational Medicine. 10, 85</span>
  </p>
  <p id="p0968" num="0968" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[75] https://www.uniprot.org/uniprot/P15056</span>[75] https://www.uniprot.org/uniprot/P15056</span>
  </p>
  <p id="p0969" num="0969" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[76] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>[76] Soltani MH et al, (2005) Am J Pathol;166:1841-50</span>
  </p>
  <p id="p0970" num="0970" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[77] Xie (2016); Med Res Rev; 36,2: 300-312</span>[77] Xie (2016); Med Res Rev; 36.2: 300-312</span>
  </p>
  <p id="p0971" num="0971" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[78] Bloch et al. (2016) Eur Cytokine Netw.;27(3):63-67</span>[78] Bloch et al. (2016) Eur Cytokine Netw.;27(3):63-67</span>
  </p>
  <p id="p0972" num="0972" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[79] Mohanty et al. (2015) J Infect Dis, 211(7) 1174-1184.</span>[79] Mohanty et al. (2015) J Infect Dis, 211(7) 1174-1184.</span>
  </p>
  <p id="p0973" num="0973" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[80] Fernandez-Ruiz et al.,(2015) Vaccine 201533(51)</span>[80] Fernandez-Ruiz et al.,(2015) Vaccine 201533(51)</span>
  </p>
  <p id="p0974" num="0974" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[81] Morel et al., (2011) Vaccine, 29(13) 2461-2473.</span>[81] Morel et al., (2011) Vaccine, 29(13) 2461-2473.</span>
  </p>
  <p id="p0975" num="0975" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[82] Leal et al.,(2001) Immunol 103(3) 375-381</span>[82] Leal et al.,(2001) Immunol 103(3) 375-381</span>
  </p>
  <p id="p0976" num="0976" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[83] Knudsen et al. (2016), Sci Reps, 6 (19570).</span>[83] Knudsen et al. (2016), Sci Reps, 6 (19570).</span>
  </p>
  <p id="p0977" num="0977" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[84] Su et al.,(2008) Vaccine 26(40), 5111 -22</span>[84] Su et al.,(2008) Vaccine 26(40), 5111-22</span>
  </p>
  <p id="p0978" num="0978" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[85] Song, Mol Ther 2007</span>[85] Song, Mol Ther 2007</span>
  </p>
  <p id="p0979" num="0979" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[86] Li et al, (2007) J Immunol, 178(8), 5271-5276</span>[86] Li et al, (2007) J Immunol, 178(8), 5271-5276</span>
  </p>
  <p id="p0980" num="0980" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[87] Coffman et al.,(2012) Immunity 33(4) 492-503</span>[87] Coffman et al.,(2012) Immunity 33(4) 492-503</span>
  </p>
  <p id="p0981" num="0981" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[88] Ruan et al. (2014) Acta Virol. 58(4):356-8</span>[88] Ruan et al. (2014) Act Virol. 58(4):356-8</span>
  </p>
  <p id="p0982" num="0982" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[89] Wang et al. (2016) Oncotarget. 20; 7(51)</span>[89] Wang et al. (2016) Oncotarget. twenty; 7(51)</span>
  </p>
  <p id="p0983" num="0983" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[90] Fraietta, Nat Med 2018</span>[90] Fraietta, NatMed 2018</span>
  </p>
  <p id="p0984" num="0984" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[91] Zhou, Blood 2010</span>[91] Zhou, Blood 2010</span>
  </p>
  <p id="p0985" num="0985" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[92] Glenn and Whartenby (2014) World J Stem Cells.; 6(5): 526-539.</span>[92] Glenn and Whartenby (2014) World J Stem Cells.; 6(5): 526-539.</span>
  </p>
  <p id="p0986" num="0986" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[93] Heng et al. (2004) Cardiovasc Res. 2004 Apr 1 ;62(1):34-42.</span>[93] Heng et al. (2004) Cardiovasc Res. 2004 Apr 1;62(1):34-42.</span>
  </p>
  <p id="p0987" num="0987" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[94] Fulop et al</span>[94] Fulop et al</span>
  </p>
  <p id="p0988" num="0988" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[95] Bektas et al. (2017) J Leukoc Biol.;102(4):977-988.</span>[95] Bektas et al. (2017) J Leukoc Biol.;102(4):977-988.</span>
  </p>
  <p id="p0989" num="0989" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[96] Fulop et al (2016) Rev Invest Clin.;68(2):84-91.</span>[96] Fulop et al (2016) Rev Invest Clin.;68(2):84-91.</span>
  </p>
  <p id="p0990" num="0990" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[97] Fulop et al. (2018) Front lmmunol.;8:1960.</span>[97] Fulop et al. (2018) Front immunol.;8:1960.</span>
  </p>
  <p id="p0991" num="0991" class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">[98] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol., 54, 9-24. 
</span>[98] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol., 54, 9-24.
</span>
  </p>
</description>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
            <div class="flex flex-width style-scope patent-result">
              <section id="claims" class="style-scope patent-result">
                <h3 class="style-scope patent-result">
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result">Claims <span class="style-scope patent-result">(16)</span></div>
                    <div class="collapse style-scope patent-result">
                      Hide Dependent <iron-icon style="height: 15px; width: 15px;" icon="expand-less" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M12 8l-6 6 1.41 1.41L12 10.83l4.59 4.58L18 14z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </div>
                  </div>
                  <div class="layout horizontal style-scope patent-result">
                    <div class="flex style-scope patent-result"></div>
                    <div class="righthead style-scope patent-result">translated from Spanish</div>
                  </div>
                </h3>
                <patent-text name="claims" enable-text-selection="" class="style-scope patent-result" style="padding-top: 0px;">
    
    
    <template is="dom-if" restamp="" class="style-scope patent-text"></template>
    <overlay-tooltip id="tooltip" class="style-scope patent-text" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      
    </div>
  </overlay-tooltip>
    <div class="layout horizontal style-scope patent-text">
      <section id="text" class="flex style-scope patent-text"><claims mxw-id="PCLM330793482" lang="EN" load-source="google" class="style-scope patent-text">
  <claim-statement class="style-scope patent-text">
    <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">REIVINDICACIONES
  </span></span></claim-statement>
  <claim id="clm-0001" num="1" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">1. Una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, para su uso en el tratamiento de enfermedades estimulando el sistema inmunitario, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16S que es por lo menos un 97% idéntica a la SEQ ID NO: 1.</span>1. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , for use in treating diseases by stimulating the immune system, wherein the bacterial strain has a 16S rRNA gene sequence that is at least 97% identical to SEQ ID NO: 1.</span>
    </claim-text>
  </claim>
  <claim id="clm-0002" num="2" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">2. Una composición que comprende una cepa bacteriana del género <i class="style-scope patent-text">Megasphaera</i>, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 95% idéntica a la SEQ ID NO: 1; (a) para su uso en el tratamiento o prevención del cáncer, (b) para su uso en el tratamiento, prevención o retraso de la inmunosenescencia, (c) para su uso como adyuvante de vacunas, o (d) para su uso en terapia con células T con receptores de antígenos quiméricos (CAR-T), terapia de células madre mesenquimales (MSC), o terapia de trasplante de células madre; en un sujeto humano.</span>2. A composition comprising a bacterial strain of the genus <i class="style-scope patent-text">Megasphaera</i> , wherein the bacterial strain has a 16s rRNA gene sequence that is at least 95% identical to SEQ ID NO: 1; (a) for use in the treatment or prevention of cancer, (b) for use in the treatment, prevention, or delay of immunosenescence, (c) for use as an adjuvant to vaccines, or (d) for use in chimeric antigen receptor T cell (CAR-T) therapy, mesenchymal stem cell (MSC) therapy, or stem cell transplant therapy; in a human subject.</span>
    </claim-text>
  </claim>
  <claim id="clm-0003" num="3" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">3. La composición para el uso de la reivindicación 1 o 2, para su uso en el tratamiento o prevención del cáncer, como melanoma metastásico, cáncer de mama, cáncer de ovario, cáncer de cuello uterino, glioblastoma, carcinoma, cáncer de pulmón, leucemia linfocítica crónica, cáncer de próstata, linfoma, cáncer gástrico, cáncer colorrectal y/o enfermedades malignas hematológicas.</span>3. The composition for the use of claim 1 or 2, for use in the treatment or prevention of cancer, such as metastatic melanoma, breast cancer, ovarian cancer, cervical cancer, glioblastoma, carcinoma, lung cancer, chronic lymphocytic leukemia, prostate cancer, lymphoma, gastric cancer, colorectal cancer and/or hematological malignancies.</span>
    </claim-text>
  </claim>
  <claim id="clm-0004" num="4" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">4. La composición para el uso de acuerdo con la reivindicación 3, en donde la composición tiene actividad inhibidora de histona deacetilasas, y/o en donde la composición regula por incremento citoquinas proinflamatorias.</span>4. The composition for use according to claim 3, wherein the composition has histone deacetylases inhibitory activity, and/or wherein the composition up-regulates pro-inflammatory cytokines.</span>
    </claim-text>
  </claim>
  <claim id="clm-0005" num="5" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">5. La composición para el uso de la reivindicación 1 o 2, para su uso en el tratamiento, prevención o retraso de la inmunosenescencia.</span>5. The composition for use of claim 1 or 2, for use in the treatment, prevention or delay of immunosenescence.</span>
    </claim-text>
  </claim>
  <claim id="clm-0006" num="6" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">6. La composición para el uso de la reivindicación 1 o 2, para su uso como adyuvante de vacunas.</span>6. The composition for use of claim 1 or 2, for use as a vaccine adjuvant.</span>
    </claim-text>
  </claim>
  <claim id="clm-0007" num="7" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">7. La composición para el uso de la reivindicación 1 o 2, para su uso en terapia con CAR-T, terapia con MSC o terapia de trasplante de células madre.</span>7. The composition for the use of claim 1 or 2, for use in CAR-T therapy, MSC therapy or stem cell transplant therapy.</span>
    </claim-text>
  </claim>
  <claim id="clm-0008" num="8" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">8. La composición para el uso de cualquier reivindicación anterior, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a cualquiera de las SEQ ID NO: 8, 9. 10, 11 o 12 o en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s representada por cualquiera de las SEQ ID NO: 8, 9, 10, 11 o 12.</span>8. The composition for the use of any preceding claim, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 98%, 99%, 99.5% or 99.9% identical to any of the SEQ ID NO: 8, 9. 10, 11 or 12 or where the bacterial strain has a 16s rRNA gene sequence represented by any of SEQ ID NO: 8, 9, 10, 11 or 12.</span>
    </claim-text>
  </claim>
  <claim id="clm-0009" num="9" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">9. La composición para el uso de cualquier reivindicación anterior, en donde la cepa bacteriana es de <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>9. The composition for use of any preceding claim, wherein the bacterial strain is <i class="style-scope patent-text">Megasphaera massiliensis.</i> </span>
    </claim-text>
  </claim>
  <claim id="clm-0010" num="10" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">10. La composición para el uso de cualquier reivindicación anterior, en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s que es por lo menos un 98%, 99%, 99,5% o 99,9% idéntica a la SEQ ID NO: 1 o en donde la cepa bacteriana tiene una secuencia génica de ARNr 16s representada por la SEQ ID NO: 1; opcionalmente en donde la cepa bacteriana es la cepa depositada con el número de registro 42787 en el NCIMB.</span>10. The composition for the use of any preceding claim, wherein the bacterial strain has a 16s rRNA gene sequence that is at least 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 1 or wherein the bacterial strain has a 16s rRNA gene sequence represented by SEQ ID NO: 1; optionally wherein the bacterial strain is the strain deposited under accession number 42787 with the NCIMB.</span>
    </claim-text>
  </claim>
  <claim id="clm-0011" num="11" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">11. La composición para el uso de cualquier reivindicación anterior, en donde la composición es para administración oral, y/o en donde la composición comprende uno o más excipientes o portadores farmacéuticamente aceptables, y/o en donde la cepa bacteriana está liofilizada; o un producto alimenticio que comprende dicha composición, para el uso de cualquier reivindicación anterior.</span>11. The composition for use of any preceding claim, wherein the composition is for oral administration, and/or wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers, and/or wherein the bacterial strain is lyophilized; or a food product comprising said composition, for the use of any preceding claim.</span>
    </claim-text>
  </claim>
  <claim id="clm-0012" num="12" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">12. Una composición que comprende una célula de la cepa bacteriana definida en cualquiera de las reivindicaciones 1, 2 o 8-10 en donde la célula expresa uno o más antígenos heterólogos; para su uso como vacuna; opcionalmente en donde la célula presenta el uno o más antígenos heterólogos.</span>12. A composition comprising a cell of the bacterial strain defined in any of claims 1, 2 or 8-10, wherein the cell expresses one or more heterologous antigens; for use as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
    </claim-text>
  </claim>
  <claim id="clm-0013" num="13" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">13. Una célula de la cepa bacteriana definida en cualquiera de las reivindicaciones 1, 2, o 8-10, en donde la célula expresa uno o más antígenos heterólogos; para su como vacuna; opcionalmente en donde la célula presenta el uno o más antígenos heterólogos.</span>13. A cell of the bacterial strain defined in any of claims 1, 2, or 8-10, wherein the cell expresses one or more heterologous antigens; for your as a vaccine; optionally wherein the cell presents the one or more heterologous antigens.</span>
    </claim-text>
  </claim>
  <claim id="clm-0014" num="14" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">14. Una cepa bacteriana para su uso en terapia, en donde la cepa bacteriana tiene una secuencia de ARNr 16S que es por lo menos un 99,5% o 99,9% idéntica a cualquiera de las SEQ ID NO: 8, 11 o 12.</span>14. A bacterial strain for use in therapy, wherein the bacterial strain has a 16S rRNA sequence that is at least 99.5% or 99.9% identical to any one of SEQ ID NO: 8, 11 or 12.</span>
    </claim-text>
  </claim>
  <claim id="clm-0015" num="15" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">15. Una cepa bacteriana que tiene la secuencia de ARNr 16S representada por cualquiera de las SEQ ID NO: 8, 10, 11 o 12 para su uso en terapia.</span>15. A bacterial strain having the 16S rRNA sequence represented by any one of SEQ ID NO: 8, 10, 11 or 12 for use in therapy.</span>
    </claim-text>
  </claim>
  <claim id="clm-0016" num="16" class="style-scope patent-text">
    <claim-text class="style-scope patent-text">
      <span class="notranslate style-scope patent-text"> <span class="google-src-text style-scope patent-text">16. La cepa bacteriana depositada con el número de registro NCIMB. 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, o NCIMB 43389, para su uso en terapia. 
</span>16. The bacterial strain deposited with the registry number NCIMB. 43385, NCIMB 43386, NCIMB 43387, NCIMB 43388, or NCIMB 43389, for use in therapy.
</span>
    </claim-text>
  </claim>
</claims>
  </section>
      <div id="margin" class="style-scope patent-text">
        <div id="createHighlight" style="top: 0px;" class="style-scope patent-text" hidden="">
          <iron-icon id="comment" icon="editor:insert-comment" class="style-scope patent-text x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M20 2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h14l4 4V4c0-1.1-.9-2-2-2zm-2 12H6v-2h12v2zm0-3H6V9h12v2zm0-3H6V6h12v2z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
        </div>
      </div>
    </div>
  </patent-text>
              </section>
            </div>
          </div>

          <div class="footer style-scope patent-result">

            
            <h3 id="patentCitations" class="scroll-target style-scope patent-result">
              Patent Citations (36)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JPS5557520A/en"><a id="link" href="#" class="style-scope state-modifier">JPS5557520A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">1978-10-26</span>
                    <span class="td style-scope patent-result">1980-04-28</span>
                    <span class="td style-scope patent-result">Nisshin Flour Milling Co Ltd</span>
                    <span class="td style-scope patent-result">Preparation of carcinostatic substance 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2002080947A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2002080947A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-04-06</span>
                    <span class="td style-scope patent-result">2002-10-17</span>
                    <span class="td style-scope patent-result">Kyodoken Institute For Animal Science Research &amp; Development</span>
                    <span class="td style-scope patent-result">Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0127916D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0127916D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2001-11-21</span>
                    <span class="td style-scope patent-result">2002-01-16</span>
                    <span class="td style-scope patent-result">Rowett Res Inst</span>
                    <span class="td style-scope patent-result">Method 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20040005304A1/en"><a id="link" href="#" class="style-scope state-modifier">US20040005304A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2002-07-08</span>
                    <span class="td style-scope patent-result">2004-01-08</span>
                    <span class="td style-scope patent-result">Mak Wood, Inc.</span>
                    <span class="td style-scope patent-result">Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB0307026D0/en"><a id="link" href="#" class="style-scope state-modifier">GB0307026D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-03-27</span>
                    <span class="td style-scope patent-result">2003-04-30</span>
                    <span class="td style-scope patent-result">Rowett Res Inst</span>
                    <span class="td style-scope patent-result">Bacterial supplement 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN101856348A/en"><a id="link" href="#" class="style-scope state-modifier">CN101856348A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2003-08-29</span>
                    <span class="td style-scope patent-result">2010-10-13</span>
                    <span class="td style-scope patent-result">斯隆-凯特林癌症研究所</span>
                    <span class="td style-scope patent-result">The therapeutic alliance method for cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201112091D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201112091D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-07-14</span>
                    <span class="td style-scope patent-result">2011-08-31</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterial strains isolated from pigs 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201117313D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201117313D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2011-10-07</span>
                    <span class="td style-scope patent-result">2011-11-16</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Bacterium for use in medicine 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/BR112015011933A8/en"><a id="link" href="#" class="style-scope state-modifier">BR112015011933A8</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2012-11-23</span>
                    <span class="td style-scope patent-result">2022-09-20</span>
                    <span class="td style-scope patent-result">Seres Therapeutics Inc</span>
                    <span class="td style-scope patent-result">
  SYNERGIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP2951283A4/en"><a id="link" href="#" class="style-scope state-modifier">EP2951283A4</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-02-04</span>
                    <span class="td style-scope patent-result">2017-01-25</span>
                    <span class="td style-scope patent-result">Seres Therapeutics, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201306536D0/en"><a id="link" href="#" class="style-scope state-modifier">GB201306536D0</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-04-10</span>
                    <span class="td style-scope patent-result">2013-05-22</span>
                    <span class="td style-scope patent-result">Gt Biolog Ltd</span>
                    <span class="td style-scope patent-result">Polypeptide and immune modulation 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6585041B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6585041B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-07-18</span>
                    <span class="td style-scope patent-result">2019-10-02</span>
                    <span class="td style-scope patent-result">ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ</span>
                    <span class="td style-scope patent-result">
  Methods for enhancing the capacity of immune cells
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN104415060A/en"><a id="link" href="#" class="style-scope state-modifier">CN104415060A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-08-30</span>
                    <span class="td style-scope patent-result">2015-03-18</span>
                    <span class="td style-scope patent-result">深圳华大基因科技有限公司</span>
                    <span class="td style-scope patent-result">Edible composition as well as preparation method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2015038731A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2015038731A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-09-12</span>
                    <span class="td style-scope patent-result">2015-03-19</span>
                    <span class="td style-scope patent-result">The Johns Hopkins University</span>
                    <span class="td style-scope patent-result">Biofilm formation to define risk for colon cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116370507A/en"><a id="link" href="#" class="style-scope state-modifier">CN116370507A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2013-11-25</span>
                    <span class="td style-scope patent-result">2023-07-04</span>
                    <span class="td style-scope patent-result">赛里斯治疗公司</span>
                    <span class="td style-scope patent-result">Synergistic bacterial compositions, methods of manufacture and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9650654B2/en"><a id="link" href="#" class="style-scope state-modifier">US9650654B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-06-25</span>
                    <span class="td style-scope patent-result">2017-05-16</span>
                    <span class="td style-scope patent-result">William Marsh Rice University</span>
                    <span class="td style-scope patent-result">Making C4+ products in bacteria 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10366793B2/en"><a id="link" href="#" class="style-scope state-modifier">US10366793B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-10-21</span>
                    <span class="td style-scope patent-result">2019-07-30</span>
                    <span class="td style-scope patent-result">uBiome, Inc.</span>
                    <span class="td style-scope patent-result">Method and system for characterizing microorganism-related conditions 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US10688166B2/en"><a id="link" href="#" class="style-scope state-modifier">US10688166B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-03</span>
                    <span class="td style-scope patent-result">2020-06-23</span>
                    <span class="td style-scope patent-result">Cerus Corporation</span>
                    <span class="td style-scope patent-result">Compositions and methods for improved car-T cell therapies 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MA41020A/en"><a id="link" href="#" class="style-scope state-modifier">MA41020A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2014-11-25</span>
                    <span class="td style-scope patent-result">2017-10-03</span>
                    <span class="td style-scope patent-result">Evelo Biosciences Inc</span>
                    <span class="td style-scope patent-result">
  PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/JP6783247B2/en"><a id="link" href="#" class="style-scope state-modifier">JP6783247B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-01-23</span>
                    <span class="td style-scope patent-result">2020-11-11</span>
                    <span class="td style-scope patent-result">テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション</span>
                    <span class="td style-scope patent-result">
  Use of short-chain fatty acids in cancer prevention
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2016149449A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2016149449A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-03-18</span>
                    <span class="td style-scope patent-result">2016-09-22</span>
                    <span class="td style-scope patent-result">Tufts University</span>
                    <span class="td style-scope patent-result">Compositions and methods for preventing colorectal cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MA41060B1/en"><a id="link" href="#" class="style-scope state-modifier">MA41060B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-06-15</span>
                    <span class="td style-scope patent-result">2019-11-29</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ME03003B/en"><a id="link" href="#" class="style-scope state-modifier">ME03003B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-20</span>
                    <span class="td style-scope patent-result">2018-10-20</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20180083894A/en"><a id="link" href="#" class="style-scope state-modifier">KR20180083894A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2015-11-24</span>
                    <span class="td style-scope patent-result">2018-07-23</span>
                    <span class="td style-scope patent-result">세레스 테라퓨틱스, 인코포레이티드</span>
                    <span class="td style-scope patent-result">
  Designed bacterial composition
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2018008523A/en"><a id="link" href="#" class="style-scope state-modifier">MX2018008523A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-01-11</span>
                    <span class="td style-scope patent-result">2019-05-15</span>
                    <span class="td style-scope patent-result">3Plw Ltd</span>
                    <span class="td style-scope patent-result">Lactic acid-utilizing bacteria genetically modified to secrete polysaccharide-degrading enzymes. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN107028985A/en"><a id="link" href="#" class="style-scope state-modifier">CN107028985A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-02-04</span>
                    <span class="td style-scope patent-result">2017-08-11</span>
                    <span class="td style-scope patent-result">深圳华大基因研究院</span>
                    <span class="td style-scope patent-result">Application of the heavy wall mushroom probiotics in preventing and/or treating diabetes and its relevant disease 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20190125808A1/en"><a id="link" href="#" class="style-scope state-modifier">US20190125808A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-03-30</span>
                    <span class="td style-scope patent-result">2019-05-02</span>
                    <span class="td style-scope patent-result">The Trustees Of Columbia University In The City Of New York</span>
                    <span class="td style-scope patent-result">Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US9999641B2/en"><a id="link" href="#" class="style-scope state-modifier">US9999641B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-06-14</span>
                    <span class="td style-scope patent-result">2018-06-19</span>
                    <span class="td style-scope patent-result">Vedanta Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Treatment of clostridium difficile infection 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN116196425A/en"><a id="link" href="#" class="style-scope state-modifier">CN116196425A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-09-27</span>
                    <span class="td style-scope patent-result">2023-06-02</span>
                    <span class="td style-scope patent-result">得克萨斯系统大学评议会</span>
                    <span class="td style-scope patent-result">Methods of enhancing immune checkpoint blocking therapies by modulating microbiome 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018094190A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2018094190A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-11-18</span>
                    <span class="td style-scope patent-result">2018-05-24</span>
                    <span class="td style-scope patent-result">Sanford Burnham Prebys Medical Discovery Institute</span>
                    <span class="td style-scope patent-result">Gut microbiota and treatment of cancer 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018112365A2/en"><a id="link" href="#" class="style-scope state-modifier">WO2018112365A2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-12-16</span>
                    <span class="td style-scope patent-result">2018-06-21</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2018112363A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2018112363A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2016-12-16</span>
                    <span class="td style-scope patent-result">2018-06-21</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Methods of treating cancer using parabacteroides 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/RS61367B1/en"><a id="link" href="#" class="style-scope state-modifier">RS61367B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2021-02-26</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20200015575A/en"><a id="link" href="#" class="style-scope state-modifier">KR20200015575A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2020-02-12</span>
                    <span class="td style-scope patent-result">4디 파마 리서치 리미티드</span>
                    <span class="td style-scope patent-result">
  Compositions Containing Bacterial Strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">TW202014513A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result">2020-04-16</span>
                    <span class="td style-scope patent-result">英商4D製藥研究有限公司</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/SG11202106230XA/en"><a id="link" href="#" class="style-scope state-modifier">SG11202106230XA</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">2021-07-29</span>
                    <span class="td style-scope patent-result">4D Pharma Res Ltd</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                </div>
              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="citedBy" class="scroll-target style-scope patent-result">
              Cited By (10)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication number</span>
                    <span class="th style-scope patent-result">Priority date</span>
                    <span class="th style-scope patent-result">Publication date</span>
                    <span class="th style-scope patent-result">Assignee</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  <template is="dom-repeat" class="style-scope patent-result"></template>

                  <div class="tr style-scope patent-result">
                    <span class="td famheader style-scope patent-result">Family To Family Citations</span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                    <span class="td famheader style-scope patent-result"></span>
                  </div>

                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11492587B2/en"><a id="link" href="#" class="style-scope state-modifier">US11492587B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-01-31</span>
                    <span class="td style-scope patent-result">2022-11-08</span>
                    <span class="td style-scope patent-result">Kansas State University Research Foundation</span>
                    <span class="td style-scope patent-result">Microbial cells, methods of producing the same, and uses thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR20200015575A/en"><a id="link" href="#" class="style-scope state-modifier">KR20200015575A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-06-14</span>
                    <span class="td style-scope patent-result">2020-02-12</span>
                    <span class="td style-scope patent-result">4디 파마 리서치 리미티드</span>
                    <span class="td style-scope patent-result">
  Compositions Containing Bacterial Strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/MX2020004078A/en"><a id="link" href="#" class="style-scope state-modifier">MX2020004078A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2017-10-20</span>
                    <span class="td style-scope patent-result">2020-09-25</span>
                    <span class="td style-scope patent-result">Ms Biotech Inc</span>
                    <span class="td style-scope patent-result">Methods of producing ensiled plant materials using megasphaera elsdenii. 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/TW202014513A/en"><a id="link" href="#" class="style-scope state-modifier">TW202014513A</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result">2020-04-16</span>
                    <span class="td style-scope patent-result">英商4D製藥研究有限公司</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US11541105B2/en"><a id="link" href="#" class="style-scope state-modifier">US11541105B2</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-06-01</span>
                    <span class="td style-scope patent-result">2023-01-03</span>
                    <span class="td style-scope patent-result">The Research Foundation For The State University Of New York</span>
                    <span class="td style-scope patent-result">Compositions and methods for disrupting biofilm formation and maintenance 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3893906A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3893906A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">2021-10-20</span>
                    <span class="td style-scope patent-result">4D Pharma Research Limited</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2021252861A1/en"><a id="link" href="#" class="style-scope state-modifier">WO2021252861A1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2020-06-11</span>
                    <span class="td style-scope patent-result">2021-12-16</span>
                    <span class="td style-scope patent-result">Evelo Biosciences, Inc.</span>
                    <span class="td style-scope patent-result">Compositions and methods for treating diseases and disorders using megasphaera sp 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112877275B/en"><a id="link" href="#" class="style-scope state-modifier">CN112877275B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-04</span>
                    <span class="td style-scope patent-result">2023-03-31</span>
                    <span class="td style-scope patent-result">中国农业科学院兰州兽医研究所</span>
                    <span class="td style-scope patent-result">HDAC2 gene knockout BHK-21 cell line and construction method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CN112980878B/en"><a id="link" href="#" class="style-scope state-modifier">CN112980878B</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-02-04</span>
                    <span class="td style-scope patent-result">2023-03-31</span>
                    <span class="td style-scope patent-result">中国农业科学院兰州兽医研究所</span>
                    <span class="td style-scope patent-result">HDAC8 gene knockout BHK-21 cell line and construction method and application thereof 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                      <template is="dom-if" class="style-scope patent-result"></template>
                      
                      <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/KR102551061B1/en"><a id="link" href="#" class="style-scope state-modifier">KR102551061B1</a></state-modifier>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      *<template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-05-26</span>
                    <span class="td style-scope patent-result">2023-07-03</span>
                    <span class="td style-scope patent-result">중앙대학교 산학협력단</span>
                    <span class="td style-scope patent-result">A composition comprising SAHA as an active ingredient for inhibiting the formation of biofilm generated by Salmonella spp. 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>

              </div>
            </div>
            <div style="padding: 10px 12px; font-size: 11px;" class="style-scope patent-result">* Cited by examiner, † Cited by third party, ‡ Family to family citation</div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="similarDocuments" class="scroll-target style-scope patent-result">
              Similar Documents
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Publication</span>
                    <span class="th style-scope patent-result">Publication Date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2916601T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2916601T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-07-04</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20230173001A1/en"><a id="link" href="#" class="style-scope state-modifier">US20230173001A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-06-08</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/CA2988686C/en"><a id="link" href="#" class="style-scope state-modifier">CA2988686C</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2023-01-24</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/ES2705157T3/en"><a id="link" href="#" class="style-scope state-modifier">ES2705157T3</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-03-22</span>
                    <span class="td style-scope patent-result">
  Compositions comprising bacterial strains
 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/AU2016278066B2/en"><a id="link" href="#" class="style-scope state-modifier">AU2016278066B2</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-09-23</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/EP3970733A1/en"><a id="link" href="#" class="style-scope state-modifier">EP3970733A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-03-23</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/US20210283194A1/en"><a id="link" href="#" class="style-scope state-modifier">US20210283194A1</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2021-09-16</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA20345A/en"><a id="link" href="#" class="style-scope state-modifier">OA20345A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2022-06-02</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains. 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td style-scope patent-result">
                      
                        <template is="dom-if" class="style-scope patent-result"></template>
                        
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/OA18810A/en"><a id="link" href="#" class="style-scope state-modifier">OA18810A</a></state-modifier>
                        <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                      <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td style-scope patent-result">2019-07-19</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains. 
     </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="relatedApplications" class="scroll-target style-scope patent-result">Priority And Related Applications</h3>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
            <h3 id="appsClaimingPriority" class="scroll-target style-scope patent-result">
              Applications Claiming Priority (8)
              <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
            </h3>
            <div class="responsive-table style-scope patent-result">
              <div class="table style-scope patent-result">
                <div class="thead style-scope patent-result">
                  <div class="tr style-scope patent-result">
                    <span class="th style-scope patent-result">Application</span>
                    <span class="th style-scope patent-result">Filing date</span>
                    <span class="th style-scope patent-result">Title</span>
                  </div>
                </div>
                <div class="tbody style-scope patent-result">
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        EP18171893<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-05-11</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <template is="dom-if" class="style-scope patent-result"></template>
                        EP18178136<template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-06-15</span>
                    <span class="td style-scope patent-result"></span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201810386D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1810386.1A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-06-25</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201813460D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1813460.1A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-08-17</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201817642D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1817642.0A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-10-29</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201820256D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1820256.4A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/GB201820264D0/en"><a id="link" href="#" class="style-scope state-modifier">GBGB1820264.8A</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2018-12-12</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
     </span>
                  </div>
                  
                  <div class="tr style-scope patent-result">
                    <span class="td nowrap style-scope patent-result">
                        <state-modifier act="{&quot;type&quot;: &quot;OPEN_RESULT&quot;, &quot;result&quot;: &quot;$result&quot;}" class="style-scope patent-result" data-result="patent/WO2019215346A1/en"><a id="link" href="#" class="style-scope state-modifier">PCT/EP2019/062238</a></state-modifier><template is="dom-if" class="style-scope patent-result"></template>
                        <template is="dom-if" class="style-scope patent-result"></template>
                    </span>
                    <span class="td nowrap style-scope patent-result">2019-05-13</span>
                    <span class="td style-scope patent-result">Compositions comprising bacterial strains 
       </span>
                  </div>
                  <template is="dom-repeat" class="style-scope patent-result"></template>
                </div>
              </div>
            </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            <template is="dom-if" class="style-scope patent-result"></template>

            
              <h3 id="concepts" class="scroll-target layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">Concepts</div>
                <a href="#title" class="style-scope patent-result"><iron-icon icon="arrow-drop-up" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon></a>
              </h3>
              <div class="layout horizontal style-scope patent-result">
                <div class="flex style-scope patent-result">
                  <span id="conceptsWarning" class="righthead tooltip-hint style-scope patent-result">machine-extracted</span>
                  <overlay-tooltip positioning-target="#conceptsWarning" direction="bottom" class="style-scope patent-result" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      The concepts are extracted by a computer and may be incomplete or incorrect.
    </div>
  </overlay-tooltip>
                </div>
                <span class="headerButton style-scope patent-result"><a href="#" target="_blank" style="display: inline-block;" class="style-scope patent-result"><iron-icon icon="icons:file-download" class="style-scope patent-result x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M19 9h-4V3H9v6H5l7 7 7-7zM5 18v2h14v-2H5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon> Download</a></span>
                <span class="style-scope patent-result">
                  <dropdown-menu multi="true" label="Filter table" show-label="true" change-action="RESULT_CONCEPT_MENU" class="style-scope patent-result">
    
    <span class="label style-scope dropdown-menu">
      <span class="style-scope dropdown-menu">Filter table</span>
      <span id="selected" class="style-scope dropdown-menu" hidden="">
        <span style="margin: 0 4px 0 2px" class="style-scope dropdown-menu">·</span>
        <span class="style-scope dropdown-menu"></span>
      </span>
      <iron-icon icon="icons:arrow-drop-down" class="style-scope dropdown-menu x-scope iron-icon-0"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 10l5 5 5-5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon><iron-icon icon="icons:arrow-drop-up" class="style-scope dropdown-menu x-scope iron-icon-0" hidden=""><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M7 14l5-5 5 5z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
    </span>
    <iron-dropdown allow-outside-scroll="" horizontal-align="left" vertical-align="top" class="style-scope dropdown-menu" aria-disabled="false" aria-hidden="true" style="outline: none; display: none;">
    

    <div id="contentWrapper" class="style-scope iron-dropdown">
      <div class="dropdown-content style-scope dropdown-menu" slot="dropdown-content" id="menu" multi="">
        <div class="style-scope dropdown-menu">
          
            <div class="item style-scope dropdown-menu">Anatomy</div>
          
            <div class="item style-scope dropdown-menu">Chemical class</div>
          
            <div class="item style-scope dropdown-menu">Chemical compound</div>
          
            <div class="item style-scope dropdown-menu">Chemical group</div>
          
            <div class="item style-scope dropdown-menu">Diseases</div>
          
            <div class="item style-scope dropdown-menu">Drugs</div>
          
            <div class="item style-scope dropdown-menu">Effects</div>
          
            <div class="item style-scope dropdown-menu">Human genes</div>
          
            <div class="item style-scope dropdown-menu">Inorganic materials</div>
          
            <div class="item style-scope dropdown-menu">Methods</div>
          
            <div class="item style-scope dropdown-menu">Natural products</div>
          
            <div class="item style-scope dropdown-menu">Nutrition</div>
          
            <div class="item style-scope dropdown-menu">Polymers</div>
          
            <div class="item style-scope dropdown-menu">Proteins</div>
          
            <div class="item style-scope dropdown-menu">Species</div>
          
            <div class="item style-scope dropdown-menu">Substances</div>
          
            <div class="item style-scope dropdown-menu">Toxicity</div>
          <template is="dom-repeat" class="style-scope dropdown-menu"></template>
        </div>
      </div>
    </div>
  </iron-dropdown>
  </dropdown-menu>
                </span>
              </div>
              <div class="responsive-table style-scope patent-result">
                <div class="table style-scope patent-result">
                  <div class="thead style-scope patent-result">
                    <div class="tr style-scope patent-result">
                      <span class="th style-scope patent-result">Name</span>
                      <span class="th style-scope patent-result">Image</span>
                      <span class="th style-scope patent-result">Sections</span>
                      <span class="th style-scope patent-result">Count</span>
                      <span class="th style-scope patent-result">Query match</span>
                    </div>
                  </div>
                  <div class="tbody style-scope patent-result">
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mixture</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">644</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">bacterial effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">title,claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">338</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">diseases, disorders, signs and symptoms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">119</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">disease</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">116</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Megasphaera</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">71</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">16S ribosomal RNA</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">45</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proteins and genes</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">42</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">immune system</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">33</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stimulating effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,abstract,description</span>
                        <span class="td nowrap style-scope patent-result">21</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">300</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">treatment</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">295</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">204</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">187</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Species style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Megasphaera massiliensis</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">173</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">prevention</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">116</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigen</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">antigens</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">66</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Histone deacetylase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Histone deacetylase</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">61</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Colon cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">54</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Colorectal Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">43</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Methods style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">therapeutic procedure</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">40</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Hematologic Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">35</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">32</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">32</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Ovarian neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">30</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">inhibitory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">30</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lymphocytic Chronic B-Cell Leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Ovarian cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">29</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Breast cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Breast neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Human genes style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cytokines</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">28</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Cervix carcinoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Prostate cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Prostatic Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Uterine Cervical Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">cervical cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">glioblastoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">26</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Stomach Neoplasms</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">gastric cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stomach cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">25</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lung neoplasm malignant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">24</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">B-cell chronic lymphocytic leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Carcinoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">chronic lymphocytic leukemia</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lung cancer</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">lung neoplasm</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">23</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Lymphomas</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">22</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Effects style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">proinflammatory effect</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">22</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Metastatic malignant melanoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">20</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Diseases style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">metastatic melanoma</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">20</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Drugs style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">vaccine</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">19</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">pharmaceutical excipient</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">17</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">T-lymphocyte</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">14</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">drug carrier</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">13</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">mesenchymal stem cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">10</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Anatomy style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">stem cell</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">9</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Nutrition style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">food</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">8</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Substances style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">adjuvant</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">7</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    
                      <div style="background-color: rgba(129, 201, 144, 0.000)" class="tr layout horizontal conceptDomain Proteins style-scope patent-result">
                        <span class="td flex style-scope patent-result">
                          <concept-mention class="style-scope patent-result">
    
    <span id="target" tabindex="0" aria-label="Details of concept" role="link" class="style-scope concept-mention">
      
        <iron-icon class="inline-icon style-scope concept-mention x-scope iron-icon-0" icon="icons:label"><svg viewBox="0 0 24 24" preserveAspectRatio="xMidYMid meet" focusable="false" style="pointer-events: none; display: block; width: 100%; height: 100%;" class="style-scope iron-icon"><g class="style-scope iron-icon"><path d="M17.63 5.84C17.27 5.33 16.67 5 16 5L5 5.01C3.9 5.01 3 5.9 3 7v10c0 1.1.9 1.99 2 1.99L16 19c.67 0 1.27-.33 1.63-.84L22 12l-4.37-6.16z" class="style-scope iron-icon"></path></g></svg>
    
  </iron-icon>
      <template is="dom-if" class="style-scope concept-mention"></template>
      
                           <span class="style-scope patent-result">Chimeric Antigen Receptors</span>
                          
      <template is="dom-if" restamp="" class="style-scope concept-mention"></template>
    </span>
  </concept-mention>
                        </span>
                        <span class="td nowrap style-scope patent-result">
                          <template is="dom-if" class="style-scope patent-result"></template>
                        </span>
                        <span class="td nowrap style-scope patent-result">claims,description</span>
                        <span class="td nowrap style-scope patent-result">3</span>
                        <span class="td nowrap style-scope patent-result">0.000</span>
                      </div>
                    <template is="dom-repeat" initial-count="25" class="style-scope patent-result"></template>
                    
                      <div class$="tr layout horizontal conceptDomain" class="style-scope patent-result">
                        <a href="#" class="td flex style-scope patent-result">
                          Show all concepts from the description section
                        </a>
                      </div>
                    <template is="dom-if" class="style-scope patent-result"></template>
                  </div>
                </div>
              </div>
            <template is="dom-if" class="style-scope patent-result"></template>

            <div id="notices" class="vertical layout center style-scope patent-result">
              
                <span class="style-scope patent-result">Data provided by IFI CLAIMS Patent Services</span>
              <template is="dom-if" class="style-scope patent-result"></template>
            </div>
          </div>
          <div class="bottombar style-scope patent-result">
            <bottom-bar class="style-scope patent-result"><template is="dom-if" class="style-scope bottom-bar"></template>
</bottom-bar>
          </div>
        </div>
      </div>
      <template is="dom-if" class="style-scope patent-result"></template>
    </div>
  </patent-result>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
    <template is="dom-if" restamp="" class="style-scope result-container"></template>
  </result-container>
        </div>
      </div>
    
        </div>
      </div>
      <search-footer class="style-scope search-ui">
    
    

    <div id="footer" class="vertical layout center style-scope search-footer">
        <span class="links style-scope search-footer">
          <overlay-tooltip positioning-target="#footerAbout" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Learn more about data coverage, search syntax and other features.
    </div>
  </overlay-tooltip>
          <a id="footerAbout" data-proto="ABOUT" href="https://support.google.com/faqs/answer/6390996" target="_blank" class="style-scope search-footer">About</a>
          <overlay-tooltip positioning-target="#footerFeedback" direction="top" class="style-scope search-footer" style="display: none;">
    
    <div id="arrow" class="style-scope overlay-tooltip" hidden=""></div>
    <div class="style-scope overlay-tooltip">
      Send feedback about technical issues or feature requests for Google Patents.
    </div>
  </overlay-tooltip>
          <a id="footerFeedback" data-proto="SEND_FEEDBACK" href="#" onclick="sendFeedback();" class="style-scope search-footer">Send Feedback</a>
          <a data-proto="PUBLIC_DATASETS" href="https://console.cloud.google.com/marketplace/product/google_patents_public_datasets/google-patents-public-data" target="_blank" class="style-scope search-footer">Public Datasets</a>
          <a data-proto="TERMS" href="https://www.google.com/policies/terms/" target="_blank" class="style-scope search-footer">Terms</a>
          <a data-proto="PRIVACY_POLICY" href="https://www.google.com/privacy/privacy-policy.html" target="blank" class="style-scope search-footer">Privacy Policy</a>
          <a data-proto="SEARCH_HELP" href="https://support.google.com/websearch/" target="_blank" class="style-scope search-footer">Help</a>
        </span>
    </div>
  </search-footer>
    </div>

  </search-ui>
  </search-result>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <template is="dom-if" restamp="" class="style-scope search-app"></template>
    <paper-toast id="toast" duration="3000" class="style-scope search-app x-scope paper-toast-0" aria-hidden="true" style="outline: none; display: none;">
    

    <span id="label" class="style-scope paper-toast"></span>
    
      <div id="noticeContent" class="style-scope search-app"></div>
    
  </paper-toast>
  </search-app>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  

<iframe id="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.32482061" name="apiproxyddf475d63cd8173a637a287407211e3c7614fb050.32482061" style="width: 1px; height: 1px; position: absolute; top: -100px; display: none;" src="https://scone-pa.clients6.google.com/static/proxy.html?usegapi=1&amp;jsh=m%3B%2F_%2Fscs%2Fabc-static%2F_%2Fjs%2Fk%3Dgapi.lb.en.IKZeRvoAYNY.O%2Fam%3DAAAQ%2Fd%3D1%2Frs%3DAHpOoo-SMWTzMRJrTty6iE5dL_aWGYOnuw%2Fm%3D__features__#parent=https%3A%2F%2Fpatents.google.com&amp;rpctoken=874337561" tabindex="-1" aria-hidden="true"></iframe><iron-a11y-announcer>
    
    <div class="style-scope iron-a11y-announcer" aria-live="polite"></div>
  </iron-a11y-announcer></body></html>